[
  {
    "id": "b769a6bf212d1514514b73bc716dbffd",
    "title": "Boehringer Ingelheim Ohio Subsidiary Enters Consent Decree - CHEManager",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZ1JmQzNFTXdpY290STRFckRYNDJiS0t4OVF6RVJjYzhvNEtvMS1QT3ZCVEdiN29GbTF1a2xpWFdJUzlINUpGbnY4Sks5cGJQSVhlOTJDSTQ3S1dBM0k3N3kxd18zZ21JdW1pQnJLQ0p3RG00RlpUZzhpSWphVVQ5aXc3Y0dKQ2JkTFNqd3BJWkZZb0FiRzB2SEF6Nm8?oc=5",
    "date": "2025-05-15T22:05:27.000Z",
    "dateFormatted": "15/05/2025",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Boehringer Ingelheim Ohio Subsidiary Enters Consent Decree  CHEManager",
    "company": "TBD",
    "types": [
      "consent_decree"
    ],
    "severity": 10,
    "priority": 3
  },
  {
    "id": "23421e295ace570fae832ee2507ce3b8",
    "title": "FDA obtains permanent injunction against Deltex Pharmaceuticals - Reliable Plant",
    "link": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOVWZ1MFJvdzFsa1dSRmF5TmdRYkYyTzhtTy1LRmlCeFhJaUV1T0hUeTV2Q3h1dl9fQUhrNGZJNTR1bi1aQ09WNXozWS1ORUpGWU12b3habU9SelNvajFDanlyVjE3cU9uV2dUVGd4NXJqR29tN3l4U0c2dFVkTExrOExDbWc?oc=5",
    "date": "2025-01-18T08:00:00.000Z",
    "dateFormatted": "18/01/2025",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA obtains permanent injunction against Deltex Pharmaceuticals  Reliable Plant",
    "company": "TBD",
    "types": [
      "consent_decree"
    ],
    "severity": 10,
    "priority": 3
  },
  {
    "id": "21383066353ea0daf8cd6ea1adab7b29",
    "title": "FDA, DOJ Enter Consent Decree of Permanent Injunction Against Boosted LLC - CSP Daily News",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPbER3Z0JOVnRaTlZCRjNvYko3akJGN292dmhJRDZvOEhqMnRlWWNXZ09objJNWm9xdlBRMzlmR1ZvY1ExRUFLOTNFU09KRlYtMjNVOVBYWkJXd0RSb3drSXplVVl0SFNhOWNSQ2VBMjZ2Wmhtc2tiLTlYOXQ3NzRRZmhlbnFJbXJwcDd2TFU5V0FxX09uRF9WWkZSeG9yLUFXUkFlQQ?oc=5",
    "date": "2024-06-17T07:00:00.000Z",
    "dateFormatted": "17/06/2024",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA, DOJ Enter Consent Decree of Permanent Injunction Against Boosted LLC  CSP Daily News",
    "company": "TBD",
    "types": [
      "consent_decree"
    ],
    "severity": 10,
    "priority": 3
  },
  {
    "id": "92ab638a4472403a9fb9e7e19094558c",
    "title": "U.S. Court Vacates Modified Consent Decree Imposed on Xellia’s Cleveland Facility - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPbFFaSS1yZUhkOUpHdXhtVS16WWhMZ2R3NDV6Ym5qR096WVFmTGpGTmpOWXl1d1o5enl0Y1lNZG9CRXphMGhjWTRJZ2lSOUxGS0R2NEluU19Danc4M2NIcUhtWWdGRmxqZEhDd1FwUWxSVmp5RU9pblFLQlVUcXJrZlRaN2x0QWpwajBXSFJaT002V2hXd3ZTY1BOcENrR1hjM2M0bElWNGtfamt0SkpVNzFFWGMzVGdnWWtRam5DQTl5dw?oc=5",
    "date": "2024-04-29T07:00:00.000Z",
    "dateFormatted": "29/04/2024",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "U.S. Court Vacates Modified Consent Decree Imposed on Xellia’s Cleveland Facility  Contract Pharma",
    "company": "TBD",
    "types": [
      "consent_decree"
    ],
    "severity": 10,
    "priority": 3
  },
  {
    "id": "85f40c4643785f29004f4bdb20221c73",
    "title": "Philips consent decree ‘worst case scenario’ for respiratory business - MedTech Dive",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNU1EtanVqMnZWMDU5VXhrc1BXQ0JtWWszYXhRTkRYbWd3YzdNNU1QTXhUV01nVkxrZkRhVzBONVdhLXpMaWNkZ3FqcW1xakt4NmFleGNhUUV4NkllNi12WFotc0ZwSl9vMFpJTU8tUUluOHBoT0FXWDhyV0lLLUtBTk5CLUdyZVNE?oc=5",
    "date": "2024-02-06T08:00:00.000Z",
    "dateFormatted": "06/02/2024",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Philips consent decree ‘worst case scenario’ for respiratory business  MedTech Dive",
    "company": "TBD",
    "types": [
      "consent_decree"
    ],
    "severity": 10,
    "priority": 3
  },
  {
    "id": "988707c9819da5800b0d072a269d5077",
    "title": "FDA Announces Federal Court Enters Consent Decree Against Oklahoma Drug Compounder - PR Newswire",
    "link": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQenFuRnhmdEdkN3BGdHhZS1kwcEJxN1hFSHRCTHZ6Y3JHQ1NvLVhuMXd6TGo0VjRzMERJc2RZcU0tNWtQaXFZSlM2b3h4RFFYWGhLM0pvLXgzSXNvY3JaSW9oSDhlc3VKY2Y2dWVGdnBfQjlxOVVYVGxiYUstZFJtWTN6WGsxSGVmSkEycVpRTTU3R3BlMEs2WTVhQzhIM3Bxck1mdVJCbzBKWDV2Unk4d2dwNFNyZm96RlNCWEpaMHNJaUprSlZvM2RRc2lOYzF5VG9UOA?oc=5",
    "date": "2022-12-19T08:00:00.000Z",
    "dateFormatted": "19/12/2022",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA Announces Federal Court Enters Consent Decree Against Oklahoma Drug Compounder  PR Newswire",
    "company": "TBD",
    "types": [
      "consent_decree"
    ],
    "severity": 10,
    "priority": 3
  },
  {
    "id": "0094675767e1b4954849fd6f8ea58bb2",
    "title": "Deconstructing the Consent Decree: A Primer and Recent Trends for FDCA Injunctions - Food and Drug Law Institute (FDLI)",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNNXUtLWlFQ21fc2hXWF9Eb0VIRUhZRG1meHNSUEo3RXFDdEJ6SUotWEZnUE9oVUlDUXhwZW4xSmNKZkpldlVXS0pvVHJiQ0tmYXpwSDUwNS1IRnFCSnJwZ1cyYXNLZW4zVy1UMlJFV1FWdjJSdzJNNHM3NlFRaXJTUWc5dWdidFhmVjU4SVhqN1VrWGdCX2dmZG1zaExROVhCQ09nTFlGejdiWGlzcnJlQw?oc=5",
    "date": "2020-11-15T08:00:00.000Z",
    "dateFormatted": "15/11/2020",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Deconstructing the Consent Decree: A Primer and Recent Trends for FDCA Injunctions  Food and Drug Law Institute (FDLI)",
    "company": "TBD",
    "types": [
      "consent_decree"
    ],
    "severity": 10,
    "priority": 3
  },
  {
    "id": "984234aad61134f0db877f60abf702e6",
    "title": "J&L Grocery enters consent decree with DOJ, FDA - Southwest Times Record",
    "link": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPSE94NHkyN2FmbkcwUEFpRG81cjVrak5yaVVDQXRMT2hvZmFjRXRpMDNST3dKRjBhQ3U1dXpwM2dubkQ3NUJIUzhpR2RSUDZjVnhEbmR3VEVIRjZkS05naVN5c2dVSGJPUUN0ZEdDZlFhMTU2LWFYYWdXOGdRY0FmNGpDOUd0d3Yyd1lzd3NuUQ?oc=5",
    "date": "2019-07-19T07:00:00.000Z",
    "dateFormatted": "19/07/2019",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "J&L Grocery enters consent decree with DOJ, FDA  Southwest Times Record",
    "company": "TBD",
    "types": [
      "consent_decree"
    ],
    "severity": 10,
    "priority": 3
  },
  {
    "id": "1bf7ef6e4314ca63d2797d81a7527b6a",
    "title": "FDA modifies consent decree for Xellia on closed Ben Venue plant - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQN05yeWdUY1hRbS03aFd6V1JzTko5cXhkSk9LWGhvSUNkVV92bWNqUjFVT1ZPQzBhV3ZNS29URXJJc0RMM1RaLVZXQ3lnM3A0Rks0eHFtSzktNEJENXd5bjNJNE9aRy1XZTc5NFlwaTJNQU9HdFJVODRuZ3NqWldJVkYxQVN1T09sLUNvUXVqZzk3WnozUmRLVWlJZzlKSWI0OGk2VmdXYw?oc=5",
    "date": "2016-05-03T07:00:00.000Z",
    "dateFormatted": "03/05/2016",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA modifies consent decree for Xellia on closed Ben Venue plant  Fierce Pharma",
    "company": "TBD",
    "types": [
      "consent_decree"
    ],
    "severity": 10,
    "priority": 3
  },
  {
    "id": "f65c7f341a4a2b74939c19cb93b4fe90",
    "title": "Saol Therapeutics Receives Complete Response Letter from FDA for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD) - PR Newswire",
    "link": "https://news.google.com/rss/articles/CBMipgJBVV95cUxOZVhnWmVHcXRYbDZOckpfajZnZHk1cWhDVFlPdmlDOUNyY3I0X0ptSG1iazNEdFc3N0lfYTBmVHVBazIwazAzOXlkaVRDdWdkaWpvQmVqVmtHSnN3dVk4TzRhX2tqMjNJc05mSkRNY3ctNmMyMFVtNmpwVDVLV21VMHhyVm5LZlVISThzWkxXNjVIWW4xT1hPX0Q4VXBtc0l3WkxHREtibkFTUDh6ek9ITGhTRnVlZXFVTTh1dzZHRTBnWU9pSHBjX0lieEVxRFlpLVdxTEFPRndaSU9JODZpeS1lY0RkTU9VUl9oUXFneG41MmRESnZ3UkF4Q25EOE1lb1FaWXVxbXlUOGhNaFNSNVVDRXhQcUhDWUczQ1hXVTZHb2g4akE?oc=5",
    "date": "2025-09-08T15:36:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Saol Therapeutics Receives Complete Response Letter from FDA for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD)  PR Newswire",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "8cf4f0ecabad78e1563bac709be64326",
    "title": "Saol Therapeutics gets FDA Complete Response Letter for SL1009 (DCA) in treating PDCD - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOT18zTFJTSWhCaUFzNzVRMm9EY0xnNXIxQ3E4cWpSaDlPSUdZN1hPS0JCVkhUQjlFakdMNTBwU0pIdVp3eGZQblo1TldsY0djX0h4bFlwVnQwZXBzUDVLaDNUVVFjelkxMEFiZzV4bXp0cmwzTWxHSUl0MG9ueUtGRUNXUnIxQjB1YXFDdnROOWtLNzRoZHZIWG5QdHlWUk1IMzRlR1dTQ054dl9zVlRoZWJQR0pOcE9aTFI0WmI4Q19VZTVOdm9jdEVKZHFGeE1MekE?oc=5",
    "date": "2025-09-08T13:09:45.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Saol Therapeutics gets FDA Complete Response Letter for SL1009 (DCA) in treating PDCD  MarketScreener",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "2dc627e0bd21958c3a67b8ca597daceb",
    "title": "Lexicon Pharmaceuticals Submits Additional Clinical Data for Zynquista NDA Resubmission Following FDA Complete Response Letter - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxPSTkzMGVqS2FrOVlsZzMzRkRPZWlBckEtSEFIYXVRTVM5Vlp2bUw5aXJXeExoaE1IdnFrUFBEa0tnRDhWRzBrZ0FUbHdwVzFHREo0WF85QjFrbXFDOTFsZGlDMjlRVWs4b0VKV0MwYlhMZkE0V04wc1FDaTdwV0syb1JhYV9sVWpfeWNYY3pfMVVQTHZES1V0bVBpNkFIejA1Wk9HSEY3OUFSUG1IOU9uSDBQb3Vudzl1OHcySWxDem1OTWNJSzFnUEQ2NW5Dd3lvcUJiRTZ4aGR4X3Y3WGo2Mzk5S2tHRWplNU1VV0Y1YWo?oc=5",
    "date": "2025-09-08T12:43:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Lexicon Pharmaceuticals Submits Additional Clinical Data for Zynquista NDA Resubmission Following FDA Complete Response Letter  Quiver Quantitative",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "29b25be9bae26e3712b3a2e4a954f5a5",
    "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
    "date": "2025-09-05T18:56:15.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "a85b237591b5632b3cb3880dab629e23",
    "title": "FDA to publish CRLs in real time; PEPFAR to distribute Gilead’s Yeztugo",
    "link": "https://www.biopharmadive.com/news/fda-complete-response-letters-gilead-pepfar-yeztugo-ac-immune-layoffs/759306/",
    "date": "2025-09-05T15:15:00.000Z",
    "dateFormatted": "05/09/2025",
    "source": "BioPharma Dive",
    "sourceCategory": "trade",
    "summary": "The FDA also unveiled a batch of 89 previously unpublished complete response letters, including rejection notices to Capricor and Replimune.",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "4cb071a024d39cd234df2573ad427ab4",
    "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
    "date": "2025-09-05T02:37:30.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "f63607daf8c23697f0d3a9c330bae316",
    "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
    "date": "2025-09-05T00:09:00.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "d82230611ec1be0c1cb7e995f1083ee7",
    "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
    "date": "2025-09-04T16:10:06.000Z",
    "dateFormatted": "04/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "ce08e2db79279f2d210a0750681f9d31",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "date": "2025-09-04T15:41:34.000Z",
    "dateFormatted": "04/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "f867ee21a867f639feeb36d833c984bb",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
    "date": "2025-09-04T13:23:32.000Z",
    "dateFormatted": "04/09/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 1
  },
  {
    "id": "52c2f3493f56a2335b2b1c4617319856",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNVFdoVlBOSnBCeWZqcUs5by1MMXJwU29qMUlEelRwRFZXYk0yUUlrQmpPSmUtb0ZkNVU0SlRHeVk0bjNjbDRibVNKeTRyX3NmMU41UjREQ1NwQ1N4MC04WXBTRDZwelAydml6Q0RPV2hkME5paWxEWXlFOVR1dXBxWGlZRG9HMVVFeXJkT0NaOUdXSkNjQW90OTRVemszYm9BcUlsNmNXX01xRXBJZzhyX0dnNEltRkVtUnFoakxrSFdWS20yMFZvVzJyOG1BUTM3bE5QMEcyVVFnOU1NenM4Uw?oc=5",
    "date": "2025-09-04T04:00:00.000Z",
    "dateFormatted": "04/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89  fda.gov",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "3f7adc9e4b56b3b13f8acaf43b7d624d",
    "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
    "date": "2025-09-02T21:45:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "c767fbfb70097cad76352756cb4fbd0b",
    "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
    "date": "2025-09-02T12:44:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "dbadbc8ee2de9d262c4ddc68bd225833",
    "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "013137fc2b8af7aac6f2f4e1c0ae116d",
    "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "8b9b7c2de7968642b440298b4a96baf0",
    "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "1ae357e27428eafe079cc842d4c746c5",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "78a3c4d65ead9081121827dd0e33036e",
    "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
    "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
    "date": "2025-08-27T22:51:27.000Z",
    "dateFormatted": "27/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "d6acf7a0a5440f4861892116f580d0cf",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "date": "2025-08-21T07:00:00.000Z",
    "dateFormatted": "21/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "0d37b320b6c4a6d23e75f49d2551247c",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "date": "2025-08-20T18:08:52.000Z",
    "dateFormatted": "20/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "a8e09baca676b76f53eca05262d66e4e",
    "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
    "date": "2025-08-20T07:00:00.000Z",
    "dateFormatted": "20/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "a340bd8f0626edf037575f5ddff969c1",
    "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
    "date": "2025-08-19T13:56:19.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "72b2e0fb1db19b74785d46dac8be30f6",
    "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
    "date": "2025-08-19T07:00:00.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "a911b54eb27434034def9192446c4de4",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - MSN",
    "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZmI0WlRSMDNhNURtOWxSbkJrLVY3UFFNODhiTmxEc3NxeTB6VEhVSURFWEh5VUxCTFZKLUJsT2lEZjVlcEhlM3Rpb2htdjdLcnVoLURIcHhxaDcxVFI2YVRtOWNET0Q0OVVEU3ZtQkZVaGpTQWNuUXR2anotbHdpY3ZGTkZzU2V3OGQ2bFoxVDdtaG5CWDgyRnhHRXNkWXJqY2lpVzlKeEc?oc=5",
    "date": "2025-08-19T07:00:00.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  MSN",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "1eac0294da46b1ae88b1128713d7c5f0",
    "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
    "date": "2025-07-30T07:00:00.000Z",
    "dateFormatted": "30/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "f3fc5a839b5bfce368472d2a5259cd84",
    "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
    "date": "2025-07-22T07:00:00.000Z",
    "dateFormatted": "22/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "fe51c60006dfcb66ac45dd9a79945061",
    "title": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOTHUxdXliYVhkdDUzQTJtZFBuN3oxQzlub3FHaVVtclNlOHQtTHNSdWNPYzhiWXdST2V1VnlMSlBmLVdvSFEwLUsxMXk4WTgzUkE3N1ZSOUp6Mk1tTnZCb0tLY1RITmRoY3YzdS1PVkdBVW5nYkJFV1dDdVdFNzFhWFhSX2QzQ3gxa21vMEhSYWJfZWREMFZRckN2ZFJaTmNGZ01jNHhXc0NIaEZuM0RieV80dnFpZmFNM2J5MHRLODdJYnBJMi1EeDQ5aWs2ZUJ4WW80bkxUaw?oc=5",
    "date": "2025-07-22T07:00:00.000Z",
    "dateFormatted": "22/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment  geneonline.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "d38700df5268b8a335e52c81021cde94",
    "title": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZXlhSFNScVd3dFNhSDBQemMyMVpNUExDeXRYNDlYeFNhZ1F5RGlFcmhPbURGX05tZUhkNFpNdVVrYzRQWnpFS0pyZFFabnNZUXRjNzdRazBZdmV4RS1ZLVFUNFVlbjI1ZVZTQ1RZTzJ3NU9hbzZJZ1dDZ1lremdyUENyU2tlRkZwSVNsTHJweWlXLWtXRVZjRVNSYnNMVW1xTUFMZXlHZllZVHFWR3c4MkptbFpjTGM?oc=5",
    "date": "2025-07-21T07:00:00.000Z",
    "dateFormatted": "21/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy  Targeted Oncology",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "ce0697167fb73f2739ccf5cd2c9d379d",
    "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
    "date": "2025-07-18T07:00:00.000Z",
    "dateFormatted": "18/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "14f42976af3d886349477b6be50a5d62",
    "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
    "date": "2025-07-14T07:00:00.000Z",
    "dateFormatted": "14/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "171d43bdbc3d5624a424eb4eeb773f7c",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "date": "2025-07-14T07:00:00.000Z",
    "dateFormatted": "14/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "1eb1ef23f0e6ba8b4d454333c248d835",
    "title": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNT0w3NDFEdGlZTG51M1VtMnZhS21xSGlCNjA5U0dTeTZmS01iUDFHbGNvR3R4Szl2LThwcE1ETjVtTmFOUFQ5ZzFZQUdwa3ZSWEZGR2s5YnBOZzVkZHpaNVQ5MHlVRndUaHlCZXRjVXd4cnY0UmhxbVBycjVSX19oaVNKdnI5UmlLQWZwSUllLVBqQ3RvQTNHN3JCUzdxT3M5S0E0X2ZWVEJWelBZR3Fyek9XNUZhcGc?oc=5",
    "date": "2025-07-14T07:00:00.000Z",
    "dateFormatted": "14/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application  geneonline.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "9ac3b948c05f446399ab8622fb77d395",
    "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "559572f4371a4449d7100790f9632337",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "ff107edff6060d03c3d6c97f20b6a6a2",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "8ba2e9736e5cbd77026fe51f2d237587",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "a4acfc255623093ec83e3c59424a4092",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "16ddecb6313b5332f384f6bef680bf7b",
    "title": "Just how radical is the FDA's complete response letter move? - pharmaphorum",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQlpqYUp3SmJZY2JTam1VUGhNdHh3YWFjdXN3OWYxYkhDbnNLWVJqUWoySHpqWnlwdnRlNXJYWGwwclBwOW9NdllJX1c0RWRjaHpleDVpbHlMVkFkM0NxUzA4N0wwU0FUQXNBMWpIWnpWMVV1OUl2U1liY3luODUzQzRUcG9NNmxs?oc=5",
    "date": "2025-07-10T07:00:00.000Z",
    "dateFormatted": "10/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Just how radical is the FDA's complete response letter move?  pharmaphorum",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "0b31fe784b05ca57000ada2a68863533",
    "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
    "date": "2025-07-02T07:00:00.000Z",
    "dateFormatted": "02/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "1c30479f9e898a98be3c56dfc8e7ca9b",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "date": "2025-07-01T07:00:00.000Z",
    "dateFormatted": "01/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "97f84f1f50ace4a939498b0c99bba861",
    "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
    "date": "2025-06-30T07:00:00.000Z",
    "dateFormatted": "30/06/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "bc69f650cf18fcc9a32a4cbb89e8456e",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "date": "2025-06-30T07:00:00.000Z",
    "dateFormatted": "30/06/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "03437aeda17b0bb38b9497f13e1d996d",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "date": "2025-06-16T07:00:00.000Z",
    "dateFormatted": "16/06/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "213d5bdd6cb2455abec72c0f9457cdab",
    "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
    "link": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQVmIyemZUbEpPZmx3cGNyNTg1blVBQ1hUNEN1R0JXRDlST05aNzVuTTU3ZXJHbW5LREFmdnU0c3pad0lmN0pycnY5ZW0yU2lBLWgtY0R1aHpnbkNLQktHTlp3eW5GSkoxWDdfcm1fcmMxWnVYcGFRdGh0c29kWWNrMWw1NENHS0RKMVFsdTIwV2JmU0NWTUJ0by1QWXp1Qmd6ZmhWYlducDBaYTlkX19UcU41NzN4LUo2MWpKb0FpMUhNTU40aGczVTJOZ2dhZm1GT1VldExRNkhLalMxSk42TXF4WFFFRVA4S0FqZw?oc=5",
    "date": "2025-05-06T07:00:00.000Z",
    "dateFormatted": "06/05/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "4260b8c5aee99dcaabbf5bafee6b782e",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "date": "2025-04-03T07:00:00.000Z",
    "dateFormatted": "03/04/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "6d3b8b614b2723f6436b018ee7c5e87b",
    "title": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLTlmaDFOclA3OUhtMkdzQjBtQXk3S1JKbl93VzJBM3R2bGRDRUpWQWQxQnZhY05qS0pOTXhNcnJpZE5jTVJnbmlvR1pGa1EweWc2aFkxTldEUEQ2RDZOaTZsS184ZUYxVHN0YmNEOXZlUUt1N3hqNl9VVjJNQ3BKZ19HQkxYbFBRNWdMYnZ1aWJVdlJxb2RweTBfendMM2NQU2I4NVd0MUo1M21Kc3FqS1oyVWwxWE5pZVVzVHVuZUk2dHJiSmhVcGRicDMyMlNVRVE5b1YyRmRIT3BXRzBCOEZDRzA4TWtFNGc?oc=5",
    "date": "2025-04-03T07:00:00.000Z",
    "dateFormatted": "03/04/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis  Pharmacy Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "756dc9bcdca198b75cdd908c50a98062",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "date": "2025-01-16T08:00:00.000Z",
    "dateFormatted": "16/01/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "006aa4a0d68d04820c8f5d32b42eb880",
    "title": "Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings - JD Supra",
    "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQUGhhVWRtUDA3TEtVa0p6VElTMGE1eXNMcl9mMG1fY3FsdU1xSFdIODBGNWdMVlUtekUxUVFDbFVtZmpxVTF5WVdEblE0MTI0aFllWHJ2ZEM0UkhRcWNYRUdwbTlibUlJUzdPMmEwOUFRdWlTVXZGc2VMa0tvS3NaRXhRRHM4SGQwZGc?oc=5",
    "date": "2025-01-15T08:00:00.000Z",
    "dateFormatted": "15/01/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings  JD Supra",
    "company": "TBD",
    "types": [
      "warning_letter",
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "b6f07ff03eed0d9264a1c56d0228b5a8",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "date": "2024-12-21T08:00:00.000Z",
    "dateFormatted": "21/12/2024",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "5d84bfcbef1c9017ec1a6f0e27ba550a",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "date": "2024-12-17T08:00:00.000Z",
    "dateFormatted": "17/12/2024",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "5ed461b9f749d5f546d4cd278479a621",
    "title": "US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY) - Modern Retina",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNZUhiM1ZrQ20xX0NZb3hEQlZzczhsV04yQlZkdldQMjBzTm94UjBfd3A3TlhjX0xVMGtHWWZzak9ONnBjR1JMTUFqYlpIMW9zNHFLTzRoc3dtV1Fqa05KVlVxckVWUXRSakJTNV9sb2RoWGpEUFpvZjY2TDhMT2tiTjV4TUhJcGNyR2NuSXBDam9mU0VUazVWWlAtRjJMU3A1Ymw1TXZRb21rZXh4Tjc5N2xfUnZpX2hyMXo2WjVEUGMxRjky?oc=5",
    "date": "2024-11-19T08:00:00.000Z",
    "dateFormatted": "19/11/2024",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY)  Modern Retina",
    "company": "TBD",
    "types": [
      "crl"
    ],
    "severity": 9,
    "priority": 3
  },
  {
    "id": "9ebfe06a74a5a5412272a687f48e36c6",
    "title": "Trew Balance",
    "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trew-balance-709880-08252025",
    "date": "2025-09-09T13:00:01.435Z",
    "dateFormatted": "09/09/2025",
    "source": "FDA Website Direct",
    "sourceCategory": "official",
    "sourceType": "warning_letter",
    "summary": "",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 1
  },
  {
    "id": "d75fdbdbabd9027c30fb023ac4d24c14",
    "title": "Homeopathic Educational Services dba Homeopathic Family Medicine",
    "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/homeopathic-educational-services-dba-homeopathic-family-medicine-708635-08252025",
    "date": "2025-09-09T13:00:01.435Z",
    "dateFormatted": "09/09/2025",
    "source": "FDA Website Direct",
    "sourceCategory": "official",
    "sourceType": "warning_letter",
    "summary": "",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 1
  },
  {
    "id": "5773a6ab626757e9488cd4d6f3fda81b",
    "title": "Mel Honey US",
    "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mel-honey-us-709535-08252025",
    "date": "2025-09-09T13:00:01.435Z",
    "dateFormatted": "09/09/2025",
    "source": "FDA Website Direct",
    "sourceCategory": "official",
    "sourceType": "warning_letter",
    "summary": "",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 1
  },
  {
    "id": "203ad6ea5f2064eeeec1ad02ebf25cb1",
    "title": "chillzoneusa.com",
    "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chillzoneusacom-715556-08272025",
    "date": "2025-09-09T13:00:01.434Z",
    "dateFormatted": "09/09/2025",
    "source": "FDA Website Direct",
    "sourceCategory": "official",
    "sourceType": "warning_letter",
    "summary": "",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 1
  },
  {
    "id": "d29d04d2332ffd468a6f66e3be552226",
    "title": "Synergy Animal Products, Inc.",
    "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/synergy-animal-products-inc-712860-07162025",
    "date": "2025-09-09T13:00:01.434Z",
    "dateFormatted": "09/09/2025",
    "source": "FDA Website Direct",
    "sourceCategory": "official",
    "sourceType": "warning_letter",
    "summary": "",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 1
  },
  {
    "id": "9d71c21b047f32dc2ef2eb0668691118",
    "title": "Wisconsin Pharmacal Company, LLC",
    "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wisconsin-pharmacal-company-llc-710329-08222025",
    "date": "2025-09-09T13:00:01.434Z",
    "dateFormatted": "09/09/2025",
    "source": "FDA Website Direct",
    "sourceCategory": "official",
    "sourceType": "warning_letter",
    "summary": "",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 1
  },
  {
    "id": "a41e6167a82d171a3dab0f732ff06c09",
    "title": "Supply Center USA",
    "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/supply-center-usa-710859-08252025",
    "date": "2025-09-09T13:00:01.434Z",
    "dateFormatted": "09/09/2025",
    "source": "FDA Website Direct",
    "sourceCategory": "official",
    "sourceType": "warning_letter",
    "summary": "",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 1
  },
  {
    "id": "31161ea0554eccf6640672cce4b38e01",
    "title": "ejuices.com",
    "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ejuicescom-715645-08272025",
    "date": "2025-09-09T13:00:01.433Z",
    "dateFormatted": "09/09/2025",
    "source": "FDA Website Direct",
    "sourceCategory": "official",
    "sourceType": "warning_letter",
    "summary": "",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 1
  },
  {
    "id": "5431bb111285ca11e4cd74c2dd66f909",
    "title": "Chromatography Institute of America dba Compounder’s International Analytical Laboratory",
    "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chromatography-institute-america-dba-compounders-international-analytical-laboratory-708944-08202025",
    "date": "2025-09-09T13:00:01.433Z",
    "dateFormatted": "09/09/2025",
    "source": "FDA Website Direct",
    "sourceCategory": "official",
    "sourceType": "warning_letter",
    "summary": "",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 1
  },
  {
    "id": "69d10419046d6d9c874e952b7478850c",
    "title": "Amneal Pharmaceuticals, LLC",
    "link": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amneal-pharmaceuticals-llc-709894-08272025",
    "date": "2025-09-09T13:00:01.411Z",
    "dateFormatted": "09/09/2025",
    "source": "FDA Website Direct",
    "sourceCategory": "official",
    "sourceType": "warning_letter",
    "summary": "",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 1
  },
  {
    "id": "f06dddd6c1b85bfa898fda16f441852c",
    "title": "Staying Ahead of Enforcement: Executive Strategies To Prevent FDA Warning Letters - Med Device Online",
    "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOMlh0TnFnZkd6d2hLOEF3dUhfN1RKQmZQQ3J0UGl6SXdraUhiWXZYd2JZMVltRzRJRkZXUWQ0NU5ncE1UcUIyalVEcU1sQnpfQXdYZEdONzhySk9uMUJvakRGNmhtd0xYVGhMbXA4WnJmZ0RaWWF4ZE1IaVhQaEhiZmFrZEFUN0ZMcHdKdGxIdzdmY29qRHJpRXdLcGJ6VVFzWWgzd1J6VXdCWF9fVnZJdzdFZjZxVU8wMnRSellR?oc=5",
    "date": "2025-08-19T07:00:00.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Staying Ahead of Enforcement: Executive Strategies To Prevent FDA Warning Letters  Med Device Online",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "38a23ad83a5f966f9dd9eac0510d9c6b",
    "title": "The Warning Letter Wake-Up Call In 2025: What FDA Enforcement Is Really Telling Us - Med Device Online",
    "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPSWFHZV9SUHFlSUYzbS1VQVlBdURxT3dXR0k5QzlYOF9fM3VzOVZ1S250V290cE9FQ21Oa1liS2VWZkliVlVRYUJGcUhJZVFpOE1pWTNpVHZXLUg1TTJSaVU2QlBpWVpTUkZJQmVVN0NsSDBnbDNZLVJZRTRodDRWV1pLZ1E0WVZUNVhuQmdUTFpxd0QwSWd4Q3p2SWlXcm5XMWRMQzFKODBteDZMS0MtRWNLZFV3MXpW?oc=5",
    "date": "2025-08-12T07:00:00.000Z",
    "dateFormatted": "12/08/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "The Warning Letter Wake-Up Call In 2025: What FDA Enforcement Is Really Telling Us  Med Device Online",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "4679789ac7d424e55daa06312a80bd9c",
    "title": "QuVa Pharma, Inc. Sugar Land, TX. Untitled Letter issued 06/18/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/quva-pharma-inc-sugar-land-tx-untitled-letter-issued-06182025",
    "date": "2025-08-11T13:13:34.000Z",
    "dateFormatted": "11/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request Please post to the OII FOIA Electronic Reading Room\nRecord Date 06/18/2025\nShort Title (70 char) QuVa Pharma, Inc. Sugar Land, TX. Untitled Letter issued 06/18/2025\nFEI Number 3012053582\nFirm Name QuVa Pharma, Inc\nRecord Type Untit\nState TX\nEstablishment Type Outsourcing Fac",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 1
  },
  {
    "id": "a457e4e176f617ed572b31b78d70c68f",
    "title": "How to Avoid FDA Warning Letters - Quality Digest",
    "link": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPUGFtcW8tNVkzQlRvell6cmZ6YU9IWlJYTkV4OHdINlcxTGRudlI1RnFLRWpXbjhYTU9fX25RbFd2UEp4dHRLcGQ2OXczNXE3eS1IWWhGMXVYRlZPS0xHOHZyVDYxQVdma19fSXBEYjhzSl9fSS1UR2dMLXJCREhReXlST2tBLTQxT2dDNGF4Z21SXy01UHZzN0R5Y05GcTI5a3Z3?oc=5",
    "date": "2025-06-17T07:00:00.000Z",
    "dateFormatted": "17/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "How to Avoid FDA Warning Letters  Quality Digest",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "1b70bbb7266d3b78f7c495b425582116",
    "title": "India's Aspen Biopharma Labs hit with FDA warning letter citing infrastructure, contamination and records problems - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWjNlOVMwM2ZqWHVoYWFaRHFrYzd5bGlvNDZiTkYyTGNiaF9odWpQSGJ5RUIwNXI1RTUyRjhCZ2ZLeVVhLUdhRFppeE9XTm1RZjV5aWZTSjBrME9Mc210UXhTRzNFamlpWHYtdHFGWklpYm9qbklkdUFmSHF0NFN2RzhRaTY1T3JFNjlTSExackZHLXJMVVNYdl9zUmF1VldyS3dCNXJjVmpsZnJYZXA1a1N6dVdrZ3NUT1hGNnAxX1BzR0E?oc=5",
    "date": "2025-03-26T07:00:00.000Z",
    "dateFormatted": "26/03/2025",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "India's Aspen Biopharma Labs hit with FDA warning letter citing infrastructure, contamination and records problems  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "70a397d04bd8607d69d68b12fbdbb7a4",
    "title": "Lytgobi Untitled Letter - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1hbkNVUXl3dGVocUdqdjhfYlFRcnl1ODBPaUFsbTkwRjRaelRCWVJmWjhTcFd6T2FqemZFOS1reTMwb1lpN0RvOWVlai0tdGF1VGMw?oc=5",
    "date": "2025-03-21T07:00:00.000Z",
    "dateFormatted": "21/03/2025",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Lytgobi Untitled Letter  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "4217616ef7ea2e02cd323e6b116bbec5",
    "title": "Dexcom receives warning letter based on FDA inspections of 2 plants - MedTech Dive",
    "link": "https://news.google.com/rss/articles/CBMidEFVX3lxTE1kZDFOS1BEdVY5c3h0X3NBWWxRdWhpUW1VTWRldDRSVXloWDAyUTdGUGZHcDZ0YlFhLVF6TF9vVndpaXVQR3gySWNKeXlFR0t3MG9mRU1uMzRQLXcxcngxbHkwZVZzV2FwekFnZ3JfeEdfeW1t?oc=5",
    "date": "2025-03-10T07:00:00.000Z",
    "dateFormatted": "10/03/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Dexcom receives warning letter based on FDA inspections of 2 plants  MedTech Dive",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "207fd6fbecd1fa696a9aff21b3f5f320",
    "title": "FDA hits pair of Indian API makers with warning letters, import alerts - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOcXZfQ0h3UUNRNHloVkowSHFBa1hyblNzMklrdGloN3NtakVTbDhlSjFVYXlxVzR2YmFVaVEyWWwzazQ4dU84RGxGd3hnYWxMVUFmNGNtbEM0T215cTEzd2NtSGZ6TE92b3ZmWGZyUlVkaHVQVktpRDBWWEx5R0lNNzh3ZWExX2NfR1o2OWw0dDlKZGx6bW9rd3BB?oc=5",
    "date": "2025-02-20T08:00:00.000Z",
    "dateFormatted": "20/02/2025",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA hits pair of Indian API makers with warning letters, import alerts  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter",
      "import_alert"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "91f8e96c0530d540bb86ce51d7e49a0f",
    "title": "FDA slaps China-based API makers with separate warning letters outlining quality, testing shortfalls - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOckJqX1lIckFjTEQ1c3R3YWRlZnp4cVFfb2VtVVRoUC1SeTVMMGxFSGI3WEhXUUR1c0lVN0JHU2JKdGd0Zml6TjhXNy1wZ0hNME85d0cxaFZTemc5dXVTVS10RE9iN1FTUWprRWk0T0ZPRDR4Y3FIQWN5ZVM3Q2Q1dURDQzVTc3lhWVN1V0xxMTktRlhIM3VOSC1tdXNuRWR5UTh5TTBDb1VrOWx2bFpPOEV5TDRKRVVxSGJGWU5HSVJIajRt?oc=5",
    "date": "2025-02-11T08:00:00.000Z",
    "dateFormatted": "11/02/2025",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA slaps China-based API makers with separate warning letters outlining quality, testing shortfalls  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "7bb8e525887cdf78e01bab388e1eaead",
    "title": "Hemady Untitled Letter - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5kdEExSnlhODhtc0RISHdGRFNuZjlyNHNRUVcweUFTNmltY1BzXzlmV05qZkU3S1kydWwzWWEtb3BQLTNVTDQ3VnB5aFlJZFNCeU5j?oc=5",
    "date": "2025-02-03T08:00:00.000Z",
    "dateFormatted": "03/02/2025",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Hemady Untitled Letter  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "5070cce26f21bbce567b944d63abc23f",
    "title": "FDA warning letter reveals quality control, data integrity issues at Viatris plant in India - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNLVZtZVpSekVIb2VmQXJFQzJNamNBc3Z0ek83MkNMdHp3cHlhQjhuN0NIVlFNR1pxX25FR2xkNG01X0R4cjdINUNSZGZCd3llem5fWjl0S2xHVlRVaDdjYzFoVWRjYUFhRnc3alVPa193RWVNY3BjZFVzOVQwNDQ3VkVJNUVpSWNpcVNtT1A1cDZJakVqbm4xdWZtQnVJMUJETE4yM2VtRDJrdUVwWVRJQ3FNcHpCcTBteUtZYld6Vjk0Zw?oc=5",
    "date": "2025-01-06T08:00:00.000Z",
    "dateFormatted": "06/01/2025",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA warning letter reveals quality control, data integrity issues at Viatris plant in India  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "4b492b7ecb665d2efbfa411267f81241",
    "title": "Viatris says India plant hit with FDA warning letter, import ban on 11 products - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQU1djX0V1eHMxNzQxTnRva3Zhaldfa2VxN2Z3ckFTS20waFh3TlhfQ1ZoMnlod3pKZzJRSzdZZFA3WUhlWjZ6UlBub01SRFNyc284aTJPN0xNS3locmtnamF3SkVSSEVLdTFXOFRLTF9sYkYzYlNlQkJoY3JNS3h4R0RfY2Y2ekhsVnc2eW4zQ19wRDBrN3MtYW5laWVNTXE2N2g1RHVzaE1aNkdWWXc?oc=5",
    "date": "2024-12-23T08:00:00.000Z",
    "dateFormatted": "23/12/2024",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Viatris says India plant hit with FDA warning letter, import ban on 11 products  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter",
      "import_alert"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "a9ea0884b713e9b55d7fa54412db10e3",
    "title": "Krazati Untitled Letter Close-out - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9qUEFwVmhXTDdZVjZqSmRXU2NwNk45MlpFTF9JQzdGeEFwUU9CQXJXS05tMGxMcTRRUXhlNEc0Q1NpMmZKZGVMTTd2VndlcVlUc2Yw?oc=5",
    "date": "2024-12-11T08:00:00.000Z",
    "dateFormatted": "11/12/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Krazati Untitled Letter Close-out  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "f824c6a5f0514f3ed949fff22386fb4c",
    "title": "Xeomin Untitled Letter - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE05S0tqazhsQklPTVhoYm1sVWVISXJoQXVjUFhETWlpTHZlMDR4R3pJNENqS2pCWmRtcmZRUlQ2MDRjbzk1dFR1Q1pDUVF0bDROeFo0?oc=5",
    "date": "2024-10-31T07:00:00.000Z",
    "dateFormatted": "31/10/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Xeomin Untitled Letter  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "ee901a23389e6f139645993190d94b6d",
    "title": "Ubrelvy Untitled Letter Close-Out - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1KRUhxeG5PM0xrZHRsQnQxOFYyc0xQNWNUNVdmYjB4MzE3OGZHZEsxV1BxQjRYenptTnNleXpNYjUwelo0OUdQVk9ET1lQaWxCc2U0?oc=5",
    "date": "2024-10-30T07:00:00.000Z",
    "dateFormatted": "30/10/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Ubrelvy Untitled Letter Close-Out  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "e032311b38e640cde92cbe6a4d198241",
    "title": "Auvi-Q Untitled Letter Close-Out - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFA1NzJybGdldjd1UVhCcmlrOGtieU1wTEJPUlFtR2hYTHItQTJER3VXNXJjeDMtVWlUbGJHcXpoclZjV0pqcUVGSTRlVHI5R0JwazNB?oc=5",
    "date": "2024-09-27T07:00:00.000Z",
    "dateFormatted": "27/09/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Auvi-Q Untitled Letter Close-Out  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "1251cff4ae08b3b7d475d522aa409b15",
    "title": "India's Zydus hit with warning letter as FDA flags glass contamination concerns and more - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPdUJnWl9iUGV2TDhjaVVORHBacVJMdlFzMUYxQ0tYWFJucGdxNE5hQU9NTWhYNUxub21pdEpzTF9CeWMwcldpd3h1a2tyanY4U1d1VVBJSTFpNVdiU3h2QUdTOTFGMVZVUmVLS2MtYjREMTZQdWtXV3hubkRwLTh4RjdEclpDcmhST01FQ0lleVhkdkw2NzJpc0FGUjNoenVfSVp6ZWdKbDhLRVhhSERNcE9oaw?oc=5",
    "date": "2024-09-11T07:00:00.000Z",
    "dateFormatted": "11/09/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "India's Zydus hit with warning letter as FDA flags glass contamination concerns and more  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "5e44d9575afbe9deb904e2945dc66a99",
    "title": "FDA scrutiny of India’s Zydus results in warning letter - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPRXZjSjVUeGNPbmx2ZFRReEFsTXVwcF9UeU1janhzR1g1LWdaV0hMRGtoaVdUUVhUYldkdU1iekxmUU5Fd1NPeWZtOW1YVTlSWDh1NlRKZW1lb2N3YVNJMFZfRmZ5ajNmR3RfaDFYS3hNb2RsamNuMTZiRjFrQUJlMkNjVEJFNjVsWGNGMGpFMWp2RDhMRnc?oc=5",
    "date": "2024-09-03T07:00:00.000Z",
    "dateFormatted": "03/09/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "FDA scrutiny of India’s Zydus results in warning letter  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "fdec0c54d4df1ab91ada32cf85df04a2",
    "title": "Untitled Letter for Ubrelvy - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9yalJfd1ZKUUZ3cDNKbjZCdjlxb3kzZEgyWkVuLXM1UGY0UWRNS05fM2c3Zk1neXFCT1JuVDI5bllBNmJTakZSLWRvdGJQNzMyekI4?oc=5",
    "date": "2024-08-29T07:00:00.000Z",
    "dateFormatted": "29/08/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter for Ubrelvy  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "f41717ca2dd7d00148053c1daa975701",
    "title": "Untitled Letter Krazati - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9lRk91bnpySjZ5ZnJEQWlzOHNxSm9uS01BVGVrVVFuZVJhTGhVYU1XYXpCU2VrclZCcnRMZm5rSWc0aktIMHZiZ1pLWDRqNWExbXdZ?oc=5",
    "date": "2024-08-01T07:00:00.000Z",
    "dateFormatted": "01/08/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter Krazati  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "09137608b6f5221028060316d988c836",
    "title": "Untitled Letter Auvi-Q - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE12dkF5Vl9GT0NTeFhHNHNmSV9hNDZCUnBkSWlzazRBWUtVcWs0LV9KUjVlTmwzdUxkX2R2a0xUOFhZWUhXdXRQRkpsZllrblRpRHV3?oc=5",
    "date": "2024-07-17T07:00:00.000Z",
    "dateFormatted": "17/07/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter Auvi-Q  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "4e1da7877efdc329b342dd3f4b1d14d9",
    "title": "FDA Issues Warning Letters to 14 Online Retailers for Selling Unauthorized E-Cigarettes - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPdU1HSlNGLXo1dVlyX01Ub1Bqam9zNUcxc2lncU9oOWVOdkE2WXhRT3Z4eEhRQWRUU0RxUTBWbEpSUmtkRFpkRmo5LXRUT1BVRmtNRG1mOF9wSE5aLVNQYkxPNjhDYy03d2JEdlRfZ240ZkVLUGpHbHMxTEx1TEN5NEprRGFmZXIzX2p6eTZjSnU1LWE0SXEwVS15MXZHcWcxSnRTVHdnLUwyZ25SS2F0Q1hUaEFMcWRYSWJIYlR5NUlYaE1LT1N2WGNn?oc=5",
    "date": "2024-05-01T07:00:00.000Z",
    "dateFormatted": "01/05/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Issues Warning Letters to 14 Online Retailers for Selling Unauthorized E-Cigarettes  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "76aae865e33844afd984b1cb1a4dffbe",
    "title": "Import alerts, warning letters, drug recalls — why ‘pharmacy to the world’ is facing US FDA heat - ThePrint",
    "link": "https://news.google.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?oc=5",
    "date": "2024-04-23T07:00:00.000Z",
    "dateFormatted": "23/04/2024",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Import alerts, warning letters, drug recalls — why ‘pharmacy to the world’ is facing US FDA heat  ThePrint",
    "company": "TBD",
    "types": [
      "warning_letter",
      "import_alert",
      "recall"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "384be62c09a59d66d6e7c1506981f252",
    "title": "Kisqali Untitled Letter Close-Out - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBDbGloT2FuMEozdXVocG9JVzJSNU5MR2E3TDdNN1R3YjE0S1JJNEZPNTR4UlBYY2p6aWJlcUxLYTlVNkJmYk5GVnJXYjlKX0M2MU53?oc=5",
    "date": "2024-03-15T07:00:00.000Z",
    "dateFormatted": "15/03/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Kisqali Untitled Letter Close-Out  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "4b0579a6b71507b2250321866a84a60e",
    "title": "“Modernized” Food Manufacturing Enforcement: Trends in FDA Warning Letters - Food and Drug Law Institute (FDLI)",
    "link": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNdkRnbllwMnU3bWxjaWFEOEE3TV9hT19oQ2RlNkh0OTBoTzRiZG01clZsWVZfWXB1UHk2SjNOUkNUSEpBcnBJdlB1YjByU3VISlpnY1ZIYWJwMWk1bHJqeUdaQl9CeEE5Q052cXp1dkNPWGV0M09NQ0UxZjEweWtQanZZTGNVN1JtZi1SSDhHZGx3eGx6cGdOQWJhV1habmc2VUFR?oc=5",
    "date": "2024-03-08T08:00:00.000Z",
    "dateFormatted": "08/03/2024",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "“Modernized” Food Manufacturing Enforcement: Trends in FDA Warning Letters  Food and Drug Law Institute (FDLI)",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "491890649bede63c5f25b7bfe0b68780",
    "title": "FDA unleashes multiple warning letters targeting insanitary manufacturing and online sales of unapproved Mounjaro, Ozempic - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPaV9WcHBaQ09CSjBXQlpDMmJyVm9SX0hhU205NlRNUlhNNzFYR3dMcWt3OTRoLUdYd1VlVGUxclNTV1B2N0o2djVIcllXQUgxWEhvZGNsckh2ejNoeFdab1E1c3F6ZXY4UU4zcXpyUTJZUTJFSGJTc3Z0OGlTWF82Y2tOMWFRZTlwaEdDOFJuaU5lRnY4SDRTelVaVnNTX1VrZ2xaU1lDd2tLS2t6RXZMeWxab1hiT0NzcW9JdDlYSm91TlZ5?oc=5",
    "date": "2024-02-14T08:00:00.000Z",
    "dateFormatted": "14/02/2024",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA unleashes multiple warning letters targeting insanitary manufacturing and online sales of unapproved Mounjaro, Ozempic  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "899bd9b1ae0dd04c923e3f3a15fb4275",
    "title": "Issuance of Untitled Letters - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNUEVmaE1sTE92WWpYLXUxSjE1ckxTR2NMbXVVNUNKS2lzTzVVOHpoVHJ5bHpIZDFMNjNLSjI1ZTQ0dDVRbVoydlE4LW96SnVFd2oxalJnM0VGYTdQOU1VR2lGX1k5TWo3UmVUa1JGZWt1bllOcVVRbjZuVFNrUzJZeWZDc0lIbE1VYUhHTTNaOTdYODd4b2JPTE5BQk52NFpKeWV3eW1acTU1Uk1zRUMwS3huR0E2TVlOV29URTl6SFlvbjdZRWJTR0haX1gtZFhRRTZaZndBa2FWQQ?oc=5",
    "date": "2024-02-07T08:00:00.000Z",
    "dateFormatted": "07/02/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Issuance of Untitled Letters  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "8ac72e3103123bd55f98e1caf3f5bb95",
    "title": "Untitled Letter Kisqali - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1ycENkVW5IWnZVcVNjZlJ5UGJXOXp1dTkyWUxaelNrXzJsTV9xUnFENDgzNExLcmdkQUV4QlVpMVIwWmVkcTVWbmRSNDU3WnBzc0hJ?oc=5",
    "date": "2024-01-18T08:00:00.000Z",
    "dateFormatted": "18/01/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter Kisqali  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "d4a507caf32664a8f0004e014e027caa",
    "title": "Untitled Letter Close-Out Phexxi | January 2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE81dnlKMHUxSko2dFcxZkp0U3c0azd4WGVfQy1Ecmo1aXFsSWJNSkJxUDdPeW9kd3FHV1hDMHl0RGtKaXgxa2xDdUJaMHlLd2p3Rkl3?oc=5",
    "date": "2024-01-05T08:00:00.000Z",
    "dateFormatted": "05/01/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter Close-Out Phexxi | January 2024  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "b70cff01e3ccd6bd21659fd648f825ce",
    "title": "Untitled Letter Close-Out Rexulti - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBDNENpUzJxVnNRYUVhSkM1bFduRUNxXzlRVDlIY00wdWJtejJNbjBPRXlxVGcyN1YzMEhsaWhSc25xQl9oNTNKRlcxeFNQeWVHSnY4?oc=5",
    "date": "2023-12-20T08:00:00.000Z",
    "dateFormatted": "20/12/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter Close-Out Rexulti  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "284b12368b65a0b238f911956ca3c10c",
    "title": "Intas Pharmaceuticals Hit with Another FDA Warning Letter, Put on Import Alert - BioSpace",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPVVRudEJxcG1NTnJ1c2phcm5nQ3ZDcGRqXzVEeXdXclJMMy1Fendobk1WamNBNDFrZHZRQU9LNWFrRE92TWpUbEhvSS1FTWJCRW9YNFJnamZxN21xcF8tVmdkeFhuNjdyYnpUYkhSaTlTR1YzT3pWSEZnMkNuVWZvWTZsS1M0RkhnRjdjTlJiMG1WMjQ0bUxmMHUtQ05scHRONzVhaQ?oc=5",
    "date": "2023-11-30T08:00:00.000Z",
    "dateFormatted": "30/11/2023",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Intas Pharmaceuticals Hit with Another FDA Warning Letter, Put on Import Alert  BioSpace",
    "company": "TBD",
    "types": [
      "warning_letter",
      "import_alert"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "5c79efdd55de5e960040e2a04a3dcedb",
    "title": "Intas on import alert as FDA flags data manipulation, management failures in warning letter - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQLWJaYmJ6bmdjMDU1ZHl4TVU4eWxtcFZwVUhaZnQ2M1BmOEphQ1JFRE82V2NZamFNNVNPUHBNcmZvTDFHbEJkV3NKbzJBN25PTVlaZ2N6OTFZalFmYnA5ai0tcXFnVklLWEtmVjJDRDVEa19mQ2tSMkJQbkhPbmdKME02dWEzc0tfVGVZTU5HbVotTnQzc1A3T3luNkdNbjR0LWFYVnYzUjJ1U1BBZ2s1Rw?oc=5",
    "date": "2023-11-29T08:00:00.000Z",
    "dateFormatted": "29/11/2023",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Intas on import alert as FDA flags data manipulation, management failures in warning letter  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter",
      "import_alert"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "ec649b964db0fc90307d79c85239d72a",
    "title": "Untitled Letter Rexulti - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE01TkNQOFZyTXprWkVONXVtYnpiWk03TkMtMnNoUGNJZ3hxSEl6V09XTUtfczJMUFZxMFpwRHFjdFBJWnE3M3hpOVh2Nl9WZURUZjZJ?oc=5",
    "date": "2023-10-31T07:00:00.000Z",
    "dateFormatted": "31/10/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter Rexulti  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "f09cbd3f74388fa2dec3228d143c1e93",
    "title": "Untitled Letter Phexxi - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9TdV92Slg0Sm5rYVdQT2RUQk1VeWVQaWxpLURlQ0E4YURvSjF0YmVOQ1dnaF9DbnhSbEI2dzE3eXNRTDZaTW1iZ0xNXzBTeDNNTm40?oc=5",
    "date": "2023-10-31T07:00:00.000Z",
    "dateFormatted": "31/10/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter Phexxi  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "34a272a0ea3bde87475e44b0044d5d4e",
    "title": "Office of Prescription Drug Promotion Untitled Letters - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPbTF2UUdtQmpZempPSVVJZlhlS1BMMmQ4ZHdCRkpVT01KOWJ4ZEpoX00ydGxLcmJTemZTZGRzRFpMQUNaY09ZZ1FHNzFNNVBjUE92ZFNwYXNVRlNuR1pXZFQway1POGhUaTFOcDY0dElHN0Rpb250TDRsM1hidThXb1JPYXB6MmxUc0dQQ2JsY0xuR2VWT09oUG5wemJIS2FJMndUZEZqcTFodXd5YkJoSHZR?oc=5",
    "date": "2023-10-25T20:05:34.000Z",
    "dateFormatted": "25/10/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Office of Prescription Drug Promotion Untitled Letters  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "50bd028dfa44294808773d0cb7abac96",
    "title": "Warning Letters and Notice of Violation Letters to Pharmaceutical Companies - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQOWhBYlN5dHpxRS13ZXBES2QyLXVfRk90WDBxY2pjSGFBSW5Za3JJN2pVNHJORjVRdmRWTXBGLXFpOHE3WUxjU0hzOW43V04tMjFxUWRoUjBsMk1CdWVuZzhVRVd1VHZkNkZaUW5uN0o0QkszU21KMVRLVUYwaDVFLWJzNWt2c2lTa3h2eUhJQnJ0Sy1CQzVvQ0JpQWRMR1JnRWs1QmlvalhNWXp5ZHlBMFFGVy1lTGNOb1l4RUFscw?oc=5",
    "date": "2023-10-25T07:00:00.000Z",
    "dateFormatted": "25/10/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Warning Letters and Notice of Violation Letters to Pharmaceutical Companies  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "758e25c6a9aee9db8d465f39a18384e7",
    "title": "FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOc1VHNmJUR3dFN2lEMWtTeXF5eFduR1hpclZHd21OaHJVXzNKNFhucXdIS19LYng4cDNMMl9jd0pibXpleWFDc0Y4ZHJoSE1WUTBrdUYtcUpIZ1RjUU9iX3dqbEVNRDgxYWNjVDNXaHp4dk9HZmVYSjdrQUw1aUNqS0JYdmk3TnFKal9xa0NwY1gxLTNuN0xtdVJPN0ZPbzFOTTVJZVBpMEFvcFNjVVhBU2lwQUNCanVwRUE?oc=5",
    "date": "2023-09-12T07:00:00.000Z",
    "dateFormatted": "12/09/2023",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "82a69502df44fbed33e6e954baa7253a",
    "title": "Untitled Letter for Slynd - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBtUmZzU3BteEN5WktDRHJSYU5YNkMwQzIzbUQyY1lUSHhfZGtERnZFMkZVNl85cXBEUWJIR3NmYXRGQXIzeE5UM3NSUlU4LXhDdnVZ?oc=5",
    "date": "2023-08-11T07:00:00.000Z",
    "dateFormatted": "11/08/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter for Slynd  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "b2550dc88362c48849173752c1374060",
    "title": "Untitled Letter Close-Out Recorlev - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBFNk5wOW1xS2JHYVBUTFhNWFBqOHY2el9QR2tYVUx0WWtPUGdDMUZMN3hDRWMwM2FnSXdsVktrQkU3QUNZeko5bmlfcnNWQTVWcjFR?oc=5",
    "date": "2023-08-09T07:00:00.000Z",
    "dateFormatted": "09/08/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter Close-Out Recorlev  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "811036f296cf991fef16ceb2138e115a",
    "title": "Untitled Letter Recorlev - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1JY2dLc1UwLXlWakpqZUROeVEyU3BFaG9oYkNOelZOblh0eGo2S2xGNFNnaE0xdDN3Q2Y4Sm9QZW9senl4NDZ0NDBTQk9RMGRLUFQ4?oc=5",
    "date": "2023-07-06T07:00:00.000Z",
    "dateFormatted": "06/07/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter Recorlev  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "8b125b49c3537573e5a5e6fec6bc9b42",
    "title": "Sun Pharma facility under an import alert handed a warning letter - Endpoints News",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxORV8yakNTNHpLTi1La05mSEdOSFYzZkw4Q3EtUXlzcDAzdGxhTEpiRk5vbUd2WEVmYVd6N1FMdmU4RlJYT3BXdjRXTldna1k0bVphLXJObzlyTVFINldjMHI2dkFtUXdiOEJsWnNVTGxtQjlScnRaMk9HUnU4YlZOc2tnby1YWHZ6MWlwdUEwQ2lQckk?oc=5",
    "date": "2023-01-11T08:00:00.000Z",
    "dateFormatted": "11/01/2023",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Sun Pharma facility under an import alert handed a warning letter  Endpoints News",
    "company": "TBD",
    "types": [
      "warning_letter",
      "import_alert"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "95a5878d47ac402cd67aee34da475ddc",
    "title": "Mexico's Glinsa suffers warning letter and import alert after refusing FDA manufacturing inspection - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPY1NQeEVCRFFGMGdOQXg4R1E4T1pzYmFucmZFZWthX2pvY2I3RTkxQktHTlNSWHRNc2pmbGpEbmVIYUxXUjNlN0tnUFkzTUZLMXRfUDFjUENlclB6Z1hsSUhOcV9fQVlPR09iOUl6d1hoY0ZTLU9HYWVJTXNFNFRUd1ZRMTZGVDdDaXN1cFZpMkVKNDNtNjdZOHBGUUFEa2htYkNBN1BzaW82R0J0eXl3QXZjRnZpdEhFX3pKSGRCbU82N3dC?oc=5",
    "date": "2022-06-23T07:00:00.000Z",
    "dateFormatted": "23/06/2022",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Mexico's Glinsa suffers warning letter and import alert after refusing FDA manufacturing inspection  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter",
      "import_alert"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "e9cc5abb95b9115d3ec37c36d45995de",
    "title": "Untitled Letter Roszet - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE95R1JUMkZWRmxNU2QyalV1bkgxd1FXdEoyQWhxcGZDa05PUDVkMWp2VF9GVDZMcUZtLTJhY0gweF9tRm9iZm1pU281QUxod3ZrOFJF?oc=5",
    "date": "2022-06-02T07:00:00.000Z",
    "dateFormatted": "02/06/2022",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter Roszet  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "40ae9925125820f4b96a45e9b4955592",
    "title": "Untitled Letter DUOBRII - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9yeUFKQVhWNzItMUZyV0lmUkhOM2s5dTVNdGxmTW5qSWM2NE9lSFB5ZVl5RUVIZGZQdkE3WjFua1dIS1daRG5XTG5EX1RzQXdYclBJ?oc=5",
    "date": "2022-03-31T07:00:00.000Z",
    "dateFormatted": "31/03/2022",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter DUOBRII  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "b112ba5be88004510dc253c9572d949d",
    "title": "Untitled Letter | NEULASTA® (pegfilgrastim) injection, for subcutaneous use - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9jT1pjaC1aWVJPSS1FdEQ3SU9aejhsdDJuTGlXRy1ESFBDUWhVSWVhWHdUZEZHTmdsbzRFQnRLMEdEcnp4RTdMWmljX0tlc3k3ZEI4?oc=5",
    "date": "2022-01-11T08:00:00.000Z",
    "dateFormatted": "11/01/2022",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter | NEULASTA® (pegfilgrastim) injection, for subcutaneous use  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "62713487c1ac1c4311d7f916befe1c45",
    "title": "RESPONSE TO UNTITLED LETTER | EMGALITY - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBlbzNtdXNnZEJLaWlwNnVWVXBWSTd2TlRaa2w3eUpFbzJDazVvNzJEMlJZcmZyTHFtT09ybDVrQUJnbGRKX0kxQklzeXd3UFVrWTgw?oc=5",
    "date": "2021-12-21T08:00:00.000Z",
    "dateFormatted": "21/12/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "RESPONSE TO UNTITLED LETTER | EMGALITY  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "8eb521347cedfadbf16efca6acea79db",
    "title": "Emgality Untitled Letter - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBfN0szeDVZTG1TRXNKa2FhRTJkUFhhTnhmejFKa1Y1NjhYMzZRUnJ5TmI1NFR4MXM3UWxad0R5TW9VM2UyUU1fUW04Z0JtUFNJUlNV?oc=5",
    "date": "2021-12-13T08:00:00.000Z",
    "dateFormatted": "13/12/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Emgality Untitled Letter  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "1a35fd1deb63f1a3090c1734812d2e23",
    "title": "Untitled Letter | NURTEC ODT (rimegepant) orally disintegrating tablets, for sublingual or oral use - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5DWWhZUVQ2cldOTDdFb2tKRUl1TkhrUmdteHYwYTJIdGhzRjJXMHhNUmMzZ3ZVY3laOGppYnVqZlZWdWdNR1VNaGpmazB5Q1J1V3pR?oc=5",
    "date": "2021-11-19T08:00:00.000Z",
    "dateFormatted": "19/11/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter | NURTEC ODT (rimegepant) orally disintegrating tablets, for sublingual or oral use  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "257337a645431dc9db793aaca9ee18fa",
    "title": "After triggering a global valsartan recall 3 years ago, Chinese drug manufacturer overcomes FDA warning letter - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNTktObVVMQXZ2QlMwWVlVNFBPakZkSEVwTDMtaVFPalBrQVA1dDhfSHpobnVMWG1JcFRCSXJubkFFRUtQb2R6UFEtaEJXLUVodnRySENkNXVvNjAteUg0NUhldmVDN3h4NlowTm5PbmxkYTlRS0dIUmlGTjA3RU90Y0tSWEtEaGN1LWsxSHJPaXBkbHZ2WmRmZzAzd0FHaTJ5X3BXeE1XQnpQV0IxbnRlb0xIdHdLa2gwRm5vaG9uMlptZU4t?oc=5",
    "date": "2021-11-15T08:00:00.000Z",
    "dateFormatted": "15/11/2021",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "After triggering a global valsartan recall 3 years ago, Chinese drug manufacturer overcomes FDA warning letter  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter",
      "recall"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "b144e7a3a44d2fe8196e1e02659363d1",
    "title": "Untitled Letter | ALKINDI® SPRINKLE (hydrocortisone) oral granules - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBtX3doR00zQVlRWGVTLS1mRXNMTDlIZWJSZ1p3RWdLS3RiU2JkLXphQjB0VFhTeWYzZEVSTlNtd29NTjJ6WExqMFpDYUFRRmlDVVdz?oc=5",
    "date": "2021-10-04T07:00:00.000Z",
    "dateFormatted": "04/10/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled Letter | ALKINDI® SPRINKLE (hydrocortisone) oral granules  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "cd89d143cd92e44d34afac07ab6fa8cb",
    "title": "FDA warning letters detail violations at China, Mexico drugmakers already under import alert - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPdG5panZOR0dXUjZrbUh4VjM1c01NNnB2NzNvdHZzMWdiOXVHQm5tQVdJMWlneFJTSHAxUHppQU9mSWhQNlc5SEtTOERuMGo2Y0dORmRoYXBTMl9yNGMxaGt6bm1YNVBJN2RoeEpjc2RzNlBocmJlODZrOGpnYmdNSzAxUVFvMTd4UlpFeHBMem02SGxQS2hqbEdfb1NxaTJZTmNrSWVLOA?oc=5",
    "date": "2021-03-17T07:00:00.000Z",
    "dateFormatted": "17/03/2021",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA warning letters detail violations at China, Mexico drugmakers already under import alert  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter",
      "import_alert"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "bb03a712d54fae0e693ea85b361fec9e",
    "title": "WARNING LETTER - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBYTFRCbFBpYnp2c0JLSDhwRThuajFFZjF3Z0ZtTDl3Si1TM3k1RW9VdDhQcUQ4Q1ZYRDRyd0lqZ1JYdjZyenU0aFZpOWV5VEc2c05F?oc=5",
    "date": "2020-09-22T07:00:00.000Z",
    "dateFormatted": "22/09/2020",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "WARNING LETTER  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "3d69d5327aff419b3b790eccf23edb50",
    "title": "WARNING LETTER - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFA3eGJVXzVDSGxHclRKYTRqRDFqY1dVZE8wcEJTb1FIWW5QSmYybTNJam9vUjRKOUNjaVluRlRYeXlQSHBkNmVOTG94OFZJVnoyTTJF?oc=5",
    "date": "2019-08-16T07:00:00.000Z",
    "dateFormatted": "16/08/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "WARNING LETTER  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "c2bbdb5879256ed9ecd4676ff328f27e",
    "title": "An Analysis Of FDA FY2018 Drug GMP Warning Letters - Pharmaceutical Online",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNQV9IQVAxQWhXZnh3ZUN3cWl0aFlWZjNIN3ZmRmNfRVExM0R6U0lWbEk5R3A4OU1sN1BrWDdYazdnLXoxb19tTmJRdWtKUENVLWNnM2JiVXJYbmRRMGV5MFFFYVhFcEVJNGNlSGhMWXZVTVBxTG9fZHVyWERxb1EzNEE3aER1VkRtdnNkbldxdU1fdTNrVGJz?oc=5",
    "date": "2019-02-01T08:00:00.000Z",
    "dateFormatted": "01/02/2019",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "An Analysis Of FDA FY2018 Drug GMP Warning Letters  Pharmaceutical Online",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "4acc52494343f22963a3d1950a121b4f",
    "title": "Dear Dr. Woodcock, I am writing to bring to your attention a Warning Letter that Vanda received from the FDA on October 22, whic - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE51ZFIybzZCOG0tY3oyWVZrTGpDbEhkODNncUNYYXI0dWU4bDI5TnZYMzFYQjh0eWlNNEV2Y0lGMVUzZ2JTYUVkczE5RTJjM0NGMWtB?oc=5",
    "date": "2018-10-22T07:00:00.000Z",
    "dateFormatted": "22/10/2018",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Dear Dr. Woodcock, I am writing to bring to your attention a Warning Letter that Vanda received from the FDA on October 22, whic  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "99871369968fe8065921fd20ccab3484",
    "title": "WARNING LETTER - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE10aThhZ3k1N3pKUE9xd1JhazU2dUNaQmlLamxmeWFmZGZKeFZCbGFNYzVYOVJUSFAtVlV3LTI3ZThaejBfYTVMS1hrRnl5ODF0Qzkw?oc=5",
    "date": "2018-10-22T07:00:00.000Z",
    "dateFormatted": "22/10/2018",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "WARNING LETTER  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "ca0d8d21914a08a103dfee4f13fdb317",
    "title": "WARNING LETTER - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE50czRfM05aa2dzMmluM3E0ZVg3T0cyaGppcFczeEZRalVrVWEtN2RlSkJEblFmVGRrTkdjTXlLbURkMXFXcG5BUlN4WUNsMTdVTXEw?oc=5",
    "date": "2018-10-05T07:00:00.000Z",
    "dateFormatted": "05/10/2018",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "WARNING LETTER  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "85db6ac8b28a951100b9abb829733ebf",
    "title": "FDA warning letter tells India's Goran Pharma to get professional help - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOcnVvdlRNOGt2dV9pa1lvS0VvT1VIQ1U2OVhXMFRUV3J6ZWJsS2RsbUdXcVo3MkNGVndBa3JCc0g5UHJrUzR0czg4TTRLRkhRbVRRSkJaN1RZVTJ2RDVvZ2JURFVRZ1NfZ0xvMDJGTjJhMkw2QnkybFNWbWN5UlhTS1hSSmstMDU2anQzQVBMYnBxYmQteEFLTWR4TndNNWd1Sk1HWDRDVlJLaW1sano2MkxHUQ?oc=5",
    "date": "2018-05-10T07:00:00.000Z",
    "dateFormatted": "10/05/2018",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA warning letter tells India's Goran Pharma to get professional help  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "c6d5a7b95604fbab2d837876a139605a",
    "title": "FDA hits Dominican Republic drug manufacturing plant with warning letter - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxONF8yZEliV1J5b1EwNm1ISjc5YUF4VjhSTVdURFdKaDkySEZManc2Um5ic2g1R2ppU2ZTUkUtenlDWlFBemxOYWNDNDJHV0NnSTJxTm13NTZvdUhQRURleko0em9YaDdCWGU3aDNYSkdsWl9WdWJEcnBuQ3lfbWFHWHFNaUJGX0UtWjFnekNmRzg2dWN2U0dhd3hNWVVRS0JrZGZibk1CbFN5S0tmbnJj?oc=5",
    "date": "2018-04-03T07:00:00.000Z",
    "dateFormatted": "03/04/2018",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA hits Dominican Republic drug manufacturing plant with warning letter  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "d2ce75a55016dea35526ba7626316853",
    "title": "February 27, 2018 Untitled Letter - IDELVION - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPTU1UV1RVdjlHbENseVIwTXJKdnBHTEtpM1FTUWp1cUd6OVR6d2k5Xzl0RV9FM2xZdEtDT0d6SjBGdEFTbkNWUkxYYU9DdWdQRDdqdFVWamFRWDdYa3VHeWVueGdsNjZrR3RmM05aZk81ck1HOHlGbEFxTmt4UjJOR0N4dVBTSGR6TWVnOWdyU0dJbUxJdUJyRVdFSHJzSVJHamxNMS14cVp3NWRNVFA4c2h4ZEZLMVIxc0Nsb2VOdw?oc=5",
    "date": "2018-02-27T08:00:00.000Z",
    "dateFormatted": "27/02/2018",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "February 27, 2018 Untitled Letter - IDELVION  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "998646e8a54de30419a4145d5c3920f2",
    "title": "Lost in translation, FDA slaps Chinese drugmaker with warning letter for mixing up APIs - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPbXdmN25YWDA2MURzYkhXMFNNS2YxVWRBdkZxQzBHb19oRWxHRklyQ2lJT1NwSXFvZVM3ZWtoTmNHMjc1SUJaTGZUWl9IOHYtLVZrZW9MZ1FPQXVXWVgwMEtSSFBsVXpBODhpcl9TWG1MejA5TXBjNV9WMnMyOXYyNDlBOXVabEpMU3RQVXl3dmktM1VYYVIxank2LS1EX0tvQVJHOEhGWVR6OWRmMExKbDNNUXZJRUdvRS1KVFVn?oc=5",
    "date": "2017-11-08T08:00:00.000Z",
    "dateFormatted": "08/11/2017",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Lost in translation, FDA slaps Chinese drugmaker with warning letter for mixing up APIs  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "07fa321faf914fe474bcc3cccdca5ce4",
    "title": "South Korean drugmaker slapped with FDA warning letter, import alert - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNUFc1MzVUdUdrNk5Ud3hFMG5qTjhrdW1uMjlocWRleTZydExIU1RidmRqM21ibjFwUkh1VG5DRXNGYzF1MUh5UmhIZTZrYnBKUEEyaGFidHExZUlTVDNNdVFJWllMZnVMQlBYTEZIbWowaGw5bjJjU2RyNVZMQkJIWUItTFV5MUdTY3hrc1dYS05BRVdXRDRHbTFfcU5iTEVldHl3bzA3MkE?oc=5",
    "date": "2017-09-21T07:00:00.000Z",
    "dateFormatted": "21/09/2017",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "South Korean drugmaker slapped with FDA warning letter, import alert  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter",
      "import_alert"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "f05ce8c1e08e2cd9c986bc9e308b7929",
    "title": "Orexigen Therapeutics, Inc. (Contrave) Untitled Letter 5/18/2017 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPQ3JlRXQ1eG9BcWp1RG5iR0h1aW11blJvMkRGXzI1ZWJNZ2RCd1N0bTlwSVpCVHpISUVEWExwRWNpN013NFdIbk1MTWRxVDM0ODBHbGlQUjhMeU1YazFWdFk5d2FxbmZOYnM4NjhCOFU1dXJTVUJmODFfYzZtYXE4cUVvbVNQb3hYMTRiV2VTUUlMV1M4Mkx4WVItQzVJNndxd3B2NkY1TUY2NGZYNEFid2dfdFdMOHNJSnM5R28tdG5QUURHVkFYbTBiUmtWZllkRTBSZTZoODJtdEZZT2xzelZtQjNSVm9yeVE?oc=5",
    "date": "2017-05-23T07:00:00.000Z",
    "dateFormatted": "23/05/2017",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Orexigen Therapeutics, Inc. (Contrave) Untitled Letter 5/18/2017  fda.gov",
    "company": "TBD",
    "types": [
      "warning_letter",
      "opdp"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "342d410d0e0018715fc8aedf2ffd8351",
    "title": "Import ban extended as India's Pan Pharma racks up third FDA warning letter - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQS0RQc0FMZm5LYmRKa1dqV1ZPbVJINmxJUGVVX0w1cWJRbFVLcXZJOF9oclcwd3pZNFRZaWFtRGxVd1ZFeGM4azFaLVNKZzFkcmpjODJ6cnVaMGc4RGpFRlRuUlZGSDRhX2k2cFk1Z2hPNndCVjNxRzR5SEg3bVI4RTRoZklNbUxDWTMxZWx6QmpLblcxUXFnclg1Z3BkVkxtR095T2ZyblJpOGs?oc=5",
    "date": "2016-09-07T07:00:00.000Z",
    "dateFormatted": "07/09/2016",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Import ban extended as India's Pan Pharma racks up third FDA warning letter  Fierce Pharma",
    "company": "TBD",
    "types": [
      "warning_letter",
      "import_alert"
    ],
    "severity": 8,
    "priority": 3
  },
  {
    "id": "2545a5914e74ecd3baaf506dfac523e6",
    "title": "Middlefield Original Cheese Co-Op Recalls Organic Gouda, Colored Cheddar, Mozzarella/Provolone, Pepper Jack, Swiss, Dilly Pickle Cheese and Monterey Jack Due to Possible Listeria Monocytogenes Contamination - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxPTlZacnRpbENfWnFmNzdyU3JFY2lUTXpELUJiQlA0UUh4RC1vbEZPeTM5NXRxYlo5U1RxcG9WQTJKR3FfaFpfSmdveTJfcHJNUm42OTU3VEFxSTRLLTdEWUZPQmx2ejUweG5ETUhzQ01RM2VsOURndG5fWTVGVEFtRllaWmxOSk52cWIxRU9lbHktRnl0dDk2UnUzVFVWSXVYcW1IcG1mbEpUUWJ1VmdkN1VSTldRdzM5WGxCVmR1YXRMWnEzZ3puQktqVHBMRkg3cVp6eXRmRHpBSDBGTE1FTzhwMXJXUTVvRlpyVjRmaERDY3V0bWcwQmxB?oc=5",
    "date": "2025-09-05T15:48:00.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Middlefield Original Cheese Co-Op Recalls Organic Gouda, Colored Cheddar, Mozzarella/Provolone, Pepper Jack, Swiss, Dilly Pickle Cheese and Monterey Jack Due to Possible Listeria Monocytogenes Contamination  fda.gov",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "96f4c2ab7a6828081e9650a98ad6952f",
    "title": "FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-launches-green-list-protect-americans-illegal-imported-glp-1-drug-ingredients",
    "date": "2025-09-05T15:05:29.000Z",
    "dateFormatted": "05/09/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "The U.S. Food and Drug Administration today established a “green list” import alert to help stop potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the U.S. market.",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 1
  },
  {
    "id": "637be30f9b33fb1b5073dc055211f42d",
    "title": "Endico Potatoes Inc. Recalls 2.5lb Bags of Frozen “Peas And Carrots” and “Mixed Vegetables” Because of Possible Health Risk - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxPeVU5TjBJMEMwSlUxLU5xODJHZDU1RlJyVjVZRFA4Z0hVZ3NBNUhOOVNXbXJaM3ladTFpS1h0UDJJWXdOakx1RThaVnhPeEcwbDBoUjAtLXY4aXBKTHVuSDYtU2tTMnlsUDgtMUxxWjVsVVlLUTc1UURzSERDR3piNGY3dFVFWEtyNVJucXkybzd4c3lyWk10b1ZwdFFOUm1aYlhjZnZVZ041dzdVTkdiZnVaYXc1dVFGaG9fUUFkRVJNNEJTRmNJb2hvVzBmRnlNa1Z1WXBTUi1JRllaRXZyQnUtcHZPdWhqT0xtaHc2N2VkcHBmSldXYk1aUQ?oc=5",
    "date": "2025-09-03T15:26:00.000Z",
    "dateFormatted": "03/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Endico Potatoes Inc. Recalls 2.5lb Bags of Frozen “Peas And Carrots” and “Mixed Vegetables” Because of Possible Health Risk  fda.gov",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "71057f70e45f3dacac6a3120a66b3c72",
    "title": "Breathing Circuit Set Recall: Hamilton Medical, Inc. Removes Coaxial Breathing Circuit Set Due to Possible Inner Blue Tube Cracks That May Impact Ventilation",
    "link": "http://www.fda.gov/medical-devices/medical-device-recalls/breathing-circuit-set-recall-hamilton-medical-inc-removes-coaxial-breathing-circuit-set-due-possible",
    "date": "2025-08-29T04:00:00.000Z",
    "dateFormatted": "29/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "Hamilton Medical is recalling certain coaxial breathing sets due to a defect that may cause cracks in the inner tube, risking patient rebreathing exhaled gases.",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 1
  },
  {
    "id": "d18b6f73370993e58b6d60e207236591",
    "title": "Manual Resuscitator Recall: Ambu Inc. Removes SPUR II Resuscitators Due to Blocked Manometer Port",
    "link": "http://www.fda.gov/medical-devices/medical-device-recalls/manual-resuscitator-recall-ambu-inc-removes-spur-ii-resuscitators-due-blocked-manometer-port",
    "date": "2025-08-29T04:00:00.000Z",
    "dateFormatted": "29/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "A blocked manometer port on the Ambu SPUR II resuscitator may delay ventilation or cause barotrauma",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 1
  },
  {
    "id": "66f40e048c939af23daeca4bd43b8a38",
    "title": "Mobile Power Unit AC Power Cord Recall: Abbott Medical Removes AC Power Cord Associated with HeartMate Mobile Power Unit (MPU) Due to Potential Risk of the Cord Not Locking into Place",
    "link": "http://www.fda.gov/medical-devices/medical-device-recalls/mobile-power-unit-ac-power-cord-recall-abbott-medical-removes-ac-power-cord-associated-heartmate",
    "date": "2025-08-29T04:00:00.000Z",
    "dateFormatted": "29/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "Abbott Medical is removing power cords associated with the HeartMate Mobile Power Unit due to a potential risk of the cord not locking into place.",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 1
  },
  {
    "id": "e53ac245e8e2c8dbd4f4a9c75abe2ecf",
    "title": "Aquastar (USA) Corp Recalls Cocktail Shrimp 6oz Because of Possible Health Risk - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNNnhHdnpSV0hRYlVld1pnYW5MSDJUVDB3VjdhM3FFeGd3Q1djcVlXRjBSMUNQcmtJZTR3a0R0YWNtWEZHX3V6NFVVdnBQczZnU3NZYTE1UHY2RU9ZOGZUenRxd0g3UDJSVUg4Yk1rcEtpbTgwOGNmeVVVdzNjMGVDb25zYWF6dUlXRDktRjl1NXVfZ2pMdVFGVExtcjY0MzBFQ1hDZzhiQ3pnQzlObnJxcFl1N2FpT3R4YXJ6N2IwMlRmRVVWRFYzRXNBTEYxSG55c0Z4cW9VU1pmQQ?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Aquastar (USA) Corp Recalls Cocktail Shrimp 6oz Because of Possible Health Risk  fda.gov",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "806f6af18543f419346ddefc7a72b9ab",
    "title": "Applicator Recall: Integra LifeSciences Removes Extended Tip Applicator Due to Potential Sterility and Endotoxin Concerns",
    "link": "http://www.fda.gov/medical-devices/medical-device-recalls/applicator-recall-integra-lifesciences-removes-extended-tip-applicator-due-potential-sterility-and",
    "date": "2025-08-28T04:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "Extended Tip Applicator recall due to potential non-sterile product and high endotoxin levels. May cause inflammation or infection if used.",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 1
  },
  {
    "id": "8039ff673c4e51aa820add8d138b1dcd",
    "title": "DermaRite Industries Expands Voluntary Nationwide Recall Due to Potential  Burkholderia cepacia Contamination",
    "link": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dermarite-industries-expands-voluntary-nationwide-recall-due-potential-burkholderia-cepacia",
    "date": "2025-08-28T04:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "DermaRite Industries, LLC is expanding the voluntary recall initiated on July 16, due to potential microbial contamination identified as Burkholderia cepacia complex. Out of an abundance of caution the voluntary recall has expanded to include additional products and lots, which can be found in the t",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 1
  },
  {
    "id": "e85c2cf6fa83513b94378c86c93668cb",
    "title": "DermaRite Industries Expands Voluntary Nationwide Recall Due to Potential Burkholderia cepacia Contamination - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQcDlSOTY4Tk13MVJyQTJkQjdrM041bmU5OXdPOHhLY0llbkNUc0lSMUVOYmpRRWFRTjFLLUV2UFlaNERZTEdSVnpVZ0tyNnA2WXI2eVJHQ0JUMWNydzdPTU5ZU0Q3UUZ2aDIwbTQ3QUFyRVZzLVJDZDZiMG55TFJUZ1VOdndZN2l6R3BBaUJLb25CZ0NVcVNzSHQyWGlvbW82RDI1OUduY0pLRlhhMVprMnpLVHAzNy0wUXpwSG9Vdl8xc081QlZqZnlCSzdIM21ZOHEzMFZsU3lZVUFkT2l4V3hXX3lqeE9INEtjb09zMnU?oc=5",
    "date": "2025-08-27T07:00:00.000Z",
    "dateFormatted": "27/08/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "DermaRite Industries Expands Voluntary Nationwide Recall Due to Potential Burkholderia cepacia Contamination  fda.gov",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "18faacbbd9f22430cb82b24e0c32448d",
    "title": "Unichem Pharmaceuticals (USA) Inc. Issues Voluntary Nationwide Recall of Cyclobenzaprine Hydrochloride Tablets USP 10 mg, Due to Mislabeling",
    "link": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/unichem-pharmaceuticals-usa-inc-issues-voluntary-nationwide-recall-cyclobenzaprine-hydrochloride",
    "date": "2025-08-27T04:00:00.000Z",
    "dateFormatted": "27/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "08/27/2025– East Brunswick, NJ, Unichem Pharmaceuticals (USA), Inc. is voluntarily recalling one (1) lot of Cyclobenzaprine Hydrochloride Tablets USP 10 mg, to the consumer level. The Cyclobenzaprine 10mg (90ct) label was inadvertently placed on a bottle containing Meloxicam",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 1
  },
  {
    "id": "db74d0aebb6d3cdb9a87d1ec869def22",
    "title": "Vascular Stent Recall: Boston Scientific Removes Carotid WALLSTENT Monorail Endoprosthesis Due to Risk of Resistance During Device Withdrawal",
    "link": "http://www.fda.gov/medical-devices/medical-device-recalls/vascular-stent-recall-boston-scientific-removes-carotid-wallstent-monorail-endoprosthesis-due-risk",
    "date": "2025-08-22T04:00:00.000Z",
    "dateFormatted": "22/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "Boston Scientific Removes Carotid WALLSTENT Monorail Endoprosthesis due to risk of resistance during device withdrawal",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 1
  },
  {
    "id": "cbb053f21fd8abdb5d6ae36433b92450",
    "title": "Southwind Foods, LLC Recalls Frozen Shrimp Because of Possible Health Risk - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNMGxUMk9TMnF4ZkpRQmE2eTl3eXJlTjYxWWc3V2NrOUI4QWpneGRUczV3WF9oYWVYSlZyREt0OW81Mm5LWlo3dHBUUGhPTjROWlRLVTNFbk5wYk55Y3NyM3dGYWs2Y09Jc0VwVFp6RDR2OGNYRnNaaG5SenBRMWpFSmRWMGppcW9fX1k2akVsTW1za0VGVkRONEFyR2RpVm1NdXNDNEpyM0U2WVNjcDFrVFB3NUtBN2hHYmpXdUhoQ0x6US13TzdWenBVN2NXeUNjRkdqTw?oc=5",
    "date": "2025-08-21T07:00:00.000Z",
    "dateFormatted": "21/08/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Southwind Foods, LLC Recalls Frozen Shrimp Because of Possible Health Risk  fda.gov",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "1ca31494f98ecfeaf668883c6faca195",
    "title": "B. Braun Medical Issues Voluntary Nationwide Recall of Lactated Ringer’s Injection USP 1000 mL and 0.9% Sodium Chloride Injection USP 1000 mL Due to the Presence of Particulate Matter",
    "link": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/b-braun-medical-issues-voluntary-nationwide-recall-lactated-ringers-injection-usp-1000-ml-and-09",
    "date": "2025-08-19T04:00:00.000Z",
    "dateFormatted": "19/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "For Immediate Release - BETHLEHEM, PA – August 19, 2025 – B. Braun Medical Inc. (B. Braun) is voluntarily recalling two lots of Lactated Ringers Injection USP 1000 mL,and 0.9% Sodium Chloride Injection USP 1000 mL to the hospital level due to the presence of particulate matter inside the container.",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 1
  },
  {
    "id": "6e82692d9d4f43f51911ccb8cb5e26d5",
    "title": "Early Alert: Cardiac Cannula Issue from Medtronic",
    "link": "http://www.fda.gov/medical-devices/medical-device-recalls/early-alert-cardiac-cannula-issue-medtronic",
    "date": "2025-08-15T04:00:00.000Z",
    "dateFormatted": "15/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 1
  },
  {
    "id": "732e5e4a2b03094d63f27064c1c10adb",
    "title": "Breathing System Filters Recall: Draeger Removes SafeStar and TwinStar Filters Due to Risk of Misleading Carbon Dioxide (CO₂) Readings",
    "link": "http://www.fda.gov/medical-devices/medical-device-recalls/breathing-system-filters-recall-draeger-removes-safestar-and-twinstar-filters-due-risk-misleading",
    "date": "2025-08-12T04:00:00.000Z",
    "dateFormatted": "12/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "Draeger recalls SafeStar, TwinStar filters due to misleading carbon dioxide waveforms, may result in unnecessary treatment, potentially causing harm or death",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 1
  },
  {
    "id": "2779230254b44ac1beae00f7ff9b2125",
    "title": "Max Mobility / Permobil Announces Worldwide Expanded Recall and Removal of all SpeedControl Dials from the Market Due to Intermittent Cable Connection Concerns of the Dial with the SmartDrive MX2+ Motor. Users Must Use an Alternate Control Method for their SmartDrive MX2+ Power Assist Device. ",
    "link": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/max-mobility-permobil-announces-worldwide-expanded-recall-and-removal-all-speedcontrol-dials-market",
    "date": "2025-08-12T04:00:00.000Z",
    "dateFormatted": "12/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "Max Mobility/Permobil has voluntarily expanded its recall of the SpeedControl Dial, a wired control option for the SmartDrive MX2+ Power Assist Device, due to safety and performance concerns. This voluntary action applies to all SpeedControl Dials manufactured and distributed between the dates of Ap",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 1
  },
  {
    "id": "f7dc8e0228ad2f2f18fee53e37665bd0",
    "title": "DermaRite Industries Issues Voluntary Nationwide Recall of DermaKleen, Dermasarra, Kleenfoam, and Perigiene Products Due to Burkholderia cepacia Contamination",
    "link": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dermarite-industries-issues-voluntary-nationwide-recall-dermakleen-dermasarra-kleenfoam-and",
    "date": "2025-08-09T04:00:00.000Z",
    "dateFormatted": "09/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "DermaRite Industries, LLC is voluntarily recalling individual lots of products in the table below due to microbial contamination identified as Burkholderia cepecia.",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 1
  },
  {
    "id": "56b6a5211e193902c32c0ddd4fc02ee3",
    "title": "FDA puts two Chinese API makers on import alert after failed inspections - Endpoints News",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNb3gtX0daUzZFT3M3cWFEMjd4YmthbThjWHk3T0p2SXk1NXpLTnZFc19OR3lBSG5XR3B2TmtrbldER0w2ckVqdlc0ZEFxQjFGdkhoOWduWG9IWjdqSkJfZmZoc2p0VXV6ckJ3cmRFTDByY2NYczhmdUpKbEQ5OFY5NV83bWp1WEtsTFduVmhLOHBlNG5PSUpTMk12bHM?oc=5",
    "date": "2025-02-11T08:00:00.000Z",
    "dateFormatted": "11/02/2025",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA puts two Chinese API makers on import alert after failed inspections  Endpoints News",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "b1b2ded86b0620df9c5e06444bec64f8",
    "title": "Another Disappointing Drug Import Alert from India - The People's Pharmacy",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPMnZ3QTI4ZG5mdy0wd194QXU3TkZYeFVkTlNWc2xIOVNFLXQzOFU0UGFXWFRBTE81TDl5S1B6WWV1RjgtU0k0VXpuTmg0b2l6bFNaUFEyc00weUFPZkdjOXo1cmpwRWRuM2FWRjJ6enBjZ1UwNE9Tb25leFpSRWFORHk3Sk9SZlVrYVBqbjNjb3daYmJNb1E?oc=5",
    "date": "2025-01-13T08:00:00.000Z",
    "dateFormatted": "13/01/2025",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Another Disappointing Drug Import Alert from India  The People's Pharmacy",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "a17a9fb57dbf0515bb431e2b294d2011",
    "title": "Rx Import Alert: CVS Branded Generic Drugs Singled Out In Bloomberg Report For Most Recalls - Coalition For A Prosperous America",
    "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQSkpGOG5oUF9MNUZ0akJ4MjNiRGFNOUZjUTk5WGxTY0I2SWU5eDJYVkY1TzZxenQxWmhfZ1NJcmRFZmw0bGVEdGlwckxTcmN5YW8yZlpZaWw0U0lQZm9yUFBLWDhQY1hWd085bDVlRFowSlNFVW0zUDFUOGFDbGFZdjdwM0tyTVFhSUZMMmlRVTFqaXdYcVBBUVRLb2twQS0zSm9XeHd6OGNRc2xYak1PZE9WNVE4UlYxcFZZQVpR?oc=5",
    "date": "2024-06-13T07:00:00.000Z",
    "dateFormatted": "13/06/2024",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Rx Import Alert: CVS Branded Generic Drugs Singled Out In Bloomberg Report For Most Recalls  Coalition For A Prosperous America",
    "company": "TBD",
    "types": [
      "import_alert",
      "recall"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "a9d5dcdaf6b5308ed76f8adb7ae4564a",
    "title": "FDA issues import alert, additional recommendations against using plastic syringes made in China - American Hospital Association",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOelVWVDlETVIwU1pMbnR4YklmeVBMdVpFbnk2bTQ1b3VySjZuVUR3S3QyWlR3eFJVT1ZoRkhMZFRNOEI0aXpzTXhiMDhvc2l4anFuc2dQYW1FU1ItQTh1aVFFYnIzeEtWWFNJVElhLXIzeU5DandPWUpTT2FzZGU2OWpFQjVJY1FncF9MeXVFTXctM2NJeDhMcVhya0tpMzBaREdyUUUwOG9rMkp0QnZiRGg3LXlndC1vNmlNZkdRTXRubjFBTnBOSkRTdHlrLXNPbmlF?oc=5",
    "date": "2024-05-17T07:00:00.000Z",
    "dateFormatted": "17/05/2024",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA issues import alert, additional recommendations against using plastic syringes made in China  American Hospital Association",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "d21f36281ec1d6f181d016358da4e64e",
    "title": "FDA issues import alerts against 2 more plastic syringe manufacturers - MedTech Dive",
    "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQQ1h3Y2lyczZScFdHa19neURiS1AtcGpYdjE2Z2QwekRYd0cxanl2VzdvdXo4MEFwdHg0Y0J6eWtQZnFwSTRISjlEWl85d1IwN1BtUFVBTjlCR01ZQ1E3bzM1aVJtVHJFWnRGanQxbU15RmU2Q053ZnNpRk5idmV5bUhiUTRKaE91X0haYVBuY2MtZUhWTjVLWXV3?oc=5",
    "date": "2024-05-17T07:00:00.000Z",
    "dateFormatted": "17/05/2024",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA issues import alerts against 2 more plastic syringe manufacturers  MedTech Dive",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "f14ae827462fa6cacfbaa6528d43c852",
    "title": "FDA expands import alert to block all plastic syringes from Chinese manufacturer - MedTech Dive",
    "link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNaUh0NmljV2M1R21qeDFaQ0gtbWRUbzlxZmZFSWdaVW1fZU40TTduWWwwM3p2QTF0Q2ZfUDBTb1lQSGQ1ZzJHdWVvclItcVkyTDlHLUFGU1NlVm1jajF4MHhySzgxNzhJVzNER09UREdvdG9ZY203ZXFuT0J4Q05Xdm00Vy1rT0pueENQT3BXM0w?oc=5",
    "date": "2024-04-11T07:00:00.000Z",
    "dateFormatted": "11/04/2024",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA expands import alert to block all plastic syringes from Chinese manufacturer  MedTech Dive",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "4033efc232e3c11cbbb26de47d91427f",
    "title": "Ipca Labs undergoes crucial US FDA inspection at Ratlam facility amid import alert - CNBC TV18",
    "link": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPWlc5dDVhOUdZQkMwMUFTZmI1d2ZpdVZWWEhwaGU4NEZ0d3N5TGVoYkZ1ZDVnNHNPQWhjVDNZYUNNcFRHckhYekstTkFfNnlULUdHSnNxT2NTUVUyZ3RDRDhpMUdzWDAxdllFY28yUGpCUUx4M04wVTB5TlhvQXlmQ01CbW9tY092MHdZeW9pLWFFbVVyYlcyUFRLcTRoQk1pQ0dJLXhaWnJ2cGRKWWptX3RVSTZBNHM4ek5udXB3MUxwN21RdElMMU0wNjIyVDAwRUJJNHdn0gHbAUFVX3lxTFBYejZ5Nzc3QWtkeWlUNHVrTklkeWc0dFBQT2daaVg3Ql9ZQUR1ZFByejhMVDlnOF9SOEZUNjVKSVFJclRnQWlfVVlXVkdvRGl2NkJva2NZcGdmWmlkQlItZlg4UnpXVlk0U09KV3gzcTc0el9JWUJQWkc0X1FiUkZrV1JYR0QtdF9peHRwYUZ0VHpWam15MnVhOGNfYTZqRzlPNWtEb292ZUIzamhQUjNDb1g3T2l6bjFhMGpNLTlsa0Rfc2cxcVg1N1o4OFJPMzNzTW9sU3FfWE9lNA?oc=5",
    "date": "2023-06-06T07:00:00.000Z",
    "dateFormatted": "06/06/2023",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Ipca Labs undergoes crucial US FDA inspection at Ratlam facility amid import alert  CNBC TV18",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "0e75162b623a767703a0b9fd6e5999e6",
    "title": "India’s Intas gets more bad news from FDA with an import alert - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOeUJ0LXhfRWozMXJhMndnZG54Y0wxYXFBZm1ZeDh1MnFTR0hETm1mNFdqdTJtNzc1V2VWa3h4NHRPR05XUVBBZC1STlhsUmxNZFNJYmxveFF0bEdaZHNtaFJvaExYM1Y4R21JbnAzdVRQQWVzQTlUSno0VmxiU0FOQ0JnSGFJczVWandGMjFGZ3VwRF9WSUE?oc=5",
    "date": "2023-06-05T07:00:00.000Z",
    "dateFormatted": "05/06/2023",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "India’s Intas gets more bad news from FDA with an import alert  Fierce Pharma",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "dd2960a536e1b7a8db4b2397700aff09",
    "title": "Intas Pharma’s Ahmedabad facility gets import alert from US FDA - Forbes India",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPdFdBV0FraFJHd09qM0U1clZ1enItZnZvWFFsalRLS3lBRnVsaHFyTy1FQTJLR1NjNXFnSGpVdDdmOFVuZU5nSEdxXzlrZHlXdTBzUlFjVndaNlNVR21VNWZwSmprd21sU1I1bUtzV0QzT2JOcTNVQ2g5am5zYWVNbzF6d24tdFFDWENpLUhXUENXQTBLS3FFVmI3WGhPdFBvQ2VJX29RZ0h2SFJpS3ItOA?oc=5",
    "date": "2023-06-05T07:00:00.000Z",
    "dateFormatted": "05/06/2023",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Intas Pharma’s Ahmedabad facility gets import alert from US FDA  Forbes India",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "e60c8481d638d29032dfad5bdbe56365",
    "title": "Intas gets USFDA ‘Import Alert’ but allowed to supply 24 critical drugs - BusinessLine",
    "link": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOanlpVmtzUGtCNnF1MGNPLUd1MVlOSVM4Q2NaUm5PdnZoVzR4XzItcWdGbnpoVkJLSU1hdFdBZUZ6OFROeloyMll2LW1qM29NdFlwY09jaFVMLW42TFN3NVNWTGpiMkZsVnRRX2hqM1h4VkZhV2Nsck82U2NjeWs3ZEFhdWNXZ1JTMEZmYUI3VnJ1ajRFbVQ1X25PSGk2QkZRelEtRVdEQXJ4ZVFoVnpaQzNjcDlFRHQ5ZVk5cdIBwwFBVV95cUxNdng0ZG5IM0NacVM0Ylh5V3NwR1V0bVV0MWlqUXNiZEJDdDNjVWFXRVpoU2d3SXNCNExicWRyU3dHOWQ4UXdFbS1rNUU3VjY0NElCXzhWUFNza1NYY253Z1RaNGJleDd6Z2RXdl9Na0Z4MEhrNFRhYndYVElYU09SNk4yU2FSNWN0YTJ1cTVaV0hVOGx6c3IxcGczQkVfaXdSTEpLX1M1Q3ZMcFNQM1FDSDNVWFRfOHpHQXRkcENCRVBEUzA?oc=5",
    "date": "2023-06-03T07:00:00.000Z",
    "dateFormatted": "03/06/2023",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Intas gets USFDA ‘Import Alert’ but allowed to supply 24 critical drugs  BusinessLine",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "e0fbb2aa77bc57c3b2a52b23b1df85e7",
    "title": "US import alert for Sun Pharma’s Halol plant could lead to sales loss: Nomura, Credit Suisse - Moneycontrol",
    "link": "https://news.google.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?oc=5",
    "date": "2022-12-09T08:00:00.000Z",
    "dateFormatted": "09/12/2022",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "US import alert for Sun Pharma’s Halol plant could lead to sales loss: Nomura, Credit Suisse  Moneycontrol",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "718d1d897ac921a36c5d5ba048cc9c5b",
    "title": "US FDA Issues Import Alert On Sun Pharmas Halol Facility - Zee Business",
    "link": "https://news.google.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?oc=5",
    "date": "2022-12-09T08:00:00.000Z",
    "dateFormatted": "09/12/2022",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "US FDA Issues Import Alert On Sun Pharmas Halol Facility  Zee Business",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "5ddb56eb34faa6e9c83292595682c120",
    "title": "FDA slaps Sun Pharma plant with import alert after inspectors find production problems - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOQTlveWdFcFpoRjd6SERNMzhRU3BpZlZhUVF5ODNuZVY4TFdNVkRyVWl4a0dPRVJ0XzFGelFDZ2NPUWdHeFU0NEp3eU1uWlVVeDI4TXNMQTkyUG1WTEE5N1RuNktiM3NScHMzYVNNdjZid2V0SlhROHdRYlZMY0xYRzF3YWdnOU93bDNDazFnX0g0ZkQ1bVU5aG8xd29FcjlQ?oc=5",
    "date": "2022-12-08T08:00:00.000Z",
    "dateFormatted": "08/12/2022",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA slaps Sun Pharma plant with import alert after inspectors find production problems  Fierce Pharma",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "420abcc452c8a359b9e45823b594c5f6",
    "title": "Sun Pharma says Halol unit listed under US FDA import alert, shares slip nearly 3% - Mint",
    "link": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNU2Z0bnhBSlp5Y0kwYzl1ZGp0VmdSNjBJNXFKNFRIOEhCektvNWgxQmlrTmNYcEFmbmpJVjZJd2JQYnFnVUgtUEhKTXBRRTlheTRieGc5ZkFEbTBiT3pGeUNhT2ZhczhMQU1ucllqa1NxX05wcFJNYnFxT3FmUnhPSWF1LVBFQk8tZUlHUml5Y0FBUUFRZEFPTkFXQkRyWVdrWi1TWUxqM3hna1hQc0dSUXdjdDRBdlFCNE9NUkpGclRSaHVrSEhqc0RoS2ZPZUdMa1U2QTZQNDJxWThXWkJUcXBR?oc=5",
    "date": "2022-12-08T08:00:00.000Z",
    "dateFormatted": "08/12/2022",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Sun Pharma says Halol unit listed under US FDA import alert, shares slip nearly 3%  Mint",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "c99fc90b48a507a06dbde412e7fdfa34",
    "title": "Sun Pharma’s Halol facility listed under U.S. FDA import alert - The Hindu",
    "link": "https://news.google.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?oc=5",
    "date": "2022-12-08T08:00:00.000Z",
    "dateFormatted": "08/12/2022",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Sun Pharma’s Halol facility listed under U.S. FDA import alert  The Hindu",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "894f34d1383e5eb546589275a3526404",
    "title": "US FDA lists Sun Pharma's Halol unit under 'import alert' - The Economic Times",
    "link": "https://news.google.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?oc=5",
    "date": "2022-12-08T08:00:00.000Z",
    "dateFormatted": "08/12/2022",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "US FDA lists Sun Pharma's Halol unit under 'import alert'  The Economic Times",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "795cf6ed0280517861ad48cefca4a98a",
    "title": "Sun Pharma clarifies on US FDA import alert on Halol plant - Moneycontrol",
    "link": "https://news.google.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?oc=5",
    "date": "2022-12-08T08:00:00.000Z",
    "dateFormatted": "08/12/2022",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Sun Pharma clarifies on US FDA import alert on Halol plant  Moneycontrol",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "724ed454140649415493054dce691442",
    "title": "Sun Pharmaceuticals' Halol plant gets 'import alert' from USFDA - Business Standard",
    "link": "https://news.google.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?oc=5",
    "date": "2022-12-08T08:00:00.000Z",
    "dateFormatted": "08/12/2022",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Sun Pharmaceuticals' Halol plant gets 'import alert' from USFDA  Business Standard",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "b7add6fee171a1ae16ab1b6d0ba9f20e",
    "title": "USFDA issues import alert on Glenmark Pharma's Baddi plant - Express Pharma",
    "link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOVkNsTUV4VFRiNzF4MkVlTGtGdmxTaWd3MWFOV2FmY0lGcDQ2UnJfZDc4S2JRTF8xQ1R4SkNQcExwdXpvV2p3RHI4OWt4YkxMWTFyWE9sZUl5U2pVVlB5UTJXRGVDdFlZRmZ0eF85M0dUSDg3Umw3bHlHUkdJdi00SW4yMjA4U3ZqeHVlWHA3SlnSAZYBQVVfeXFMUFRNRWZ0dUZ6QUJWT2JYVmxZM0FoZUR2SnR3WkxESmZwVnpaYzZZbzVOZDI0a2tfT3NyaG81R2pYUjY4UExpYUhnZ1RJb2hMMG5xQ000d3RGekFLenVMd2lIUUQ1el9Zam9adXZqVmVvaENHQTNQY0NJMDdVanEzRFNlOXJZRXhQUlNYMTU4b3pnU3h5UnNR?oc=5",
    "date": "2022-10-27T07:00:00.000Z",
    "dateFormatted": "27/10/2022",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "USFDA issues import alert on Glenmark Pharma's Baddi plant  Express Pharma",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "dc2e718aa0c1c9344c4e9c8e4580db03",
    "title": "USFDA issues import alert on Glenmark Pharma's Baddi plant - Moneycontrol",
    "link": "https://news.google.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?oc=5",
    "date": "2022-10-26T07:00:00.000Z",
    "dateFormatted": "26/10/2022",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "USFDA issues import alert on Glenmark Pharma's Baddi plant  Moneycontrol",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "08b48be7dbc1854194ebafacb7480087",
    "title": "FDA slaps import alert on India's Shilpa after sterile injectables issues multiply - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNUmNTS3V2elVTWkVxYkRtSllqLUM2c2Q2TDdsR2pvRngyeG4xQVlwR0xXOE84dTJXNUt5Z1NkSFdPLUppTzlDYkNzaE1TRUxVbjRxWVNaeU03VUZkV1VhYVlaeDVhenlveVVQOWlHeU5VVFhocm5WT3BTdU02UGNxNW1NUWFuaU1BZVdsbHJhMkVSWnJROVVNcENqQmhxd1BuTDI2dEFOV0l1LXh6ZTA3WVVKUThyOVNoS3RqNlBfOVNKWUp5bVE?oc=5",
    "date": "2021-02-19T08:00:00.000Z",
    "dateFormatted": "19/02/2021",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA slaps import alert on India's Shilpa after sterile injectables issues multiply  Fierce Pharma",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "06320495cce41ad59467861b3089e22e",
    "title": "Dietary Supplement Manufacturer ABH PHARMA Recalls All Products - Food Poisoning Bulletin",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPSFFCcWcxbHpXTllvczREUmdXTmpfMVZVTkh0MUxZdDFyaEdLZzc1ZFNrSlpTdWE2eXU1V2ZtWFVZa2ZPX0dYYTFBZ1BDMFJFeTRlcDJtbTN0VW9WSExxUXNrNUZPbVpTTDNJOW9rVjBRd2VmZmVSVGlrc3FWZDBUZE1BZ2Z0SDNIZTFBTjk5dDI2YVg5NXZod1haeE56SFdGVHRyZUVn?oc=5",
    "date": "2020-01-22T08:00:00.000Z",
    "dateFormatted": "22/01/2020",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Dietary Supplement Manufacturer ABH PHARMA Recalls All Products  Food Poisoning Bulletin",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "86bdde5ea1eb73531587cd6449174ef7",
    "title": "FDA grades new Medtronic SynchroMed II recall as Class I event - MedTech Dive",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNUmgzVjY2X3VNRV9Mdy1RM3B6MDEzX09oSjJyN3ZfVE91WXFwamZGU1lTeC1Nd043Wk04TUZhTFJQN3c1MjNMaFVEMlVFREtpQ09CY1JQZHAxSHB1bmplZlhxTVJaRnIyMy1uY0NMMzZfb2hGSV91OGxtUnN5YTZZNGxmMGZsZGtDdDZ6Wlc3dW52U2s4Rld1ZzgySFRxYWlScU5Qa1F3?oc=5",
    "date": "2019-12-05T08:00:00.000Z",
    "dateFormatted": "05/12/2019",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA grades new Medtronic SynchroMed II recall as Class I event  MedTech Dive",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "dd68401758aa49dcd088ccf83108cd8e",
    "title": "Recall Alert: FDA Warning About Two Thyroid Medications - CBS News",
    "link": "https://news.google.com/rss/articles/CBMie0FVX3lxTE80UkJodTdPc3pEZ0JTd1o5SjRodjJoYy00RGFGbVQySGtOV185YVF5T3lwUm44WUx6aFp1anU2WUhzUF8zbE1jTVdfRUJSU2xJbUR3S0FkM2tyTGJGSTRyRnJPQUJ6WklqZ2ZqaXVVcm5QZG5JT3V1NWhKdw?oc=5",
    "date": "2018-08-15T07:00:00.000Z",
    "dateFormatted": "15/08/2018",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Recall Alert: FDA Warning About Two Thyroid Medications  CBS News",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "2c2d698e56e316d5412d9fea1038dea0",
    "title": "US FDA lifts import alert on Divi’s Lab unit - Mint",
    "link": "https://news.google.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?oc=5",
    "date": "2017-11-15T08:00:00.000Z",
    "dateFormatted": "15/11/2017",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "US FDA lifts import alert on Divi’s Lab unit  Mint",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "3bf0e79f20d3c480844b41cc24b37e47",
    "title": "India's Mahendra Chemicals API plant put on FDA import alert list - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQcTFtdmZ0WExmVjRIbE5WM3JJSWxMZlpmX285OTA0Y2pueEJNdi1uMkttX2JiaThBTU4ta01CYXpRcmtORkFzSXVwQ0RNSGZGU1Faa1FIaXA3SWp0NWFIcjlYSmdtSnNVVXBRZENlQkxmWFpieXhsM3ZVR0tTeVJ4MWZja0s3RV9pX29uLVBGVnJnSGJ2V0ktcjI5RFhMT0RYaVA3VzB4SlE?oc=5",
    "date": "2017-08-30T07:00:00.000Z",
    "dateFormatted": "30/08/2017",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "India's Mahendra Chemicals API plant put on FDA import alert list  Fierce Pharma",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "b6a63fc0641a08f66d899b7ee980402a",
    "title": "FDA outlines data integrity problems with Chinese API maker under import ban - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNWUpZYnNQTHJ6bGo0ZE5mZzlfUHd2WFhmbVd4UTRyU2NQX096bzVkOWkwc281OEphVjk1NUxmMG43ZEVOMzFBYnRwYUNBdV93VE8zRjFoMGsxUld5RFFuM2lTa2xfOG85dTBMMXBZZjZYUU1Mbnk3OUd1UWRfcFVSclByRTB2MVo2WTloVlNPdGdqcU55T3hLdWJjRTVJdWZONldkelg2b3lrdjNRc1BBZC1xOE0?oc=5",
    "date": "2017-06-21T07:00:00.000Z",
    "dateFormatted": "21/06/2017",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA outlines data integrity problems with Chinese API maker under import ban  Fierce Pharma",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "a640f8799b3935733d1c7fd2ca69c21c",
    "title": "Divi’s Labs says US FDA import alert on Vizag unit to hit revenue by less than 5% | Company Business News - Mint",
    "link": "https://news.google.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?oc=5",
    "date": "2017-03-28T07:00:00.000Z",
    "dateFormatted": "28/03/2017",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Divi’s Labs says US FDA import alert on Vizag unit to hit revenue by less than 5% | Company Business News  Mint",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "124ac5d7df10f4b58daf7bd237a05f50",
    "title": "Divi's Labs barred from exports to US after FDA import alert on Vizag unit - Business Standard",
    "link": "https://news.google.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?oc=5",
    "date": "2017-03-22T07:00:00.000Z",
    "dateFormatted": "22/03/2017",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Divi's Labs barred from exports to US after FDA import alert on Vizag unit  Business Standard",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "b9b0e79cd5ec8ad9aeaa17aab6be5838",
    "title": "Sun Pharma says US FDA to lift import alert on Mohali drug plant - Mint",
    "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbWpjVU82TE5UQnk1T2t2SmxSaDI5WEhWZnJveV95amNQd1FKd1VVamFmSElUdWxKUE5KbkFSUFZDQnFjV19sZVJGV3NPSnNPZHl4a09Zc3VTelU5RktkYVpraTRFRGJDUHppU0Fsa3RuRTAxTFoyMXQxNkwyTkI4WUxfaGdQVDRadEYydERUZC15bE9pY280Q1JZamlHbXhGNnpIODBDUm5aQU9yWWdPeDh0Ui1NWFd4?oc=5",
    "date": "2017-03-14T07:00:00.000Z",
    "dateFormatted": "14/03/2017",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Sun Pharma says US FDA to lift import alert on Mohali drug plant  Mint",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "1488d295849d0520eb3728e7e750884e",
    "title": "US FDA issues import ban on Ajanta Pharma’s Kamagra tablets - Mint",
    "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxObWFOQXVxTnA2U0ZtR2Z4U0RzaG9DUkw2d2xXcm5lUVA5UFlTX2hsSGN1NnoyRGhiekJpZTJEWFJOQ2NFMEU4Q19DZnpFTndkcllrNGlISVEtSmc2a1BXbEJfMWExMXRMcnVsZFFZLW1tbVpqUnRZMGMtU09kd05KeDA5SnczWGV4LVBndW9sckR3amtWRHpGdjZXaGhuX01SelZ0RTduT2phWHpPVXR2R2Z3TnhxaDd1ZnlvSFVn?oc=5",
    "date": "2017-01-24T08:00:00.000Z",
    "dateFormatted": "24/01/2017",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "US FDA issues import ban on Ajanta Pharma’s Kamagra tablets  Mint",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "f501eb0476393bde12cf8bfbc528334d",
    "title": "Wockhardt gets import alert from US FDA - Business Standard",
    "link": "https://news.google.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?oc=5",
    "date": "2016-08-06T07:00:00.000Z",
    "dateFormatted": "06/08/2016",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Wockhardt gets import alert from US FDA  Business Standard",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "1676f4b23609b36654af2e8dadfb874f",
    "title": "FDA lifts import ban on Chinese API to prevent shortages - Generics and Biosimilars Initiative (GaBI)",
    "link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUkwwNjJXOVFRemVmZDhpZFkzSUF5RDVUQVEtMEVzVU0xSXg4MVB5RVYzRGlKZm93NUFERkY4UnlGZFNpX08tcFlNSi1uYlFtNzNhUTNkRzdwZndVejMtTG5ZbkFfbi1XcU9fVy1qMEZnMllkSWczcHF4cl9TejBxWGN4eUNrOEoyUVA4d1UtSzZXVHN4eFpvVW9jVmZXWmZoX0hGMk5BU3lWVWJUMzVrb09uei03djlldHdVQ0RCTFdZRFlMUmZocg?oc=5",
    "date": "2016-03-18T07:00:00.000Z",
    "dateFormatted": "18/03/2016",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA lifts import ban on Chinese API to prevent shortages  Generics and Biosimilars Initiative (GaBI)",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "6c30bd5d6bf0136b317f9d5649d083a9",
    "title": "Ipca Labs: Under pressure after US FDA import alert on Ratlam plant - Business Standard",
    "link": "https://news.google.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?oc=5",
    "date": "2015-01-27T08:00:00.000Z",
    "dateFormatted": "27/01/2015",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Ipca Labs: Under pressure after US FDA import alert on Ratlam plant  Business Standard",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "ebd97fc6ef259f12007d69c7d6efa816",
    "title": "Import Alert: FDA Working Toward Consistency, Better Decision Making - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOY1hZTlU4LUNSa25NZVZjZFdSaXVtc055cWV2U1VjWnBlRG5kclVGbDFBU0dUVXY1SmhfU1I3elc5NWo5aWo4VXlhOUw5aGZyVl9IOHVhcDEycDlLcU5GeGpialBxNC12d0ZCYmtiNHFlNllkMVdaQ1J6MU9FZmxpbGFqVWpfVXFpVkRrZHdITVBEcnFIWHRLUE03ajBqNmJZcUMxaHNqZHVwT3BlcmtVQXZCbDhnZ1BlSVBTVE5rekJkcElsb0VhS0V2MkV5Z1Fkc0dv?oc=5",
    "date": "2014-10-12T07:00:00.000Z",
    "dateFormatted": "12/10/2014",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Import Alert: FDA Working Toward Consistency, Better Decision Making  insights.citeline.com",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "7569545e973749d0772457439906a64d",
    "title": "FDA import alert for Sun Pharma’s Karkhadi plant - Mint",
    "link": "https://news.google.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?oc=5",
    "date": "2014-03-14T07:00:00.000Z",
    "dateFormatted": "14/03/2014",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA import alert for Sun Pharma’s Karkhadi plant  Mint",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "71d531ad94b010560c0f4644f873b8f3",
    "title": "FDA imposes import ban on Ranbaxy’s Mohali plant - European Pharmaceutical Review",
    "link": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPYTRMRHUyRGFvR2pvelV4b2tZUjJHUkRFd1dSMGxaLUsydndjaFo5NjR0VGlTa2M1UDVjcHBicWFRM3VjaFJCUFY5cDJURU1LTWV0cU1rY0FkMnlqM3ZvMVF2MmtPSlFFX3l6S25RNUxuQUIwX1ZKMFFMelE4OENucnhwZ0xCcTJZeDRVNUpBN0NnNTlxNUhvbVp2WlFjMWVveTRN?oc=5",
    "date": "2013-09-24T07:00:00.000Z",
    "dateFormatted": "24/09/2013",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA imposes import ban on Ranbaxy’s Mohali plant  European Pharmaceutical Review",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "b516c805ded394d95a05e62937993a0d",
    "title": "US FDA imposes import alert on Ranbaxy drugs - BioSpectrum Asia",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNbWJNbFExWXV3eFBCVlBaYmRhVlI4QU54N0g3LWRCT2pHRV93d0ZWVjZaQ1BtRFgtMC1ESk82SUNiTF9DNE02eWQ1SVdTRmxyS3ZVcUIxZjJpei1rdmZkQXB5MVh0SEkyWjRpdUFNaXEtcDdiOTdyZ2ZyU3lmQ3lxRkItQ0QyR0NKaVlGOGNmV0JLczQ1cFY0S0REN2EzeEtiT1E?oc=5",
    "date": "2013-09-17T07:00:00.000Z",
    "dateFormatted": "17/09/2013",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "US FDA imposes import alert on Ranbaxy drugs  BioSpectrum Asia",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "32dd211ee9786d8bd6a8bb4b78c20ee1",
    "title": "USFDA issues import alert on Ranbaxy Laboratories' Mohali plant - Business Today",
    "link": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNQUo5bThjbnAzeHRxbTN6aXJCMmlyb0RSams5R3hnZm1Dc0N2NnE4eXluTGhubHhSLUd5Vm9vNDRsSWk4Y2ZOM1RBaXo2Q3VmMGZSb2JmaTYtWFVSTVJMVFdRZ1Ffd0lucEExSFFETUNKNDY1VU1TQS1wMUFwYkdLZUo5cl9QeVVtb3dhMVBIbHhuY0MwaGNBWXdxSW1McGxqVDZxbWVjLW4zZDE1SWk0bkZMVnNBV1ozLVNzLTNpNHBfQQ?oc=5",
    "date": "2013-09-16T07:00:00.000Z",
    "dateFormatted": "16/09/2013",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "USFDA issues import alert on Ranbaxy Laboratories' Mohali plant  Business Today",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "4708a484eb74dc974239b1ab234f46a3",
    "title": "Dabur gets US FDA import alert - Business Standard",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQbFpyaDEySVl0QXRWNWdBZnJJT0VNWGI3bWlpM1RkOHV3ZndVMzdKUTA2S3pac1J6ZFpQZzBCVUxsLTZkYVM4ckJ3ajhkeVFRZWtIcGdNdXRxYnFTbDlscHZoZHNYQlNNaXFIZC1VZkZpM3dUZFgwalptTThEMXJTT3NZX2tVVEJtNlVjX1ljTndLTXlGLVNYZXJ6MHFLN2hiMmlCQtIBqgFBVV95cUxOak5SWjVkSExoS1FYdnlIalFuLWJ4RHh5X3Rjd3M3d3VIb2ZicUdVQkhscEp3S2FYbU1jd0dHLUVId19wODBjamxLMkU0cEtURW1WczNhMW1ZWkJfem1PeUN4Z1lydmVvT1ZPM1J4Z083RHFVUjJDd0RFX3lTam9mR1A2cUZ6UXZQbmotOXc1YW1QQm4xd1AyZ0dfcDNvcTBCck5YMl95QkRaUQ?oc=5",
    "date": "2013-06-15T07:00:00.000Z",
    "dateFormatted": "15/06/2013",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Dabur gets US FDA import alert  Business Standard",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "b3c2dd790ddf0e3ed5b9381a0fb657b8",
    "title": "Wockhardt hit by FDA import alert on drug plant - Reuters",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxObl9TYzFSUVhvSUpTNjhaWkZocmxoNWtqU0EyeHdMZG9oZmY1MzF0ZWhyMUhuT2FMSVFNcW5LUURFVndjNFFJMnFqRmFTR3gwTXh1S0hfdUI5Mmxnb3VzZHZrSS1Za3pSNUJRbFMySmRNT2g2dTR2bmtoNkNNdFQ5REF4VkNqdHNwV3VPZ1pyUXI5TkkydEhaekFtQVplbTVzN2c?oc=5",
    "date": "2013-05-23T07:00:00.000Z",
    "dateFormatted": "23/05/2013",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Wockhardt hit by FDA import alert on drug plant  Reuters",
    "company": "TBD",
    "types": [
      "import_alert"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "f8cd05fa66588531c6cdf4544f9121e3",
    "title": "FDA Requires Federal Oversight of J&J Plants After String of Drug Recalls - AboutLawsuits.com",
    "link": "https://news.google.com/rss/articles/CBMiakFVX3lxTE5rMW1mR001M2hIUnJfd3R1WXprX2xGcE12cW1sclJXYXR0TGJ3MTcxbmRHQkVRTGRObUZ0Q2hJLUs0aTdpZ2t6X1NyaWhEZGp1OVY4U3V5OWM3cWRTaG51T1ZhTU0ycmg2WVE?oc=5",
    "date": "2011-03-11T08:00:00.000Z",
    "dateFormatted": "11/03/2011",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA Requires Federal Oversight of J&J Plants After String of Drug Recalls  AboutLawsuits.com",
    "company": "TBD",
    "types": [
      "recall"
    ],
    "severity": 7,
    "priority": 3
  },
  {
    "id": "250451a256dffb6cffaa2def7386284d",
    "title": "USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unit - The Economic Times",
    "link": "https://news.google.com/rss/articles/CBMi_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?oc=5",
    "date": "2025-09-05T14:59:30.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "USFDA issues Form 483 with 8 observations to Aurobindo's Telangana unit  The Economic Times",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "4bc195f399da1894b7b9c65cce763e84",
    "title": "FDA 483 Observations Highlight Ongoing Issues in Quality Control and cGMP Compliance - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOeU9EMEZNc0kxSG8wekZiUWtmWVlxVHNhelFmck9IYlcyeFhBYl85UnJqWUh3M0JDNW00UWVnZi1BNENYdFBaRzRlcm9jeHp5MHphTGE4R1dWTGRMUnJLWERBZ0FOM3A1U2dISjU1VXMxNk9iemx1VnF4U05PZmdPVzNPT1BaYUtGeVZVM1drOTZsT3VwakpsS3ZKUUZZMmViYzMzajFISnBKQmdTM2h2XzJB?oc=5",
    "date": "2025-08-28T14:08:33.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "FDA 483 Observations Highlight Ongoing Issues in Quality Control and cGMP Compliance  geneonline.com",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "999f28fff85aa84cedaadf5b6c86b68f",
    "title": "Novo plant acquired in Catalent buyout faces renewed FDA scrutiny with Form 483: Stat - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNbHR0a3hLWml2bzhKdWl0RWszdXM3ZlQ4THY1LU05SkwzU24tbDdnaHpQeFFOSTRBemxUeFpPVWJWWG5PVWlpYmt2MFpfcXExdGk5MEVOSnFzVElGU2JJaXlEbHVGRUxiVXFvaFdPMzFrUnVMT2ZXc3FDNGJNUmpYTlh2NndnR0ZpTDJHN25TYy1PcHRPTnplVVpQc0ExTl94NHNsVHFUZzNzS2VEeVZDQ0Zjd1liNFlpdVpB?oc=5",
    "date": "2025-08-22T07:00:00.000Z",
    "dateFormatted": "22/08/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Novo plant acquired in Catalent buyout faces renewed FDA scrutiny with Form 483: Stat  Fierce Pharma",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "fedf9e82e79430dc143e3ebcb3cd52a9",
    "title": "A Shifting Trend In FDA Form 483 Disclosure Obligations - Law360",
    "link": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOUWFxdHp2UWZCVXlRMEVtM2Rmbm1uTWtMdzVXa01YR05VWlRoOGNXREd4R1RQTjBqNlVJa3FBVXI1elNGLU5JRzlibTRjTmlfaDBIaTFpYTRqdjA0dmNrYm50ZGdqSTdOMExORXdmRE9obzJpZ0tpMFE1ODMyMlNjWkJnbHVPVzhhWkl1YzVtdms4a2Q2VEhhOVdtNNIBVkFVX3lxTFA4NjhhLVMwRWRIT3lkbmdtXy1MNEpGNHVlYlJtaUJvUVMwN1Q0OXRtUThGVkppZTNhVzZZZUd6NjZZYTF0THNuMkhvV25KYk5iQTh2UUlB?oc=5",
    "date": "2025-08-22T07:00:00.000Z",
    "dateFormatted": "22/08/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "A Shifting Trend In FDA Form 483 Disclosure Obligations  Law360",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "f24de987eb5f73bf362d3e4ee1a53eaa",
    "title": "Dr Reddys Gets Form 483 With Seven Observations From USFDA After Inspection At Andhra Unit - NDTV Profit",
    "link": "https://news.google.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?oc=5",
    "date": "2025-07-18T07:00:00.000Z",
    "dateFormatted": "18/07/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Dr Reddys Gets Form 483 With Seven Observations From USFDA After Inspection At Andhra Unit  NDTV Profit",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "32c34d993103d98460ae6a833275b591",
    "title": "Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2 - Indian Pharma Post",
    "link": "https://news.google.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?oc=5",
    "date": "2025-07-18T07:00:00.000Z",
    "dateFormatted": "18/07/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2  Indian Pharma Post",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "2aea21b682bc11456063093f35e04d37",
    "title": "Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1 - Indian Pharma Post",
    "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQdTBGaXNDb1ktYURkZ3FfQjhTbmxnTTRvVlN1aWVfWkZwaURpYmNXZjhmNk91c25ZZ0d0dkZLUDRVek9TVG9UbzE4WUFGaGROQkdJY0t6dW1HbkFkTVNLTUJscm9taU5FMU9NazhoZDBvYkhlcXZzQXFULWxualRsdWNJc2haZ1NXVnZDandCRWtfdkpQMEZzWEFadTJ6MGtqVzNMNEJSZWRJbTBpQ2FWeVlzLXF0ay1tMVpTcE1RMnA1TkdSN1RpYUFpVmM2X3NacnhMNzhYSjlKZw?oc=5",
    "date": "2025-06-23T07:00:00.000Z",
    "dateFormatted": "23/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1  Indian Pharma Post",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "ab3bdf2e6298b29104b619ee88515938",
    "title": "NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit - Business Standard",
    "link": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNV3Y2eS1EMHMzN3JYVmd4VHItZ2xyQllZTW52N0hMaHNlVDZRSjBTb2F1ZzIxYU1USXlMeHNJTEh4QUFzNzctS2ptYURWUFdIN2RtNTVmREpuWFlINHU3VnBHR0lPWHYwYzNXTUF5a0hWVGMzdXgxTTI3NGd3YThONkUzdXVhZWxLYTRBOFNXVENCRmNHSXloUGdEa0RiMG5FSlRtSEVTX0hQcHJNMFBuaWctSUlnQ1RUQ24wTWRVajM3U3hBMF8ta1Qwd1hsS1IzdWxTVUp1VlFkWE8zbVhEeEtSLVQ2T2sxUjhHRGVQZ1RfTjB4OG5ER1BR0gH_AUFVX3lxTE8yTUJ4N0xocHZvdUFXOHR3aEJhdUtPRmJ4WUF0aF80elRXc2RZV0hVMURFeHUwb0QzeGFmNnFOOExyakhJU3djVDNESXR0VXZCY0xxTGVpYjhIYnBFNWNwREhDTEw3M0JDd1FabUVJQ1RiRzEtbEFDU2FkRXRjb044eXN5YmtTTkU4YTZwVXp5ZkpKTXh5OVFhNGxWMF9xakQ0UnhaVmhVd1JYOFBvZ0tKdEdRYUFrVGMybDJqbzM2TG1zVUJFT3BYRGFCV3huRFBQRWhfSm10MnZkWE1LdlNMUm15b253ZFpaTHA3RzlpQzFHTWREYWk5TmZFaUhmdw?oc=5",
    "date": "2025-06-14T07:00:00.000Z",
    "dateFormatted": "14/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit  Business Standard",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "fcd76674fa00187a8cf46bb04bbc28c8",
    "title": "US FDA inspects Sun Pharma’s Halol plant, issues Form 483 with 8 observations - CNBC TV18",
    "link": "https://news.google.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?oc=5",
    "date": "2025-06-14T07:00:00.000Z",
    "dateFormatted": "14/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "US FDA inspects Sun Pharma’s Halol plant, issues Form 483 with 8 observations  CNBC TV18",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "9d1a7be1484f9dc0a772c48b40230286",
    "title": "Capricor says FDA inspection brought Form 483 with several observations - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNODRhYzJFMkRaVEpPNHlJa2NFdl81TXdXc0Q5azc3UGJuQ1F6YnI1dnQtWk4xMEswYWNuMDR4VG12RlRpQW9UYmJhZ2ZYZ0dDaTdEaG9UYkxvUEFubzVDLXBhaVRHM0Zwd2tqTjctU1YxM1diaDRZRUZpN3lCMm95N042X1NnV2tpWmc?oc=5",
    "date": "2025-06-12T07:00:00.000Z",
    "dateFormatted": "12/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Capricor says FDA inspection brought Form 483 with several observations  Yahoo Finance",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "7934cbf8c3a13c5403b91d0c23743ae1",
    "title": "Dr Reddys Labs' manufacturing facility gets two form 483 observations from US FDA - Business Standard",
    "link": "https://news.google.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?oc=5",
    "date": "2025-05-26T07:00:00.000Z",
    "dateFormatted": "26/05/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Dr Reddys Labs' manufacturing facility gets two form 483 observations from US FDA  Business Standard",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "533820329aa43b82ec1c66071233f624",
    "title": "Dr Reddy's NY API plant gets USFDA Form 483 with 2 observations - MSN",
    "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQbjZjajl3ZjVoRk5BYV9nUkdRQ0twV1hVVFVJYWVmWG9IblJxV1ZQY3BCQklGSDAzWDJYdDJxT0hjLUtGX09fX0dNY2wyUVcwYlMyZzh3TW16ek0yWnhHU0x2cXF0S285WVpSWkZGblVsUU9WR0c3a25yLUpXeF9wVWxudENNaVZNMXd4NFJpd3lDbHZzVGtrajVXek1WbHF0clRHX3ExZjNOQThRZ3cyWk8xQWt5MzlkUXg1RnhVRjdfcmxfcnpMamI5aFVZaHN1RUI2QThUdWx1NFZB?oc=5",
    "date": "2025-05-17T17:34:26.000Z",
    "dateFormatted": "17/05/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Dr Reddy's NY API plant gets USFDA Form 483 with 2 observations  MSN",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "8e28bed6a6baf8c9f888dfbde1add3ad",
    "title": "Dr Reddy's NY API plant gets USFDA Form 483 with 2 observations - Times of India",
    "link": "https://news.google.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?oc=5",
    "date": "2025-05-17T07:00:00.000Z",
    "dateFormatted": "17/05/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Dr Reddy's NY API plant gets USFDA Form 483 with 2 observations  Times of India",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "714185dd6edf15879ec12675993d1353",
    "title": "Aurobindo gets Form 483 scolding from FDA at North Carolina inhaler plant - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQdUNLZzdXMDZhVExlZlNXeldtWWk5RHpQTHpDQ3l5S1JqckFNNmtOUFpUX3NhU3RnNVB6ZFJ6S1U1VWItNkY5a3NuUFFLaXFENmx1WDByMmd3RkR3cmxGS0xBUkY0ZFNoLW85aG95ZlRDdUZqMzZBQUZTRC1DRGY1MzBMNVUzbFNJUmUzVXlTNmdHa29jTzVQd0lTNWtmQVdUb3FMRDdRNW9pZw?oc=5",
    "date": "2025-04-14T07:00:00.000Z",
    "dateFormatted": "14/04/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Aurobindo gets Form 483 scolding from FDA at North Carolina inhaler plant  Fierce Pharma",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "70e9d7ca7c51bb5a346f8f66b046405e",
    "title": "USFDA issues Form 483 with 11 observations to Raleigh plant of Aurobindo Pharma arm - The Economic Times",
    "link": "https://news.google.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?oc=5",
    "date": "2025-04-11T07:00:00.000Z",
    "dateFormatted": "11/04/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "USFDA issues Form 483 with 11 observations to Raleigh plant of Aurobindo Pharma arm  The Economic Times",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "14932f5ee3eac97ff32b6d5f64923125",
    "title": "Aurobindo Pharma's Aurolife plant in North Carolina faces US FDA scrutiny, gets Form 483 with 11 observations - CNBC TV18",
    "link": "https://news.google.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?oc=5",
    "date": "2025-04-11T07:00:00.000Z",
    "dateFormatted": "11/04/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Aurobindo Pharma's Aurolife plant in North Carolina faces US FDA scrutiny, gets Form 483 with 11 observations  CNBC TV18",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "c8225ba3f924658b5bac803e0cd9a445",
    "title": "Alembic Pharma's Vadodara facility gets one Form 483 observation from US FDA - Business Standard",
    "link": "https://news.google.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?oc=5",
    "date": "2025-03-08T08:00:00.000Z",
    "dateFormatted": "08/03/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Alembic Pharma's Vadodara facility gets one Form 483 observation from US FDA  Business Standard",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "f48e6b02943ef3374bf6cdecd73bc6e0",
    "title": "Shilpa Medicare's Raichur units gets Form 483 with one observation from US FDA - Business Standard",
    "link": "https://news.google.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?oc=5",
    "date": "2025-03-08T08:00:00.000Z",
    "dateFormatted": "08/03/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Shilpa Medicare's Raichur units gets Form 483 with one observation from US FDA  Business Standard",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "6d5e652e9c2aa3446b3ed645f062f4d6",
    "title": "USFDA issues Form 483 with 3 observations to Gland Pharma's Sterile APIs unit - Indian Pharma Post",
    "link": "https://news.google.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?oc=5",
    "date": "2025-02-27T08:00:00.000Z",
    "dateFormatted": "27/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "USFDA issues Form 483 with 3 observations to Gland Pharma's Sterile APIs unit  Indian Pharma Post",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "9e93d45aadb7d1c51ca2c4a6c6daa50d",
    "title": "FDA dings Piramal API plant with Form 483 detailing problems tied to quality control, equipment cleaning and more - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQUlJZeTVjUGkzaXhRcjcwamh2ZmxIVnFldjgxYVFTMS1TMGhBX2xTZFZQczRkMXhJYVFmNnlTWGpRSkZ2UEN2M1FWb0k4YnJpZERJVE1zQUVpSXVRbnViM1I0OVhTRW1hczdPTDJHMk5MV0VrSUVfWTRDRklkcUYtdEpYWE9HX0Z3V3FyWk9ZU3ZUbDU5bGJQMm5fM0oxcW9Bbm9aOEU3b1cweE80VzdMZFFFWnFES2dESGpN?oc=5",
    "date": "2025-02-26T08:00:00.000Z",
    "dateFormatted": "26/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "FDA dings Piramal API plant with Form 483 detailing problems tied to quality control, equipment cleaning and more  Fierce Pharma",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "2ab3c85a9ef54d05f6168f9dc6910460",
    "title": "USFDA issues Form 483 with 3 three observations to Gland Pharma's Visakhapatnam unit - The Economic Times",
    "link": "https://news.google.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?oc=5",
    "date": "2025-02-25T08:00:00.000Z",
    "dateFormatted": "25/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "USFDA issues Form 483 with 3 three observations to Gland Pharma's Visakhapatnam unit  The Economic Times",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "ef60c18d7e58d8d0d3d02d83d4901b92",
    "title": "Piramal Pharma declines after US FDA issues Form 483 with 6 observations to Turbhe unit - Business Standard",
    "link": "https://news.google.com/rss/articles/CBMi_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?oc=5",
    "date": "2025-02-19T08:00:00.000Z",
    "dateFormatted": "19/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Piramal Pharma declines after US FDA issues Form 483 with 6 observations to Turbhe unit  Business Standard",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "684e3719561c791a362d16b5741ee6c6",
    "title": "Lupin's Somerset -based facility completes US FDA inspection with zero Form 483 observations - Business Standard",
    "link": "https://news.google.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?oc=5",
    "date": "2025-02-03T08:00:00.000Z",
    "dateFormatted": "03/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Lupin's Somerset -based facility completes US FDA inspection with zero Form 483 observations  Business Standard",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "47cbf6e06a50823107145834186475bd",
    "title": "Laurus Labs' US arm gets Form 483 from FDA after 'adverse experience' probe - CNBC TV18",
    "link": "https://news.google.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?oc=5",
    "date": "2025-01-22T08:00:00.000Z",
    "dateFormatted": "22/01/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Laurus Labs' US arm gets Form 483 from FDA after 'adverse experience' probe  CNBC TV18",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "d1879d8bbc6730dc723cae29be30f99b",
    "title": "Cipla's Goa-based facility gets one form 483 observation from US FDA - Business Standard",
    "link": "https://news.google.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?oc=5",
    "date": "2025-01-21T08:00:00.000Z",
    "dateFormatted": "21/01/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Cipla's Goa-based facility gets one form 483 observation from US FDA  Business Standard",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "656eedfa3d7c0a161a89a74df43801e1",
    "title": "FDA Releases Form 483 to Taylor Farms Colorado Springs Facility - Food Safety Magazine",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNTVlWEdUOXJncDJRT2dBZkc2WTZJaEwwVUVob0M1S1liRnZuN3F5U3VGQ3A1QWVSSTF5YklwUkpfbUwyNl9ZVW1wM2k3OGFUVDhaalVPVV9TRkJnenhuaDNFZS04NDdXMk5PT01rT2hXbXZGRWF3MjJYQm52blRJVDlBSk9PNldOM1BjOTBLNWl1bU1CU01XZDFfRUVEX1AxbktGbGpKVzladw?oc=5",
    "date": "2025-01-14T08:00:00.000Z",
    "dateFormatted": "14/01/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "FDA Releases Form 483 to Taylor Farms Colorado Springs Facility  Food Safety Magazine",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "79943ef22eadee3ae3c8936f22796a89",
    "title": "Dr. Reddy’s API unit issued Form 483 with 7 observations by U.S. FDA - The Hindu",
    "link": "https://news.google.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?oc=5",
    "date": "2024-11-19T08:00:00.000Z",
    "dateFormatted": "19/11/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Dr. Reddy’s API unit issued Form 483 with 7 observations by U.S. FDA  The Hindu",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "2bb98d836462048f8f715e87424000f7",
    "title": "Shilpa Medicare slips after US FDA issues four form 483 obersvations to Bengaluru facility - Business Standard",
    "link": "https://news.google.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?oc=5",
    "date": "2024-10-31T07:00:00.000Z",
    "dateFormatted": "31/10/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Shilpa Medicare slips after US FDA issues four form 483 obersvations to Bengaluru facility  Business Standard",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "a238e212028c3a5df78dcae1eb504f45",
    "title": "Apitoria Pharma gets Form 483 with 10 observations from USFDA - Indian Pharma Post",
    "link": "https://news.google.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?oc=5",
    "date": "2024-10-01T07:00:00.000Z",
    "dateFormatted": "01/10/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Apitoria Pharma gets Form 483 with 10 observations from USFDA  Indian Pharma Post",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "1b851237c5acac257ccb5f18ccd9d8ca",
    "title": "FDA issues Form 483s to Japanese, Indian drugmakers in wake of plant inspections - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRFZDZXhpX2U1U2RjMHN1c1B2WGY1aVIyNExmOEo5TGE0VDlQTEJfcVVwejNza0JjdTN2Y1I3Qk1jQnZ4cW4zOTRRWjJDTWVjTTNXbl9JUXU3dW9wNGlYSklOR1BOcFlCT3JRLU5xWC1vTkFSSUw4cDJUbXdlUXVCTy05UG1mMzZEVll0LVQ4SnlSWjgwOHZNbV9KRDkyMjlRd1gtX09nRVhZZTA?oc=5",
    "date": "2024-09-10T07:00:00.000Z",
    "dateFormatted": "10/09/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "FDA issues Form 483s to Japanese, Indian drugmakers in wake of plant inspections  Fierce Pharma",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "651d140f393ef38c62d9b88806b7b4f8",
    "title": "API maker Global Calcium stung with Form 483 filing after FDA inspection of Indian plant - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPOGVwY1NZaktiWnJxNDEySjlsRUQ4dS1ENW1maHF5dEN6V2syVjZQQzFVQ3BYclFHcDNGNlBuNmxGeFVRVk1wTjVfOG83Q3FzSUNtdDBJT0RBeUhnN0JaTm5UTXpmOFJEbmRoNlYwcHJvaG45TnJ6Y3RHaDZCeWZ5ZTJVM3hjcl9tVF8zTG1qWXNIUFJid1hObVhaQmFkNnowQ2VrTldtQnB4TVBBNXhuc0s0dw?oc=5",
    "date": "2024-08-29T07:00:00.000Z",
    "dateFormatted": "29/08/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "API maker Global Calcium stung with Form 483 filing after FDA inspection of Indian plant  Fierce Pharma",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "e0e641da63a7d1f9148c1bb7e05564cd",
    "title": "That Time FDA was ‘Unusually Thorough’ on a Form 483 - Medical Device and Diagnostic industry",
    "link": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPUDV4YWgyWHZ4YmNWYk8ya2lxSFNZMWozR3JmakNGU2QwSlNmOUQ4eVRjYzM4dWRTXzJaTTl5a0t0eW5EbDl1NkV2S3I0dDN2Zm9wTEl5cG9IMjRUdW40OUVSak1ULXBXdUYtdzd1MWlBRGx1RjJXQ2dYY2w5X0k3SngzQW5jNExrYjlB?oc=5",
    "date": "2024-08-19T07:00:00.000Z",
    "dateFormatted": "19/08/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "That Time FDA was ‘Unusually Thorough’ on a Form 483  Medical Device and Diagnostic industry",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "5918217ee4aff033c1e0bc38be7754af",
    "title": "2023–2024 Trends In FDA Form 483s For Pharmaceutical Formulation Facilities - Pharmaceutical Online",
    "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNRUFyTmtXYWsyTWRvX29VU1pkTUFKSkQ2amdscHQ4b0lSTDRjSVNaLVhhSEduVEJOOE5zZ2kweEFfM3JWaXFHTG5GaEdLTGZYS01NSVdURzJXXzJybVdIU2h5NDNqU2JzME5BdUgzVk16QXB1ZG5tZnhJdDlOVFRWY05IYzBOQlBrdmdrcjR0QXBhZ0VVTGdFazZueFVkcktVRnRza3c0OTFQU25GQ0pSeFFEclUtMzlMZzJGRnBB?oc=5",
    "date": "2024-08-01T07:00:00.000Z",
    "dateFormatted": "01/08/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "2023–2024 Trends In FDA Form 483s For Pharmaceutical Formulation Facilities  Pharmaceutical Online",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "87580be2d07555e0641d92bce65e11be",
    "title": "FDA flags 10 observations in another Form 483 for a Zydus plant - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxORTRTdjd0QmlpWWxyOE0xODZHdlVYanJtNkUybmVSTnhoZUtKVUM2ZFRSRXZzX1VmNE5JdHI3TmhZZTk0a193QTdyY0hKVTBSSjY3c21YQkpVTllDSXdUSGlfNV9OQVdXUjM5SU1icDFJWWtWM3BMQVMtSDVGaWtBQ1NkX2t0VXlLY2hzQjhkc25LNFFFcmZ0WnNTQ2JCQQ?oc=5",
    "date": "2024-05-06T07:00:00.000Z",
    "dateFormatted": "06/05/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "FDA flags 10 observations in another Form 483 for a Zydus plant  Fierce Pharma",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "864dfcd2df9838656ca2d447c99895e5",
    "title": "Piramal API plant in Michigan hit with FDA Form 483 write-up - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOa0NYYjJTU1JqZElDOEs4UmRJajRJSll4TE0weU5Sd2NHNnd3MUoxZW9ubHdUX19vX1dqZ2U5VHRmekpDYU52M2V4cEtzM1FQWnB0VkhRZjIwT01fM0hFcE1Cd1VzT0VLbXp6bklIb2RHVWFOMmlyZy1Ud1N1ek1SNXE3c3RFM2ptNkJDUUhkd3JMM3lad2c?oc=5",
    "date": "2024-02-09T08:00:00.000Z",
    "dateFormatted": "09/02/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Piramal API plant in Michigan hit with FDA Form 483 write-up  Fierce Pharma",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "40ba79560fb8f447a0c4e4f5343ee57b",
    "title": "FDA slams trio of Indian drugmakers with Form 483 filings after December inspections - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQVS16dVlxMldRdUJWNDJVRG1Sc3QydmtUSDQwOUFqamViaE5ROTBGRjhiNWR4cGpSSmVHVk05Z2I0bE1sQ1Fvd0dMb1pkZkVfOUR3V0pQRlpzdU11RldzN005a2R4aURwZ1BXQlF2cFY0M1h2VXNaUkl2VDl0ZDhXakotWW1DQlpqd054bGZla3F3bW1vMzlyYVFPY2VlMm5fNEp5SHljTkRQendxYWN4LXh3?oc=5",
    "date": "2024-01-03T08:00:00.000Z",
    "dateFormatted": "03/01/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "FDA slams trio of Indian drugmakers with Form 483 filings after December inspections  Fierce Pharma",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "fe752bc349a8b933782456e21abc7401",
    "title": "FDA hits Torrent Pharma with a Form 483, citing 5 observations - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQMVRfMW1odTNyNTBRMkR4bnFoZEs5WFdnNXJkX1RrSzMzNjVzVy1hWWRBcktWX1hMQXZnT2h5Ym5LUURrV0JrUGZXa2FPd3ZCc0VQYzhULTdabjZPaG9HdVd1NGQ0Q3RYU3lwN1J1dEFUdWVsU3BWNEszcDJ3VUtvamx1Y0RnRWFHaGVyT2c3amM5Vl83ak5rVWZZUktOTTRmZ0E?oc=5",
    "date": "2023-12-13T08:00:00.000Z",
    "dateFormatted": "13/12/2023",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "FDA hits Torrent Pharma with a Form 483, citing 5 observations  Fierce Pharma",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "d0e37d9b7c1feea3eb5b48c97e6fe163",
    "title": "FDA puts New Jersey drug ingredients maker Spectrum through the wringer in scathing Form 483 - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQU0JFWlBzYnRLcHQ4VUNmRHFRbVFlSnBySzhHMllXTlRaelBMdVk1WkpHVGoya0VNWmVVMTFyN1huc2llaTBGZGFBaTJmRWZSTXRxZk10bmF4NGhjTzdESFNhQ2tWbVZhMlk0MjVLUHMwTUtQZ0xMbVB4TUFPRjVyWEF0OWtnRFZyTHVrQ1lYandpRVNvcnBRWjJUbjdXRzFPeVlzdEhrWGxLUFBKdUlqNl9Zbw?oc=5",
    "date": "2023-10-11T07:00:00.000Z",
    "dateFormatted": "11/10/2023",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "FDA puts New Jersey drug ingredients maker Spectrum through the wringer in scathing Form 483  Fierce Pharma",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "67d4c876f92388eb3da49ebfd40f5631",
    "title": "Alembic hit with Form 483, citing 4 observations at Panelav plant in India - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNVlBZemFGZmV0cjBwZ3ptbEUxbGhoSnJ6bmZESXNQS2xPR2FzOHNkMGNhT0IzLUZHSjc4eGx2SEg4QVV1N2hWNmswa0F4V0dEdkFLZjdfRFhTTDkyZ1BNWnh1cFgteG9BXzNJQXltUW5EbFQwMVR4MmNKNzdQMzZxT2xQTlk3WDdhSzk4MmRKZjUzcDJxcGhHbmRac1FHZE9RTW9hS3E3dURoT3Vwa2RZWEZLTGJXNVZYVnc?oc=5",
    "date": "2022-10-20T07:00:00.000Z",
    "dateFormatted": "20/10/2022",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Alembic hit with Form 483, citing 4 observations at Panelav plant in India  Fierce Pharma",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "83bc7129484c23d1688c30c2f114d298",
    "title": "FDA FY2020 Drug Inspection Observations And Trends - Pharmaceutical Online",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNSGdpeDRlNmR1U0R3NW5YMkljdHQwNHVkNjRqMHN2M3hCZ2dpdFFuNldVM1c2bmpSOTNjcC0yUW1QVWp4UnN1Y3dYRmFXb0ZDRmotTC1pOXY5Wnh5QkMtbV9iX2FGWUtIRWJGS2xFbHlzY2pIQlFWaWNyc3hIWDAtXy1rSEdjNGVuMFpRQ3FlRm9MUjZKZ3Jv?oc=5",
    "date": "2020-12-09T08:00:00.000Z",
    "dateFormatted": "09/12/2020",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA FY2020 Drug Inspection Observations And Trends  Pharmaceutical Online",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "5d440c366e7590b52e84774fcf17c24b",
    "title": "FY2017 FDA Drug Inspection Observations And Trends - Pharmaceutical Online",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQQ3BsXzNPcFIzY1Aya1FJcUlWMUhmRVZqV0JvWDNmWkd3VWtyeElVQ0NCdFJHNUVnZnRzWlBPc1c2NXoxS0JPTFNmWjVFb3htTHhieURHazFsTkRIYkR6U0t2dmxsZC0yVk54b05SSkRSU3dndDNZYkhKVW1nZko2QjR3b1d0dDJmVlJmTjE2SGRHUDVIUWw0?oc=5",
    "date": "2018-04-18T07:00:00.000Z",
    "dateFormatted": "18/04/2018",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FY2017 FDA Drug Inspection Observations And Trends  Pharmaceutical Online",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "454403051385d51597d28c66c7445bcb",
    "title": "US FDA Inspections in China: An Analysis of Form 483s from 2015 - Regulatory Affairs Professionals Society | RAPS",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOdmZlN2FoYjk2UlBZNG9JdW9uZENla095VUdGamZtQ0lNelVEOG55UnAtMERuME1GYjVRcFhkQ21Pc0ZobHczUXNVR0p3MldyZjhjSHB4ekJWUEpDX01keUh3N3dKUW9ILWhGTDN0OWhhNGhQZ0xyaHlSc05hbVBndWxFZDhMSktkR1Zla0kzZ3YzRnFtcHpYNXFUX1RoSDdSSmdmX2hJQmR1ckdnb3c?oc=5",
    "date": "2016-02-10T08:00:00.000Z",
    "dateFormatted": "10/02/2016",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "US FDA Inspections in China: An Analysis of Form 483s from 2015  Regulatory Affairs Professionals Society | RAPS",
    "company": "TBD",
    "types": [
      "form_483"
    ],
    "severity": 6,
    "priority": 3
  },
  {
    "id": "aeb743957a316c6028f6539017851d8d",
    "title": "FDA issues warning to AcelRx for making false and misleading claims about the risks and benefits of Dsuvia - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPSFRJdDk2OHJxN2dmUFN4TS0tRk1OXzI2ZUxiM3VfVFNjbVJ5UXk0YnQtT1ZGX0Q5VFdpU1kwOFI2Zm1rNFFHUEFsX2c3UTNpOHVXSmlZNWF4amVUclAxS3hDSjdHSkxnQTR2YURKVHhnUVEwNklmVUR2WDg0a1RjRzdBbThHcmFieFU4LUV3VXNRLVdEbUVwNURoMDExdEpTQkxhblNoNVhrOVA2RVhreEVGNWRtVE5DWEJkVC1FX2NjOWIyb280dVhBdlc2OE9NRTd0d0NCeThnQkNfYURVMg?oc=5",
    "date": "2021-02-16T08:00:00.000Z",
    "dateFormatted": "16/02/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "FDA issues warning to AcelRx for making false and misleading claims about the risks and benefits of Dsuvia  fda.gov",
    "company": "TBD",
    "types": [
      "opdp"
    ],
    "severity": 5,
    "priority": 3
  },
  {
    "id": "1b5c48ce3778a1f49593dd4be516e277",
    "title": "INSTRUCTIONS FOR COMPLETING FORM FDA 2253 – TRANSMITTAL OF ADVERTISEMENTS AND PROMOTIONAL LABELING FOR DRUGS AND BIOLOGICS FOR - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAxNUVsUHFxaVMzYnVkMGZkSVdFRDJzeS13SGFobVVSVVk5TmNyNkpueDJRM0JKY2tqQnVWWlF2a1Fja1BBWlduaDZua0FDWVdsMHVV?oc=5",
    "date": "2019-11-01T09:36:26.000Z",
    "dateFormatted": "01/11/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "INSTRUCTIONS FOR COMPLETING FORM FDA 2253 – TRANSMITTAL OF ADVERTISEMENTS AND PROMOTIONAL LABELING FOR DRUGS AND BIOLOGICS FOR  fda.gov",
    "company": "TBD",
    "types": [
      "opdp"
    ],
    "severity": 5,
    "priority": 3
  },
  {
    "id": "34fc917b7559ffe15b6749e89292d5df",
    "title": "Providing Regulatory Submissions in Electronic and Non-Electronic Format - Promotional Labeling and Advertising Materials for Hu - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9tZDI3aFBOLWpBSFRNSU13OVBZQkxpVUN1WWpRMFl6VDBOdzRydlRwdWhicTNCRHlNNVpfUG5EbW5UUUNsc3RYcGRBSm1ZQU5xX3gw?oc=5",
    "date": "2019-06-21T17:04:33.000Z",
    "dateFormatted": "21/06/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Providing Regulatory Submissions in Electronic and Non-Electronic Format - Promotional Labeling and Advertising Materials for Hu  fda.gov",
    "company": "TBD",
    "types": [
      "opdp"
    ],
    "severity": 5,
    "priority": 3
  },
  {
    "id": "4574848ff4c15dcc996732bcf269abeb",
    "title": "Over-The-Counter Monograph Drug User Fee Program (OMUFA)",
    "link": "http://www.fda.gov/industry/fda-user-fee-programs/over-counter-monograph-drug-user-fee-program-omufa",
    "date": "2025-09-09T12:43:40.000Z",
    "dateFormatted": "09/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "A user fee program for nonprescription (over-the-counter or OTC) monograph drugs would be a potential funding mechanism to supplement congressional non user-fee appropriations.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "2008ef1503d7a98583335cc031f74d82",
    "title": "Abbreviated New Drug Application (ANDA) Forms and Submission Requirements",
    "link": "http://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-forms-and-submission-requirements",
    "date": "2025-09-09T12:30:41.000Z",
    "dateFormatted": "09/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "The FDA aspires to assist applicants in developing abbreviated new drug applications (ANDAs). To facilitate the development of an ANDA, agency provides the following resources on ANDA forms and submission requirements.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "40b14700704bec2dd4da3e5dd1a7fc3d",
    "title": "STAT+: Obesity drugs may be pricey, but they’re also cost-effective, analysis finds",
    "link": "https://www.statnews.com/pharmalot/2025/09/09/wegovy-zepbound-novo-lilly-icer-value-price-obesity-weight/?utm_campaign=rss",
    "date": "2025-09-09T12:00:00.000Z",
    "dateFormatted": "09/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "Despite high price tags, the Wegovy and Zepbound obesity drugs are considered to be cost-effective, according to a new preliminary analysis.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "786243a37857bbded5e24cc3cab376c1",
    "title": "Drugs@FDA Data Files",
    "link": "http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files",
    "date": "2025-09-09T11:57:29.000Z",
    "dateFormatted": "09/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "535a6d9c97f1c28d7b393215812f2873",
    "title": "Eli Lilly offers AI models to biotechs with TuneLab launch",
    "link": "https://endpoints.news/eli-lilly-offers-ai-models-to-biotechs-with-tunelab-launch/",
    "date": "2025-09-09T11:00:16.000Z",
    "dateFormatted": "09/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Eli Lilly is offering an unusual deal to any biotech: contribute some data, and in exchange, get access to many of Lilly's own AI models.\r\n\r\n The initiative, called TuneLab, debuted Tuesday with a dozen biotech ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "67328b8e38890fc5e074771b6a6a6ba0",
    "title": "STAT+: Lilly will let small biotechs use its AI models at no cost",
    "link": "https://www.statnews.com/2025/09/09/eli-lilly-ai-tunelab-biotech-drug-insitro/?utm_campaign=rss",
    "date": "2025-09-09T11:00:00.000Z",
    "dateFormatted": "09/09/2025",
    "source": "STAT News Biotech",
    "sourceCategory": "trade",
    "summary": "Lilly is opening up its proprietary AI models to biotech companies that want to use them to jumpstart their science.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "af1c61812c4dcc281003a2cf1550f8ee",
    "title": "Novartis to spend $1.4B on Tourmaline Bio, gaining new heart drug",
    "link": "https://endpoints.news/novartis-to-spend-1-4b-on-tourmaline-bio-gaining-new-heart-drug/",
    "date": "2025-09-09T10:47:20.000Z",
    "dateFormatted": "09/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Novartis said Tuesday that it would buy Tourmaline Bio for $1.4 billion in a bid to revitalize its cardiovascular offering.\r\n\r\n The Swiss pharma said it would pay $48 per share in ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "948ca5ade26b07c7efb96d83ce618b80",
    "title": "Ridge Bio raises $25M to help drugmakers come up with better ADCs",
    "link": "https://endpoints.news/ridge-bio-raises-25m-to-help-drugmakers-come-up-with-better-adcs/",
    "date": "2025-09-09T10:00:04.000Z",
    "dateFormatted": "09/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "A new California startup announced itself Tuesday with $25 million in seed funding, some major scientific backers, and the hope of helping biopharma companies make better antibody-drug conjugates and other biologics.\r\n\r\n Ridge Biotechnologies says it ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "7eb54448e484e41225771fc802fb2d74",
    "title": "STAT+: Novartis to buy Tourmaline Bio, gaining promising heart medicine",
    "link": "https://www.statnews.com/2025/09/09/novartis-tourmaline-bio-heart-disease-acquisition-pacibekitug/?utm_campaign=rss",
    "date": "2025-09-09T07:43:55.000Z",
    "dateFormatted": "09/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "Novartis said it would buy Tourmaline Bio in a deal worth $1.4 billion, building out its pipeline with a promising heart medicine.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "ad46cdcd66e376bd75c0fcaa561b6196",
    "title": "BioNTech says dual-acting lung cancer drug helped shrink tumors",
    "link": "https://www.biopharmadive.com/news/biontech-bristol-myerspumitamig-lung-cancer-phase-2-results/759523/",
    "date": "2025-09-08T23:14:00.000Z",
    "dateFormatted": "09/09/2025",
    "source": "BioPharma Dive",
    "sourceCategory": "trade",
    "summary": "The Bristol Myers-partnered bispecific antibody kept small cell lung cancer under control in participants enrolled in a Phase 2 trial.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "9ba005ab1433bfe0ab3a8a31637b138e",
    "title": "Safety Labeling Change Orders",
    "link": "http://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/safety-labeling-change-orders",
    "date": "2025-09-08T19:53:44.000Z",
    "dateFormatted": "08/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(o)(4)) authorizes FDA to require application holders for certain drugs to make labeling changes based on new safety information. Learn more.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "bbdc88e9650420902104648b5c3ff968",
    "title": "A new class of sleep drugs draws Wall Street’s attention",
    "link": "https://www.biopharmadive.com/news/orexin-data-takeda-alkermes-eisai-world-sleep-medical-conference/759530/",
    "date": "2025-09-08T19:48:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "BioPharma Dive",
    "sourceCategory": "trade",
    "summary": "Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "80ccf6db495ed70d8687634073a0fce4",
    "title": "Biosimilars Guidances",
    "link": "http://www.fda.gov/vaccines-blood-biologics/general-biologics-guidances/biosimilars-guidances",
    "date": "2025-09-08T19:39:27.000Z",
    "dateFormatted": "08/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "This page lists Biosimilars Guidance documents.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "43b4c1a819774e8cfc402f774afe0b7a",
    "title": "Newly Added Guidance Documents",
    "link": "http://www.fda.gov/drugs/guidances-drugs/newly-added-guidance-documents",
    "date": "2025-09-08T19:39:25.000Z",
    "dateFormatted": "08/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "Guidance documents represent the FDA's current thinking on a particular subject. New guidance documents are listed here for three months.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "0b35a9383591902f93722555914da013",
    "title": "Recently Issued Guidance Documents",
    "link": "http://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents",
    "date": "2025-09-08T19:39:17.000Z",
    "dateFormatted": "08/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "This page lists Recently Issued CBER and Cross-Center Guidance Documents.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "654f0f803170f4ae27e6a44caece1d62",
    "title": "What’s New for Biologics",
    "link": "http://www.fda.gov/vaccines-blood-biologics/news-events-biologics/whats-new-biologics",
    "date": "2025-09-08T19:38:43.000Z",
    "dateFormatted": "08/09/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "Latest news from the Center for Biologics Evaluation and Research",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "679d43808a86538681d7868859b67d69",
    "title": "What's New Related to Drugs",
    "link": "http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs",
    "date": "2025-09-08T19:36:48.000Z",
    "dateFormatted": "08/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "e1f044946e45dd11a11db9ef3809284d",
    "title": "E6(R3) Good Clinical Practice (GCP)",
    "link": "http://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp",
    "date": "2025-09-08T19:34:43.000Z",
    "dateFormatted": "08/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "The Food and Drug Administration is announcing the availability of a final guidance for industry entitled “E6(R3) Good Clinical Practice.”  This revision incorporates flexible, risk-based approaches and embraces innovations in trial design, conduct, and technology.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "901ef12880376be310866b8c5aba8a0a",
    "title": "Human Drug Compounding Outsourcing Facility Fees",
    "link": "http://www.fda.gov/industry/fda-user-fee-programs/human-drug-compounding-outsourcing-facility-fees",
    "date": "2025-09-08T19:32:46.000Z",
    "dateFormatted": "08/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "Human Drug Compounding Outsourcing Facility Fees",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "e44af238ff0364c3aae3294404eaff29",
    "title": "Summit plays defense for the first time as questions loom over Phase 3 data",
    "link": "https://endpoints.news/summit-plays-defense-for-the-first-time-as-questions-loom-over-phase-3-data/",
    "date": "2025-09-08T19:01:44.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Did Summit Therapeutics set expectations too high?\r\n\r\n Excitement has been building over its cancer drug ivonescimab over the last two years as the company, investors and clinicians all wondered if it could pose a major ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "caaeee8796171ba35108b73a977115eb",
    "title": "New FDA approval pathway for n-of-1 therapies coming soon, Prasad says",
    "link": "https://endpoints.news/new-fda-approval-pathway-for-n-of-1-therapies-coming-soon-prasad-says/",
    "date": "2025-09-08T18:57:01.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "The success story of baby KJ’s customized CRISPR therapy and the prospects for others like it have the FDA readying a new approval pathway for those with extremely limited treatment options.  ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "78c09800ff4a7d841bebf487f96bc5bb",
    "title": "Pfizer reports new Covid-19 vaccine data from open-label study",
    "link": "https://endpoints.news/pfizer-reports-new-covid-19-vaccine-data-from-open-label-study/",
    "date": "2025-09-08T18:13:38.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Pfizer says a new formulation of its Covid-19 vaccine boosted antibody levels by at least four-fold in adults ahead of the upcoming respiratory season.\r\n\r\n The biopharma and Comirnaty co-developer BioNTech released",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "5ecc6a952e593e5bde646cf85a76a222",
    "title": "Eli Lilly’s Jaypirca shows ‘striking’ results in first-line lymphoma patients ",
    "link": "https://endpoints.news/eli-lillys-jaypirca-shows-striking-results-in-first-line-lymphoma-patients/",
    "date": "2025-09-08T17:22:51.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Eli Lilly’s Jaypirca met the primary endpoint in a Phase 3 blood cancer trial, bringing the BTK inhibitor one step closer to a potential approval for previously untreated patients with a type of lymphoma.  ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "f0b42f8e1f8fdaecdb2824b70023b5ec",
    "title": "Pfizer, BioNTech showcase new data supporting COVID booster",
    "link": "https://www.biopharmadive.com/news/pfizer-biontech-immunogenicity-data-covid-booster/759504/",
    "date": "2025-09-08T16:01:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "BioPharma Dive",
    "sourceCategory": "trade",
    "summary": "The companies said their updated shot spurred an increase in neutralizing antibodies against currently circulating strains, answering calls for more corroborating evidence.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "7f72e9c5d9a09d0ef935d4e0dbc49141",
    "title": "New Summit data clouds approval pathway in lung cancer",
    "link": "https://www.biopharmadive.com/news/summit-ivonescimab-chemotherapy-lung-cancer-harmoni-wclc/759476/",
    "date": "2025-09-08T15:53:48.000Z",
    "dateFormatted": "08/09/2025",
    "source": "BioPharma Dive",
    "sourceCategory": "trade",
    "summary": "A combination of ivonescimab and chemo didn’t extend survival over chemo alone in a global trial, missing a key goal often emphasized by regulators.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a7c0e8209e38e35b84377226a65c017e",
    "title": "Rapport shares double on better-than-expected seizure drug data",
    "link": "https://www.biopharmadive.com/news/rapport-seizure-phase-2-study-results-stock-double/759486/",
    "date": "2025-09-08T15:50:15.000Z",
    "dateFormatted": "08/09/2025",
    "source": "BioPharma Dive",
    "sourceCategory": "trade",
    "summary": "One analysts called the Phase 2 study results a “best-case scenario” for a drug Rapport is developing to treat focal onset seizures.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "810d2154d9b81987bebd21df1bddc23f",
    "title": "Dianthus’ selective complement inhibitor yields Phase 2 success in myasthenia gravis",
    "link": "https://endpoints.news/dianthus-selective-complement-inhibitor-yields-phase-2-success-in-myasthenia-gravis/",
    "date": "2025-09-08T15:29:39.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Dianthus Therapeutics on Monday shared positive mid-stage data in generalized myasthenia gravis for an antibody candidate that it believes has “pipeline-in-a-product” potential for neuromuscular diseases.\r\n\r\n The drug, called claseprubart, hit multiple efficacy endpoints in the ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "2ec5bb92376d77a4b2b5045772bc3ae9",
    "title": "Generic Drug Facilities, Sites and Organization Lists",
    "link": "http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists",
    "date": "2025-09-08T15:05:58.000Z",
    "dateFormatted": "08/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "Generic Drug Facilities, Sites and Organization Lists",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "355881c97536c50287f976bbce6a469e",
    "title": "FDA’s Sixth Online Controlled Substances Summit - 09/11/2025",
    "link": "http://www.fda.gov/drugs/news-events-human-drugs/fdas-sixth-online-controlled-substances-summit-09112025",
    "date": "2025-09-08T15:02:56.000Z",
    "dateFormatted": "08/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "FDA, in partnership with the Reagan-Udall Foundation, will host the sixth Online Controlled Substances Summit on September 11, 2025.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "7c96eaccd8564330425acda5ac7c9509",
    "title": "#WCLC25: BioNTech, Bristol Myers tout PD-L1xVEGF results in small cell lung cancer",
    "link": "https://endpoints.news/wclc25-biontech-bristol-myers-tout-pd-l1xvegf-results-in-small-cell-lung-cancer/",
    "date": "2025-09-08T15:00:45.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "BioNTech and Bristol Myers Squibb said their PD-L1xVEGF drug used alongside chemotherapy showed promise in a mid-stage study for an aggressive form of lung cancer.\r\n\r\n In the Phase 2 trial, the companies tested two different ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "2348472eb0accba061c3f8140765bd76",
    "title": "FDA Demurs on GLP-1 Compounding Fight, Debuts Consumer ‘Green List’ Instead",
    "link": "https://www.biospace.com/policy/fda-demurs-on-glp-1-compounding-fight-debuts-consumer-green-list-instead",
    "date": "2025-09-08T15:00:40.000Z",
    "dateFormatted": "08/09/2025",
    "source": "BioSpace",
    "sourceCategory": "trade",
    "summary": "While a win for consumers, the regulatory action did nothing to stem the manufacture of compounded versions of the popular obesity drugs that are made by Novo Nordisk and Eli Lilly. In fact, the FDA seems to be signaling that “some level of compounded product is acceptable,” according to BMO Capital Markets.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "4aaa9d7420c6aa806973704991e15e61",
    "title": "After FDA rejects Saol’s ultra-rare disease prospect, advocacy groups urge patients to press Congress - Fierce Biotech",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNTmVlY2Y4UEtVYVZqNkN5Vjl5VUlWMXZ0TGJQSnRQanBPY29iV1ZOMTFzbFF3NXZ2ZkhsdXpNcUtYVDRqOEpqUkNKNVBmMTlEZVBVWHZQTnZLYWMxdi1wQ1htQmdUZk04LWRjOTBjanBxVEIzc19kcHo5cjV2TWludWM1ZFN4LVd2aFRVblRyVWJYLWwxRFFQVWNiRV90a3BHaWY0RllJSFU3MC1pMDFCQ0Z0MGc2ejFTektEUFBzbDIwQXNSNEE?oc=5",
    "date": "2025-09-08T14:59:03.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "After FDA rejects Saol’s ultra-rare disease prospect, advocacy groups urge patients to press Congress  Fierce Biotech",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "9720c9d54d6fed7afdb2d6df6f8c6225",
    "title": "LB Pharma seeks $228M in proposed IPO with hopes to be industry's first since February",
    "link": "https://endpoints.news/lb-pharma-seeks-228m-in-proposed-ipo-with-hopes-to-be-industrys-first-since-february/",
    "date": "2025-09-08T14:58:58.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "LB Pharmaceuticals, a biotech developing a twist on the decades-old schizophrenia treatment amisulpride, estimates it could gain net proceeds of $228 million from a Nasdaq IPO.\r\n\r\n The New York-based biotech could garnish that amount if ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "8a08b3c14a0c7c15b43a61ffaacb2f35",
    "title": "REUMA KING may be harmful due to hidden drug ingredients",
    "link": "http://www.fda.gov/drugs/medication-health-fraud-notifications/reuma-king-may-be-harmful-due-hidden-drug-ingredients",
    "date": "2025-09-08T14:53:24.000Z",
    "dateFormatted": "08/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "FDA laboratory analysis confirmed that REUMA KING contains dexamethasone, diclofenac, and methocarbamol not listed on the product label.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "090baed670ada80a1339ad1c71118437",
    "title": "Exclusive: Cancer care startup Daymark Health raises $20M",
    "link": "https://endpoints.news/exclusive-cancer-care-startup-daymark-health-raises-20m/",
    "date": "2025-09-08T14:49:51.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Cancer care startup Daymark Health has raised $20 million in Series A funding less than half a year after its seed raise, Endpoints News learned exclusively.\r\n\r\n That's according to a securities filing dated Sept. 3 ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "4c289ad0422b2370d8e69dcb345eaaf2",
    "title": "A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria",
    "link": "https://www.biopharmadive.com/news/nrg-therapeutics-series-b-parkinsons-als-mitochondria-mptp/759403/",
    "date": "2025-09-08T14:13:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "BioPharma Dive",
    "sourceCategory": "trade",
    "summary": "The venture arms of Merck KGaA and Novartis are among the investors involved in raising $67 million for NRG Therapeutics, which aims to bring its first medicine into clinical testing next year.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d9b2f8c0b124bc1c96448ca0e63b7099",
    "title": "BridgeBio's Phase 2 hypoparathyroidism data; FDA clears second pig kidney trial",
    "link": "https://endpoints.news/bridgebios-phase-2-hypoparathyroidism-data-fda-clears-second-pig-kidney-trial/",
    "date": "2025-09-08T14:11:52.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Plus, news about Saol Therapeutics, Eisai, Takeda's Vonvendi, Junshi Biosciences, Belite Bio, Integra Therapeutics, Novonesis and Novo Nordisk:\r\n\r\n 📊 BridgeBio’s positive hypoparathyroidism results: The biotech’s encaleret normalized urine ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "0a22566002ce33a1c578f43595ed8e4b",
    "title": "STAT+: Pig kidneys to enter FDA-backed human trial next year",
    "link": "https://www.statnews.com/2025/09/08/biotech-news-pfizer-biontech-arena-takeda-alkermes/?utm_campaign=rss",
    "date": "2025-09-08T13:58:49.000Z",
    "dateFormatted": "08/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "And other biotech news, brought to you by The Readout.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "67c5b8a5139319885d09a30dfa9ec5cf",
    "title": "STAT+: Pharmalittle: We’re reading about FDA and imported GLP-1 drugs, a race to develop sleep meds, and more",
    "link": "https://www.statnews.com/pharmalot/2025/09/08/who-diabetes-teva-merck-perrigo-sleep-fda-glp-obesity-compounding/?utm_campaign=rss",
    "date": "2025-09-08T13:11:02.000Z",
    "dateFormatted": "08/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "The FDA is tightening oversight of imports of GLP-1 drug ingredients amid concerns many of the items may be adulterated and pose a safety risk",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "d0af8faf38b2aa3c6d796df98fed99f4",
    "title": "Classification Categories for Certain Supplements Under BsUFA III",
    "link": "http://www.fda.gov/regulatory-information/search-fda-guidance-documents/classification-categories-certain-supplements-under-bsufa-iii",
    "date": "2025-09-08T13:05:04.000Z",
    "dateFormatted": "08/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "Classification Categories for Certain Supplements Under BsUFA III",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "68c81e4ba4bc6d4689faf83e13e04d66",
    "title": "Saol CRL Suggests Gap Between US FDA Rare Disease Flexibility Promises And Outcomes - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMinwJBVV95cUxQM3FzVVFYVFdiTE53czlLRTlwNzE2YXVQYlNLS1dPUWlvaHV5SkljVE0xQnhndFc3bS1GZ3dxdlVpQVhHV1ZlbmR0N3ROUXZXU09GU19NVkcxNkNDQmlDUmhJVUg4ZlhEaUk4NWZlUDNNcFRiOTUxclc2SXJuclJQd3BoVFdBOElMeEJnZjlBX0E0Vl8xNk05MWJ2NmdPZGpkd0pFcmZqZVlYWVA3OXFhTDlDZXZpdHFULTVVMU1IbU9UUU1aLUVDMU9SZEw1bjlwbGRmeWZrM2hkYk1BbENPRVRBSUI3SGNBR1l4V0JiOTNVYTFYT0tSaV80M1FjWEdCV0NRS1NpNVY2WUZOekEtZzFXSC16bFBYajVQS1JkUQ?oc=5",
    "date": "2025-09-08T13:01:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Saol CRL Suggests Gap Between US FDA Rare Disease Flexibility Promises And Outcomes  insights.citeline.com",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "b10e88e1371feaef588fbf42c9dd242e",
    "title": "Development of Therapeutic Protein Biosimilars:  Comparative Analytical Assessment and Other Quality-Related Considerations   Guidance for Industry",
    "link": "http://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-therapeutic-protein-biosimilars-comparative-analytical-assessment-and-other-quality",
    "date": "2025-09-08T12:58:32.000Z",
    "dateFormatted": "08/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "Development of Therapeutic Protein Biosimilars:  Comparative Analytical Assessment and Other Quality-Related Considerations   Guidance for Industry",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "16f7b847ad85e3366d4ea426910fadb7",
    "title": "Inside pharma’s race to deliver new treatments for dwarfism",
    "link": "https://www.pharmavoice.com/news/pharma-drug-dwarfism-tyra-biomarin-achondroplasia/759430/",
    "date": "2025-09-08T12:00:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "PharmaVoice",
    "sourceCategory": "trade",
    "summary": "By targeting the underlying genetic mutation that drives the condition, researchers hope to increase height and address debilitating complications.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a176f83380d8c80d2414cb5b3aec4ad6",
    "title": "Biotech vet Harvey Berger steps into CEO role at Arena BioWorks",
    "link": "https://endpoints.news/biotech-vet-harvey-berger-steps-into-ceo-role-at-arena-bioworks/",
    "date": "2025-09-08T11:00:33.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Less than two years after making their public debut, the founders of Arena BioWorks have tapped longtime biotech pro Harvey Berger to take over as CEO.\r\n\r\n And he’s just completed his first task by narrowing ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "58a40884bbba54fe6f01c73e69ace02f",
    "title": "STAT+: Biotech veteran Harvey Berger takes over as CEO of billionaire-backed Arena Bioworks",
    "link": "https://www.statnews.com/2025/09/08/arena-bioworks-harvey-berger-ceo/?utm_campaign=rss",
    "date": "2025-09-08T11:00:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "STAT News Biotech",
    "sourceCategory": "trade",
    "summary": "Arena BioWorks, the research institute that launched last year with $500 million from a group of high-profile billionaires, has brought on a new CEO.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "bba13e93e2a2d1e96817c8a43843be6c",
    "title": "STAT+: Rapport shares soar after successful mid-stage seizure trial",
    "link": "https://www.statnews.com/2025/09/08/rapport-rap219-focal-seizures-epilepsy-trial-results/?utm_campaign=rss",
    "date": "2025-09-08T10:55:13.000Z",
    "dateFormatted": "08/09/2025",
    "source": "STAT News Biotech",
    "sourceCategory": "trade",
    "summary": "A Rapport Therapeutics seizure medicine succeeded in a mid-stage clinical trial, sending company shares soaring.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "ce418b297083f37d34b5f83159de280a",
    "title": "Rapport reveals promising open-label study data for epilepsy pill, heads to Phase 3",
    "link": "https://endpoints.news/rapport-reports-promising-open-label-study-data-for-epilepsy-pill-heads-to-phase-3/",
    "date": "2025-09-08T10:00:35.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Rapport Therapeutics' shares {$RAPP} jumped 170% at market open Monday after it posted topline mid-stage data indicating that its epilepsy pill can cut seizure frequency.\r\n\r\n However, the trial was small and ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "92eaa8126671d60058eb1004e58eb24a",
    "title": "Driving precision oncology development: Integrated biomarker testing solutions that deliver impact",
    "link": "https://www.biopharmadive.com/spons/driving-precision-oncology-development-integrated-biomarker-testing-soluti/759259/",
    "date": "2025-09-08T09:00:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "BioPharma Dive",
    "sourceCategory": "trade",
    "summary": "Driving precision oncology with integrated biomarker testing that delivers results.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d67a110be2749d0a58bad1972516e75a",
    "title": "How sponsors are staying ahead in the obesity trial landscape",
    "link": "https://www.biopharmadive.com/spons/how-sponsors-are-staying-ahead-in-the-obesity-trial-landscape/759209/",
    "date": "2025-09-08T09:00:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "BioPharma Dive",
    "sourceCategory": "trade",
    "summary": "Aligning digital innovation with thoughtful design is accelerating progress.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "9c441a0eda03e29cdd473b6242bcfe2b",
    "title": "Harnessing the power of AI to detect ATTR-CM",
    "link": "https://www.biopharmadive.com/spons/harnessing-the-power-of-ai-to-detect-attr-cm/758919/",
    "date": "2025-09-08T09:00:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "BioPharma Dive",
    "sourceCategory": "trade",
    "summary": "From accelerating drug discovery to improving disease detection, AI is transforming the way we understand and manage health.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a1ae8b41d72eadbccdccce8ae5063fea",
    "title": "#WCLC25: AstraZeneca’s Tagrisso combo extends survival by 10 months in EGFR-mutant lung cancer",
    "link": "https://endpoints.news/wclc25-astrazenecas-tagrisso-combo-extends-survival-by-10-months-in-egfr-mutant-lung-cancer/",
    "date": "2025-09-08T08:22:44.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "The combination of AstraZeneca’s Tagrisso and chemotherapy cut the risk of death by 23% compared to Tagrisso alone for patients with advanced EGFR-mutant lung cancer.\r\n\r\n In the FLAURA2 study's key overall survival endpoint, patients who ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "460f64a27cc6a4c69641e270926a6347",
    "title": "#WorldSleep2025: Alkermes’ success in Phase 2 narcolepsy trial is clouded by side effects",
    "link": "https://endpoints.news/alkermes-success-in-phase-2-narcolepsy-trial-is-clouded-by-side-effects/",
    "date": "2025-09-08T07:15:52.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Alkermes’ narcolepsy drug candidate alixorexton significantly improved how long patients can stay awake in a mid-stage trial, but a high rate of vision-related side effects could cause trouble for the treatment.\r\n\r\n Back in July, the ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "9995b3444cd1c1b6953ee040502f2cc0",
    "title": "#WorldSleep2025: Takeda’s Phase 3 narcolepsy results could make it first mover in multibillion-dollar market",
    "link": "https://endpoints.news/takedas-phase-3-narcolepsy-results-could-make-it-first-mover-in-multibillion-dollar-market/",
    "date": "2025-09-08T07:15:19.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Takeda has shared detailed data from two Phase 3 trials of its orexin agonist in narcolepsy type 1, bringing the Japanese drugmaker a step closer to a market that Wall Street says could generate sales ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "c3302394172c43792a54e3f5d79596ca",
    "title": "STAT+: Alkermes, Takeda show encouraging data on narcolepsy drugs",
    "link": "https://www.statnews.com/2025/09/08/alkermes-takeda-narcolepsy-sleep-medicines/?utm_campaign=rss",
    "date": "2025-09-08T07:15:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "STAT News Biotech",
    "sourceCategory": "trade",
    "summary": "Alkermes and Takeda released data on drug candidates that could fuel the race to develop a new class of therapies and transform sleep medicine.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "ab50b76dbae06632533c1b7e999ad136",
    "title": "Mitochondrial startup gets £50M to test lead drug in ALS, Parkinson's",
    "link": "https://endpoints.news/mitochondrial-startup-gets-50m-to-test-lead-drug-in-als-parkinsons/",
    "date": "2025-09-08T07:00:40.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "A British startup trying to target a mitochondrial pathway for neuro disorders has a heap of cash to work with, and it's going after a new frontier in one of the most challenging drug development ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "02bb0bdd7a956ed32cd32abfb28f0005",
    "title": "Servier buys Medicxi startup's fragile X candidate for up to $450M",
    "link": "https://endpoints.news/servier-buys-medicxi-startups-fragile-x-candidate-for-up-to-450m/",
    "date": "2025-09-08T06:30:05.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "French pharma Servier will pay up to $450 million for an experimental fragile X syndrome drug from UK-based startup Kaerus Bioscience, the companies said Monday morning.\r\n\r\n The deal for KER-0193, an oral small molecule that ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "a9d7e04465a653e2e6778efbc9383f91",
    "title": "FDA Expert Panels Lack Balance in Pursuit of ‘Gold Standard Science’",
    "link": "https://www.biospace.com/fda/fda-expert-panels-lack-balance-in-pursuit-of-gold-standard-science",
    "date": "2025-09-08T06:01:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "BioSpace",
    "sourceCategory": "trade",
    "summary": "New FDA expert panels, such as recent meetings on SSRI use during pregnancy and on hormone replacement therapy during menopause, are drawing criticism for being one-sided. One leader says such panels are designed to reach a specific conclusion.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "549bbf86fd76b72da638c7729b302b88",
    "title": "5 Companies Caught on a Carousel of FDA Confusion",
    "link": "https://www.biospace.com/fda/5-companies-caught-on-a-carousel-of-fda-confusion",
    "date": "2025-09-08T04:02:00.000Z",
    "dateFormatted": "08/09/2025",
    "source": "BioSpace",
    "sourceCategory": "trade",
    "summary": "Amid an unprecedented turnover in leadership at the FDA and mass layoffs of staff, communication has crumbled and uncertainty runs rampant, leaving small and medium biopharma companies without a clear path forward for their therapies.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "82bdf7fbb5e6b0048600930fa04fe2d5",
    "title": "China biotech Epigenic raises $60M to test CRISPR epigenetic therapies",
    "link": "https://endpoints.news/china-biotech-epigenic-raises-60m-to-test-crispr-epigenetic-therapies/",
    "date": "2025-09-08T02:00:04.000Z",
    "dateFormatted": "08/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Epigenic Therapeutics has raised a $60 million Series B financing to ramp up clinical tests of what it hopes could be a cure for chronic hepatitis B, using a version of CRISPR gene editing that ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "ad2213b438447e4ed1f640cd8b222d93",
    "title": "#WCLC25: Merck and Daiichi Sankyo head to FDA with ADC for small cell lung cancer",
    "link": "https://endpoints.news/wclc25-merck-and-daiichi-sankyo-head-to-fda-with-adc-for-small-cell-lung-cancer/",
    "date": "2025-09-07T21:31:10.000Z",
    "dateFormatted": "07/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Nearly half of patients with an aggressive form of lung cancer saw their tumors shrink substantially after receiving an antibody-drug conjugate developed by Daiichi Sankyo and Merck, according to the results of a mid-stage trial ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "d4a6a02e76b76a379e5e7c4421a311ee",
    "title": "STAT+: Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster",
    "link": "https://www.statnews.com/2025/09/07/summit-therapeutics-lung-cancer-ivonescimab/?utm_campaign=rss",
    "date": "2025-09-07T08:45:00.000Z",
    "dateFormatted": "07/09/2025",
    "source": "STAT News Biotech",
    "sourceCategory": "trade",
    "summary": "Summit Therapeutics may have a geography problem with its lung cancer drug ivonescimab.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "9ad7845d9efc8c83048d82da56c0dfc9",
    "title": "#WCLC25: Summit reports full Phase 3 data from first group of Western lung cancer patients",
    "link": "https://endpoints.news/wclc25-summit-reports-full-phase-3-data-from-first-group-of-western-lung-cancer-patients/",
    "date": "2025-09-07T07:30:43.000Z",
    "dateFormatted": "07/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Summit Therapeutics released a much-anticipated cut of data in North American and European lung cancer patients on Sunday, trumpeting a new analysis in which its drug ivonescimab, when added to chemotherapy, reduced the risk of ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "7ae6ec5d77d11d63e33ce9fe01c77046",
    "title": "Maraganore, Meanwell team up; FDA publishes CRLs; Endpoints 11: Where are they now?; and more",
    "link": "https://endpoints.news/maraganore-meanwell-team-up-fda-publishes-crls-endpoints-11-where-are-they-now-and-more/",
    "date": "2025-09-06T10:00:53.000Z",
    "dateFormatted": "06/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "Welcome back to Endpoints Weekly! It’s almost time for the Endpoints 11 event in Boston, where we’ll unveil our team’s choice of companies shaping the future of biopharma. Until then, check out Kyle LaHucik’s story ...",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "02919ea1d6c4e96f31478a9b58b9255c",
    "title": "FDA Approves Expanded Use of Vonvendi for von Willebrand Disease, Including for Certain Uses for Children",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-vonvendi-von-willebrand-disease-including-certain-uses-children",
    "date": "2025-09-05T21:34:10.000Z",
    "dateFormatted": "05/09/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "The U.S. Food and Drug Administration today approved expanded use of Vonvendi [von Willebrand factor (Recombinant)] for routine preventative (prophylactic) use in adults (age 18 years and older) with all types of von Willebrand disease (VWD) and on-demand and treatment of bleeding episodes and perio",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "ddcb6ddba647ea328346ee1d11f005e5",
    "title": "Completed BsUFA III Deliverables",
    "link": "http://www.fda.gov/industry/biosimilar-user-fee-amendments/completed-bsufa-iii-deliverables",
    "date": "2025-09-05T20:23:57.000Z",
    "dateFormatted": "05/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "Since the passage of the Biosimilar User Fee Act (BsUFA) in 2012, user fees have played an important role in expediting the process for the review of biosimilar products.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "fd0b49204920fc5af74b37e9763133b6",
    "title": "Pain and Arthritis Products Containing Hidden Ingredients",
    "link": "http://www.fda.gov/drugs/medication-health-fraud-notifications/pain-and-arthritis-products-containing-hidden-ingredients",
    "date": "2025-09-05T20:20:55.000Z",
    "dateFormatted": "05/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "Learn about the warnings for pain and arthritis products that contain hidden drugs and other hidden ingredients.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "8dda11165dde1f9a25be2f91a58f55a1",
    "title": "FTX PLUS may be harmful due to hidden drug ingredients",
    "link": "http://www.fda.gov/drugs/medication-health-fraud-notifications/ftx-plus-may-be-harmful-due-hidden-drug-ingredients",
    "date": "2025-09-05T20:18:10.000Z",
    "dateFormatted": "05/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "FDA laboratory analysis confirmed that FTX PLUS contains dexamethasone phosphate and diclofenac not listed on the product label.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "dfd68ef67713f02da52d320044b4356a",
    "title": "Patient-Focused Drug Development: Workshop #2 to Discuss Methodologic and Other Challenges Related to Patient Experience Data - 09/18/2025",
    "link": "http://www.fda.gov/drugs/news-events-human-drugs/patient-focused-drug-development-workshop-2-discuss-methodologic-and-other-challenges-related",
    "date": "2025-09-05T20:10:22.000Z",
    "dateFormatted": "05/09/2025",
    "source": "FDA CDER Updates",
    "sourceCategory": "official",
    "sourceType": "drugs",
    "summary": "On September 18 and 19, 2025, the U.S. Food and Drug Administration (FDA) is hosting a virtual public workshop to discuss methodological challenges related to patient experience data encountered, including the submission and evaluation of patient experience data in the context of the benefit-risk assessment and product labeling, as well as other ar",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "ce8c4533a774799e858c77b457c44217",
    "title": "FDA chief says agency is probing Covid-19 vaccine deaths in kids",
    "link": "https://endpoints.news/fda-chief-says-agency-is-probing-covid-19-vaccine-deaths-in-kids/",
    "date": "2025-09-05T19:30:39.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Endpoints News",
    "sourceCategory": "trade",
    "summary": "FDA chief Marty Makary said the agency is investigating whether the Covid-19 vaccines caused any deaths in kids, building on the government's monthslong effort to question the safety of the products.\r\n\r\n In",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "e3c1921cf6a75c9ba5aca2f7829ee643",
    "title": "US FDA tightens control over obesity drug ingredient imports amid safety concerns - Reuters",
    "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPNUVkeGR2M2RqYjNiU3VMQlV4eGpCZVR5Q1ZGNGY4REEtS2V1Ukxpd3NBRDNMWGdIQV9VT3BoOUpmazZBcVNlTUpSR2Fya3ZlRVVrclU1QkdFaEhReFlfMjN1SExsOTRRRC1QTGhyX0ItN09SUUtiRFFSckE1ejhWSlQ4aGY5MTlIcnA0RmtqN2NVcDd5bUs1WDczdllFUlYwOExvZ0lQblJxTHJxSHlyZ2c5U3JKWVNaSkpEalZ0WFRPeEQwbVlSeHRzWlpTemFienJkdjNSc1ZNZjlL?oc=5",
    "date": "2025-09-05T19:01:25.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "US FDA tightens control over obesity drug ingredient imports amid safety concerns  Reuters",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "5b9e6ffdde2e6c81c012c970554fb1ef",
    "title": "STAT+: Patient groups cheer as the WHO adds diabetes and cystic fibrosis drugs to its essential medicines list",
    "link": "https://www.statnews.com/pharmalot/2025/09/05/who-medicines-pharma-biotech-diabetes-obesity-cystic-fibrosis-vertex-lilly-novo-sanofi/?utm_campaign=rss",
    "date": "2025-09-05T18:48:39.000Z",
    "dateFormatted": "05/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "For the first time, the WHO has added various high-cost treatments for diabetes and cystic fibrosis to its list of essential medicines.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "c0873da30533c17f7b2105668c9a6cb0",
    "title": "Biologics Electronic Reading Room (eFOIA)",
    "link": "http://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/biologics-electronic-reading-room-efoia",
    "date": "2025-09-05T16:09:17.000Z",
    "dateFormatted": "05/09/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "The Biologics eFOI Reading Room provides access to documents posted throughout the \"Vaccines, Blood & Biologics\" and other sections related to the Center for Biologics Evaluation and Research on the FDA.gov Web site.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "feb2843834b27e2132a2e92aabe95fe6",
    "title": "US FDA tightens control over obesity drug ingredient imports amid safety concerns - Yahoo News Canada",
    "link": "https://news.google.com/rss/articles/CBMidEFVX3lxTE5JZjVQcElqc3V2SUFfVFdid1lac1ZXS1ZuWi16ZzNZRE9hQWJ1bEk3QWk2TFQ2amp2YXBfOHRpeEhSSS1fYmFnTzMwaXdOV0hNSkNQUHluT1ZoUXR1dmRaTXliR21wZkw3a3pMamlnS0daWnp2?oc=5",
    "date": "2025-09-05T16:06:43.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "US FDA tightens control over obesity drug ingredient imports amid safety concerns  Yahoo News Canada",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "5f860bf702c219dc29d7d71e87171908",
    "title": "STAT+: FDA commissioner says agency is looking into question of pediatric deaths from Covid vaccines",
    "link": "https://www.statnews.com/2025/09/05/fda-investigating-childhood-deaths-from-covid-vaccine/?utm_campaign=rss",
    "date": "2025-09-05T15:36:02.000Z",
    "dateFormatted": "05/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "Commissioner Marty Makary said the FDA will release a report within weeks on childhood deaths that he said are linked to Covid shots.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "bf95a6ab97adca21edc7f80b0c20a686",
    "title": "'Several concerning observations': FDA sheds more light on reasons it rejected drugs - Fierce Biotech",
    "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSnluVHU4Znp2MXRyZ2dXUDFUcXh4VTB2aXNsdzZsVHYwN2poQXZmVHc2TjNtT2xVYWRRQnZJTDlXMXFqV0FuR1NCbUVHUzE3NFFXenBVOS1abklsTDFfLWpITUhFT1FsUnoxN0toazNBYjZ3ano3V2ZJbFU3Z1JXS3VQNmtidkNZWjRBM3dLeGtKcTZEYWdzdDEyQmk5SURBR0pOcDB1bDc?oc=5",
    "date": "2025-09-05T14:45:39.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "'Several concerning observations': FDA sheds more light on reasons it rejected drugs  Fierce Biotech",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "1086ae7cf3c6c8ab57b639c82c166b95",
    "title": "STAT+: Up and down the ladder: The latest comings and goings",
    "link": "https://www.statnews.com/pharmalot/2025/09/05/jobs-biotech-pharma-ladder-sanofi-genmab-merck-icon-iqvia/?utm_campaign=rss",
    "date": "2025-09-05T13:49:40.000Z",
    "dateFormatted": "05/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "566b997ce8a44bb2114842056e50dabc",
    "title": "STAT+: The FDA is getting more transparent about drug rejections",
    "link": "https://www.statnews.com/2025/09/05/biotech-news-fda-lsd-gilead-pfizer/?utm_campaign=rss",
    "date": "2025-09-05T13:32:27.000Z",
    "dateFormatted": "05/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "And more biotech news stories brought to you by The Readout.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "cf139f37db8801741a5bd4b0ccb5a000",
    "title": "STAT+: Pharmalittle: We’re reading about PEPFAR and a Gilead drug, the FDA’s rejection letters, and much more",
    "link": "https://www.statnews.com/pharmalot/2025/09/05/medicare-trump-gilead-pepfar-hiv-aids-fda-crl-cvs-wegovy-zepbound-novo-lilly-jnj-bristol-india-weight-obesity/?utm_campaign=rss",
    "date": "2025-09-05T13:11:53.000Z",
    "dateFormatted": "05/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "The FDA said it would start releasing rejection letters soon after they are provided to drugmakers, a victory for those who wanted more transparency.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "32bb114b16a0db29d40047e4e494049b",
    "title": "At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves",
    "link": "https://www.pharmavoice.com/news/kennedy-rfk-senate-hearing-vaccines-cdc-crisis-acip/759335/",
    "date": "2025-09-05T11:38:01.000Z",
    "dateFormatted": "05/09/2025",
    "source": "PharmaVoice",
    "sourceCategory": "trade",
    "summary": "Robert F. Kennedy Jr. faced criticism Thursday even from Republican lawmakers over changes to federal vaccine policy as well as a leadership crisis at the CDC.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "580004721f08d64b397219788507a9fa",
    "title": "Biocon Biologics’ Bengaluru Unit Gets 5 US FDA Observations, Shares Up 1% - Equitypandit",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPamxjOEVXM2RYbDhPdnpRaXNCNTk1b05RV0lCMU0tYzg2Ml9KMEZ0QURRbzVfa0xZMnR6azBOQ2xrWWdqWlNFWER2bEFLejBpRzNmMkM4NnRZX3ZtVW9zNDl6aUUwSzlOMlphQ3NRNnF3Z04zTlhRd21pemQzMlV2MGpzTllvZERZWFowTnF4VldlVENnZEZWVFJoRkdKb1ZzTXc?oc=5",
    "date": "2025-09-05T08:54:26.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Biocon Biologics’ Bengaluru Unit Gets 5 US FDA Observations, Shares Up 1%  Equitypandit",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "c3745d931510737450854c71d9e7d6e7",
    "title": "STAT+: Donavon Decker knew a gene therapy experiment wouldn’t help him. To help others, he still said yes",
    "link": "https://www.statnews.com/2025/09/05/gene-therapy-pioneer-donavon-decker-remembered/?utm_campaign=rss",
    "date": "2025-09-05T08:30:00.000Z",
    "dateFormatted": "05/09/2025",
    "source": "STAT News Biotech",
    "sourceCategory": "trade",
    "summary": "Long before there was Sarepta's gene therapy for muscular dystrophy, there was Donavon Decker and his offer to test a gene therapy.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "dc499be17549c486a2cba616458c434c",
    "title": "FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOeUpYZ0JlQzltX2t3WFVraHZCLWl4VEszY2N3MDAzdnVud2xxT3B5Zi1tTGx5VEU5aGFEYVlBUndraXlTU0prcU5Sd0c1SHVQN3d2aGszX0ZOUFVzcU0tOUoyRzhySzd5NkNCVzhzNDhsT0huMkpXY2d5ZjNSdDhWYkh2OGhSQUZFemw2dFdyeGd4YkxYTTRJUFljdWtMd3VFQ1ZLQzVIdkptMW9rVW5xYTN2QmJvc3hobFRlZ00yTjA2LVpQZ3dPNGFFUDVzZw?oc=5",
    "date": "2025-09-05T04:00:00.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6901999da09855b3991f96b0f9205934",
    "title": "FDA Approves Expanded Use of Vonvendi for von Willebrand Disease, Including for Certain Uses for Children - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNc25Xa2plaGx0Z0dkRlpVdm9mRjlnbmdQY25SMVYtcnN4RXJ3N21ISHRvajRDZzhXWFUyVl90UjJ6LW5XOS1WVlUydENiTFVUeEVjYy1ranE2Mk1DVkxqbm9SNGpTR2M4dEU0S3NnRi1hUk9Nemk0WDlLMFYzSU5oN2NfZmp2cFpDbUtYM0F0N2wyNnFIdUxFZDZka01xZndoMjF5UzlOdm16eHNTaDl4QXZTQW5Dc2JHVEw0S3ZLUFdMRFh4XzdDUkVsMGFudTFQcnRLc3FXNlE?oc=5",
    "date": "2025-09-05T04:00:00.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Approves Expanded Use of Vonvendi for von Willebrand Disease, Including for Certain Uses for Children  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "112d51668081ef5fd274c0ff357df692",
    "title": "FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPMmF0blZZSEctSzFyVmZ2a3RkSnZoSG5jTW9JRV9Qa05IdUpwRlM1MlM3N1FLMmdJQnVJOXFTd2w0S1RkOGpOZURQcy1ydlRuV3BtQWVyOTdtNGtVYUV2WVdDVEhRbjNBSWN0MmZvNGhFdVktbHdmN09TNUt3NEtHSjFneXBxeDBfLVdmZ3I1YjRKSXFWTkRRWU5OMXJyLUJpeDZoNGJsTV9yZ3NWeTItTWQzWlNRaXc2ZWN6YUpISWoyYjFKbUdhSHY0Z2k5VUZrRDk0?oc=5",
    "date": "2025-09-05T00:00:00.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "29ab2708e1cf237d89fb0d2240f5b4b0",
    "title": "FTX PLUS may be harmful due to hidden drug ingredients - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPa0U3MEpnWG9MUkFNdzR4YUlrMXE0djRMOGI0ODR1aXg1SlByOTVxQnF4UzM3bTNTc0RwNmNHVFU5Z2VQTTgwamsxaTlWZFgzTlVoQjhneXFVSnlaT2dkSUJnZFRBN2YxZTNhTlJnVXVpUGZYTUdEQlI1QkE2anhTU3lSYzdDTmhTWXVkcHV3MlZiVkZPNzlqd2JqcG5yems2UWNhek9CeVVZUFdvZ1VQQ0o2SVJtdw?oc=5",
    "date": "2025-09-05T00:00:00.000Z",
    "dateFormatted": "05/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FTX PLUS may be harmful due to hidden drug ingredients  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "1cb85cc56bd45043bb6b7113b87d437f",
    "title": "STAT+: Trump administration confirms plan for PEPFAR to distribute Gilead’s new HIV prevention drug",
    "link": "https://www.statnews.com/pharmalot/2025/09/04/gilead-hiv-aids-pepfar-trump-lenacapavir-licensing/?utm_campaign=rss",
    "date": "2025-09-04T20:56:03.000Z",
    "dateFormatted": "04/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "\"This is a really significant moment in the fight against HIV and AIDS.”",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "7942717618d0c5c46c2cada399633f79",
    "title": "FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub - Fierce Biotech",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPcThla0JHRzd3ci1sWnVhWUluMmliSWFmeEFQUTdNaG5WREpNU2xQZHRURGNuSFV6ZEpzaTNObDZ2OWkxWHVJS3Bvd2xmS3dfNjhiNUEyb2NKMU9CQUJTd21EbVFiVWFzak5oM1ZCcllXVnNDN2VqNHoxVlFDbDc0TkJQanpNd2FQbDZsZXoyVnhvZTdMRUZiQ1FqX1BqXy1JTkJaZ2FHeUZqdEc5V1RDRWFpVUhmRlN5ZFNhQ2o5ZEJxRkF0?oc=5",
    "date": "2025-09-04T17:45:28.000Z",
    "dateFormatted": "04/09/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub  Fierce Biotech",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "244e847dd1c182f6938e0912ff20ffbf",
    "title": "FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future 'Real-Time' Access",
    "link": "https://www.biospace.com/policy/fda-drops-another-cache-of-heavily-redacted-rejection-letters-promises-future-real-time-access",
    "date": "2025-09-04T16:54:14.000Z",
    "dateFormatted": "04/09/2025",
    "source": "BioSpace",
    "sourceCategory": "trade",
    "summary": "Perhaps the most interesting of the pile of FDA rejection letters was for Lykos Therapeutics’ MDMA therapy. Letters sent to Stealth BioTherapeutics, Regeneron and more were also released as the agency also promised future CRLs “promptly after they are issued to sponsors.”",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ce6aced1b1174b4053a2dc7546e22fc1",
    "title": "STAT+: In major shift, FDA to start releasing rejection letters shortly after they’re issued",
    "link": "https://www.statnews.com/pharmalot/2025/09/04/fda-crls-rejection-letters-transparency-makary/?utm_campaign=rss",
    "date": "2025-09-04T16:34:54.000Z",
    "dateFormatted": "04/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "The FDA said it would start releasing rejection letters soon after they are provided to drugmakers, a victory for transparency advocates.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "ce379255ce3b30f935ecef305eade1c7",
    "title": "STAT+: Swing Therapeutics raises $11 million, adds former Pear CEO to board",
    "link": "https://www.statnews.com/2025/09/04/swing-therapeutics-raises-11-million-adds-former-pear-ceo-to-board/?utm_campaign=rss",
    "date": "2025-09-04T15:35:54.000Z",
    "dateFormatted": "04/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "Former Pear CEO joins Swing board — did he invest? My colleague Allison DeAngelis spotted a familiar character pop up in a fresh SEC filing from Swing Therapeutics, developer of…",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "e152693db1c1ef5c72da9d33763930be",
    "title": "TACHOSIL",
    "link": "http://www.fda.gov/vaccines-blood-biologics/approved-blood-products/tachosil",
    "date": "2025-09-04T14:25:57.000Z",
    "dateFormatted": "04/09/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "Product approval information is indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "fcb56be99e63b34182051bca4e7c1006",
    "title": "Biocon Biologics’ Bengaluru facility gets five observations from US FDA inspection - CNBC TV18",
    "link": "https://news.google.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?oc=5",
    "date": "2025-09-04T14:19:05.000Z",
    "dateFormatted": "04/09/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Biocon Biologics’ Bengaluru facility gets five observations from US FDA inspection  CNBC TV18",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ed8f21218ba8688bc10161159da4c460",
    "title": "STAT+: Treeline expands Series A another $200 million",
    "link": "https://www.statnews.com/2025/09/04/biotech-news-treeline-atlas-sanofi-pfizer-agios/?utm_campaign=rss",
    "date": "2025-09-04T13:41:43.000Z",
    "dateFormatted": "04/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "Plus more biotech news from The Readout newsletter.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "f6295a713ba95fe1b89f0a9acc4f37d7",
    "title": "GenoGenix, LLC. Boca Raton, FL. 483 issued 07/18/2025",
    "link": "http://www.fda.gov/about-fda/genogenix-llc-boca-raton-fl-483-issued-07182025",
    "date": "2025-09-04T13:34:59.000Z",
    "dateFormatted": "04/09/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request Please post to the OII FOIA Electronic Reading Room\nRecord Date 07/18/2025\nShort Title (70 char) GenoGenix, LLC. Boca Raton, FL. 483 issued 07/18/2025\nFEI Number 3032144832\nFirm Name GenoGenix, LLC\nRecord Type 483\nState FL\nEstablishment Type Outsourcing Facility",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "570e689d11a6469d323a69791cfd6688",
    "title": "STAT+: Pharmalittle: We’re reading about FDA and Covid shots, a Sanofi setback, and much more",
    "link": "https://www.statnews.com/pharmalot/2025/09/04/pfizer-bourla-trump-covid-vaccines-nobel-sanofi-eczema-amneal-contamination-novartis-argo-cardiovascular-jobs-layoffs-fda-prasad/?utm_campaign=rss",
    "date": "2025-09-04T12:58:36.000Z",
    "dateFormatted": "04/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "FDA memos show that the agency’s vaccine chief overruled staff scientists who favored widespread access to Covid shots",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "f9ce34543273f7ea9f5a891ff4c8396a",
    "title": "‘All Wrapper, No Gift’: FDA Releases New Rare Disease Approval Framework",
    "link": "https://www.biospace.com/fda/all-wrapper-no-gift-fda-releases-new-rare-disease-approval-framework",
    "date": "2025-09-04T12:46:38.000Z",
    "dateFormatted": "04/09/2025",
    "source": "BioSpace",
    "sourceCategory": "trade",
    "summary": "While the new framework signals continued flexibility at the FDA regarding rare disease approvals, some analysts and advocates question what tangible impacts the new guidelines will have.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "b10125ab27ee841cd6cbed916dde8fae",
    "title": "International appeal: Europe and UK lure US scientists with financial incentives",
    "link": "https://www.pharmavoice.com/news/europe-uk-us-scientists-financial-incentive/759213/",
    "date": "2025-09-04T11:42:05.000Z",
    "dateFormatted": "04/09/2025",
    "source": "PharmaVoice",
    "sourceCategory": "trade",
    "summary": "With slashed budgets and decimated research programs, American scientists are increasingly looking for career opportunities abroad.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "0c8a3914bec82e6cd693e9451577e173",
    "title": "STAT+: Biotech VC raises $400 million ‘opportunity’ fund in sign of possible industry rebound",
    "link": "https://www.statnews.com/2025/09/04/atlas-venture-biotech-opportunity-fund/?utm_campaign=rss",
    "date": "2025-09-04T11:00:00.000Z",
    "dateFormatted": "04/09/2025",
    "source": "STAT News Biotech",
    "sourceCategory": "trade",
    "summary": "Prominent biotech VC firm Atlas Venture has another $400 million to invest in drug companies.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "2fb89f44864af78ea81a9bfbbd92f060",
    "title": "STAT+: Sanofi shares drop after disappointing trial results",
    "link": "https://www.statnews.com/2025/09/04/sanofi-amlitelimab-immunology-atopic-dermatitis-eczema/?utm_campaign=rss",
    "date": "2025-09-04T10:33:01.000Z",
    "dateFormatted": "04/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "Sanofi shares slid Thursday after the company reported underwhelming results from a closely watched trial in the skin condition atopic dermatitis.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "069c0c313b6420911c0d45dbf348cd76",
    "title": "STAT+: Is biotech back? Don’t jinx it, but the signs are encouraging",
    "link": "https://www.statnews.com/2025/09/04/biotech-back-encouraging-signs/?utm_campaign=rss",
    "date": "2025-09-04T10:30:00.000Z",
    "dateFormatted": "04/09/2025",
    "source": "STAT News Biotech",
    "sourceCategory": "trade",
    "summary": "Is biotech back? Industry stocks, collectively, return to positive territory for the year.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "111efd5b3a2d2c12f267b17dfca3463d",
    "title": "STAT+: Amneal Pharma is scolded by FDA for using contaminated bags for a sterile injectable drug",
    "link": "https://www.statnews.com/pharmalot/2025/09/03/amneal-infusion-sterile-epidural-injectable-fda-contamination/?utm_campaign=rss",
    "date": "2025-09-03T20:54:12.000Z",
    "dateFormatted": "03/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "A pharmaceuticals company relied on contaminated bags for a sterile injectable drug, among other infractions, the FDA found.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "bf4250fbd29f16abd237b842e348c6d8",
    "title": "FDA Advances Rare Disease Drug Development with New Evidence Principles",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-advances-rare-disease-drug-development-new-evidence-principles",
    "date": "2025-09-03T17:59:25.000Z",
    "dateFormatted": "03/09/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "FDA advanced Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability for the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "2a9f89ad4fb803b9fd6d9c905016ec79",
    "title": "STAT+: Why biotech stocks did unusually well yesterday",
    "link": "https://www.statnews.com/2025/09/03/biotech-news-xbi-index-acip-rsv-gilead/?utm_campaign=rss",
    "date": "2025-09-03T16:03:08.000Z",
    "dateFormatted": "03/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "And more biotech stories brought to you by The Readout.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "3eb474e2491233c8e96e338c8b655411",
    "title": "Patient Engagement Collaborative",
    "link": "http://www.fda.gov/patients/learn-about-fda-patient-engagement/patient-engagement-collaborative",
    "date": "2025-09-03T15:53:06.000Z",
    "dateFormatted": "03/09/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "The Patient Engagement Collaborative (PEC) is an advancement in the FDA’s efforts to strengthen its relationship with patient communities and is being coordinated by the FDA’s Public Engagement Staff.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "13dc58845feb44915beb488fa80b9c45",
    "title": "STAT+: Pfizer’s CEO defends Covid vaccines, suggests Trump may deserve a Nobel Peace Prize",
    "link": "https://www.statnews.com/2025/09/03/pfizer-responds-trump-covid-vaccine-safety-effectiveness/?utm_campaign=rss",
    "date": "2025-09-03T15:10:19.000Z",
    "dateFormatted": "03/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "Pfizer CEO Albert Bourla defended the development of Covid vaccines and suggested President Trump may deserve a Nobel Peace Prize because of Operation Warp Speed.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "778badd323ac02c23101f095fdc96cad",
    "title": "Prasad Signals Steeper Requirements for COVID-19 Vaccines",
    "link": "https://www.biospace.com/fda/prasad-signals-steeper-requirements-for-covid-19-vaccines",
    "date": "2025-09-03T15:03:49.000Z",
    "dateFormatted": "03/09/2025",
    "source": "BioSpace",
    "sourceCategory": "trade",
    "summary": "In a series of memos last week, Center for Biologics Evaluation and Research Director Vinay Prasad outlined the FDA’s thinking on the recent limited approvals for updated COVID-19 vaccines.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d8e425f94618f67c66e774f63e1d1b27",
    "title": "CDER/CBER Rare Disease Evidence Principles (RDEP)",
    "link": "http://www.fda.gov/industry/fda-rare-disease-innovation-hub/cdercber-rare-disease-evidence-principles-rdep",
    "date": "2025-09-03T13:54:40.000Z",
    "dateFormatted": "03/09/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "CDER and CBER propose a new regulatory process for the approval of drugs to treat rare diseases with very small patient populations with significant unmet medical need.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "2229b811de4154336fd74b338b1293f3",
    "title": "STAT+: Pharmalittle: We’re reading about Gilead price hikes for HIV drugs, a Novartis China deal, and more",
    "link": "https://www.statnews.com/pharmalot/2025/09/03/gilead-hiv-drugs-novartis-china-deal-cdc-novo-vaccines/?utm_campaign=rss",
    "date": "2025-09-03T13:11:33.000Z",
    "dateFormatted": "03/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "Gilead is seeking to boost prices significantly for several HIV treatments distributed by state AIDS Drug Assistance Programs",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "a8d8462b5440251f495e9c7346017b85",
    "title": "FDA-TRACK: Prescription Drug User Fee Act Meeting Goals Summary",
    "link": "http://www.fda.gov/about-fda/fda-track-agency-wide-program-performance/fda-track-prescription-drug-user-fee-act-meeting-goals-summary",
    "date": "2025-09-03T12:06:32.000Z",
    "dateFormatted": "03/09/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "FDA-TRACK: Prescription Drug User Fee Act Meeting Goals Summary",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "432671b24baf1cd3bca2352b3d22f3bf",
    "title": "FDA-TRACK: Prescription Drug User Fee Act Procedural Goals Summary",
    "link": "http://www.fda.gov/about-fda/fda-track-agency-wide-program-performance/fda-track-prescription-drug-user-fee-act-procedural-goals-summary",
    "date": "2025-09-03T12:05:51.000Z",
    "dateFormatted": "03/09/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "FDA-TRACK: Prescription Drug User Fee Act Procedural Goals Summary",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "31fce4297983e4bd73ef8c6908286ff2",
    "title": "FDA-TRACK: Prescription Drug User Fee Act Review Goals Summary",
    "link": "http://www.fda.gov/about-fda/fda-track-agency-wide-program-performance/fda-track-prescription-drug-user-fee-act-review-goals-summary",
    "date": "2025-09-03T12:05:28.000Z",
    "dateFormatted": "03/09/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "FDA-TRACK: Prescription Drug User Fee Act Review Goals Summary",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "78b5edc07805ec3d202bb3a6a0d5e7be",
    "title": "Why drugmakers may need to borrow from quantum theory to confront tariff and pricing threats",
    "link": "https://www.pharmavoice.com/news/pharma-quantum-theory-deloitte-tariff-pricing/759095/",
    "date": "2025-09-03T11:52:32.000Z",
    "dateFormatted": "03/09/2025",
    "source": "PharmaVoice",
    "sourceCategory": "trade",
    "summary": "With so many unknowns surrounding regulatory and policy shifts, pharma companies might need to consider fundamental changes to how they operate, a Deloitte analyst said.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "9605f42eb0a06673c118688b7a2fd030",
    "title": "FDA Advances Rare Disease Drug Development with New Evidence Principles - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNLUJvcWxQNGxCelFnUTZDUHlZUlRETmduY0VPRWxtLTFQa2lKWm5ZOWxFaFJTOWsxYzlncTV5dUpjSzd6dGtYU1YyMmdTYllia3pDRHJoX2NqbEMzTHBFY0dZMnk0V0RtZzc5ZmtKMzhlUjk5STVvcXBwb3owRHdyR29VOFZoVDlLamNxVFRraElGX2RqTkFoQlhITGpBMm9IVWlKMVlwMEQyd3pCSVVVRGV1YzZGYUtSeXc?oc=5",
    "date": "2025-09-03T04:00:00.000Z",
    "dateFormatted": "03/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Advances Rare Disease Drug Development with New Evidence Principles  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e5ecfe978872d141d407ed189977df17",
    "title": "FDA Notifies Pet Owners That Tests Show H5N1 Contamination in Certain Lots of RAWR Raw Cat Food Chicken Eats - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNMDRQQUdMUWcxVTJ2b1Ffa20zcHFxTlZrdXdrSW5PaU9IVlNFVUtBSkxVTWg4dFNPa2ZIUzA4ZVQwYldHRjRnQjlIRmpxd25LVmhqbGJZVXBnVXN0Rl80YUxiNWhyaFUyTjhvTDZUQzY5YVh6aDM5a2psNzB3Ym9VaHF5YmZNbDN0SDJ1NlprbHc2T2VTSHJ0VHUyS3pMWXBrZ2g2TFlnanBGYXMycEJkVE5xUE9LWERWdmFqSEFQblViOWhwbDZSVzJhbVZBZ1hUM3dTMUg0d0N3MzVKbFczTg?oc=5",
    "date": "2025-09-03T00:00:00.000Z",
    "dateFormatted": "03/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Notifies Pet Owners That Tests Show H5N1 Contamination in Certain Lots of RAWR Raw Cat Food Chicken Eats  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "06f454324d300f7806ebb202729356b1",
    "title": "CDER/CBER Rare Disease Evidence Principles (RDEP) - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQbUFhbXdHeEgxS1BpSVBIVTU1emVXV1FMTWhHREhpRWhtWFM1amE1NTVpVzFlZUhaU1p4MlVGM2c5eEpqa1Z0TW1xM3EzS0E4ZENkSnBfZzhudUVNbFdWX2lLNk5QZy0yLUU3Y2Zna21walJkbTZWLWpXTG1Cb1BMMVJObkZHbXBvVVNiemdHMUZoUmdmcjFuQ2h2aF96cjBzTXdMcmduU3Q1U2s?oc=5",
    "date": "2025-09-03T00:00:00.000Z",
    "dateFormatted": "03/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "CDER/CBER Rare Disease Evidence Principles (RDEP)  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6a86e9421b9339b568a4a663c391bb0f",
    "title": "Offit Out at FDA Vaccine Advisory Committee After HHS Rebuff",
    "link": "https://www.biospace.com/fda/offit-out-at-fda-vaccine-advisory-committee-after-hhs-rebuff",
    "date": "2025-09-02T21:00:45.000Z",
    "dateFormatted": "02/09/2025",
    "source": "BioSpace",
    "sourceCategory": "trade",
    "summary": "Paul Offit, longtime member of the FDA’s vaccine advisory committee and an outspoken critic of Health Secretary Robert F. Kennedy Jr., was recently informed by the Department of Health and Human Services that his services are no longer required.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ce65da04749295e769ea6837b3097c7b",
    "title": "DG Gel Card 125445, 125449, 125450 - 125457 ",
    "link": "http://www.fda.gov/vaccines-blood-biologics/dg-gel-card-125445-125449-125450-125457",
    "date": "2025-09-02T20:12:24.000Z",
    "dateFormatted": "02/09/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "Product approval information is for:\n•DG Gel 8 AB (x4) card is for the determination of human A and B antigen on the surface of red blood cells in four separate blood samples. For use with the DG Gel System. For in vitro diagnostic use.\n•DG Gel 8 A/B/D card is for the determination of human A, B and",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "050b71dc0c65757df30f2725ce7d103d",
    "title": "STAT+: Gilead wants state AIDS drug programs to pay significant price hikes for HIV meds",
    "link": "https://www.statnews.com/pharmalot/2025/09/02/hiv-aids-drugs-medicines-pharma-gilead-adap-prices-inflation-descovy/?utm_campaign=rss",
    "date": "2025-09-02T15:47:01.000Z",
    "dateFormatted": "02/09/2025",
    "source": "STAT News Pharma",
    "sourceCategory": "trade",
    "summary": "Gilead Sciences is seeking to boost prices significantly for several treatments that are widely distributed by state AIDS Drug Assistance Programs.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "059c168abde99f4e1db67cc627636a55",
    "title": "Consumer Updates",
    "link": "http://www.fda.gov/consumers/consumer-updates",
    "date": "2025-09-02T15:10:26.000Z",
    "dateFormatted": "02/09/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "Science-based health and safety information you can trust.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "fa070883a2c23688dc91d850c2963aa5",
    "title": "FDA Urges Nicotine Pouch Manufacturers To Use Child-Resistant Packaging Following Increasing Reports of Accidental Exposure  ",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-urges-nicotine-pouch-manufacturers-use-child-resistant-packaging-following-increasing-reports",
    "date": "2025-09-02T14:59:10.000Z",
    "dateFormatted": "02/09/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "The U.S. Food and Drug Administration calls on nicotine pouch manufacturers to use child-resistant packaging to protect American children from accidental, harmful exposure.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "2a616ab43142b4bd185e9e04b458b90f",
    "title": "STAT+: Trump pressures drugmakers amid CDC turmoil",
    "link": "https://www.statnews.com/2025/09/02/biotech-news-corsera-ionis-replimune-cytokinetics/?utm_campaign=rss",
    "date": "2025-09-02T13:36:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "STAT News Biotech",
    "sourceCategory": "trade",
    "summary": "And other biotech news brought to you by The Readout.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "d4a890acdf5849fd81c9e8174bd389be",
    "title": "Biogen, Eisai Win FDA Nod for Subcutaneous Maintenance Leqembi",
    "link": "https://www.biospace.com/fda/biogen-eisai-win-fda-nod-for-subcutaneous-maintenance-leqembi",
    "date": "2025-09-02T12:33:03.000Z",
    "dateFormatted": "02/09/2025",
    "source": "BioSpace",
    "sourceCategory": "trade",
    "summary": "While the approval of Leqembi Iqlik bodes well for Biogen and Eisai’s planned application for a subcutaneous induction regimen next year, its financial impact remains “uncertain,” as potentially higher revenues from the injection could be offset by steeper costs of production, according to Jefferies.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ebaefd514d834de69a95b263bf61fe83",
    "title": "AnazaoHealth Corporation. Las Vegas, NV. 483 issued 08/08/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/anazaohealth-corporation-las-vegas-nv-483-issued-08082025",
    "date": "2025-09-02T12:19:53.000Z",
    "dateFormatted": "02/09/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request\tPlease post to the OII FOIA Electronic Reading Room\nRecord Date\t08/08/2025\nShort Title (70 char)\tAnazaoHealth Corporation. Las Vegas, NV. 483 issued 08/08/2025\nFEI Number\t3011152407\nFirm Name\tAnazaoHealth Corporation\nRecord Type\t483\nState\tNV\nEstablishment Type\tOutsourcing Fa",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "4927538d8de829b4358c0546b537e935",
    "title": "How AI advances will shape the drugmaker of the future",
    "link": "https://www.pharmavoice.com/news/ai-drug-discovery-pharma-immunai-pfizer-novo-nordisk-cradle/758994/",
    "date": "2025-09-02T12:00:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "PharmaVoice",
    "sourceCategory": "trade",
    "summary": "An AI revolution is taking place, and leaders from tech to Big Pharma are forecasting what drugmakers of the future will look like.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "47f9630ae8b6b89153ea3b175ede6036",
    "title": "STAT+: Ionis drug lowers triglycerides, reduces pancreas damage in late-stage studies",
    "link": "https://www.statnews.com/2025/09/02/ionis-olezarsen-triglycerides-drug-study/?utm_campaign=rss",
    "date": "2025-09-02T11:00:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "STAT News Biotech",
    "sourceCategory": "trade",
    "summary": "Ionis Pharmaceuticals released new data on a rare disease drug that opened up the possibility it could become a blockbuster opportunity for the biotech.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "71158b44d46a763b6874a66d40a8856b",
    "title": "STAT+: Biotech veterans John Maraganore, Clive Meanwell launch new heart disease startup with lofty goals",
    "link": "https://www.statnews.com/2025/09/02/biotech-corsera-maraganore-meanwell/?utm_campaign=rss",
    "date": "2025-09-02T10:30:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "STAT News Biotech",
    "sourceCategory": "trade",
    "summary": "Biotech veterans John Maraganore and Clive Meanwell are launching Corsera, a new heart disease startup with lofty goals.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "4779aa62a9f7acbf837a180b5f7656af",
    "title": "Pouches Can Be Dangerous to Kids if They Use, Touch, Chew on, Eat Them - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQnpTT28tYmlkcklyRXV3WDVWV1BOclNiVHQtcDEzcTEyYXNSbWZuUU9FbnlpSGNBa2RJNGJVTzl4YnVITlNRNDJrdUVUbmNPX2owVnduN0JRX0hZY3FobnVDcU1aeXpSUkozVGhFYmo1RTM3aW9MZE00bEI3czl4SGlCWG1fNjJrWGdkWUdsN3JpN0E2Ni0zSk5UV2dnTndrOXJ5OE5vWGdXRGswN21NQVRWYVAyY2ZCUFBVN1JTZWpzZw?oc=5",
    "date": "2025-09-02T09:00:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Pouches Can Be Dangerous to Kids if They Use, Touch, Chew on, Eat Them  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "490fabc44421971662a7bfe2a086f3a7",
    "title": "Rare Diseases Secure Four FDA Firsts in August",
    "link": "https://www.biospace.com/fda/rare-diseases-secure-four-fda-firsts-in-august",
    "date": "2025-09-02T04:26:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "BioSpace",
    "sourceCategory": "trade",
    "summary": "Aside from the rare disease market, Novo Nordisk also scored a key regulatory win last month for its blockbuster GLP-1 drug Wegovy, which can now be used to treat patients with metabolic dysfunction-associated steatohepatitis.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "734a13a7641dd47f40ab123b4b05b519",
    "title": "FDA’s New Radiopharma Guidance a Greenlight for an Accelerating Space",
    "link": "https://www.biospace.com/fda/fdas-new-radiopharma-guidance-a-greenlight-for-an-accelerating-space",
    "date": "2025-09-02T04:01:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "BioSpace",
    "sourceCategory": "trade",
    "summary": "With a flurry of recent Big Pharma investment in radiopharmaceutical therapeutics, the FDA issued draft guidance last month in a move former FDA Commissioner Stephen Hahn sees as the regulator “trying to get ahead on a new set of therapy that they see becoming very important for cancer.”",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "925c85263c97a23974352169a3d89639",
    "title": "Ice Cream Factory Issues Allergy Alert on Undeclared Almond in Vanilla G.Nutt Ice Cream - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxONGJZQThsbEIyT2ZtQ0JVcW8tWVhMcFY4cUFjQUkyZ1NPVDVPVlNTQ1g3M0MtcFBLQTMyRTQtSzFraERHNFVkak1fVTZlQ0VDT0E5b1pxTEJJdjc5djB3WU1yc2xuMXdKeXRHQktYT0lhUFBHN2lqMi1YQUV2azRWb2pHdGtHdDl4THRTdzQwbmxRRDN2RWIyTWR6QWFrWWNPd29vb0xsMl9EVXY1cnlpWGRzZVgxSDZxQTNoWDVSVXZ2c2J4Ujkxdlg5Z2Y1cG1fWjM3cUhKbk1UajFROVlyMHhR?oc=5",
    "date": "2025-09-02T04:00:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Ice Cream Factory Issues Allergy Alert on Undeclared Almond in Vanilla G.Nutt Ice Cream  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ad794f4beb7676698ae06f2b23f60d62",
    "title": "FDA Urges Nicotine Pouch Manufacturers To Use Child-Resistant Packaging Following Increasing Reports of Accidental Exposure - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPMnR2SDZWaGg0eGFiMGdrcERVdkNqQldUVG9XTndsaWxsajdfc3lrcm43emlBXzRLUjlHODJrLV8ySXp5Z2pnZ0t3ZXQzRnRrdVlDdHFuOW92Z1BDWGdYcTdQeDYzbVFhWFFldXJIaFBaU3ZMallyZXhkcjdTWGZqMnJjYVdQZWZGcGI5M19xdGZ2dUhFQk9PaldRZmN0cXhILURpeW9zb1JYTmRkeFZsSTNQM1g2VmNKYzJ5VU1za3RfYVNJRTBISldQRERCeF9KSUNfckRkZ1Bfbk40ejlqbjVjaw?oc=5",
    "date": "2025-09-02T04:00:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Urges Nicotine Pouch Manufacturers To Use Child-Resistant Packaging Following Increasing Reports of Accidental Exposure  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e5c9380372f32496a3d17ec422b733ec",
    "title": "FDA Approves Drug to Treat Adults with Persistent or Chronic Immune Thrombocytopenia - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPTGg2SkV3VFQ0V2dLOV81Tjk3bW1hUGFDMlpSRng3X2dPM2VYZFhLa2s1Uml1UXppX0J3QTU5SmcxTDhKOEdlQTN6c2Y4M3NrM3gxaFZNU1ZJcF9CdjlEMUZqZmEzcUZxZ1FKdDVBU0ZpR3VmaEtYLV9INHB3dDFNd1hTdkRyZTFKSzUzUDd1ZF9CVUZ1X3M5RWlQUU1FTEpPMVZBeGp5S2ZxX0plMGNmUkZHTVlSZHlqcHNXT1VQSHY4SEtC?oc=5",
    "date": "2025-09-02T00:00:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Approves Drug to Treat Adults with Persistent or Chronic Immune Thrombocytopenia  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "2898b545ed2aa2973c635c8707f4b893",
    "title": "Assessing Novel Efficacy Endpoints in Ophthalmologic Rare Disease Drug and Biologics Development - 09/17/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQb1BsYnRhWHlLQ2F6VWFSWGxnUFFXZHVBVThreVdSVW44XzVqZ3JCb1l4dEw4Ymlhc1dYM2hLQ25DNGV1SWRJZERwLTJjN3ZTOWprTTktQlAxSEdMeHhqSkdFMGVuOHl3TnJTZ0gyQnZFSmtYTThUaHhOZW9HeDFuc0ZBOUxPVkQyUHU1STNNUXdRUFJBS1VORnhGTGZkWTRpZGJBbkxpT054VDFLVWU2UlU3ZlU2ckRsb2JuVTdKd3puRjJ6V21KVVMyc1I0dXhSZUZQQzJPX2tWR0E?oc=5",
    "date": "2025-09-02T00:00:00.000Z",
    "dateFormatted": "02/09/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Assessing Novel Efficacy Endpoints in Ophthalmologic Rare Disease Drug and Biologics Development - 09/17/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "4c1637a3e800f832551e515ccbbc3826",
    "title": "STAT+: Alnylam’s hypertension treatment did not significantly lower blood pressure in mid-stage study",
    "link": "https://www.statnews.com/2025/08/30/alnylam-hypertension-treatment-study/?utm_campaign=rss",
    "date": "2025-08-30T14:30:00.000Z",
    "dateFormatted": "30/08/2025",
    "source": "STAT News Biotech",
    "sourceCategory": "trade",
    "summary": "An investigational therapy from Alnylam did not significantly lower blood pressure in a key Phase 2 trial, new data show, but the drug is being advanced to a late-stage study.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "bd2293c4cff7fa7db84959a1d4b89e6b",
    "title": "STAT+: Cytokinetics drug yielded benefits over common therapy in patients with heart condition, study shows",
    "link": "https://www.statnews.com/2025/08/30/cytokinetics-aficamten-hcm-study/?utm_campaign=rss",
    "date": "2025-08-30T07:18:00.000Z",
    "dateFormatted": "30/08/2025",
    "source": "STAT News Biotech",
    "sourceCategory": "trade",
    "summary": "An experimental medicine from Cytokinetics showed strong results in patients newly diagnosed with a common, inherited heart condition, according to new study results.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 2
  },
  {
    "id": "c6dbbb555cf5064d988e31f3e2712a50",
    "title": "U.S. FDA issues five observations to Aurobindo Pharma arm’s API plant - The Hindu",
    "link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPUTJvaGp5Y0ZRWG5ueTFxT2pScml3MTAwTm1kb09XMFFLbXlBX3RUMUk5aHFLZVNRR0VYcS1BV3VJRGpxZ21na3ZGMF9TNEtPaFZCclZBWjlvb1l4Z2loeU8xcXdDU1p1a1hLQVh6dlZueURFaG5KcnJrZFNhVW9nc2lYSVhCelNCbUljeGVhbU81NVdwY0drckRWMzZYUUEzeHVTaWM2NVM5RldHekNDSzhYT1dGVjFneFdNUTZ0T0JxbXFkc0RHT9IBzwFBVV95cUxQVTNVUE1iRkVyeXRtamhXbHJIak52UU9KaWZnckdpNnZpb1c5MkYtRS1GcEdZS2hsYkR6VzFlbDdMcHV1bGF5UjZpLTM1bEdWd2xHRV9HOUQ0U3BNUWVpLVFrZWxtc3pCTmgyVHpTQWZ3Q2FDYU11UTZuLXRIV3ZCSnhWTmRuTVV5ZDdGS0xUSGdDcjVRSFh2WnNzdVlLMjg1VFRja1ByRUZJR0hybF81RWZDN2xqTDFGQVdKQUlYQXV1MEZEMEVaY2VLSlBuRzQ?oc=5",
    "date": "2025-08-30T06:03:00.000Z",
    "dateFormatted": "30/08/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "U.S. FDA issues five observations to Aurobindo Pharma arm’s API plant  The Hindu",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "5a0edbf8dc797a21c54b7ac89e3af2de",
    "title": "Coronavirus (COVID-19) | CBER-Regulated Biologics",
    "link": "http://www.fda.gov/vaccines-blood-biologics/industry-biologics/coronavirus-covid-19-cber-regulated-biologics",
    "date": "2025-08-29T17:09:00.000Z",
    "dateFormatted": "29/08/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "This page and the associated links provide information on guidance and advice relevant to the development of therapies to treat or prevent COVID-19, and contact information for developers seeking additional information or assistance.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "18fa3997672e56d48d531ed8b2087e9a",
    "title": "Health Fraud Scams",
    "link": "http://www.fda.gov/consumers/health-fraud-scams",
    "date": "2025-08-29T16:39:27.000Z",
    "dateFormatted": "29/08/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "Learn how to spot health fraud and avoid it.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "8eac5866ca0d404bff62089ade6af567",
    "title": "MedWatch: FDA Safety Information & Adverse Event Reporting Program - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNQlpkNHQtWGg5MWE5eERadGk2dUkyZEg1ZlJYdS1RYUNsa05jb0l0T3lMVVVTUHJpNU1kOFZ1Ry0yamF5OTRZcXVXWmZGa2RvdWtGNWFldE9wVTM0N2R0NC1jWmtyM1UycTZ2eTZFX04xMXBnSzBjazB3UVJVbzV2djZDS1NHZUxpRkpXeDJTc0xlUXRnMWVZMzJB?oc=5",
    "date": "2025-08-29T07:00:00.000Z",
    "dateFormatted": "29/08/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "MedWatch: FDA Safety Information & Adverse Event Reporting Program  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ded5ff67a1549c43ef83b8f109be5b2f",
    "title": "Green Lumber Holding, LLC Issues Consumer Alert on Counterfeit Products  Following FDA Findings",
    "link": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/green-lumber-holding-llc-issues-consumer-alert-counterfeit-products-following-fda-findings",
    "date": "2025-08-29T04:00:00.000Z",
    "dateFormatted": "29/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "Costa Mesa, California August 28, 2025 - Green Lumber Holding, LLC (“Green Lumber”) is alerting consumers that counterfeit products misrepresented as genuine Green Lumber have been identified and may pose health risks.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "e8093c0a5f910b9908231c25e87d8b06",
    "title": "Roster of the Vaccines and Related Biological Products Advisory Committee",
    "link": "http://www.fda.gov/advisory-committees/vaccines-and-related-biological-products-advisory-committee/roster-vaccines-and-related-biological-products-advisory-committee",
    "date": "2025-08-28T19:19:13.000Z",
    "dateFormatted": "28/08/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "This is the Roster of the Vaccines and Related Biological Products Advisory Committee",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "39b17b000801fe13d891cdad47add12d",
    "title": "Roster of the Cellular, Tissue and Gene Therapies Advisory Committee",
    "link": "http://www.fda.gov/advisory-committees/cellular-tissue-and-gene-therapies-advisory-committee/roster-cellular-tissue-and-gene-therapies-advisory-committee",
    "date": "2025-08-28T19:19:07.000Z",
    "dateFormatted": "28/08/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "This is the Roster of the Cellular, Tissue and Gene Therapies Advisory Committee.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "5277be229a2683d6dfe4672f6ecbb41e",
    "title": "Roster of the Blood Products Advisory Committee",
    "link": "http://www.fda.gov/advisory-committees/blood-products-advisory-committee/roster-blood-products-advisory-committee",
    "date": "2025-08-28T19:19:04.000Z",
    "dateFormatted": "28/08/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "This is the Roster of the Blood Products Advisory Committee (BPAC).",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "d7777285b328698fe70e04ed0fbaade1",
    "title": " NUVAXOVID",
    "link": "http://www.fda.gov/vaccines-blood-biologics/vaccines/nuvaxovid",
    "date": "2025-08-28T17:56:16.000Z",
    "dateFormatted": "28/08/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\n\nNUVAXOVID is approved for use in individuals who are:\n\n65 years of age and older, or\n\n12 years through 64 years of age with",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "1bb34ea8e89d76a9c26ec226af52e251",
    "title": "SPIKEVAX",
    "link": "http://www.fda.gov/vaccines-blood-biologics/spikevax",
    "date": "2025-08-28T17:51:53.000Z",
    "dateFormatted": "28/08/2025",
    "source": "FDA CBER Biologics",
    "sourceCategory": "official",
    "sourceType": "biologics",
    "summary": "For active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\n\nSPIKEVAX is approved for use in individuals who are:\n\n65 years of age and older, or\n\n6 months through 64 years of age with at least one underlying condition",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "e517e1a322df73089cbe1d22cb52667f",
    "title": "IntegraDose Compounding Services LLC. Minneapolis, MN. 483 issued 07/25/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/integradose-compounding-services-llc-minneapolis-mn-483-issued-07252025",
    "date": "2025-08-28T14:33:51.000Z",
    "dateFormatted": "28/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request Please post to the OII FOIA Electronic Reading Room\nRecord Date 07/25/2025\nShort Title (70 char) IntegraDose Compounding Services LLC. Minneapolis, MN. 483 issued 07/25/2025\nFEI Number 3014483112\nFirm Name IntegraDose Compounding Services LLC\nRecord Type 483\nState MN\nEstabli",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "7d3421b86274ad64b15bf0117542e5d6",
    "title": "FDA approves updated COVID boosters, but narrows use",
    "link": "https://www.pharmavoice.com/news/covid-booster-fda-approval-limits-kennedy-pfizer-moderna/758840/",
    "date": "2025-08-28T12:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "PharmaVoice",
    "sourceCategory": "trade",
    "summary": "In a post on X, HHS Secretary Robert F. Kennedy said the FDA has cleared vaccines from Pfizer, Moderna and Novavax for use in \"high risk\" individuals.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "8bfab062974361ae4a789591bceaf888",
    "title": "How a SpaceX mission could speed drug discoveries on Earth",
    "link": "https://www.pharmavoice.com/news/spacex-drug-discovery-international-space-station-pharma/758834/",
    "date": "2025-08-28T12:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "PharmaVoice",
    "sourceCategory": "trade",
    "summary": "Research enabled by blasting off into space could lead to better treatments for diseases such as ALS and Parkinson’s.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a1e448392581330ee5cac1ca17ed7616",
    "title": "FDA flags issues in review of Telix's PET diagnostic agent for kidney cancer - Fierce Biotech",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOem9yN0VVLVNDdDBEbHdycExVVDhVZ1BEZk1JWEJ2X0xab1FFWTdLRXZHWmZYdVdMUWRlWUdwU1RTM21LbnU0bXIwVTBnYkdWSVZPVGJmVDNSc1MwNVhhNkR2SjdzTW03UXk0LTJVVUFnMVcyX1NqUG1BUjV5NjR6VTdPNkZPeHZiYnYtRHpOZm9uS3RtWV9URlIzdVBkMHVkVUYzVXZn?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA flags issues in review of Telix's PET diagnostic agent for kidney cancer  Fierce Biotech",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "b24e3b791e0ac45f15404e88b64cbe15",
    "title": "Outlook Therapeutics’ outlook dims as FDA snubs reformulated Avastin in eye disease—again - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOdnhCOEtJcEJFMEd0VEFDdjB5R3k3ZG1ZcUxvNHhSX0tSeXpmSWNkczA0ZGVST0swdkJoNmV3X05XYkpZZXBzVHdfNzFiVnZGZUNGWHVYNGpKSFVGNElKRFZtM01NVFhrZ1pFTUpEWWlTTURseWFIV2RQdlBoaEt4OU5mb2dDRkdTSXF4VzN3TEg2Tjh2MDhGZGdCSUJWbk11SDBDMzlkdjEwcWR1aTd4NEVOTEZhelV5YWc?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Outlook Therapeutics’ outlook dims as FDA snubs reformulated Avastin in eye disease—again  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d2e0dfebc5089692c52bfd788edf76c5",
    "title": "FDA Requests More Efficacy Data: Outlook Therapeutics' Novel Bevacizumab Eye Drug Hits Regulatory Roadblock - Stock Titan",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTkhRc0ZnakRlRHJUNWwxTGNmZXJQYWo5X1g5NV9sRmdwU3BjN0E3UlBQRVczMG9WUDNpbnZYZnNIdVZtUzgwLXdQc0p6ZGtCYW14TDAyNWtpem1qdHpLNzJkSmVnR2d6eE1iQk1Ja2w5UGtXZ25vRUM2SnJNcjJzeGdNalJTV1A5M3BFZmpMd1lNU0NFSWVmTncwb1FRc2RHN3FWVkcySDJOekQ3eHZGcnpNeUNJdzRLTjNkSmt2YzI?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Requests More Efficacy Data: Outlook Therapeutics' Novel Bevacizumab Eye Drug Hits Regulatory Roadblock  Stock Titan",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "c06ac1f89f905a16d062952c9ab91bda",
    "title": "Outbreak Investigation of Salmonella: Eggs (August 2025) - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOZndZdzh0N0dRXy0ta05fVWdZS19IUkNpUVp1NGcxc3p4QWZ0ek1LUzQxMzZHMjdaM3lRbnlWbHpscmk1YkNtSXNkb0VVUTRMZW5INHhUTGdVN2hoU0FQMnUzX2ZwY3RBaEljTzVoSjRmajZtOWVfX01lTEVtX0F4RUxtVDBYU3QtYUp4eURXbkJrclVMWWtUejJzVjlDb1ZYTGtpLWZn?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Outbreak Investigation of Salmonella: Eggs (August 2025)  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "9349d85835003286497060794822107b",
    "title": "MNEXSPIKE - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiZEFVX3lxTFBBcFo2eU5fYTFYRmlMaUZ6ODVsckEtV1dFNkpIRkpWY2NOOFpfSF93ZERrUnJyWHVEdHVGOTNIVjRRSlBwYWVrUjllbS1XV1RHWkNQMW1aUWY3SHFhc2lBSXlvUHM?oc=5",
    "date": "2025-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "MNEXSPIKE  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ab5d6d05fee11f77049ccf744e5d5606",
    "title": "Ventilator Correction: Hamilton Medical AG Corrects HAMILTON-C6 Due to Risk of Ventilation Interruption from Defective Circuit Board",
    "link": "http://www.fda.gov/medical-devices/medical-device-recalls/ventilator-correction-hamilton-medical-ag-corrects-hamilton-c6-due-risk-ventilation-interruption",
    "date": "2025-08-28T04:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "Hamilton is repairing certain HAMILTON-C6 ventilators to replace a defective circuit board that can interrupt ventilation, risking serious injury or death.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "b628c5a007ad4c88c08e75591b57ec51",
    "title": "Infusion Pump Correction: ICU Medical, Inc. Issues Correction for Plum Duo Infusion System Due to Software Possibly Resulting in Pump Becoming Unresponsive",
    "link": "http://www.fda.gov/medical-devices/medical-device-recalls/infusion-pump-correction-icu-medical-inc-issues-correction-plum-duo-infusion-system-due-software",
    "date": "2025-08-28T04:00:00.000Z",
    "dateFormatted": "28/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "ICU Medical is correcting the Plum Duo infusion system due to pump software issues that may cause the device to become unresponsive.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "ec411a0ef9179b96d2b0e266ed91cec1",
    "title": "Hikma Injectables USA Inc. Dayton, NJ. 483 issued 08/08/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/hikma-injectables-usa-inc-dayton-nj-483-issued-08082025",
    "date": "2025-08-27T16:22:45.000Z",
    "dateFormatted": "27/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request\tPlease post to the OII FOIA Electronic Reading Room\nRecord Date\t08/08/2025\nShort Title (70 char)\tHikma Injectables USA Inc. Dayton, NJ. 483 issued 08/08/2025\nFEI Number\t3022897129\nFirm Name\tHikma Injectables USA Inc.\nRecord Type\t483\nState\tNJ\nEstablishment Type\tOutsourcing Fa",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "2155028f409e877aad5c90daef8faf4f",
    "title": "A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant",
    "link": "https://www.pharmavoice.com/news/glp-1-big-pharma-biotech-implant-vivani-medical/758677/",
    "date": "2025-08-27T11:19:15.000Z",
    "dateFormatted": "27/08/2025",
    "source": "PharmaVoice",
    "sourceCategory": "trade",
    "summary": "Newcomers looking for a way into the obesity space are developing unique methods to snag market share.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "25fc526df9ef770c1b0263195dfacd78",
    "title": "Amneal Pharmaceuticals, LLC - 709894 - 08/27/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNd1YwdlVFRDRBZDdQQXVscFdMYjA5bjJHZ2JTaGVQUkl2QTR1dVlKTWJpWnZvRHo0bnJZWWc4X2xTaGpiOG9Yb29STlQ2RkRxZHNEQXluWnEtaTg1OWw2LTlia1BDQjNhcl9KTFVoeE1HVHA3YmpkOW9DU0ZrdEs2bEJCRlVaTjE3UFE2N0lpOUlNdHZEbTh6MDhDakM4VlBhTUI1Vkk1Yk9TMXZxRnJfdWl0WklyNXhsN3c0a3RTZDVqcUc2WktUV0Y1cW1MR0EwMHBzMnFuSVQ?oc=5",
    "date": "2025-08-27T07:00:00.000Z",
    "dateFormatted": "27/08/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Amneal Pharmaceuticals, LLC - 709894 - 08/27/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "14bb9137f2570d9d875f6566da6f34aa",
    "title": "AbbVie dives back into the neuro pool with a $1.2B psychedelics play",
    "link": "https://www.pharmavoice.com/news/abbvie-gilgamesh-psychedelic-depression-bretisilocin-acquisition/758563/",
    "date": "2025-08-26T12:00:00.000Z",
    "dateFormatted": "26/08/2025",
    "source": "PharmaVoice",
    "sourceCategory": "trade",
    "summary": "Following a major clinical failure last year, AbbVie’s purchase of a psychedelic depression treatment has the potential to revive a touch-and-go market.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "77e7f8ed94f5801a0071f0adacdda9a3",
    "title": "Why an FDA decision for a new drug could ripple through the ultra-rare disease space",
    "link": "https://www.pharmavoice.com/news/fda-ultra-rare-disease-stealth-biotherapeutics-barth/758562/",
    "date": "2025-08-26T12:00:00.000Z",
    "dateFormatted": "26/08/2025",
    "source": "PharmaVoice",
    "sourceCategory": "trade",
    "summary": "All eyes are on Stealth BioTherapeutics as it awaits a long-delayed approval for its first-in-class treatment for Barth syndrome.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "cf4fbdd7e799bb40c1a7fe78595f5c2f",
    "title": "FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License: FDA Safety Communication",
    "link": "http://www.fda.gov/safety/medical-product-safety-information/fda-update-safety-ixchiq-chikungunya-vaccine-live-fda-suspends-biologics-license-fda-safety",
    "date": "2025-08-25T04:00:00.000Z",
    "dateFormatted": "25/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "On August 22, 2025,the US FDA’s Center for Biologics Evaluation and Research has suspended the biologics license for Valneva Austria GmbH’s Ixchiq (Chikungunya Vaccine, Live). This vaccine was initially approved by FDA under the accelerated approval pathway in November of 2023 for the prevention of",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "2ba1dd50fc544b0d49ee5f2b83560697",
    "title": "Follow Instructions for Safe Use of Hyperbaric Oxygen Therapy Devices - Letter to Health Care Providers",
    "link": "http://www.fda.gov/medical-devices/letters-health-care-providers/follow-instructions-safe-use-hyperbaric-oxygen-therapy-devices-letter-health-care-providers",
    "date": "2025-08-25T04:00:00.000Z",
    "dateFormatted": "25/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "The FDA is reminding the public about the safe use of hyperbaric oxygen therapy devices and is providing recommendations to help reduce potential risks.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "4dc7aa7d933cd984111550f3cdbf0d30",
    "title": "FDA Begins Real-Time Reporting of Adverse Event Data",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-begins-real-time-reporting-adverse-event-data",
    "date": "2025-08-22T15:46:16.000Z",
    "dateFormatted": "22/08/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "The U.S. Food and Drug Administration (FDA) today began publishing adverse event data on a daily basis, giving the public faster access to information on serious medication errors and product quality complaints for prescription drugs and therapeutic biologics.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "685e221ae1312677ba31defd88677d3d",
    "title": "FDA Advises Public Not to Eat, Sell, or Serve Certain Imported Frozen Shrimp from an Indonesian Firm - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPZzByTDhrNk1RNzlzVXZ4ZnhZLU82UjdGX2tKazFkbk1aUTNVN3BPbzBuYnItRnFYSkN5RFk5WV9KOTRmNktIV2RuWW9mMjhQSWYzUDNzcUdEaGpESElPajN0SWx4dzZoOU9sTWQxRE5xYTZqVV9ydHBiT3FuSVJBS2EwYU15Q2hxbVFrU040Nl81U3FlZ05MNUptX0gzc1lldkFtZGVmWE5BOGNQYnoyUHFQcERza05OVFdMR29xdlV2ajhFem1NNzZqckpmN19xR2FPU0FKWGxIcFdibnltRU9LYw?oc=5",
    "date": "2025-08-19T13:10:09.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Advises Public Not to Eat, Sell, or Serve Certain Imported Frozen Shrimp from an Indonesian Firm  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "f3ebb9e443e38a27e657100d32cbc09e",
    "title": "HHS Allows FDA Emergency Use of Animal Drugs to Combat New World Screwworm, Protect U.S. Food Supply",
    "link": "http://www.fda.gov/news-events/press-announcements/hhs-allows-fda-emergency-use-animal-drugs-combat-new-world-screwworm-protect-us-food-supply",
    "date": "2025-08-19T12:45:21.000Z",
    "dateFormatted": "19/08/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "The U.S. Department of Health and Human Services (HHS) today issued a declaration that allows the U.S. Food and Drug Administration (FDA) to issue Emergency Use Authorizations (EUAs) for animal drugs to treat or prevent infestations caused by the New World Screwworm (NWS).",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "8405bcf44f3bb215e1c921c1ee841770",
    "title": "FDA Issues CRL for SC Daratumumab Plus VRd for Transplant-Ineligible or -Deferred, Newly Diagnosed Multiple Myeloma - OncLive",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSFVVVi1aUTFZUDJYMWF3U085ODluNXUyLVNSMENQODNUQ1p5UDU5U21uMVVZZzRwOU1acWxTVlpLWWxqRlEyejFUSlV6cmhnSi05N3F5anNfcldYNDl0al9HSkNmU3JxR1RCSEtWVGJZc1ZXeGIzWnpZT3hhQ3lXQXBRenpDVV9FTGV4S213MTJzWkRmZ05iLXZhM0dpWG5hTnJoOVNkeG5PcTVCcGtKNWcxeFJKQVpyaEJKMVpJUWR1RDA?oc=5",
    "date": "2025-08-19T07:00:00.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues CRL for SC Daratumumab Plus VRd for Transplant-Ineligible or -Deferred, Newly Diagnosed Multiple Myeloma  OncLive",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "4c18a2c072fcee2cf958677beca78880",
    "title": "FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPUjVKMU9XR0ZDSjNDOFdNYV9NX19CbXp4QnhkWm1qNV9ZZUoxVTlheHJBNjBlZUkxQW1EdVdDREJndTdxdnU4OVZDQTdycEk5dkx3ZnFQajlNM0FWYmhfMy1TQjJwS0JXOXQ4WVR6SE9TUmhSalZndzhrWjlMLUtyYV9sbWhDTGluWEtXV25Bakt4akZlMEZHenhnLWxJclBPbjBnTTFwQXNfejZMYnc3X2p6WXZFRWg2MXc?oc=5",
    "date": "2025-08-19T07:00:00.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed  Neurology live",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a89900ffefb2b0df8303a65f5908f1ed",
    "title": "US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder - Reuters",
    "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOMng1aGpKMmxPMmxqSVN5X3ZFWG5YY19QemEta0l3MVRsMjZBLWE0RWVzQ1hVNTUwTzdaWl9zN0ZUQl85Njg0SVhNZFMwc0dLWGdWaHdFMnJMb0dtTGYyU2plN1lBUWVOTUZHVXBjblRtNVZ4eHRvcldkV3Z5SXdEWTJtX1FjTTMtVkxXelRTdF8xMzV1djN4bV9ON2hBME5CME5aT3IzVXlJdkFaQ2JaVTR4eGw1RmtzY2dnVDYyenhoMGxqcnVtQTNBRG1jYlNWZ0gzV2dKT2dNN2M5?oc=5",
    "date": "2025-08-19T07:00:00.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "US FDA declines to approve PTC Therapeutics' oral drug for rare genetic disorder  Reuters",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "b2cb29bcffe7b942382d3907ae3a55e8",
    "title": "FDA rejection derails PTC Therapeutics' rare disease hopeful - Fierce Biotech",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOek1NVEJyLTYtTGwzcHlZUzRyUWF6eUtIclc5Zl9vQ1dnUjNvODVrb0xVSmxLbjRZRXB6bklCRlpoOXRCTExIVlU2d3dFcTJMV0xiUzNZeWluaGpab1BjYy12YUFuNjZPeXktTm1jNi1VUmNjQ2xFX3pYeGZVcE5UQ2NfYThRTDBoS2JqNUM4ODFhNmRsOEtSaU1ZdnY?oc=5",
    "date": "2025-08-19T07:00:00.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA rejection derails PTC Therapeutics' rare disease hopeful  Fierce Biotech",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "9e2fb76a5b8e9445f5bf436da2dede05",
    "title": "Nicotine Pouch Products Authorized by the FDA - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQUkJHN21oX1A5VFZxUkRrQjdPWDJXakFKNTFFMllJZk5TNVRhSTdab0tZMTZYVlJXRWpDZE13dzE0T3pCSXhpR2hXQUFIZHp0NVRDVUZ3NkFZNjBVYmViYXMwTXBnaDlMckJYNHNqbVdhbjhPblJNS05HLVR1ZGNYeUZGSDU2ekJwREJFZG5MakJHLWhyZkdPSVZjOHdYc1BTMERybXJ5N0RNTjZMZGRIeGQwTQ?oc=5",
    "date": "2025-08-19T07:00:00.000Z",
    "dateFormatted": "19/08/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Nicotine Pouch Products Authorized by the FDA  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "cb99b498588ecbc2e828bdcb53a57447",
    "title": "Stealth Bio submits third FDA application for rare disease candidate - Fierce Biotech",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNMDQ0VjFsZEhhcHYzM1IzMHJrZWNvd3FsSkItRDJHZ2hvcnVsZ19PNGllNmt6OW81TE9qTFh6VkZlUlVIUk5PSTBsWHd3WXQwXzBmc01iWmNialhJcDVNRGxxTl9XRzZFNGFjNEppV28xUUVfWFlkeTRORXJ2OVp4YkVxdmJIZXdoaW93Rl9XeWdEaXM2czBCcGxqVTF1TGpNdmVaVEF4WExTWXprNEE?oc=5",
    "date": "2025-08-18T07:00:00.000Z",
    "dateFormatted": "18/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Stealth Bio submits third FDA application for rare disease candidate  Fierce Biotech",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "f5fb279f2974e1b7a23e57ba30fd58d5",
    "title": "Early Alert: Infusion Pump Issue from Baxter",
    "link": "http://www.fda.gov/medical-devices/medical-device-recalls/early-alert-infusion-pump-issue-baxter-0",
    "date": "2025-08-15T04:00:00.000Z",
    "dateFormatted": "15/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "Correction Issued for the Novum IQ Large Volume Pumps, Syringe Pumps",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "13bde0a96366622914000545b2923feb",
    "title": "FDA Approves First Immunotherapy for Recurrent Respiratory Papillomatosis",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-immunotherapy-recurrent-respiratory-papillomatosis",
    "date": "2025-08-14T22:11:48.000Z",
    "dateFormatted": "14/08/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "FDA approved Papzimeos, the first-of-its-kind non-replicating adenoviral vector-based immunotherapy for use in adults with recurrent respiratory papillomatosis.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "342e2c1f7f880533636403382c43b039",
    "title": "BSO, LLC. Lakewood, CO. 483 issued 07/16/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/bso-llc-lakewood-co-483-issued-07162025",
    "date": "2025-08-14T14:05:29.000Z",
    "dateFormatted": "14/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request\tPlease post to the OII FOIA Electronic Reading Room\nRecord Date\t07/16/2025\nShort Title (70 char)\tBSO, LLC. Lakewood, CO. 483 issued 07/16/2025\nFEI Number\t3011976853\nFirm Name\tBSO, LLC\nRecord Type\t483\nState\tCO\nEstablishment Type\tOutsourcing Facility",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "c17708fd566cbd02ee78db47c5d4fa4d",
    "title": "Statement from FDA Commissioner Marty Makary, M.D., M.P.H., on Florida Restriction of 7-OH Opioid Products",
    "link": "http://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-marty-makary-md-mph-florida-restriction-7-oh-opioid-products",
    "date": "2025-08-13T18:43:49.000Z",
    "dateFormatted": "13/08/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "Statement from FDA Commissioner Marty Makary, M.D., M.P.H., on Florida Restriction of 7-OH Opioid Products",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "45f21b5f715100348431d35130815458",
    "title": "BSO, LLC. Golden, CO. 483 issued 06/27/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/bso-llc-golden-co-483-issued-06272025",
    "date": "2025-08-12T17:13:39.000Z",
    "dateFormatted": "12/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request Please post to the OII FOIA Electronic Reading Room\nRecord Date 06/27/2025\nShort Title (70 char) BSO, LLC. Golden, CO. 483 issued 06/27/2025\nFEI Number 3030548360\nFirm Name BSO, LLC\nRecord Type 483\nState CO\nEstablishment Type Outsourcing Facility",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "de5f60c646c1877ec781f54ef7feb889",
    "title": "The FDA Let Substandard Factories Ship These Medications to the U.S. - ProPublica",
    "link": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5OTWtuR3hWVllaRF9Zd1BrcVYtMnBvTlBNMXNWVG1sT1psNmUzdmhkeUhVTWtqSDk4UkNkXzVGeEJqQ1FlOVBYT1hvMm5YQWxET2Y1clBMLU5lZTloREpkclBCY2czQ3paMzVsOWwzZ1k4aTl0ZmpCX2pQUy1iWDg?oc=5",
    "date": "2025-08-12T07:00:00.000Z",
    "dateFormatted": "12/08/2025",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "The FDA Let Substandard Factories Ship These Medications to the U.S.  ProPublica",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "39b53a073531e2538e555f1a7c81faf4",
    "title": "Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps ",
    "link": "http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/tandem-diabetes-care-issues-voluntary-medical-device-correction-select-tslim-x2-insulin-pumps",
    "date": "2025-08-12T04:00:00.000Z",
    "dateFormatted": "12/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "SAN DIEGO – August 7, 2025 – Tandem Diabetes Care, Inc. (Nasdaq: TNDM) has announced a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "05c8be1aa8e7a152bad88d7bd624f04e",
    "title": "Right Value Drug Stores, LLC. Irving, TX. 483 issued 07/18/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/right-value-drug-stores-llc-irving-tx-483-issued-07182025",
    "date": "2025-08-11T13:40:30.000Z",
    "dateFormatted": "11/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request Please post to the OII FOIA Electronic Reading Room\nRecord Date 07/18/2025\nShort Title (70 char) Right Value Drug Stores, LLC. Irving, TX. 483 issued 07/18/2025\nFEI Number 3010589333\nFirm Name Right Value Drug Stores, LLC\nRecord Type 483\nState TX\nEstablishment Type Outsourci",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "303e18b3c89f97f330df30d687c838a1",
    "title": "Stokes Healthcare Inc. dba Epicur Pharma. Mount Laurel, NJ. 483 issued 05/23/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/stokes-healthcare-inc-dba-epicur-pharma-mount-laurel-nj-483-issued-05232025",
    "date": "2025-08-11T13:38:24.000Z",
    "dateFormatted": "11/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request\tPlease post to the OII FOIA Electronic Reading Room\nRecord Date\t05/23/2025\nShort Title (70 char)\tStokes Healthcare Inc. dba Epicur Pharma. Mount Laurel, NJ. 483 issued 05/23/2025\nFEI Number\t3002815949\nFirm Name\tStokes Healthcare Inc. dba Epicur Pharma\nRecord Type\t483\nState\tN",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "a32c0f62a120e2213a7e1edbe468b6a2",
    "title": "Wedgewood Connect, LLC. San Jose, CA. 483 issued 07/03/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/wedgewood-connect-llc-san-jose-ca-483-issued-07032025",
    "date": "2025-08-08T19:42:31.000Z",
    "dateFormatted": "08/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request Please post to the OII FOIA Electronic Reading Room\nRecord Date 07/03/2025\nShort Title (70 char) Wedgewood Connect, LLC. San Jose, CA. 483 issued 07/03/2025\nFEI Number 3003434972\nFirm Name Wedgewood Connect, LLC\nRecord Type 483\nState CA\nEstablishment Type Outsourcing Facilit",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "6dbb3e0f5ca46d6fe77b67c4f58cbee5",
    "title": "FDA Commissioner Makary, USDA Secretary Rollins Celebrate Proposed Modernization of Orange Juice Regulations to Benefit American Growers",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-commissioner-makary-usda-secretary-rollins-celebrate-proposed-modernization-orange-juice",
    "date": "2025-08-08T19:30:37.000Z",
    "dateFormatted": "08/08/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "U.S. FDA Commissioner Dr. Marty Makary, M.D., M.P.H., and U.S. Secretary of Agriculture Brooke L. Rollins this week announced plans to support American citrus growers and cut bureaucratic barriers by proposing an update to the standard of identity (SOI) for pasteurized orange juice.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "4a0662b2f94f11d92128b53c08a2ccb5",
    "title": "A Statement from FDA Commissioner Marty Makary, M.D., M.P.H.: Announcing Resolution of the IV Saline Solutions Shortage",
    "link": "http://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-marty-makary-md-mph-announcing-resolution-iv-saline-solutions-shortage",
    "date": "2025-08-08T15:25:35.000Z",
    "dateFormatted": "08/08/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "A Statement from FDA Commissioner Marty Makary, M.D., M.P.H: Announcing Resolution of the IV Saline Solutions Shortage",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "d35b06378bad4c3daa3806d96e5d2af9",
    "title": "Stealth Bio questions its own viability as FDA directs rare disease biotech to resubmit drug application - Fierce Biotech",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPNnN5SE0yeE5kaTB2Sk1hVEdGaVREMjVEME56M3dNQkhkdXM5UjZ6SGFteUFVZjdVaG5wbUdYM0dmdzJIWFJJdGE3b2Z3VW5rX3pmaFAtSm5ua2I3MzhJQ19kYkxnUGpSaWUwODJCdHc5anFFRUxsN2ZINGhDVkZMRGdLLWxGcnpSbVhkZmdqei1HMkZUWHhrUmNYUXNxN3VWRS0zUW5CeTJVUTJYdEZfX1c0QmRaYUxIOGc?oc=5",
    "date": "2025-08-08T07:00:00.000Z",
    "dateFormatted": "08/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Stealth Bio questions its own viability as FDA directs rare disease biotech to resubmit drug application  Fierce Biotech",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "0d2b299fffab7f1e72d3b2388d3d750b",
    "title": "Medi-Fare Drug Pharmaceutical Compounding LLC. Blacksburg, SC. 483 issued 06/06/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/medi-fare-drug-pharmaceutical-compounding-llc-blacksburg-sc-483-issued-06062025",
    "date": "2025-08-07T15:45:47.000Z",
    "dateFormatted": "07/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request Please post to the OII FOIA Electronic Reading Room\nRecord Date 06/06/2025\nShort Title (70 char) Medi-Fare Drug Pharmaceutical Compounding LLC. Blacksburg, SC. 483 issued 06/06/2025\nFEI Number 3009925820\nFirm Name Medi-Fare Drug Pharmaceutical Compounding LLC\nRecord Type 483",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "ac4acdc403a798e2efc8eb6f83dd9bde",
    "title": "Wells Pharmacy Inc. Dyersburg, TN. 483 issued 04/25/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/wells-pharmacy-inc-dyersburg-tn-483-issued-04252025",
    "date": "2025-08-07T14:45:56.000Z",
    "dateFormatted": "07/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request Please post to the OII FOIA Electronic Reading Room\nRecord Date 04/25/2025\nShort Title (70 char) Wells Pharmacy Inc. Dyersburg, TN. 483 issued 04/25/2025\nFEI Number 3011761321\nFirm Name Wells Pharmacy Inc.\nRecord Type 483\nState TN\nEstablishment Type Outsourcing Facility",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "c05a02668f2165726fc9bc5bb118b357",
    "title": "Tailstorm Health Inc dba Medivant Healthcare. Chandler, AZ. 483 issued 05/23/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/tailstorm-health-inc-dba-medivant-healthcare-chandler-az-483-issued-05232025",
    "date": "2025-08-07T14:36:33.000Z",
    "dateFormatted": "07/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request Please post to the OII FOIA Electronic Reading Room\nRecord Date 05/23/2025\nShort Title (70 char) Tailstorm Health Inc dba Medivant Healthcare\nFEI Number 3015929581\nFirm Name Tailstorm Health Inc\nRecord Type 483\nState AZ\nEstablishment Type Outsourcing Facility",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "9635453628f0f0cd574a6738fa666590",
    "title": "Boothwyn Pharmacy LLC. Kennett Square, PA. 483 issued 06/09/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/boothwyn-pharmacy-llc-kennett-square-pa-483-issued-06092025",
    "date": "2025-08-07T14:32:19.000Z",
    "dateFormatted": "07/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request Please post to the OII FOIA Electronic Reading Room\nRecord Date 06/09/2025\nShort Title (70 char) Boothwyn Pharmacy LLC. Kennett Square, PA. 483 issued 06/09/2025\nFEI Number 1000076625\nFirm Name Boothwyn Pharmacy LLC\nRecord Type 483\nState PA\nEstablishment Type Producer of Ste",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "a201a6585af8558a7a029f92e781e66c",
    "title": "MedisourceRx. Los Alamitos, CA. 483 issued 06/10/2025",
    "link": "http://www.fda.gov/about-fda/medisourcerx-los-alamitos-ca-483-issued-06102025",
    "date": "2025-08-07T14:24:54.000Z",
    "dateFormatted": "07/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request Please post to the OII FOIA Electronic Reading Room\nRecord Date 06/10/2025\nShort Title (70 char) MedisourceRx. Los Alamitos, CA. 483 issued 06/10/2025\nFEI Number 3013316698\nFirm Name MedisourceRx\nRecord Type 483\nState CA",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "3540bb6b2c11551144391e3c249e943a",
    "title": "Pharmcore Inc. dba Hallandale Pharmacy. Fort Lauderdale, FL. 483 issued 06/13/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/pharmcore-inc-dba-hallandale-pharmacy-fort-lauderdale-fl-483-issued-06132025",
    "date": "2025-08-07T13:47:21.000Z",
    "dateFormatted": "07/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request\tPlease post to the OII FOIA Electronic Reading Room\nRecord Date\t06/13/2025\nShort Title (70 char)\tPharmcore Inc. dba Hallandale Pharmacy. Fort Lauderdale, FL. 483 issued 06/13/2025\nFEI Number\t3014480778\nFirm Name\tPharmcore Inc. dba Hallandale Pharmacy\nRecord Type\t483\nState\tFL",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "bf736a9ea8d4e5996aa39dbebaee64b1",
    "title": "FDA Announces New FDA PreCheck Program to Boost U.S. Drug Manufacturing",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-new-fda-precheck-program-boost-us-drug-manufacturing",
    "date": "2025-08-07T13:32:05.000Z",
    "dateFormatted": "07/08/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "The U.S. Food and Drug Administration today announced FDA PreCheck, a new program to strengthen the domestic pharmaceutical supply chain by increasing regulatory predictability and facilitating the construction of manufacturing sites in the United States.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "f22f145279db4cc44dab1d7eb19e1782",
    "title": "Dr. Reddy's Laboratories Limited - 7/18/2025",
    "link": "http://www.fda.gov/drugs/cder-foia-electronic-reading-room/dr-reddys-laboratories-limited-7182025",
    "date": "2025-08-07T12:03:22.000Z",
    "dateFormatted": "07/08/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Dr. Reddy's Laboratories Limited - 7/18/2025. Country: India. Record Type: 483",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "f1e900273807a70e6bbde3614bd19a2d",
    "title": "FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live): FDA Safety Communication",
    "link": "http://www.fda.gov/safety/medical-product-safety-information/fda-update-safety-ixchiq-chikungunya-vaccine-live-fda-safety-communication",
    "date": "2025-08-07T04:00:00.000Z",
    "dateFormatted": "07/08/2025",
    "source": "FDA MedWatch Safety",
    "sourceCategory": "official",
    "sourceType": "safety",
    "summary": "FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Removes Recommended Pause in Use and Approves Required Updated Labeling: FDA Safety Communication",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "aeaceea386d9d8bfda4181bf0b2fb159",
    "title": "For a Second Time, FDA Denies Approval of Odronextamab in Lymphoma - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNb21KUHZqZjMxc3ZZSXlKbVpzSmdkSU5iak9xN2ZReVVjY2l4eVZ5WmdnZ3JJeTJkZ1JUektHR1dwZ1JwQ2p0aUdiU0M4OVhpcU5aYXloVG1nWnNldjFMRGhwVEh6a1VEOUtmclRSSlBmUWpmZ3AzUWRNSFVGT3E2ekdXeXdPZ1BQOThnT182Sk1oSzFPMk1ISDFkT1RYZG8?oc=5",
    "date": "2025-08-06T07:00:00.000Z",
    "dateFormatted": "06/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "For a Second Time, FDA Denies Approval of Odronextamab in Lymphoma  Targeted Oncology",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "86580996e31cfc2bf842e10577262aa4",
    "title": "FDA Names Top HHS Lawyer as Chief Counsel",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-names-top-hhs-lawyer-chief-counsel",
    "date": "2025-08-04T19:42:12.000Z",
    "dateFormatted": "04/08/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "The U.S. Department of Health and Human Services (HHS) and U.S. Food and Drug Administration (FDA) today announced that Sean Keveney has been appointed Chief Counsel at the FDA.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "d395239d42bdc2174518de9b7072cec8",
    "title": "FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPUC1mb1Z3UGRULXVCa1YyQ2NYbmRQOC05TnFTODg1RmhfcHAwU1hueGRzRG42aVBydTBsOGtJQkk3Skk3LTlpb1l2WnNVT09BVEkzbHRBV0N0NDZVYzFCbVgwRnBKaFMtQXlIQmtDaGdHdUVDSlNkeW1zc2M0bWYzSmRROGExMXhSYUR4QmtTSXFMemR3eVRUR1UzX0NjSk9K?oc=5",
    "date": "2025-08-04T07:00:00.000Z",
    "dateFormatted": "04/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma  CancerNetwork",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a6c14ead5dbb11e2405ef39d3ae33827",
    "title": "FDA Issues CRL for Odronextamab in Relapsed/Refractory Follicular Lymphoma - OncLive",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPU1kxZmpPbjFNMFl6dFd4emhZV2RqLW9NeXd4TFpFNEFMVlhBclIwb2llQVQ1REw0a3loTU96Yk1nUjYza1pGSWJIclhCNXJ0V1ZJMlRMS0Z5UjRIVGpSay1hcHA4dU5tQnhqTTRTeVctRTdWdHZXNDAzVExoWEYyazlBcmNuYWhpUTZHWlppTllRS2pSZ1dyb1BYeWhxQllOR0RCczl3?oc=5",
    "date": "2025-08-01T07:00:00.000Z",
    "dateFormatted": "01/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues CRL for Odronextamab in Relapsed/Refractory Follicular Lymphoma  OncLive",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ef51597d1f2b5901bdca79d5373ab7b6",
    "title": "Regeneron says Novo plant problems caused another CRL and will delay 2 Eylea decisions - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQQWlnbWlmSFhGYXBOTHc3MkRaMTB3QXIxbHdZU2VEMklXVVJ1X0tHZVZJRUxHMXJDU21fQjgtY2x1YlBzRWpWZlBUS19FZkF2Z2M5dVE4b0NPdldSemFpRUd1eERNQXZHWG1WRExuNlN4Sl9WT1pOYjRWZkx3X0ExTklVcExlWHIzc3puN1BCRVR0WEJsQmpocjUxLWl6THd2d05mVkJCSnJUcFhfLUZ0OW52bWZ3U0NoTnkydHJ3?oc=5",
    "date": "2025-08-01T07:00:00.000Z",
    "dateFormatted": "01/08/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Regeneron says Novo plant problems caused another CRL and will delay 2 Eylea decisions  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d740f902f3b758665aefcd938e3f18ef",
    "title": "FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-requires-major-changes-opioid-pain-medication-labeling-emphasize-risks",
    "date": "2025-07-31T19:24:28.000Z",
    "dateFormatted": "31/07/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "48c939b260b2ff7eb1d558e9abaa522c",
    "title": "Jubilant HollisterStier General Partnership - 6/14/2024",
    "link": "http://www.fda.gov/drugs/cder-foia-electronic-reading-room/jubilant-hollisterstier-general-partnership-6142024",
    "date": "2025-07-31T16:41:19.000Z",
    "dateFormatted": "31/07/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Jubilant HollisterStier General Partnership - 6/14/2024. Country: Canada. Record Type: 483",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "00f5061fcf7e0269b676611990b81a2c",
    "title": "Apollo Care LLC. Columbia, MO. 483 issued 03/27/2025",
    "link": "http://www.fda.gov/about-fda/fda-commissioner/apollo-care-llc-columbia-mo-483-issued-03272025",
    "date": "2025-07-31T13:26:10.000Z",
    "dateFormatted": "31/07/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "Task Description Request Please post to the OII FOIA Electronic Reading Room\nRecord Date 03/27/2025\nShort Title (70 char) Apollo Care LLC. Columbia, MO. 483 issued 03/27/2025\nFEI Number 3013927023\nFirm Name Apollo Care LLC\nRecord Type 483\nState MO\nEstablishment Type Outsourcing Facility",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "3437a01292a2a35979bf723958c7940b",
    "title": "Reduced or Waived Medical Device User Fees: Small Business Determination (SBD) Program - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMikgJBVV95cUxQWGdjZk9td0VZMkwzRFFTNHQ3NFlIYUJwcjhwM2NZbmtLUHNyVnMxWGtyOEh6ZHJHbkNiUXBsMTczWmVvWnZkSHFXZHFLa24ySWFjeFphdzZISFYxLWw4MXhqLTZTcWl4Q0VkNFh5S0t4bTltYXRMMGU2d0hJeXh5VUN5ZTdvaVdHNWp0RFlBOWJ0UHFPSW1xSVN0V3laOFotUThsUy1wdWp1VzFjc212LWQtVmEwVGVKTS1MQUY4RmV3aHNoZ0tmUHlnSnFYTzhsS1laOThKWEQxTFRteE5DMlBfUTRjSldZWEpONVhMUGxDWUQ0Tmo3Y3EtaVZBQmV4TEFPazV1dWhnS2tTeXdYWkp3?oc=5",
    "date": "2025-07-30T07:00:00.000Z",
    "dateFormatted": "30/07/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Reduced or Waived Medical Device User Fees: Small Business Determination (SBD) Program  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e8e874d58f8a283e2d1d264abfb23e0c",
    "title": "FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-takes-steps-restrict-7-oh-opioid-products-threatening-american-consumers",
    "date": "2025-07-29T14:41:37.000Z",
    "dateFormatted": "29/07/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "c50f030a0fec9f99f7485b6e3f3e6b2b",
    "title": "FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPdEhGM2hxUUFLS0ZoNGU4UDlLX3VTZUxidXhOV0ZlRGptbjROdTJqMGRlOExlZzhtdTNtYWpsVzBZSFJYdHZfMmthN0Fzb09OSXp2TjZGcFppVnJYQXg1OElIOVZkUjR6LXF2TXRZNi1MMEQ0ZzlFb2xOY0FrSVRZZlJhVWo3Vm42S0hsc3lqSGt6R245UkZNNFJaT090c0VlMXVjZk9RNnBtSnI5MnVzd3VRR2E2YU1IZmQ2LUFwQ0d3U3lZMmJj?oc=5",
    "date": "2025-07-29T07:00:00.000Z",
    "dateFormatted": "29/07/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "0bebc8967262c1555631aac938bb3875",
    "title": "Nikkiso Co, Ltd. - 613109 - 07/23/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNcUdHZFg2M1kteFVTNlpLY0dnc2ZSZlhpYXI3YWdfQlFKSkg4TjFmWUpueGFFQWJMdlhsZ0VrOW9XMF9yZ09YdEdfNzVsUks3R2pGWkxmT0JiN3cxNzVnSWdBZHlFZ19Ralo5d3dIS2UyYm1SWkFQTDdOdmIySWJETkNnUHZYNW0ydl9FQ2RzWWFuS0J1NmxtcTZKUTFlRXBkT0lHZnhOdXg0VEJNYm5QVHRudHIwUXhfcU1rbU5TV19YNlR0eGJhNw?oc=5",
    "date": "2025-07-29T07:00:00.000Z",
    "dateFormatted": "29/07/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Nikkiso Co, Ltd. - 613109 - 07/23/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "55e679f0c09f31a63467752c978e226f",
    "title": "5 Cs For Responding To FDA-483s — Strategies For Effective Compliance And Resolution - Clinical Leader",
    "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQVEgxdUZlOTlRTnhhbWcxLTFxVmxsQkxKZkRjek1CbndhMHFGME9pcF9waTExRV9hcGNTMk9VUjU3NDh1YjBuU2Rrdm1TQ2YxdHdnVXk5YmltQ2lzVG9YT2dkbDV2clFTajhuM0NLelpFclBiREh3X1h0WEF6RVdHR3ptcjU4a0h4bG82eG14Y1NTVGFRdkdHcmlGZ3dPZHlpanlQXzVxUjg1eG1qZjhLUFNONDI3d3ZT?oc=5",
    "date": "2025-07-29T07:00:00.000Z",
    "dateFormatted": "29/07/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "5 Cs For Responding To FDA-483s — Strategies For Effective Compliance And Resolution  Clinical Leader",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e9aa01adee32e9b24c4088c033994f89",
    "title": "FDA Recommends Removal of Voluntary Hold for Elevidys for Ambulatory Patients",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-recommends-removal-voluntary-hold-elevidys-ambulatory-patients",
    "date": "2025-07-28T20:21:55.000Z",
    "dateFormatted": "28/07/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "FDA Recommends Removal of Voluntary Hold for Elevidys for Ambulatory Patients",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "57f289bc4e54ea9e5edb8fe1eb583f19",
    "title": "FDA Investigating Death of 8-Year-Old Boy Who Received Elevidys",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-investigating-death-8-year-old-boy-who-received-elevidys",
    "date": "2025-07-25T21:25:06.000Z",
    "dateFormatted": "25/07/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "The U.S. Food and Drug Administration is investigating the death of an 8-year-old boy who received Elevidys, a Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "66b58240c02e84ea4e1d81f8073a5e7b",
    "title": "FDA Crackdown on Trial Design: What July’s CRLs to Replimune and Capricor Mean for Sponsors - Applied Clinical Trials",
    "link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOUlFwSXd5dEk5eHNMYl8xWlk1WS0xby05a1lZNGtmQ1ZXSXRib2lxYzVqb2tWbnMyVlAzalU3eHVBSVpIRUhSQWYyVDNRUkJ3Z1VfUU1VTzRxNXhmbzVUZVpWRVY3cDFQcnA0ZTZHcmsxM1p6cUVvRWIxc2FhV1NBR2d1Z1B3ZXRJVW5NVkcwLUtOWXJRam9JdHFtcjY5STA?oc=5",
    "date": "2025-07-25T07:00:00.000Z",
    "dateFormatted": "25/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Crackdown on Trial Design: What July’s CRLs to Replimune and Capricor Mean for Sponsors  Applied Clinical Trials",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "c90e85e224eede32bf93745ecd40cf00",
    "title": "Replimune CRL Fallout: How Biopharma Leaders Should Manage a New Layer of FDA Uncertainty - Pharmaceutical Executive",
    "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxNTkF4SjBPS01MdURwbjNoanNMQWJTczdSY3BvU2NkS1p6S1FpUEw0eUpJdE16RnBfOHg4OEJjdmoxQVhiZFpRRUJqRjhXajBlRWtnY3ZsT0E2UUhySHNVbmRIMmN1T3dqQ2I4c1Q4bFJEUUtPS05xTHBlazRwZ01rdkhrc2dOVUpaUXpQcTFLU0RMdXF6dHhVT2daai1BQQ?oc=5",
    "date": "2025-07-25T07:00:00.000Z",
    "dateFormatted": "25/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Replimune CRL Fallout: How Biopharma Leaders Should Manage a New Layer of FDA Uncertainty  Pharmaceutical Executive",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6eaab15687b0f9d2278114e9c09b96d9",
    "title": "DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo - Medscape",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOaVI5eGY5ZUstSlZiSHdoaEpoVGF2LUFSampJTWQ4LXpyNFlRODd6eGNzRFlUQm5nbjkyZXNzeThhOHhsUUhZSnlodmRRV25OR2MzVDRZSUVuSkxjQ2dvSS1BUUNsdk5IYUJwcEtVU0xRdUVOTl81Vm1iWUNDX3Ztblh2TXk0dkZwOXFmamY5U0xIX2M0SkVaLXpPSHp6aG51dlE?oc=5",
    "date": "2025-07-24T07:00:00.000Z",
    "dateFormatted": "24/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "DLBCL: FDA Rejects BLA for Second-Line Glofitamab Combo  Medscape",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "0e428fac3b59491f4274bb45213e8f06",
    "title": "HHS, FDA and USDA Address the Health Risks of Ultra-Processed Foods",
    "link": "http://www.fda.gov/news-events/press-announcements/hhs-fda-and-usda-address-health-risks-ultra-processed-foods",
    "date": "2025-07-23T21:44:12.000Z",
    "dateFormatted": "23/07/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "HHS, FDA and USDA Address the Health Risks of Ultra-Processed Foods",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "06dcf065cfeb4f0b52dfc4b6ff2f0ac0",
    "title": "HHS, FDA Praise Consumer Brands Association’s Vow to Remove Artificial Colors from America’s Food Supply ",
    "link": "http://www.fda.gov/news-events/press-announcements/hhs-fda-praise-consumer-brands-associations-vow-remove-artificial-colors-americas-food-supply",
    "date": "2025-07-22T18:17:07.000Z",
    "dateFormatted": "22/07/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "Today the leadership of the U.S. Department of Health and Human Services (HHS) praised the Consumer Brands Association for its pledge on behalf of the makers of the nation’s food and beverage products to remove certified Food, Drug & Cosmetic (FD&C) petroleum-based colors from America’s food supply.",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "78295b63b6dddf36083c7ded65722cde",
    "title": "FDA Issues CRL for RP1 Plus Nivolumab for Advanced Melanoma - OncLive",
    "link": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQZEl1ZFBnQWVDQlhPSWQ4N1ZwUkJuREc0WHJERS1HUV80emJFRnFmZ2F6NXA1aURxMnBiTUxUYXVtVVVIY3NMWjdWSUlVU1BNUEx3RTlDZlk0WmpUOUZacUhGZGhTTXBBajBfR2VYakhkenE2Wkt2VmpXTHAxWDVZWGJacVRnNFd6cTFHdDIyX3l2Zw?oc=5",
    "date": "2025-07-22T07:00:00.000Z",
    "dateFormatted": "22/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues CRL for RP1 Plus Nivolumab for Advanced Melanoma  OncLive",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e0f281495e0f310822e664bd9505908a",
    "title": "FDA rejects RP1 for advanced melanoma, says IGNYTE not a ‘well-controlled’ trial - Healio",
    "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNbWJBZlpidVZBdy1nNUVfTkJHZ0xKSlUxRHNzZkFhYzlfSk5EZXpsVmhFclFZRkFZVDJwTWh5aDZwVjNzOWpGZzFYdzFmRWQ2OGI3WDJiazVGR0dGS0ZNWWhLelJKVlczS2d5d2RhMUdDUmYzblhCM3dqWnNZZ05PelNuV1hUS1dxcFNXdDYwSTBXalRGY2hPZ01tVFJ2R19ENkNpNTduZm54SDdvaVZsZWhKY0tkRXdsNUZ0bmJOT1lVNE5DR21HejVubkE3UQ?oc=5",
    "date": "2025-07-22T07:00:00.000Z",
    "dateFormatted": "22/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA rejects RP1 for advanced melanoma, says IGNYTE not a ‘well-controlled’ trial  Healio",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "947e281e78534eab6ad218bcc12ceb3e",
    "title": "FDA Issues CRL for RP1 in Advanced Melanoma - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPNUp3Q2hzNDdZejRfTHhjYmRhUHpvXzRVYXRUa1JhM2p0X1l2ZUJCZlNEWHlVLTNfM2ZVU2JGZmw1R0RQbEptUS0zRlJ6Z0doQzdEZGMteVFEWndESER6MGpqTXRreHBwd1lFQlJPMG43TjU2dVh6YkFHbXF2X0QteUpR?oc=5",
    "date": "2025-07-22T07:00:00.000Z",
    "dateFormatted": "22/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues CRL for RP1 in Advanced Melanoma  Targeted Oncology",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ffec989f13532a51d0fe0a32164a4519",
    "title": "FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection - Stock Titan",
    "link": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQOXNhTTNEQmVOU18zeVU2RllzaHNkcEN6Q0hLbjdyd2trczhvQXR6QUQtbUc1VkRIVGoyV1YzSWZVNWJrajBENzlvRFNKTHlkMHFyRVpLbGp2N2ZUTFJlT0lyV0tOMlRsalZ3Smp6YjZvUnc2TWhzblVNMzZFcUVFQU5iUmhNSU9ER0NGT1NPZmZ3eGZ2bnZCOG10ZzlGd2E5VnR5TE5qRVAweS1pdUJJNFEtOEQ5QQ?oc=5",
    "date": "2025-07-22T07:00:00.000Z",
    "dateFormatted": "22/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Denies Approval for Replimune's Advanced Melanoma Treatment: What's Behind the Rejection  Stock Titan",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "583008fcc1faf01f2ebba7b95edc1381",
    "title": "FDA Issues CRL for RP1 and Nivolumab in Melanoma - Dermatology Times",
    "link": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNVjFfVW80YVZIT1NnUVdMS0ljYU5JTzFQaDExX2JpUmRfMHk2LTZEdjZqV0JoeGhOcmhrTG1wSGZIV1lDcnI2SnBYWDlxVUNGQjJmcXljdEh0WENsYUVTeEpwanNWZndEdnlqa3hVWWFGdXNydEVrbmZxRDBJM01tcWFMS2FJUmJzMndzMUFqcw?oc=5",
    "date": "2025-07-22T07:00:00.000Z",
    "dateFormatted": "22/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues CRL for RP1 and Nivolumab in Melanoma  Dermatology Times",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "26f2e27189cfe9fdf41faf4a9ca26064",
    "title": "Replimune's shares crater as FDA rejects melanoma drug - Fierce Biotech",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQSE43LURlWlUxWlJNQmlQRWkyOXdxc3ZkZE9SNVJjZW9xOGtBZjFCRzlwVGxUTS1oNWdpZi1XNzF3eDJKU05zQ3ZibEZwa1ZHRDJFV1JWQ0lzaUtDc1NWTmFpZzJEVDBvNG1YRzhYV2pXR3lrb2NNenA1NEphMVJCbUd6cFN3U0NiVmV6VUVBSFpxNjB6NEtLWldkb3Ytak9JOE1PNlpR?oc=5",
    "date": "2025-07-22T07:00:00.000Z",
    "dateFormatted": "22/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Replimune's shares crater as FDA rejects melanoma drug  Fierce Biotech",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "dc5a86b7573176d2b1f33820475f4811",
    "title": "FDA Issues CRL for Vusolimogene Oderparepvec in Advanced Melanoma - AJMC",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNM251Q1hxcTBwYmhzMnc3d3V2TWdKbWF5aTdnc0p1QVhnSzFfQTZhTjhYN3p4S0lTQXdoMl9IUlBrc25BMTVtY2x4dHRfVXNNLXYyT3ZFSUVkN2ZwQnpMbFc1cURwc0ZRWVg5eTdrWHpZSlNUVjFGeTJkWXpHZ1JFcENsSkJDeTZQWHVtbDhUcDNwN3V5cXc?oc=5",
    "date": "2025-07-22T07:00:00.000Z",
    "dateFormatted": "22/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues CRL for Vusolimogene Oderparepvec in Advanced Melanoma  AJMC",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "b59e56b750f4088347096d85881a33f2",
    "title": "Stanford faculty member George Tidmarsh, M.D., Ph.D. named Director of Center for Drug Evaluation and Research",
    "link": "http://www.fda.gov/news-events/press-announcements/stanford-faculty-member-george-tidmarsh-md-phd-named-director-center-drug-evaluation-and-research",
    "date": "2025-07-21T10:57:14.000Z",
    "dateFormatted": "21/07/2025",
    "source": "FDA Press Announcements",
    "sourceCategory": "official",
    "sourceType": "general",
    "summary": "The U.S. Food and Drug Administration today announced the appointment of George Francis Tidmarsh, M.D., Ph.D., as Director of the Center for Drug Evaluation and Research (CDER).",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "9862d3a13a52574f84fa40779cfd77b7",
    "title": "FDA Issues CRL to Glofitamab Plus GemOx in ASCT-Ineligible R/R DLBCL - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQQVhucUF6ZTNFTW5XS2hKcGVxRG9HeUFsb2dpR0l0S2tHWi05SXAwaVQyY1JaaWRZTWliM2c0WFFCTGRyVjh4UDNBc3U1TVVZQW04N0JXYkVRRjY4V2pJV28za0R1cG9TMHhzdEhFZ1VVNWVBUjF2V1FKaUpXUnBnQkdTTjZ2bGRZR3BtSy1Kak95c3JlbU02LVBLSHJvSXpGSGFOdVV3?oc=5",
    "date": "2025-07-21T07:00:00.000Z",
    "dateFormatted": "21/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues CRL to Glofitamab Plus GemOx in ASCT-Ineligible R/R DLBCL  CancerNetwork",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "fb23c3c8b66b9e531da1b7ad217a8e5e",
    "title": "FDA Rejects Glofitamab (Columvi) for Diffuse Large B-cell Lymphoma Indication - Oncology News Central",
    "link": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNZlJkekliM19uc0dzTm9pMGlUSXRVRjdZLW9GS1VuR1JCTU5hbi1RTmN4Z3dta1cwbnhSNXBtWngyQ3dRWGFJTHZQc0JlQUYtUHdJYWpheXRGWGZkS1dNTXBZS1JKTHVyNWlvUG9oMVlKdXVRLUhZb0x6d3p1SGsta1d4Yk51OWp2dm4tOG5ydjM4STQtVWczM1Y2NHJ6ZFRnT2U4UjhTY1FGbWZRckZyRUJySlk?oc=5",
    "date": "2025-07-21T07:00:00.000Z",
    "dateFormatted": "21/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Rejects Glofitamab (Columvi) for Diffuse Large B-cell Lymphoma Indication  Oncology News Central",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "5ad64a1469878c84423ced73feaa7191",
    "title": "Dr Reddy's Labs gets 7 USFDA observations for Srikakulam facility - Medical Dialogues",
    "link": "https://news.google.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?oc=5",
    "date": "2025-07-19T07:00:00.000Z",
    "dateFormatted": "19/07/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Dr Reddy's Labs gets 7 USFDA observations for Srikakulam facility  Medical Dialogues",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "359f09b78fbad2dbe71ee13ff7cf8077",
    "title": "FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL - OncLive",
    "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPTXJ2V0o3azZmTnIxeTZRclRDS0dwcFUwYWVuMGxyOWVBekJXbzF1WGQ1WUN6TTBwSlpDcTNkUzRXOE1XYk5odDVjQUZaOE1URjJQLURSb3pSMFBpcTd4YUpwcDZvY2laNE9mSzI5Rm5KWGpBV011UWI5d296V0lOejRqVlMtTC1aMWc?oc=5",
    "date": "2025-07-18T07:00:00.000Z",
    "dateFormatted": "18/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL  OncLive",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "89c9fe17a8d0c1c034c297b66040ae7a",
    "title": "FDA rejects Roche's Columvi in earlier diffuse large B-cell lymphoma, citing lackluster US data - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNMmFYcDkzS3FTbVRYZXozazVQU1N6RzAwMjctaXhfQ3Ywak82N25TRmtpRllTbnNQN1ZPaHJELWxRRXNmTF9neFNjTVhRUW9JX2ZNVU9RVFRSRG9VVlpwUk5yMTQ1QkVfM1RpdGxESlVXRm9uOXN0VkdEbmxfeDFNYUdrYk5haU1wSzhwRHlkZVZXajFJUDJoaXJId0NManFmNlB1QVFPMU9uZUV5ZHgyQVZyTHIwcGViZnYyNzF3YnQ?oc=5",
    "date": "2025-07-18T07:00:00.000Z",
    "dateFormatted": "18/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA rejects Roche's Columvi in earlier diffuse large B-cell lymphoma, citing lackluster US data  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "8cd13f6c38e4089761392f4b02d1fd4d",
    "title": "Lupin receives USFDA observations for two Pithampur manufacturing units - Medical Dialogues",
    "link": "https://news.google.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?oc=5",
    "date": "2025-07-18T07:00:00.000Z",
    "dateFormatted": "18/07/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Lupin receives USFDA observations for two Pithampur manufacturing units  Medical Dialogues",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "0ef2305a1f8cc085d48dfee757eeae67",
    "title": "E-Cigarettes, Vapes, and other Electronic Nicotine Delivery Systems (ENDS) - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOV2VTbVdDTzJMdERwTWNLWFhtQ0FUWHB0SnJCUjhaNGtxa2RSSU5nVmlFOE81SV96WVZsRXctVUotcTNNYWJ3TnRQMlFyeFRuWXhJY19WaFVkZVVNSFhvWEMyc2t4aVV1Q1kyQTdwVkZLb0xiMF9PZ1hZb25yMzRVRjNjZnUzNzZBalZVc2VZYnlsUFdJaUltaUJiNmxwWl85elpqczduTXNjd29kODFLWGVueU1xMDdRdkc4dWFOdHRWdk84Y1lqS3VtZktfZWM5YUJELTln?oc=5",
    "date": "2025-07-17T07:00:00.000Z",
    "dateFormatted": "17/07/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "E-Cigarettes, Vapes, and other Electronic Nicotine Delivery Systems (ENDS)  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "40f9acd10e4ee889cac3ff480d26a3ba",
    "title": "FDA’s Published CRLs Deliver Insight Into the Drug Approval Process - OncLive",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxONjFGNFRLejRrYVdvZk5DbWlVVWNZZlZmUlpoZFUwUnBxb2w2bC04LWwxeDlpbDcxZVFoTG50MTNVTEtkWFYyeHZzRHpNOTEyc0RkbHNLcU5qT1hCNFVKM3lwZ05IaXpsb2wwTXJCVEltbHc0LW5hbHdnWmtwLWFScW9WNmcxVHRQWVBPUGxDMnFSeW1OeC1vS0J3RVU?oc=5",
    "date": "2025-07-16T07:00:00.000Z",
    "dateFormatted": "16/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA’s Published CRLs Deliver Insight Into the Drug Approval Process  OncLive",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "2664ea3fff8bc81849ec284049c3d903",
    "title": "FDA hands down citations to 3 drugmakers after inspections found contamination, testing concerns - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPc3FLZkRYR0xpWXNvdHA0SmxXOGk2LTBkTk5RVGxpUG81d180WjE2Yld4MUVpX2I3dW52YzZHYWJPOHY3M21DaHhVdDZMNFpSOXlBVF9WdTJKdHRDMEw1dTBEeHJzSVVRaFRSdk9vcURMSC1kR2FDUF9fSmJaSDRNR2xkOTlra2twOFAzMWtod3I3RGdUNnFsOEtrLWNZdW1XZlRrNGY4VS1EN3JONjNOWVY0bkdtS2lUSHc?oc=5",
    "date": "2025-07-16T07:00:00.000Z",
    "dateFormatted": "16/07/2025",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA hands down citations to 3 drugmakers after inspections found contamination, testing concerns  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "7cb0b3e94f51f5f7866987b23718b2c9",
    "title": "An FDA inspection revealed significant problems at Empower’s new outsourcing facility - Partnership for Safe Medicines",
    "link": "https://news.google.com/rss/articles/CBMif0FVX3lxTFByaWtYV1dtTzNHams5eWZPSDU3elRxOUxQR2toT3VWVnlnZG9oNTM0bnZ4cW1TUlMwX0xfQnBKYzFjNDI5VzU5V1RYSWY1OVJSSFBjM251dWZJN0NaZGY2MmZoVjNfclZIdGhKT1hQSnlOREtiZ1VySjY2Szg5eTQ?oc=5",
    "date": "2025-07-14T23:11:33.000Z",
    "dateFormatted": "15/07/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "An FDA inspection revealed significant problems at Empower’s new outsourcing facility  Partnership for Safe Medicines",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "0ea24f6f6627db74eb78443f46ec35d3",
    "title": "Ultragenyx takes another hit as FDA snubs AAV gene therapy over manufacturing issues - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPRktpSHB2MXBlSHhSUGhMdVpISE55Z0MtZl9iV1BwaUpmbEdHVjBBUU44R0pMcDQtMDdxZk9xcjRwNUwxV1ZKeHFlYWhubzQ1ZXNyZjFRUXg4QTFrN0c3Z1ZBcG5mUHpkdDVydDRfUHZlSm4zQzQzRTI5MXRfZ04yaHVoTzYzUm1OczJzQWs5WDJVNWRPY1hTdXkzVkp6S1B2YW5lWmRjQS0tQVZ1Q3UtUGxQUkc5cjFJ?oc=5",
    "date": "2025-07-14T07:00:00.000Z",
    "dateFormatted": "14/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx takes another hit as FDA snubs AAV gene therapy over manufacturing issues  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ffe2fdc52514d058c67bae6e80b9b02e",
    "title": "Pledging ‘Radical Transparency,’ FDA Reveals Drug Rejection Letters — With Limits - MedCity News",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPc2QycUNxMXR0RnVTUUVIQnhlMzVfVlNzZG13LXgyQ1JUUnNLTUozYlFhRTZ1QUhER25YWEwyZ1dTWm10aGQ3YWNYQWotc3pRUmdsTzh4REl4cnIzVV8xam9OWklQNTVMT2ZHbTlsUGJtRTFTY25QckpsM2VMd0ZBQnlCMmpNUUYyWEUzYWZrOXhUVGc?oc=5",
    "date": "2025-07-13T07:00:00.000Z",
    "dateFormatted": "13/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Pledging ‘Radical Transparency,’ FDA Reveals Drug Rejection Letters — With Limits  MedCity News",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ba643b818e704ba68398aadf6df4e7ff",
    "title": "‘Weak’ evidence and an ‘unpleasant’ odor: FDA sheds light on drug refusal process - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPT2VnQ2dpOVVYRjBlMnFvNG9HcTdPOHFfTUhYSV8tOVZ4LVpMUjRydUJYcS1obFdiS01ob2dac1F6akEyUFBEakZ6emc5U2RBQ05KQ1Bxd1Z0Y2UwYnpHV2YyQk5WMzZPRklHb2hrdHBCblNqRVZ4MENLYjhlMFRaLXFqbGF1VDFnc1FFUU9TYU52S2tUbzExaEtKcm5rRWVjcjRYYUxjUnBlSVk?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "‘Weak’ evidence and an ‘unpleasant’ odor: FDA sheds light on drug refusal process  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e094d9b878ce5142612b79f5c0b31e36",
    "title": "New FDA Initiative Reveals Common Reasons for Drug Application Rejection - Applied Clinical Trials",
    "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPN0xiLW1pcG5NdDB0cmhKWUpNLXRZN0ktMmdqZWJqRlg0OFByX3hCQWlvSzJra3hkVzhsQnk3U2QyOURiZGlDRDJteEM1SS1EdVA3N0ZpdW1raFlaRXRPMlExc3FQRnE2R1dBamdjZDRPWC1ZMnhqQVo0aDFGUFdGbEI2bzUzRU1YMVc0UHhoRC1QYkM1T2s2MUNKeU1taG4wcl9SbHJHNnJHdzE1ckVDZTlld21BWkw1?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "New FDA Initiative Reveals Common Reasons for Drug Application Rejection  Applied Clinical Trials",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "540cbef7f9f597f68ae817884ab290fc",
    "title": "Capricor Plunges on FDA Rejection of DMD Cell Therapy - BioSpace",
    "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQMUlxSDhVN0UtanB6bm9WUzZzOXpNY29QdHk4NUVDZ083WFBEZjJPSjV1eDRMNnVEVHNtRl9rRWI4N2YxR1lLaXY3R09WaTgxMGw1d0pQZGtJYldMSWlZMGhmckFFeXllMG4wVDNVQU9hTDJ0UXR6aDBXaUNkOGdaX1ZLZTUzTVB0VlE?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Capricor Plunges on FDA Rejection of DMD Cell Therapy  BioSpace",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "03d5d3511c09455f10fb1166070790b5",
    "title": "Capricor’s BLA for DMD Cardiomyopathy Cell Therapy Deramiocel Slammed With CRL - CGTLive®",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOSHMyUkY1Nlp0Zi15dm9VeVZCRTVIeXBPSi1PVDhnemVpNVd0MlJHbjk3ZDMwemYxYlExYWJUVDFEMWplWnhvdlFTbXNOZXFlQTF3VmZTeFpzbTdiTkRVUENHaXlUNGZLMGsyb1pSZkRhTndwRTg1V2Rna0lual9SQVJtaFFHaEFfLW5Tb3htTDZDYTBUMDJieFBfNVU?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Capricor’s BLA for DMD Cardiomyopathy Cell Therapy Deramiocel Slammed With CRL  CGTLive®",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "1f0452051932a1ac90849bb39fad9a94",
    "title": "Ultragenyx Gene Therapy Faces FDA Delay: Clinical Data Strong, Manufacturing Issues Fixable - Stock Titan",
    "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNRjFYdWEzT0pObThZbExVVTc0RS1SQjhhZGs0NGRETFkwbnRrSmRsWnc3dmVYaU9sTUhUdTRnY2FzQ0U2WVhheVBhZ3dRSzVwa0hISWJhUzBaczZxLXhqb2RGanlLMnF4S2lIeG9GNkJ1ZUg5RW8zQW9Db1ZaSUhpWXpnVTBPVWZaazdkYTRxS2RxMU91UFJyWVNmNlVjTlZKRHZ5eFBHSUkzTFRRYkR2dENQU2xDUE9vbTBodUNJUQ?oc=5",
    "date": "2025-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Ultragenyx Gene Therapy Faces FDA Delay: Clinical Data Strong, Manufacturing Issues Fixable  Stock Titan",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "af0d46918a2cbf098bde0522484976d8",
    "title": "NATCO Pharma Limited - 6/19/2025",
    "link": "http://www.fda.gov/drugs/natco-pharma-limited-6192025",
    "date": "2025-07-10T11:26:33.000Z",
    "dateFormatted": "10/07/2025",
    "source": "FDA OII FOIA Electronic Reading Room",
    "sourceCategory": "official",
    "sourceType": "foia",
    "summary": "NATCO Pharma Limited - 6/19/2025. Country: India. Record Type: 483",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 1
  },
  {
    "id": "b127e38f20c6e2621bc60605aff5589f",
    "title": "FDA releases ‘initial batch’ of more than 200 drug rejection letters - Fierce Biotech",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPX0NhamdGMWx4NmFfUnNkZ2NKQlQ0Q1N2alpSdnVZc3lxaU94eWJuY0UzXzNLcWxlSzlpa3pZQWVtMlRKakE5OXd6SUJhaUkyS205UEpVRnpidldrMVJvcUtjM3VjTmlQeEFQSWNxRWVaLWNnWTBVTTMzbkxaaUE4VXVqT1V2RjA2MFdwek56TUJuaU9Kcnc?oc=5",
    "date": "2025-07-10T07:00:00.000Z",
    "dateFormatted": "10/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA releases ‘initial batch’ of more than 200 drug rejection letters  Fierce Biotech",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e52bebcfa33e1795ca512eb43aa2775f",
    "title": "FDA Releases CRLs for Previous Drug and Biologic Product Applications - OncLive",
    "link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNWVh2d1FXVWZSeWU3b2g2OFpKSTIzdEE4WHU0OVVuQUk1UGUyM2M2T1VmVXhreTllVjJUX3FOdl94clRiZXhtV0l0cE04MjhtaWtMNjdkYzhTT1gwaWt3ZWtLbUpxSXJhZVQ3Y3haSy1qWW1Bb2lZQ2g3MEdwYktZWUNmTkFVai1sR2VweHM5WEJRT2RIMFNEOUVtZm5CUUU?oc=5",
    "date": "2025-07-10T07:00:00.000Z",
    "dateFormatted": "10/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Releases CRLs for Previous Drug and Biologic Product Applications  OncLive",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e5d310376868f68c4fd9a699350df37c",
    "title": "Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future - Endpoints News",
    "link": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNa1NadUpmeHdvZW54R1NsLWs3MGVzS3o1WHlFcmczOTdxMkRJVGVsNmo4Um1BUmQ3eDlSSFdFTGZ6dkJncHNBSW9kZGN2VlZud2VtbTR5RUJMaGVnYzlTWmFxLVJlWWVGOTR5WHctd09KbGtRMFRodUpOaThuSW1kUlNMSHVBVkk?oc=5",
    "date": "2025-07-10T07:00:00.000Z",
    "dateFormatted": "10/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future  Endpoints News",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e8128176d3162108c9848ebde7e1ecc4",
    "title": "FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma - AJMC",
    "link": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOMGQ2X3REc2dndmI2ZlFRN2tVOW5wSlpJeUktYWhxT29MTlctN0RpWDVDZDhoRnlaOWNZQmJORVBhRU1Sa1pNZWVkVW1PQkRIbWNaeGlZS29fLUZwSE5fQTVnZHctZ29NaXZZckN3SDU0cGxFa1R4eXlfU2trRHpBc0h4QVlORklCa2c?oc=5",
    "date": "2025-07-02T07:00:00.000Z",
    "dateFormatted": "02/07/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma  AJMC",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "3cee62bc8ae8830c776d8998fb62847b",
    "title": "Unicycive Therapeutics Announces Receipt of Complete - GlobeNewswire",
    "link": "https://news.google.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?oc=5",
    "date": "2025-06-30T07:00:00.000Z",
    "dateFormatted": "30/06/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Unicycive Therapeutics Announces Receipt of Complete  GlobeNewswire",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6a5297f60c8aa81fadabd52911ea0084",
    "title": "Granules arm gets U.S. FDA observation resolved - The Hindu",
    "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPTDRKT0k5c01hdFEwTnFwckFSQmR3NExWUFpldVYtWXo3SnZBQ1FWSE51RFI5bDBMNW5sSldYSU55Vk0waWFfX3Z4OGFhYnhQTFA3bm43TVlCUldMcnVDeHRXeVVRdXlzaDl1eVVTWEJHbC1PRmZZMDBSZmdsM0YzdkE1bW9YZjVXVGpnaUlDRFhvVDVPWktQQk4wR1JXNEV10gGnAUFVX3lxTFBYQlR0cnRHWDhxeUU3NTNWczdXc1REWHNzRUlXeGx1TlRNTkQ2RFVSWVh2TWlIM1FxQnJBSmc1V09xY2tCYzR5VTV4RHc0VUlKRnlDYm8ycFJpdDBkNHJ3czZud0xNU0VWZUZQS253aER1allRRm9ERmVRNVBuQ3pudDAwRnJ2SlNfRmhlLUhtOFJIZHQtMGlBMzV1cWxERzFaQTI2OTBJ?oc=5",
    "date": "2025-06-28T07:00:00.000Z",
    "dateFormatted": "28/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Granules arm gets U.S. FDA observation resolved  The Hindu",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "0acbd000ec98961f9650aa91c9babbb5",
    "title": "Granules India shares in focus after US FDA flags observation at Telangana API facility - The Economic Times",
    "link": "https://news.google.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?oc=5",
    "date": "2025-06-23T07:00:00.000Z",
    "dateFormatted": "23/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Granules India shares in focus after US FDA flags observation at Telangana API facility  The Economic Times",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d82aa7a2e048f11c67e3454f23a12a98",
    "title": "Granules India's Bonthapally facility completes US FDA inspection with one observation - CNBC TV18",
    "link": "https://news.google.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?oc=5",
    "date": "2025-06-20T07:00:00.000Z",
    "dateFormatted": "20/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Granules India's Bonthapally facility completes US FDA inspection with one observation  CNBC TV18",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "41bf144087f92647dfbbc5503334030a",
    "title": "Granules Indias API Facility In Telangana Gets FDA Observation - NDTV Profit",
    "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxNMlE1bHc2MFBURzVkdzdIOTY3YTJ1aE5jYmptNmpMM2lZd2hlTTB2Q2oxVDN2MFRWYTFzdXhHRDI1cm52bnBKcklqZWRiaGdFb2hBRDgxSDBJQWR1ZjdsLWJER0xWQ08tU1dDR1BvTmwxWDNrSXRwZkNLYS0ta184TVJpZ1pTMUhoWnJ6UXhOTmhDZU1LVEwySWpIdVBlZ9IBowFBVV95cUxObmVaSjZpdmlKamp5aXlxb29uWWVleXVma0hHelE3THhHVU9LYlFDVVBrYmZIa1plX1VHaFVBelZ1ZF9hNlZrUHRzZk9EQkNub2M3cW5VZnBpRUdZMTZYOWFJOHdmYUo3WXBnek9HMHpEUzE2Q3Z1S1hWY1VLNHJnemx0ZnNldVVzVzFQbzIxZ01uLUR5OEdNbklLSDllSnVyaXBJ?oc=5",
    "date": "2025-06-20T07:00:00.000Z",
    "dateFormatted": "20/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Granules Indias API Facility In Telangana Gets FDA Observation  NDTV Profit",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "4532f20b605fb1f0475fbe5efb562047",
    "title": "U.S. FDA issues 7 observations to Natco Pharma’s formulations unit in Hyderabad - The Hindu",
    "link": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPWGxKeVQxczEweFZYZkJKekJsbHVPUXZpZjVkM1RMSWFoMU5KVDJfcGlOYm1Pd3A0bnVQZXFLRWs1Wk9FRF9sazZ5a0N0NmNJNEg5bm5aci04MDAwbWc0Mkd0ek5wMC02WEN2aVAyUDhFR3Z2bV9RbUFnTm5Xa0VaaGJXZVAxY1hqeDI5aXZod1NTS2JBdVl3OEZCb3pRdmh0QXpPZnNEcXo4QWxXSzlzUlB2VEttaVFqb041a0QtVWktejhMOTZDUkhzYTItaURtYXk2X3hBMEg0SGt6djNhMmxn0gHoAUFVX3lxTE4yVzB1ZEU5VUZmNG4zdXItU2pkTkpDZGVUYnFwTUFIMEtFZDk5VHkxVFQyVDRmc0VlM21Cc00tUWwtUmQtUXo5ZzhHOTdLemZpM3lIYnRLQlJnUG1yU1E0bHRhMGgwUXNJVE9EVS16Q3Z1LTBiM3NSNTU4eUlpYktONkNIdWNueVdSZmR1dDlCcUlPTzJ6VmVLRnJjZFgtQjZ5MVFHRGdpYW5UNXdhejBKSGxwZEp6QmpnRjY5aG1za1V4MVEwQ3Uzd3Nab2tVRXg2ZGE3UjNZbWd2MFIxdEIzT3EwSU1zbkU?oc=5",
    "date": "2025-06-19T07:00:00.000Z",
    "dateFormatted": "19/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "U.S. FDA issues 7 observations to Natco Pharma’s formulations unit in Hyderabad  The Hindu",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "01103417ffa69c2c9d94fd77e35073f4",
    "title": "Natco Pharmas Division In Hyderabad Gets Seven FDA Observations - NDTV Profit",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxObzd2UjVFS2pSaUxQQnpwMmlvbkNGdW9KcHplaGFfTUtxaW5Pb2FMSWpSdXFVNERDSkFNYTZIN2d3SGZ6dmlsV3psaXlURzk4SGZMWFQ2OFFDUzFuLUJmOU1TSmVIRGFKUnhjRE9ieTFCbnpXTmNpYUhZLURsVXA2VERRd1c1S29MbE1CWWpJWG9sdUFVMTljNldtRnVPSXI5dVFHRG9tdGRDd9IBrwFBVV95cUxQMlY0anNaVXE3bDdLR3p0ZWNBbVFKUzdmb2RCSFZqeXRZc01QX1VUTUtndmN0ZnM4cnhkNlY5WENKZkQ3TkJDcjZiWDM4NElERlE1UzFCT1FXTDFyd19uNUl2QTBwU1ZHQndtdHVxNmtZejVuRGg4NUJ5Sm1XYldseDNIQVkyMHltWW9naTl0Ukd2dkhzeFBlSU9PVlI0YTNySDZmNDNpZjZfaTd4dDhJ?oc=5",
    "date": "2025-06-19T07:00:00.000Z",
    "dateFormatted": "19/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Natco Pharmas Division In Hyderabad Gets Seven FDA Observations  NDTV Profit",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "aa75ff2b4a559cd77d158cb39f089bf8",
    "title": "NATCO Pharma gets 7 observations from FDA for Hyderabad manufacturing unit - CNBC TV18",
    "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNUElJckpwNDlkYWt5RUM1aEF1UTlDSnctczFCRmM0Unp6RkREMGRZT2R2MVhtWXNqSTVaTEtFR05nNnR5Y192UWxHdS11UFlRNk84bF9iQVFhSmJqM1hpdTc4MFlraW1JTmQ2d0hMWWhHeHFocGktc3AtbkR2djJMLVpFNU9YTV9KRU9SSVJYWTZuM3NMWTJPZEZTY2k1bkszcW0zclhDaGtqTnZsZVdIemFRY3dWVWU1UXRQVHZGclVRLUhaY1NUUm8yMGpwaHdyVHV6YzM3SWEwbEFmX2VsUdIB5gFBVV95cUxNOFAzRFViOFc3U2tvNFc1RGhrZndaTHI0a192R1RNVnQtM2ZUX3ZUSDNIZUdZY3RUQVNvZXU3YWFUZVk2T3F0YmVwUXNGNHRrbmNHeld5LUVxWG55a21vNTFfajBRSW51T3VhMzJac3h1Y3F0QXVKRTV5M09DM20tLWNrQ3BHRDlFYTdJV2V5dWVLMTI0M2hDSndTcEhMNkxCWnpiMk5HYUVkNHpyMDNXWWk3Wk9uT1FmVmowcTlmdEoyX2JqM2wtaTR0Zl9VT3Q3ZzdweHVBX3NsaHpsUXRBZXF0THpfQQ?oc=5",
    "date": "2025-06-19T07:00:00.000Z",
    "dateFormatted": "19/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "NATCO Pharma gets 7 observations from FDA for Hyderabad manufacturing unit  CNBC TV18",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "7cd3ec6cfe6c7ca9b5accca0d0ece70f",
    "title": "Glenmark Pharma’s North Carolina facility gets five U.S. FDA observations - The Hindu",
    "link": "https://news.google.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?oc=5",
    "date": "2025-06-18T07:00:00.000Z",
    "dateFormatted": "18/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Glenmark Pharma’s North Carolina facility gets five U.S. FDA observations  The Hindu",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "abc28a5bf5760fd73f1790690ee2052a",
    "title": "FDA observations, leadership change keep Sun Pharma stock in spotlight on Monday - The New Indian Express",
    "link": "https://news.google.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?oc=5",
    "date": "2025-06-16T07:00:00.000Z",
    "dateFormatted": "16/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "FDA observations, leadership change keep Sun Pharma stock in spotlight on Monday  The New Indian Express",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a4d5fbfe9cb0a34d6b95935a06459c7d",
    "title": "Compliance review: US FDA issues 8 observations for Sun Pharma’s Halol plant following GMP inspection - financialexpress.com",
    "link": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOU3JpNVdJOUVuYmlJWHRxMVM4WENyVzZHM3prTFNMUW5falhsMkdZc3JwRXZKSndUSWFmc1JuR3M3RGo0bWh6YnVMSHc0VFBYMy1pOUcxWTJEci1uN21kSGt5ei0yQnJUTDJoVEZ5RWpVSVRoZDJTZTFQaGpRWHc5d1hTZWNYRFMtWS1PYnMzbzRBS0NlMnFzd3d5VWdaeUI0Y2NoYlZWa09fUElMbkpoMkw3cEhCRGZmRk1yTTFSdVNHb3ZJSy1aY05wZEdqN1M5SDNpNjAwWmJDWFVZM1hCeTRPSkl5NEJYR2h1Rmk0N1J0bG9WdUE?oc=5",
    "date": "2025-06-16T07:00:00.000Z",
    "dateFormatted": "16/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Compliance review: US FDA issues 8 observations for Sun Pharma’s Halol plant following GMP inspection  financialexpress.com",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "81d2f9534b4ddc2a13206d3b33c7a985",
    "title": "Sun Pharma Shares Slump 2% on 8 USFDA Observations - Equitypandit",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPeU9yNWsxd3FhMll5ZGxvUFd3ZndJQTF5Q05TRDkzTm5zME9sN3VRRlRkUS1JSlNUaUkybnlhQ2E3dUFGX0VsckpLTW9oYWhvTkJTWEwtdjhKcGttUWZHWnJSd0pVc25qSC03SUVsUWJjQ3JodHF3UXVkckc3N29XQzBCcVFxQQ?oc=5",
    "date": "2025-06-16T07:00:00.000Z",
    "dateFormatted": "16/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Sun Pharma Shares Slump 2% on 8 USFDA Observations  Equitypandit",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d21b90f58a8cc399705b1ac762bb8059",
    "title": "Sun Pharma shares in focus after US FDA issues eight observations for Halol facility - The Economic Times",
    "link": "https://news.google.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?oc=5",
    "date": "2025-06-16T07:00:00.000Z",
    "dateFormatted": "16/06/2025",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Sun Pharma shares in focus after US FDA issues eight observations for Halol facility  The Economic Times",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e273eeea3240f0587387b130104a6939",
    "title": "Syngene's Bengaluru-based facility gets 'NAi' status from US FDA - Business Standard",
    "link": "https://news.google.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?oc=5",
    "date": "2025-06-14T07:00:00.000Z",
    "dateFormatted": "14/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Syngene's Bengaluru-based facility gets 'NAi' status from US FDA  Business Standard",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "f6c53b8f8eb1080ff3c6d726d46652ac",
    "title": "USFDA issues one observation for Natco Pharma Mekaguda unit - Medical Dialogues",
    "link": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPZVlTbWRmOTRSbWozWjVZcjlseU5DcVdMd3hJN284dmFtdnhTaUJ4N05Yckg3RHZyS2t0clIwWWFoX1VReFVMTi1XeHA0eG50Yk9XLV81ZmRzSnhORnF6amNfU0QwUFNlTXoxYXBrVG9pUGJJVFgyOWJpbjVoU3M2V1ZoZmNuRVZ3VmZrempOWHQzSTJSamM5Z1RkRWVaX0JwTDU0Nmh1bFRfUFlvZnRRMXZjV1RtZ9IBuwFBVV95cUxPUlFsZE9kOWNBaHh0RVJVdWVVcUlTSU9sTzBRbko1UTNqUnRxRmZzMFlpMmxCbG16V212T0F3NEV6Zi1jdXJ1dXFHeXRfYk9fSk5IdWdKRDU0VFBaS2hYQkppcXNIVEJhUEI5M0c4enRSU3pycE5fZHdLTUsxaWFyaVhGRUFKLWQ5dEpuSXFBbDNMTHBoS1lkeTlSaWYtRE5nUTJqNXJody1JOFZiVUtmWk9faWZWT3ZfeF84?oc=5",
    "date": "2025-06-14T07:00:00.000Z",
    "dateFormatted": "14/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "USFDA issues one observation for Natco Pharma Mekaguda unit  Medical Dialogues",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "5dce8bbfccd6af1cdb14d24a2e04ddc8",
    "title": "Sun Pharma gets 8 USFDA observations for Halol facility - Medical Dialogues",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOa2tjQTJhNzF6dzdZODdFLTdVTzBKcDZiaElpSXQ4NnBYZ00xSEVKVkRHVDQzejM0a21vNnMzOENsVWJrdVIwcjNQVExoenpKa3laNUg4MDVJZUlxSkZnNnUwUV9aSHhMNVlFMUdJTEFYYnY3Q0FSdmVqRW1fRGJfN3VRVEVNMDJKdDVNNUhMeTVOOHZoTTA5RnIwUzRwREFRUllrbW1PcmRNcThZX21FQtIBtgFBVV95cUxNTnNJRFNKQXZudDZGMndvQ2dSM1BEUHkzWWhYNHdJcUMxRUctV1lsbnZlSHd0b28xWi1aWTNWc25ZZVU5WVhnUkxMOTFrdjFhcDVSWURHN1RlQkhRMUFIS0FTdk9wLXUzSmRhM09hSDZEYnBWUUhTbThtQ1FCYjk4M1d5dEpoUlVmeXl1b3RpTjV2OWhnSl9RSlQzOEVyZVozM3A0ZmNsa0NUaWhZYlhoaFV5VURrUQ?oc=5",
    "date": "2025-06-14T07:00:00.000Z",
    "dateFormatted": "14/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Sun Pharma gets 8 USFDA observations for Halol facility  Medical Dialogues",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "3413c68432848e16ef9c66f707875adc",
    "title": "Natco Pharma’s API plant in Hyderabad gets U.S. FDA observation - The Hindu",
    "link": "https://news.google.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?oc=5",
    "date": "2025-06-14T07:00:00.000Z",
    "dateFormatted": "14/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Natco Pharma’s API plant in Hyderabad gets U.S. FDA observation  The Hindu",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "7bfa82715fb96ec2928c78120f1c8b2b",
    "title": "Sun Pharma’s Halol facility issued eight observations by U.S. FDA - The Hindu",
    "link": "https://news.google.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?oc=5",
    "date": "2025-06-14T07:00:00.000Z",
    "dateFormatted": "14/06/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Sun Pharma’s Halol facility issued eight observations by U.S. FDA  The Hindu",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "f324b9434e6623849cc345f67a05b9ec",
    "title": "Sprout Pharmaceuticals, Inc. - 709942 - 05/29/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQMEdDdXdDMDBVV3FET1FvVlVRM3F1UGV6dklJb29pYk12czQzZFlXNTNTY1lrdHZfVVZ4R2NOcjd4NjI3NXdvUVhkeU8tWU5yZGV0QThjVUZ5eUpRYmV4WGhJQWxxNVRmWTJ2MFAyaU9qYjd5OERsSTVVZi1rYTZuX1d5TVV0dk8ycWtKbzQtT1JiSmlIc3Zockc0SkhQc25sbUpwTEN4V21IbHFjVmlzTFZ0LVhKUDN0aFpEbng2QVFVZHZ4RWsxUURDejRCRmhCNWZDSDMwX1Y?oc=5",
    "date": "2025-06-10T07:00:00.000Z",
    "dateFormatted": "10/06/2025",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Sprout Pharmaceuticals, Inc. - 709942 - 05/29/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "58837ad2edc7842751209a9ca1e3dc3c",
    "title": "At-Home COVID-19 Diagnostic Tests: Frequently Asked Questions - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQQWxlR3o5YlZ0UExNc2NjVURMTHd2TDlveFloQjdzOGo2Y0ZMY3pHeF9laU93Z2lkT1QtOTVzWDd1dWhDMkgyX1R6VVRkMk1HQkUtWVZ1STJYTmtJZUU5TkNyeEEyVGNYWFBCb2JiUXdEMWJpZ1hvdTVRZDgwWklWbnVfN1paTmRjU2VVbkxWTnFfMkpKMkJScWlVVTZRWEdMRDJuUnlYdVg4ZUhsd2k3VVVMT0lGemlPcjhHQzhsbnZOaVM1N1FVSm5TRU55bTA?oc=5",
    "date": "2025-06-03T07:00:00.000Z",
    "dateFormatted": "03/06/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "At-Home COVID-19 Diagnostic Tests: Frequently Asked Questions  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a02b4e33644ef4435886db61e0d02ad1",
    "title": "At-Home OTC COVID-19 Diagnostic Tests - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNSXVTMmVqQ0Q2M2VPck0zdmxVTGh0czY1X25ZRlNYclRhNnNsMlh2YnBVRWlIT19ZdmZ4Tm5Yekp4bm43VWczM0w3YmQxUDFfcWRTUE1uTlhiQzYweUk0S0IxNG1CQnRSWkV0U2tMOHk3RGtwSnZvTWpXZnFiSkFpZkcxVGEtWjRneDdid0NrMjFIaDlLV1hYb09FRHVWYUw4VDRmM1ZVeWNGTVA1WUliaA?oc=5",
    "date": "2025-06-03T07:00:00.000Z",
    "dateFormatted": "03/06/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "At-Home OTC COVID-19 Diagnostic Tests  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "aaa5b2d19aa010714d3701c6d443d525",
    "title": "Mayne Pharma Close-Out Letter NEXTSTELLIS - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1lTDRQSlFFSHpXMXl5bTA0djVRU3lfVXBJaXZrQXhQOEdJblE3QWVfeklJUUxoUTdfSjZGVGRDZGhQdDl6MVItRzlYTmxXVFo4Y3pN?oc=5",
    "date": "2025-06-02T07:00:00.000Z",
    "dateFormatted": "02/06/2025",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Mayne Pharma Close-Out Letter NEXTSTELLIS  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a2aa8fccc8d583a95e7921895c6e715b",
    "title": "USFDA issues one observation for Cipla Bommasandra facility - Medical Dialogues",
    "link": "https://news.google.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?oc=5",
    "date": "2025-05-31T07:00:00.000Z",
    "dateFormatted": "31/05/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "USFDA issues one observation for Cipla Bommasandra facility  Medical Dialogues",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "cb60dc085b5005c1bcfb822ae6e0788c",
    "title": "Cipla's Bommasandra plant in Bengaluru gets single USFDA observation after cGMP inspection - CNBC TV18",
    "link": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNUHZSMS1mSWFQNkZpY2lfN0xoTmViVFJfVkJwVWFqc2lQYVBKNXJtNklyR1pwYWRYSmc2U19pWl9ySTI5ak43Z09tVjY3VndxZmE3QVJZMGtLLURvMFh4bGwzOEV2OWVWTlVXb21sbkkyenNUUy15NzlYYUk0NEZ0NmpUc1o4R3RPdFFmeEtmb2hPUXhmTDNRd3VTdXFBVDd6aE85LU9HUDZ5YmNoeGxqa3IzSnJuelNnVG9ocndwWmc2dnFrVnp2RHdKTHlEZUF5OVR2YWNhQjc4YWR5VTY1dmhHai1Jem_SAewBQVVfeXFMUFRNVUNDbE5OUFU0VnhIS1plSng2eXNHMzZ3MTd0UUxrcFVNeElnX1NIa3cya1N5aWkxaF9pZ01rSzBzWHJNSGwtbTdHcFJhVWxjcWg2V0oyTGhEbHBvcS1TcEpLR092ZXZUclVGbmdhQ3RsRFB6UjRpQzNwNEJ1bXNGbThYUG55dGFLdktiWFlWUm9TZk9fWFdvaWFLX01SU2d2SlluRTE2VWNKNFFyNDZLQmNwZmM3bnRaNkR3M01lZkdOYTRRVGVvUkttWkIwSGY2eTdIUS0xSEJ0Ym00TEl0RDlUZEZwbFFEMGY?oc=5",
    "date": "2025-05-30T07:00:00.000Z",
    "dateFormatted": "30/05/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Cipla's Bommasandra plant in Bengaluru gets single USFDA observation after cGMP inspection  CNBC TV18",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "357041f1e7fcfecf395a9a1f67558696",
    "title": "Stealth hit by FDA rejection to twice-delayed filing as it lays off staff - Fierce Biotech",
    "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOcXpCbnZPTFRLNmNrOHpMVGFzZm1KX1ZJUHZFMVNSVmM3ckYzRTJJLVdZUldFMXpNdXdERkRPc1VmSElTaDkteV9vVUEwaHRJbGRVendaQU9aQmJTbWo5RHNhSXpzbTNtYllxRHVuUi1XaW5GT0JFTEcwNC1CcW9JRDhfaDZhS1o4aUdySHRyal96RGVibGpnSkRZVXVhT0R6WEwzUGZnVjNWV0EybnVBaDBTSQ?oc=5",
    "date": "2025-05-29T07:00:00.000Z",
    "dateFormatted": "29/05/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "Stealth hit by FDA rejection to twice-delayed filing as it lays off staff  Fierce Biotech",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "586eb980258cd7e2d9e3328f974038c5",
    "title": "'Hanging on by our fingernails': Stealth CEO questions efficiency behind FDA rejection of rare disease drug - Fierce Biotech",
    "link": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOVWNOZDk3YXJidTEyOHFPWHQ2VXlkcGprZHd2RWtXZThJX2diNlhMcDFDTGpyQmxsc2FvbVIta1luSy12TlpZTFpCR3BPMU5zeXNyakNWR2xmN0NzWVVEdEF0Y3NVbDlLRk5wSHBHanlJM1Zob1hHb3J4dTNCZzlJMnNCTXhSVnUtOFJ1NFFGNU1PTUJIZGdFVHloeXRxY0ltQ19Ra0pxeTlYREs1amNaa0t2dzFEZDM3ajJrNmp0a2RvVzFtVXc0?oc=5",
    "date": "2025-05-29T07:00:00.000Z",
    "dateFormatted": "29/05/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "'Hanging on by our fingernails': Stealth CEO questions efficiency behind FDA rejection of rare disease drug  Fierce Biotech",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "302991646cc11fe93bbbaf8a3c5494e6",
    "title": "U.S. FDA issues two observations to Dr. Reddy’s API plant in Telangana - The Hindu",
    "link": "https://news.google.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?oc=5",
    "date": "2025-05-24T07:00:00.000Z",
    "dateFormatted": "24/05/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "U.S. FDA issues two observations to Dr. Reddy’s API plant in Telangana  The Hindu",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "010f9bbe9fcc29aa23f5a7862aef8f67",
    "title": "COVID-19 Vaccines (2025-2026 Formula) for Use in the United States Beginning in Fall 2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPZGhnRU9jcmJIOHN2YW90RzNTRHVnZUlvSWd0R2RHXzVYbXdybjhkeVBKYU4yMHFWRTA2bTNhMHRkdWxTYnJrOGJtcVFrSWNqSFdqWGVCUUgyS2t0MDg3RVI0N1o2Mm9Fd241VGcxRXRFWXJDbHBZR25wTG5PTnJfbUd5TDJTTDMtelhaV3ZmR0tFamNxMm40X3lpRUxqVTFNcF9OUzlEam51OGpHcWJpTmVmVUZhVmJ0LXlqUllJVDJTb1BidkhXV1haUkt3SDdTaGpJ?oc=5",
    "date": "2025-05-22T07:00:00.000Z",
    "dateFormatted": "22/05/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "COVID-19 Vaccines (2025-2026 Formula) for Use in the United States Beginning in Fall 2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "7bca290ad9f927175c9813250f704b26",
    "title": "Sarfez Pharmaceuticals, Inc. - 708901 - 04/25/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPS0YtQTRYOThjNmtMWVNIYnVoQVA3ejlUZThxbE1odldFcHZ4ZlhqRF9Qa1otaDhCVW9tajVTOFN2dzdTSHBDSTNKZkFlMGVFeWtHYndVY3RnNVZ1VDcwR2w1emhscFdxMHlMb0t2RU5kWTRTRjBOZzd1Sm9XR1JxUlZpamN4NXpHRzhEcjdVNllhUzZneV9FZTlWSTRpeWNfYjJTVjcxVTM2aC0ya3p4dVEzVDgzakhqQ1BkYXZXcVRteVMwbEZFNlU1bkFlYUhIYW5aSzBIWng?oc=5",
    "date": "2025-05-20T07:00:00.000Z",
    "dateFormatted": "20/05/2025",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Sarfez Pharmaceuticals, Inc. - 708901 - 04/25/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "92041b6c27b3ce4b8804169fa660de10",
    "title": "FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal",
    "link": "https://news.google.com/rss/articles/CBMifEFVX3lxTE5RVktfaXR0Zm9RYUY2a2RsWDFua2FrdW9IbHgwSVBnMlRKbmdpODU2QzFzTjBZTDlCd2N1SllJbUNzTXBROHBnblhFQXU4M0pNa2E0QU02MkRXcHViaWVWanA0QzFaZUlTdTVYUE5TYjBkWXVpYldHcHQ0VDE?oc=5",
    "date": "2025-05-19T07:00:00.000Z",
    "dateFormatted": "19/05/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Delivers Blow to ImmunityBio  Los Angeles Business Journal",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "4c69ae96a0beb8d4c9eac8a4b27b0bc1",
    "title": "Dr. Reddy’s Labs stock in focus amid FDA inspection report, Q4 results - The New Indian Express",
    "link": "https://news.google.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?oc=5",
    "date": "2025-05-19T07:00:00.000Z",
    "dateFormatted": "19/05/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Dr. Reddy’s Labs stock in focus amid FDA inspection report, Q4 results  The New Indian Express",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "11bf78c45d3caa045a8872060c40e2a6",
    "title": "Dr Reddys Gets Two Observations From US FDA For New York API Plant - NDTV Profit",
    "link": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE5RclFGSzNCQUZ4XzVRR3UzWTloZ0lFTXdoR2dfN0VJUWdoWnNhSGJHQnpYcWFNNHdBYnlid2ozWE5XSEs5OWcxcFB4cmZDZUxJQktuMDVtVlpfakZRZmJZ0gFkQVVfeXFMUEwxNXdZSE5pczdyUVRBRlY0c3g4d0dNRktqcHRzeDMyNUhuVjh3MlIwa3puM1M4aGZDSWZJNFlQSGpVUkJaMjJ1RVdWX2pVRDIxTzMxSllHRmE4M3lrYUU4Nm81UA?oc=5",
    "date": "2025-05-17T07:00:00.000Z",
    "dateFormatted": "17/05/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Dr Reddys Gets Two Observations From US FDA For New York API Plant  NDTV Profit",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "67dd23e6ad0b06f16b0fa038675ac797",
    "title": "FDA Issues CRL to TLX101-CDx for Glioma Imaging - OncLive",
    "link": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOcU9TZGNfSjhtUTZsWTNYQ0NiNUR6YmhGQW5vVjZEY3FSMFg0UmZ1RXBoSWhaSlRzYUtSeXFUcEdNSnVPQ1Nlank3blAtQjhrdlJlSGNzd3Utb0dldUV1dlNFUlZrM1pzNnREWmtTQUhBQUVVdlBJUFdFSkZvZzBKanlR?oc=5",
    "date": "2025-05-01T07:00:00.000Z",
    "dateFormatted": "01/05/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues CRL to TLX101-CDx for Glioma Imaging  OncLive",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "972f11c336b6fcc794e4084192327eb1",
    "title": "Mandy Edwards, Manager, Regulatory Affairs and Operations Mayne Pharma LLC 3301 Benson Drive, Suite 401 Raleigh, NC 27609 RE: - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE4zQlMzbjkzLVRhTnpjRmRKcFRlNjVuMVhCcURQMEV6SFlnZWVUWjRUaXNhRVZZR0RSaGZjQm9rQWwwUFBiV2hPY2VMUnB5WFQ1S3BN?oc=5",
    "date": "2025-04-28T07:00:00.000Z",
    "dateFormatted": "28/04/2025",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Mandy Edwards, Manager, Regulatory Affairs and Operations Mayne Pharma LLC 3301 Benson Drive, Suite 401 Raleigh, NC 27609 RE:  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "0f6c748fc0e52bdddccec03c42bd22b8",
    "title": "Marksans Pharma arm New York facility gets 1 USFDA observation - Medical Dialogues",
    "link": "https://news.google.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?oc=5",
    "date": "2025-04-28T07:00:00.000Z",
    "dateFormatted": "28/04/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Marksans Pharma arm New York facility gets 1 USFDA observation  Medical Dialogues",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "170b5f0fd9413e002c1570d78691473a",
    "title": "Empower Clinic Services, LLC dba Empower Pharma - 700962 - 04/02/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOQktfRFZKbndkaTc0S292a0tlcmFWQ2JnX0M0bV8zakJpdW50bjFpVDlnTHZYQl9jV3dGLVhPZjY3X3lMVjM3a3VLbkxzMTJob3FCY1hLOHFNRGhZb24ySVhad2MyZlR6eHFRcXBxZjRpaEFlTnBTbmRyR2FVd1p4OWJJNmlONGtPOWo3aGIwZzlMYTRyalMxZXBGVjA0THE4NnNGWWlGOGlxelNlRUVIMGtrZmpOQmNjMUs5bXFzbkN6LWF3LU5QN3FNUmE5Y3JRcHdLbFk5bHdYRWUzeUlLTXdGdnBOazdlU01LYXA1ckxESEU?oc=5",
    "date": "2025-04-22T07:00:00.000Z",
    "dateFormatted": "22/04/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Empower Clinic Services, LLC dba Empower Pharma - 700962 - 04/02/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "3d4d142d8e6a53d13b61a7afd0e2af07",
    "title": "Drop off unwanted or unused medicines at a drug take-back location - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOTkxGUFB2bDUwbEs2dnRRbHcxbjNDWlJhMlpfdFB3R1hYazl3ODc0RUY5dm1pRU82My1nUkd6OTkxdkNTWXRRVTcwTFlKXzhCNDJtbUNQMEp0UV9RVzFLSUJuQ05VbkxjODh6STN4SGc1RDlmcGNjSjVXTW9lbE1KblNSOU9xblFHblBOSm5R?oc=5",
    "date": "2025-04-16T07:00:00.000Z",
    "dateFormatted": "16/04/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Drop off unwanted or unused medicines at a drug take-back location  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "159443ac82e2369cd43bfe6af99bbae9",
    "title": "Aurobindo Pharmas US Plant Gets 11 FDA Observations - NDTV Profit",
    "link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQSlBpLXVWT0JKWmZfTi1kcXJmeC1sSld5ZGRWNjRwdXljdnZjSVlJbTNnbUM3d3dwZTJIcjRiWnVYcG1DOHg4QTNzdUF5NjBsYklydV9XbXp5ZEtTNExzM3lYLVEwdVhLMVlYX0NOdlpvcURwWE82OGd4QlREZjdITlpkZWFPTURReFFwblVmbV_SAZYBQVVfeXFMUEJDWDZEMWRHY1FUTGhjdEwxYVJIbG9CcEY3dS05QmJsS25ISkV6cHdpb1h0ZFd1RGhxVnBsYTNwZERpOWZyaDlSaU5VM1Q2ckVoSGVJOXFxcE1raFJBY1NkbUxncnRUT3FDVER3YUVnSnd2ODItNlFsMTNESzlfTXRPODQ5R2hDODlBdlZDeko4MTFYMklR?oc=5",
    "date": "2025-04-11T07:00:00.000Z",
    "dateFormatted": "11/04/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Aurobindo Pharmas US Plant Gets 11 FDA Observations  NDTV Profit",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "7bcbf3e8084b022a1b2fe2d998fca5f2",
    "title": "Aurobindo Pharma arm gets 11 USFDA observations for Raleigh Plant - Medical Dialogues",
    "link": "https://news.google.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?oc=5",
    "date": "2025-04-11T07:00:00.000Z",
    "dateFormatted": "11/04/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Aurobindo Pharma arm gets 11 USFDA observations for Raleigh Plant  Medical Dialogues",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "9704e0bef18fb0b0b09892f816f9c475",
    "title": "Shilpa Pharma Lifesciences’ Raichur API facility clears second consecutive FDA inspection with no observations - Express Pharma",
    "link": "https://news.google.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?oc=5",
    "date": "2025-04-09T07:00:00.000Z",
    "dateFormatted": "09/04/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Shilpa Pharma Lifesciences’ Raichur API facility clears second consecutive FDA inspection with no observations  Express Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6fa75c2632023bff51155ec84015e299",
    "title": "ICU Medical - 702535 - 04/04/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOVzVicUdpbFU5YXI1elZlcGZHS0pyb3gyX1RzaVE1VU96d09tbUhJR3FCMS1CM1FyazdPaEZRaVpWYXNtS01LdzFCWS1FdEVfbFZIb0JJdmZ4YTg0N0NHWDdFQVBENGtGSWV2cjAwR0ZrTUVGdGFqV0FycXJ4YzJFdlZkSThOS2pkRWdVMmI1OFdmV0RZSGJZYUFqTUJiWDMzLUVUSmN1UmY2THNTTlpyTDRFR0NORDliOGZSdnpGVDd6WDRU?oc=5",
    "date": "2025-04-04T07:00:00.000Z",
    "dateFormatted": "04/04/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "ICU Medical - 702535 - 04/04/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "79fcf33c768c3c406f979de1f61e5cb4",
    "title": "FDA Issues Second Camrelizumab/Rivoceranib CRL in Hepatocellular Carcinoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPRU56Uko2UXR2bkx3MVBSTThVSnNyTjNKYW9LSEdwaHQ3Z2c3emkzXzZpaThrVTU1NGFXbmFPZ3BqYXpuM1BWd3RJdGhFS0ZEUUJBUTM2b25QOHlBQ0Z5QXE2MktlSHZZYWJOR3lhVm42cExlWFhDMmlpcDkyQThVWlgwYi1xX3U4cjg3dnpfcEV4c2JMQW93Q3YwZjlCVzBfeU1JMG9Uak1hNTQ0LUE?oc=5",
    "date": "2025-03-21T07:00:00.000Z",
    "dateFormatted": "21/03/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues Second Camrelizumab/Rivoceranib CRL in Hepatocellular Carcinoma  CancerNetwork",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "96513b36431ea716621531e4c5ead61b",
    "title": "Vegewax Candleworx Ltd. - 675099 - 06/14/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNNENkRFJFbUY3OXdvakhYR3dmc2ZCWHB3UjFFRkdjZkFDMl9Zdzc1eTc2SHN3UjgtWTJEdjJneldUUWh5RUhMREdCaDQwMjkyRFBROHpWLUc5TXFBSVNoMjJya0V3THAxVFljTnIxbkw2dTU4ajQyMUVfUkNOUm4zdndaeVJiR1NrcmNOT2RYQ2VnMDlsd2JvVW1MRmIxZF9XZzYxR0dSdVlMUHZER0JlQmNPeEhCOFJKVlZwa1dyeGxXVnExSTVPUG5QN3lBQW9mbzNR?oc=5",
    "date": "2025-03-18T07:00:00.000Z",
    "dateFormatted": "18/03/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Vegewax Candleworx Ltd. - 675099 - 06/14/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "fce7fab6ddf39729b88d893278d7ad4e",
    "title": "MG Infusions - 696890 - 03/10/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOSjZicXNMRjd0bFhpNUExWTZEQzB1cXRPOTRaemRjTlI2T1IxVkRmVjMxMmpXZ3BtazVpbWFyTkVmWU1RaS1TMjNCREh2TGhtTXVZa1JBRnMtTzdhbGtvMDlSQk1EdzFBQU91ckxKTXVka3B3S0ZRNkZ1Sk1FdnVObFdISkFHSVBCdk82Y0Z5NkN5OXpqVDlfamZaZmJMb0xOQkJOdlBIc20xcm9WUldUaVVKSUxPSVptbGh1dF9id2ZqaUItUVE?oc=5",
    "date": "2025-03-18T07:00:00.000Z",
    "dateFormatted": "18/03/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "MG Infusions - 696890 - 03/10/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "f45f38d6268369381d027d31bd9128b5",
    "title": "Linghai ZhanWang Biotechnology Co., Ltd - 697983 - 02/25/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQOFRVeERwdTF2WEtpVjczTEVBQlV3N3lkWV9fVmZySnBLbnE0cGFVdWk4Yjl0VEdrY0FFNlNwQy1EdTZtc3Z1R2ZjamJtMVFNeUwtZWxjOTVLdVp3clNNRFFPVjNSRGtTc19QSTFnMjR6WkNrTzZOV05ySmgzaTd4TExBeW1BQjQxRGhlNThEelE1azhsdlV4eEdFU0prOFlKd3VlNWRBVC04VjZzZHZFVUg2SUVXa2FYUksxVVRYWktjWlJxMFpVaW5aWGNtSzRfaHZ3a0hmS3JPVWlyOE9VQjF3VkwxZ28?oc=5",
    "date": "2025-03-11T07:00:00.000Z",
    "dateFormatted": "11/03/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Linghai ZhanWang Biotechnology Co., Ltd - 697983 - 02/25/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "582b1c6049dcb89aa880e2e65d458d1b",
    "title": "vapingby.com - 703435 - 03/07/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPcENDLXBUaG9WUVBqR2tPZjlFUGF2UmZ3QUFka20wemVaNGJnWjN3T0JrZ0F5VTNXcnNqajFyY1BTdXhtNktBS19tY2FJaHNYNjdlR0pyYzNMaUpLZE1ycFNsNU1FZnJhT0t2U3Fpc21lZ1BPSzdmaW9EalNjSmNQTl91YnFrMWpKZ2FqelVDR0FBN000QnFOOWh2UThrRmg5ZjEyRGVRVE5TeW5JcHpETDJiSGhFWU5odUEtN3hpQ00wYVZ4?oc=5",
    "date": "2025-03-07T08:00:00.000Z",
    "dateFormatted": "07/03/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "vapingby.com - 703435 - 03/07/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "cb0339ba644d26dce5e1ab2c047df3ad",
    "title": "US FDA ends Alembic Pharma's Vadodara unit inspection with one observation - CNBC TV18",
    "link": "https://news.google.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?oc=5",
    "date": "2025-03-07T08:00:00.000Z",
    "dateFormatted": "07/03/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "US FDA ends Alembic Pharma's Vadodara unit inspection with one observation  CNBC TV18",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6f864170e1d8adbbc3dc43344582087d",
    "title": "The Bad Ad Program - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPa3pNLThkTWFSMXNRZ0lxS1c4T3kxRjhUakhHMnBaaURZUHlFYUJjU24wMy1Kc1JVSVppT1JDWE1NbVBiZ3BnUmM1akc0aXpFQVg3N2hoNVpZQ2RzX0dCaEtwYUlCZy1qY2piMWxlWVN2UUxtb1duNWlyanY4NXp1YQ?oc=5",
    "date": "2025-03-06T08:00:00.000Z",
    "dateFormatted": "06/03/2025",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "The Bad Ad Program  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "8203804e86800cbfd8e977c320d1b6dc",
    "title": "Shree Jaya Laboratories PVT. LTD. - 698690 - 02/28/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOQUxXaXQzSHdCRGlJeDJfVWpuNVNuY2REOEF5Q1Blc1pZTlBqamZEelFfdXh4RUNCUTFrM1k4S2tnT3JJMjJJVkdyYzRwMGxOX0NvQVNXLTFiWjZCWEhkQjZEcjlyZkhfNkhXZnFrRG5aaktmblE3OGM1ZEZlTW43WUVCNWs1UnV0d2F2bTVhOWlxOWEtM2tiS3otNHJLRUhrcEU4QWNyWFlLNWFvM1RQUl9NN2dpT2R0RXprclRfUS00NE5wZ3p0SUJTaWFCUUYyTXlBUl9qTGYxZTZld004?oc=5",
    "date": "2025-02-28T08:00:00.000Z",
    "dateFormatted": "28/02/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Shree Jaya Laboratories PVT. LTD. - 698690 - 02/28/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "799fe85b9fbc89dc33ec2c3318bf89ab",
    "title": "Elk River Vapor Shop - 701415 - 02/27/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOekJJNUx6NUNWaC0tSlVEcU9YUG5oTG5XeDI3LXVvQnZkYnBQYzFoZTQ5M0xLbVNfUDdFdXUxOWN4eTRraDFRVXJ6N2tnZi0tSzUxb1p2M093eXJ3MjVNeXNmdS1wZEE2M2dmS0gxdVlVMlhzYWM4RnYwQWxrcFNJRmpyRklzaVVnTFkwZzkyZVBwM3pYWS1xeW9pVzFkYjlFVXRSeUl5WmhfNlZWTDdfWEpXOXdNUmNvVzQ1QXkwaTVtWFlZTTFMR0tCTzVEM2Vf?oc=5",
    "date": "2025-02-27T08:00:00.000Z",
    "dateFormatted": "27/02/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Elk River Vapor Shop - 701415 - 02/27/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "3f58e1f3cdcc072196da1afe1e4a5a33",
    "title": "The Vapor Club LLC - 700095 - 02/27/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPRDMzdWluMjNfVTNfLWg0UVVKTy1neEthR0paN0VuN3NtREJsbzZTRTJLN0tEazB6VEVaNkE4cDNaSl9TaUVhcDN4anBlLVQxWkxNVmtJRk5MZzZTUmlZTnExcG10dXhxNGpFY0tqLWhMWUxUYmo3VWx4ZzZ1blhTWVhILW5GMWcwRjJ5ZnpEbnZVTzJEc2liMUdYMzJHWGtwUlJVUGUxR3pydWJXS0xpYWFnT2dYY3lWRnlYSGQ1WjJJWGdEcG5xZg?oc=5",
    "date": "2025-02-27T08:00:00.000Z",
    "dateFormatted": "27/02/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "The Vapor Club LLC - 700095 - 02/27/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "2b1a5b7dd2bac016b519d711e8986c1b",
    "title": "Gland Pharma Gets Three FDA Observations For Visakhapatnam Facility - NDTV Profit",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNZ24zUm1pbklnbklLbmJGWFZaOE8xV0FKTVFoUmd5VmpaNVJEbVl4Slh6OUlVTVdvMHJ3VlZHYzV2c3ZsbnJBV3NnWUJ0LVNhOW84TjIwMVZRZG0wbHFnV0hvRUE1MzhkS0J0cFM5RjhoNWZZYTJyLV9UR3ltOERod3FUVk5BWjZQci1odVp1N1hwUU84dTBRRG1Zc1JzR2prTGszNnFB0gGrAUFVX3lxTE4tNzhEMGhqdUV4ejVQRDJ4Q2Fqemd6Sk5ISGtEWUhfS0w2Mmt3NVB1LWZnWGQxNWRISXhETVQ0Y0t3OXRQVm5wQ09jUE1CNXdDaXZnTkViQjlldWJ0MDdCa2Mza2pCLUVLblVqYnFwT0ZpMTZvOUN2bi1yTmE4QjJvNlA4MHlGelBUWWxNcFJQOG1iQXZjYzFTU0Z5WDR5Z1pYSVZvbXZsOGN0NA?oc=5",
    "date": "2025-02-25T08:00:00.000Z",
    "dateFormatted": "25/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Gland Pharma Gets Three FDA Observations For Visakhapatnam Facility  NDTV Profit",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "11205bb3bc814608ac482d6ebd4a7fe7",
    "title": "U.S. FDA issues three observations to Gland Pharma’s Vizag unit - The Hindu",
    "link": "https://news.google.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?oc=5",
    "date": "2025-02-25T08:00:00.000Z",
    "dateFormatted": "25/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "U.S. FDA issues three observations to Gland Pharma’s Vizag unit  The Hindu",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "0e1e760210639975443406b8163fbf88",
    "title": "Syngene International gets 5 USFDA observations for Bengaluru facilities - Medical Dialogues",
    "link": "https://news.google.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?oc=5",
    "date": "2025-02-24T08:00:00.000Z",
    "dateFormatted": "24/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Syngene International gets 5 USFDA observations for Bengaluru facilities  Medical Dialogues",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "35baa84f1fd375f5c1db2875c00bae76",
    "title": "Mastering FDA Inspections: The Prep Work For Regulatory Success - Med Device Online",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOUEpyNGdaVlV4WkNqMnJGMUFMT3dLMGM3SnRqTVdGUzQtUEpteDNmZ1d6OVZaX19GT0txNEw4TGxVT2U5b3dlVGNOcFNYeGhIZFNXcWcyeG02TXoycHA3Z29uQ0JWZXJCMDRpaUZfWFFTdk1zUWJuSC1tVHZ1ZjNoR2lyTlJYRWVvRUs4SzVMaFNfNDhXUGVOajRUaW05LUpqS0l1dzVn?oc=5",
    "date": "2025-02-21T08:00:00.000Z",
    "dateFormatted": "21/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Mastering FDA Inspections: The Prep Work For Regulatory Success  Med Device Online",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "33a589b3037c6978d6ec0b5d9aa5fc9e",
    "title": "USFDA issues 6 observations for Piramal Pharma Turbhe facility - Medical Dialogues",
    "link": "https://news.google.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?oc=5",
    "date": "2025-02-19T08:00:00.000Z",
    "dateFormatted": "19/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "USFDA issues 6 observations for Piramal Pharma Turbhe facility  Medical Dialogues",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "0e67a650d29c76b05aadaa4519e7b6a5",
    "title": "Aurobindo Pharma slips after Andhra Pradesh facility gets 5 observations from USFDA - Business Standard",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxPYlF4YUtaaTdfRmMyc1Y1Q1hWUDlNbUNvMWNfMnlCbG5BMlpxSmlYZThBdGx5WThORGk0eU1sT1lfTFRxckJnek1tVlRwWGlUcXQwdHpTUzVzMzZSZFJzUEVuQ3lvUjM5NllhYlpOZ2M4Si1WZVgzSHVFbzFqZDU1SnZuY1NyWlJLNGRpYS1lSGlCRVJMaTdHRmdObjBmMVVEbXUxSHh0TkU3NjBORjJ6Wk1QS2ZNeDdfZEdhZXlzQ2dkU2dmaGRQWWVPcUxGaHMtaDlmUF9henE3TnZ6dXU5ZU5taXdyeVMzdWlFeHRUZkJEeGZHVjNpVdIB_gFBVV95cUxOdEt3MktIMVlsTVpHZUo2dVpCX053eUJRZ3hRX3F5SU9xcXNQdVZwT1BFRnVFMFZMVlV5aFFra1EydXBNVHo0OTk5cEVUMFBNQXU0cFJHNVFYYURGSDdqZ1o0S3cxZXZLam9XQkZsMTBPZUJ5SlY1MFNaN2lqcmpXMEVrcGpFbGNBWThZMWQwZHdOZEtkdVlWWlhjbHhmS1FZYmQtVDlwTEZOYjZBbHREV1N1NFBMY1c4RDM0bEV2WU1FX1ljSDd6aXN5dGplY0twVDBUTGNHa0hBYlRfQWlZd1hmR3JkQ19heUhqMmpUemxac0N2cm0wTU5iaC0wdw?oc=5",
    "date": "2025-02-19T08:00:00.000Z",
    "dateFormatted": "19/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Aurobindo Pharma slips after Andhra Pradesh facility gets 5 observations from USFDA  Business Standard",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "791f034bb275269c6d6e07dcde5f7cfa",
    "title": "Piramal Pharma facility gets six U.S. FDA observations - The Hindu",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNQi1Nd2d4YnhRQzhvY250dXlZX0hYaUxLekhLbDc0NkFwaWNDOEFja0VWOUUtSThRNWszYXJCU2lDQllLYmJHOUc3TVZ1d0doVXNTWW9nUEZHNXZFdjJxNmxXZFpMYU05Z1h5eXdFZnc5eWlnNVBwM2VMemVKQVZjaGhuOFl0b1I3aDJLeGZvTE5YeXFaVjJRazBsWXc5bkJyVlk5SkdRWXBzUdIBsAFBVV95cUxOeC1IUDRPM1p2ZlZYc0pZdW9kdEtEajl2TnZkVjF0ck9TRFU1Y2VDdzRhQ0RGbnB1YjZlV0xkNFhKMS1ITUtFZlZrV3owUTdTNlBvY2NuSkVDSjkwdTltOVQyTzBReFNZT195NDUtbGQ0djU0MVh0Unc2MGE0MXViaW04X0Zad3ZXNDE0T0J4aXlXd2ZZWVpCekx1Y190MTJ4RDRfVmNzTkNUQ0FSUWFuNA?oc=5",
    "date": "2025-02-18T08:00:00.000Z",
    "dateFormatted": "18/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Piramal Pharma facility gets six U.S. FDA observations  The Hindu",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e717ffcebf4c6e75606f8419cd799a41",
    "title": "Piramal Pharma's Mumbai facility gets 6 observations from US FDA inspection - CNBC TV18",
    "link": "https://news.google.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?oc=5",
    "date": "2025-02-18T08:00:00.000Z",
    "dateFormatted": "18/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Piramal Pharma's Mumbai facility gets 6 observations from US FDA inspection  CNBC TV18",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ac5b58151eb2ca150fde426c3962a098",
    "title": "Aarti Drugs shares rose 12% in fag end of trade today, here's why - Business Today",
    "link": "https://news.google.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?oc=5",
    "date": "2025-02-14T08:00:00.000Z",
    "dateFormatted": "14/02/2025",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Aarti Drugs shares rose 12% in fag end of trade today, here's why  Business Today",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "c08583076739e4b13b8181bf23aa16e4",
    "title": "Marshalls Traditional Healthcare CC - 697697 - 02/10/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOdHpSdktYWWh5WGpZc2VmS0NSZFBndzVNNFF6aU8yNm5VRkllQVJfRzJFRE9Gcm1RYWJMYXdVQ0R0clF6cDNzTk80dHdIOGpid24zbHhwNC1GYTZxU0RkR1RZRm5hbW5tSkNFT2szTkh5U1hEWGN2TmVuRW9naEVWTWZUWE1pQUxndzItUXJCOVhjbGI0dkhULTV4YlBjRUF4QnIyT2Z4aFA1NzNBWlQyZWMyWVdlUHJOVkxFWWZQS0JzS1NQMnN2cWctNHU3dWRkMklncjk5X2FCQWIxdExGanEyWUk?oc=5",
    "date": "2025-02-10T08:00:00.000Z",
    "dateFormatted": "10/02/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Marshalls Traditional Healthcare CC - 697697 - 02/10/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "9be8db4ead6717fcd9743195db838751",
    "title": "ABR Laboratory LLC - 696872 - 02/10/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOWHVCZ0o0R19oMEk2UGNlU2NQMWt3Y2tPSzlOWGlHRDA2Qlp6aVRXNUlPaWxOUnlTNDVHTllyY0l3WjFsX0FwSXBPcFQtcHdiWjBmWEllSG9Sa3k0eTdPWjVXSy1zNUpodzJuYzB5Wk04cndVVnh1eThET19tc1RleXhIQ2JlWUdPT3djR3VWOEYwTkRyWWxVSlBXb19tRkt4cEx4NDB3Qlg4ODluVEx0dkJuaEFOMERfRk14UE1EbnlmemdLT1ZPcUhoQVFIQQ?oc=5",
    "date": "2025-02-10T08:00:00.000Z",
    "dateFormatted": "10/02/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "ABR Laboratory LLC - 696872 - 02/10/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "0b025908551571ce55f2bdccb8c5594d",
    "title": "Dr Reddy’s Laboratories Hit With 10 USFDA Observations For Its Hyderabad Facility - BW Healthcare",
    "link": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOTXY1X3RJYXJGbk1Gb1VPYjZEZlBmOTRmdmFXOVdtdlZEY2ZrMXc5NzRNWkpEb2hLZDFjakJyVXZELUZyTXRjbXBEM1dDb29VMF9MNV92T2xEX1ZQV1FhQjNzWFE4UFVyaG9JdzE5TldUcVJpSnVTSlo0c0xZTFRrTC1ybDBzQ3puYU5PZE9zUzRzSGlqWXpFWEttRzV3bVQ2aWZSbVVBNzA5OG1nMFpNNnVpT0owU1FDTmhXT2hFNkYwNHl2N3hMYVpvYV9yNE10bXNTUg?oc=5",
    "date": "2025-02-09T04:03:13.000Z",
    "dateFormatted": "09/02/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Dr Reddy’s Laboratories Hit With 10 USFDA Observations For Its Hyderabad Facility  BW Healthcare",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "04aca0a2830adbcbdff8512ecf3799ea",
    "title": "ISOThrive, Inc. - 688547 - 02/04/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOa08zNFRjaHpsZWw0eXJ4eEh4VVQ4bUhsZUFZbUxZNTZLOURtNTVPWGl3QXM2NVRETDBuUElBakV1X2IwOEVUQkVCWWFtVUtTdHhpUnY1bGk0Y0dJck5jNXY1U1NXX1Q4NnpuTnZZT2NZME1haFA1V0s1cmRZUGtxOTJQc3FWR1V1QURJcE42Mm96VE5Gdkp0Wk1uR0N1QU11N2t4bHBySVZvd3B1RWJCYUpqbDY5NEdLZDRNa2JrMnF5RFhMWUo4?oc=5",
    "date": "2025-02-04T08:00:00.000Z",
    "dateFormatted": "04/02/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "ISOThrive, Inc. - 688547 - 02/04/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "44cdd864faf1ea452f6a8bea1eebb7e6",
    "title": "BioStem Life Sciences - 673788 - 01/17/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOeXRQZXVGSWdvbmhQV2pDa0xyS0lZYUxXMHVQWFMtVmlpbWRONnhTYjVwbm1DT1I1NEVkOEkybXhIVzQ3N2dzZkdGZXo4RTlXVHVGenFoZmtsc0wxYXNWZ1BhNXlYa2FhMGtjUmRPeFhaYmhCLVN5cGNfY0lEZmpUc3dGWTZYclpiaWFmNjR4ZEh0azQxbUMtaFFUY2FmVUdLZUtKQWczQ2JYODAyejA1UU44MUsxUWtUOGVCX2JsbGJnY2JUbzJ6TDdCNGY3U2RSVGc?oc=5",
    "date": "2025-02-04T08:00:00.000Z",
    "dateFormatted": "04/02/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "BioStem Life Sciences - 673788 - 01/17/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "5d98570cbb9eb19abd880f2630b7315c",
    "title": "Fagron Compounding Services, LLC dba Fagron Sterile Service - 698861 - 12/19/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMigwJBVV95cUxOV3BiRUYyR25vT1R5NnNid1AyUVRKeDl6ay1PbE5odFYwdXE4d2lfRWRQdHJUVFJ1NmFtaXVqLW01UUxOdk5zSW9MMzFHTmpUQXByUExoX0JjUzBURnItTjdITE9KUmFWYnJZVU5rb1A1OHFDZTdIZElzT2huZ3ZTd2Qxa0F3QW1EbXZ2dDVGcFh6RkQyQVhncURSOUhKSFpQbHAtZDdlV3haM1V2ZnFFRzRndHBPR2RhQVRXSlpxYnNzVnQtVnBxUkZkc3VWQ3haOW5ibmdmYmV0YV9IQkYySGgwa3pwZTBaaS1mblYyN0NqSW5zdVZHVFBwTmY0SXRyUjBB?oc=5",
    "date": "2025-02-04T08:00:00.000Z",
    "dateFormatted": "04/02/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Fagron Compounding Services, LLC dba Fagron Sterile Service - 698861 - 12/19/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "57315ebaf056737a158181306fc243e6",
    "title": "Strukmyer LLC dba Strukmyer Medical - 692686 - 01/30/2025 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQUExPQVM4Z1JfYXlPdzk5SXQ2ckhyakgwYXhla3lQczlwY0J4QkpfOHB3V1Y4Tmc5dXlnVmVESlZwa00wdGR2X1RpRG9jNnBqZnNGVi0wRF9ocTdhUFBJSXhDWVJUOE1VVlpGd09jU20zUTZWLXVkbkZrYmxsVnZhU0xPN2hpdENxUEdZbHZJRGpLTWE2WVNVS2FyMDR2a0RBR0JsZGNDeWpSRFlZaXZWOE9mTXR1WWdRYXhjUWVRSnRiYmlheUhvdTI3eGFPXzJIVVI0TU9hcE4xQ0VqS3ZKeEtGRGc?oc=5",
    "date": "2025-01-30T08:00:00.000Z",
    "dateFormatted": "30/01/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Strukmyer LLC dba Strukmyer Medical - 692686 - 01/30/2025  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6498888999b14f16bb5c079f51befc49",
    "title": "2024 Trends In FDA Observations For Sterile Drug Manufacturers - Pharmaceutical Online",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQY0gzZEdCMEdiRTZqdUFUa0w4MWtheTY0VE9VV1F5Tkt1Q3NyRmhVckZfbjdBc1RSTW1YVVVSa3VaaGtDd2pzbHBNWThnbG1RSE02MXJRTFFQakZua1owM2Zuc1R5dFlRczdyR01BV0lMV0ZRQ1pEU0VlVndzYklvSlpiZDE0c1VQQnlBWFFFeXVYN3lmck9BNzJpS1RIdG96aXI1cmNOQUJkb3M0?oc=5",
    "date": "2025-01-30T08:00:00.000Z",
    "dateFormatted": "30/01/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "2024 Trends In FDA Observations For Sterile Drug Manufacturers  Pharmaceutical Online",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "366d289b3075fa3a05987e60784e143f",
    "title": "Evolutionary Biologics Inc. - 681586 - 12/30/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOR21hcEt4b0xxMm5peDRpcFZTem5pbWs3OWhxSmJ5MFpvMDlBRTNBR3FvNUJ4M2ZMQVBrTDFGZWo3TFl4bFNIRjlHYW1tY1FtWXBGNVlCR2ZTY19tYm45aS1VeTE1dTY1X09vQkoxY3Vlb1A2dU1oTWJuX291S1VlenlGOGFPVmRORG9GcU00Sm4xeGhYS25RRWl1OTlxQ2RhYmI2c3Fzckg4TlRFemtxWEhtcUk4VkE4NkllQ0toOElTVGplcGF6alBVUnVTSDVhdE1OWVhsdUs?oc=5",
    "date": "2025-01-28T08:00:00.000Z",
    "dateFormatted": "28/01/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Evolutionary Biologics Inc. - 681586 - 12/30/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "35ce10d510309cee4965a8946991456d",
    "title": "Abbott Laboratories - 669353 - 12/12/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPeDN5R01rRVBEYVR3dXNSY2ZRc2k1OTlxb0oyU3FSSzVqcWY2Y3JuQzJ5eWRURF9Tc21QYWRSenlmQXpobHRJVHlWLXVqNkF0ZDAzbURKdkJFZTYwa2hoeWJsMUhRX1VGSEg5dHd3V2xzb3dxX0RoWndVWVgtdTlHOGhaRnlteVRUWTRuVXFtemVIeVRUSGFid1VKY25fdDNkVkk0TlFSalNSSlBQa1Zad1VoNC1FSTdqQXZ0aFdXRXpnaWJJTWY5NE5nY0xqZ0k?oc=5",
    "date": "2025-01-21T08:00:00.000Z",
    "dateFormatted": "21/01/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Abbott Laboratories - 669353 - 12/12/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "5444a1cae2348310965cb59505e6324a",
    "title": "Cipla Goa facility gets one USFDA observation - Medical Dialogues",
    "link": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPMUdDS2ljUGlxV0p4dExEanBacGJ2dURReFRtb0hIQmNDcW1TZ1RweXc0Nm40dmNLczJwZFgyWVRqLUdPYjI1REpQSmVfZUsxRUVMM2dEOW5PR1E0OVdFck85cWNyM1hISzZrbWlwdkFTenU1OE9vb29wUWs2MWJVZFJuLXhhOEhtRDdRY2hrNVB6Z3Q2b3dPU3lxQ3hfVG5wQVBF0gGoAUFVX3lxTFBsVk1zTFZQRDdiVV9TU1NJUk13OS1MaEtMQktaRVR1RXZxdGxRVllkNFJYZUFxWWt1LVlGWXNHZGZaQzdEWUNzZG5VcmVzWmhvd2lNamxZTTBaWFBzWTJXc1hPNDloNHVkWUlRbzRfaFYzQ1JvUW1nbmgxdGtXdXJ5YmNFWUFPRWdSR3FRUS1UalhaZ2dQY3V1NHpzS2w5RnNuTFdOUm9zNw?oc=5",
    "date": "2025-01-21T08:00:00.000Z",
    "dateFormatted": "21/01/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Cipla Goa facility gets one USFDA observation  Medical Dialogues",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d58ea0e5f6d6de56add51c190b09ebba",
    "title": "Cipla's Goa facility receives single USFDA observation following inspection - CNBC TV18",
    "link": "https://news.google.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?oc=5",
    "date": "2025-01-20T08:00:00.000Z",
    "dateFormatted": "20/01/2025",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Cipla's Goa facility receives single USFDA observation following inspection  CNBC TV18",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a5bcf85f2615439f9c46ac5bb7323947",
    "title": "FDA Issues CRL for Atara Biotherapeutics’ BLA for T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD - CGTLive®",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxONG85cUZMcXZGUy1kUEtGY1FWNDNCUDIxRDJ1dmdRVzBOd2tjY2xxZFdUSnFtd1A0ZVItYVZxNDJCMHlxejNFemtSUk8wTlBXUEswUUtIQnk2V01ObVIyQ2tHNG1jZVBSWkozTThySEJDWjRoczFWQTI4SnU2YTU3WC13dGZmOE1OdFJHeE1BQ0huckhhQTNQUU56NElHTktJb29fNkJDclN1R3RveWc?oc=5",
    "date": "2025-01-16T08:00:00.000Z",
    "dateFormatted": "16/01/2025",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues CRL for Atara Biotherapeutics’ BLA for T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD  CGTLive®",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "acd52b1598f71eabb0947b649e788f2a",
    "title": "Indoco Remedies Limited - 691594 - 12/16/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPUkxUVHF0NkRHaHJHaVVvWWNLaXR2dGhwU1ZYZm9vT3ZUc0RBRk0wSlBlSm9fQjJYVlZ4Y1dDUTB3M1lnOVBqcXZERkJlVmZ5WHZPa1FiWEpXZ1FVRkV4NmpNOUpEZ1BwcUdhWl9qODE0NmdjNnpUbjE3c28xWm9pQ1pUVUw2RjJCR3N2RlRiSTJTbHJLTzZ1ZmN4TDY3OTNLeGJ0b0NabDh1eEhvS2czR0oyRDNtU2czd1hZaGhCTTl3OHp6bVBMdjM5SllfbXVNM042Rw?oc=5",
    "date": "2025-01-07T08:00:00.000Z",
    "dateFormatted": "07/01/2025",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Indoco Remedies Limited - 691594 - 12/16/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "1af96567d4e1057649c6ca9dcd2d8686",
    "title": "Viatris faces FDA import restrictions at Indian facility - The Pharma Letter",
    "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxQel9hWG5uOGoxeXNFZUJyTVBMR0hVSzhRUmJoeUhaNlNJYUJ5SFpNQklTYTREaXJEV2hmYk1RZlR5WENZZ0dqZGZVZ2xRNWV1Y1A3V0N4QUVSVnlXZTZXektuY2ZpTG1rQ1dyYTBEOTBqcTdwOTB1UDVzZ1A0VDNpX3hTZm5TUlh5OU81TzhjYTFDMXVoY05YUUROT3JGQQ?oc=5",
    "date": "2024-12-24T08:00:00.000Z",
    "dateFormatted": "24/12/2024",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Viatris faces FDA import restrictions at Indian facility  The Pharma Letter",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "feafb276292bacf9ca348eb3cfc99940",
    "title": "Viatris’ Indore plant under U.S. FDA scanner, imports of certain products barred - The Hindu",
    "link": "https://news.google.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?oc=5",
    "date": "2024-12-24T08:00:00.000Z",
    "dateFormatted": "24/12/2024",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Viatris’ Indore plant under U.S. FDA scanner, imports of certain products barred  The Hindu",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "1257b182e4ba024ee7c01efbc6911e0b",
    "title": "U.S. Food and Drug Administration issues Complete Response - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiwgJBVV95cUxNT01UMVJNcTcyXzlxd00tdlE4SjRBNTUxYkNvS25IUjlHSXRWa0hpdnlDX01vMjBxcDdMbTM2eTBlTjhZTWM1UDBSVnlOSkZvLWVGcTNJeW1yZGhPeG5wVEhLXzFXdmpxTjk2cENnSk5YaGlnbDNkMEtNYWpFMWYzRHRZSTI1SHdZZElFOVoxRFJOemZyaXN0RkJwcndWQ3F3dmx0cjQ3QTVLc2tOWi1FOE4xNWNBWldWR2p3dUFjMFE0dGI0UW1DaWlSQVRWODdYV1pPc0V6dU1ON19kUGJPX3JYc2N0Qk1SYnM1Vkl3QWh3Y2VMRVBUcE1SZUIzb0FiTkpUV3lpeWlpTC1lSlF6RVROLUs4NHZjLVczOXEtMzNBZ1lETFhkTWhKNEZ5YWE3R3NYNkhFb3NHRllnb1FKcXNB?oc=5",
    "date": "2024-12-19T08:00:00.000Z",
    "dateFormatted": "19/12/2024",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "U.S. Food and Drug Administration issues Complete Response  GlobeNewswire",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "78ce109e6b8440a7f5bea17fb3bc6cd5",
    "title": "FDA Issues CRL for SC Amivantamab BLA in EGFR+ NSCLC - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNNk9hR29fdnIza3V1UVpsUHN0djA2OFlQR01ReUx5U25DNnU4aXh4cTY1OHlsMEZocUxqMjI1LVl2UHpnbU85N010d2JMZ2pQYjM2ZnJzbWtRWEd1VE1NTk9BbUpNMzdUTk1rekxOeC1vanBlRGlLeTZ6RHdSTnczNmwyUU1IY3phWUY2Ug?oc=5",
    "date": "2024-12-18T08:00:00.000Z",
    "dateFormatted": "18/12/2024",
    "source": "Google News - CRLs",
    "sourceCategory": "google",
    "sourceType": "crl",
    "summary": "FDA Issues CRL for SC Amivantamab BLA in EGFR+ NSCLC  Targeted Oncology",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "44dacc8371a9aff64bc50d77f64745f5",
    "title": "Micro Orgo Chem - 686458 - 12/03/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPNjJQaG9SeWZib0NDeWZxZGdSRTRZWmNFOU5iSW9xMW96MktnMFVmNGxHYlU4VEpzYm9UNEx0dHFFYTBoZHJDVGxZcU5OTU5ZNlFrNEE5VkFHbHljVDVvd1FFV0kzelR0ZGUxNVpoVU5id2Q4ZVlEbm5VUzZ5UW5qeXBlMGp0SHdYb0l5WjVBMUZiSVlnZmIyWWdSWUxIMDUxMEZNVVVEbTRLR3BkNHdueDhSNnZadkRoWnVFblRSZEVlUl9Wa0FDMUd3?oc=5",
    "date": "2024-12-17T08:00:00.000Z",
    "dateFormatted": "17/12/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Micro Orgo Chem - 686458 - 12/03/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "8318bd3197921e8f1bddfe00675ce88c",
    "title": "Compliance issues at Granules India’s Gagillapur plant - Times of India",
    "link": "https://news.google.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?oc=5",
    "date": "2024-12-05T08:00:00.000Z",
    "dateFormatted": "05/12/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Compliance issues at Granules India’s Gagillapur plant  Times of India",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "8eb3cc86e00e2a228294931fdc647a66",
    "title": "Han C. Phan, M.D. - 696989 - 12/03/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQbEY5VFFkTWNmeTl6UVE2b3Jzei1iOUFLdjNYSWQ1b05WaE1PdWdVb2hUTDBIdmU4cDlpa0huOGppaDVxaWk5ekszU0wza0N5TWZEVmlyd091Z2NCeURpSlliN3hwdjRCSzdfT2ZwS0k4VkgzVkI0SGRJSzBwVGN2VnJTS2lYbXNnVVNjLXpfb1JVemlxRDFPOWtIaEM1SFJyMUpyUi1ZWGxwTDg5OGc5UGJtUXVhVWV4MWFwZFhhc25oMnMwNzBR?oc=5",
    "date": "2024-12-03T08:00:00.000Z",
    "dateFormatted": "03/12/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Han C. Phan, M.D. - 696989 - 12/03/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "bef4ce9bd9c49017d41479a046091d6d",
    "title": "Dr Reddys Hyderabad API Plant Gets Seven Observations From USFDA - NDTV Profit",
    "link": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPOHdPRVFnUFU4UkZVdUVoZE9zaGZEdzgza0w3WTFHWnAyM1A3RFk4NTlVOE9tRHNmOThXNnJYTGF1S3F1SmQ0bzc1VjZSWDhTU2lNUnZxU1pRUWV2ejA5NkItRzg3U2FGLXNZVXl2WUlydzdCcjRXWGJsMjJOd0Raei1aa3c3VWZZUWpkbdIBkgFBVV95cUxPLWVDNkd5UGZ5OVRNUG0wT1BoaURWRFBkMUREQlh2aTdxNHBwaWR4emhKY2p6cllfWXJZcnZWYjh2UkdmNV9waWJDZ1p4cG1IWDdnWGV5QWdjelBnRlJjdnVINVVBMnhsYzhLTFltd0xzSkR1MGtCQXZYQVRiVHA0bWhjX2xZYU9iM2JZQ1d6VkJCQQ?oc=5",
    "date": "2024-11-19T08:00:00.000Z",
    "dateFormatted": "19/11/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Dr Reddys Hyderabad API Plant Gets Seven Observations From USFDA  NDTV Profit",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "fc9af8362758eb0f93c439d17eaf8ad5",
    "title": "National Drug Code Directory - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQc3VsZWRqbWExUm5HcE50VlNsS0RLNTRSWHNINWpDQ1RCVW45TGpBN2FGYXhYV2hRZzIzQm5QMi1fZ1JBd19FOGRlMWVQazNCOU11RFRFdldDdnhLbXdhWGY2c0M0ZkxDVjk1blpoM3BHWjkwN0swRC1sX3E0bUREYWhBOVBRR1FmVHF3?oc=5",
    "date": "2024-11-14T08:00:00.000Z",
    "dateFormatted": "14/11/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "National Drug Code Directory  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "9928867cd831d2bb4a82486d8f1fb273",
    "title": "Cipla gets eight observations after FDA inspection at Bengaluru plant - CNBC TV18",
    "link": "https://news.google.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?oc=5",
    "date": "2024-11-13T08:00:00.000Z",
    "dateFormatted": "13/11/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Cipla gets eight observations after FDA inspection at Bengaluru plant  CNBC TV18",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "36845b00644492d10e60e19cad5876a6",
    "title": "Cipla Gets Eight Observations After FDA Inspection - NDTV Profit",
    "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxOQUpOdEJ6NDlNQ1pSTFMyYUc3ZWlKdkNjcE8tX2F5OXc5aDhIVm12aEVVS3BVMTZmWG1KbGxBUjBSQ1JKMHFNQjJFeXoxWTU1ODluelVMcVdZM2hUY1BtVmoxeEo1STBiV1hNQnIzcDJsUjJmRW1SbUZYWXlCa1Z6Y3g1U2h2S1REOWZsajBCaWJZQWZYSVZZVndRNE9NQdIBowFBVV95cUxOUzMxWUtNZEhGSGo1QVZSd3dja3dZOXRVOE1nRXl4aTRnNFBXTHBSTVIyeURLZ1psZXFkM05kUVpVdmpIX01PVTBWX0RtemJDdzA4MWJTQlA1RmZ1WGdteXZ6Q05mWWFjTko4Q0cydHg0czRiWDhaSEhFSnV4bU1ScWdMLXYxQW1KNGFoMnBuenh5YnFlbHVQM213aDh2Ukp2dU1Z?oc=5",
    "date": "2024-11-13T08:00:00.000Z",
    "dateFormatted": "13/11/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Cipla Gets Eight Observations After FDA Inspection  NDTV Profit",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a3d184f4332cf1cb1ab3379f1c1e9d02",
    "title": "Novo Nordisk hit with FDA write-up over production issues at critical semaglutide plant - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPMWdjQXQ3ZERyalE1VkpFMDdXZVNrQWpNb3UtcXdsX3NtZ1BrcnBmMkh0WWs3MkhCTzJZc2dnVUxEbmhNbEtXclFFWjNmUW1MZDFKREliSURWMVlWNldFLTN2eGlpNGhlWHlKdHFULUZfQVN2Tk1nYnNWckpIRl9Jb2YzY2xKR0FOUkVoUlJBWDdQaEN4ZDQ4NGZTVlBDUVVDdzV3bkIzNFRyX1g3TUVuOERNWGZnQ09XMW1tSDVnSng?oc=5",
    "date": "2024-10-31T07:00:00.000Z",
    "dateFormatted": "31/10/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Novo Nordisk hit with FDA write-up over production issues at critical semaglutide plant  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d89c1badaf96fdb0a793e1447f9cc8a1",
    "title": "Rontis Hellas S.A. - 695160 - 10/28/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPbG1Fd3VGRGpVR0trRXNtQjM3Um9hU2FtdDQ1U3dHQmJqSWJPU0w4WC1KNlA4cWkwaDBIOTFMTnFuUlZsaEExUXM1MDAxdTlQZ1dMMGNiMHR3S2dVTFllRU1iY0hTb1Y5SDZDelA0N05BM0JGcHZsMnhUZEVSeUFpakZMeTg4VFIzLXF5OEdTalRIbndmaEQza3oxWDNSeE50cXpSUHpxNWpUNm5UQk5qbGlHbUYyZzFLRTltTUM2S0dXU0JpOFJQY1ZLMA?oc=5",
    "date": "2024-10-28T07:00:00.000Z",
    "dateFormatted": "28/10/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Rontis Hellas S.A. - 695160 - 10/28/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a71ef5219cc07af448e1b882fb865383",
    "title": "Namita A. Goyal, M.D. - 677324 - 10/10/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOTFR0SU9vQzZMNkF3NkJzOVNkX1NYQkpNd2QxWkRNbHRGVTZEUHJzVlJ5MExlM29LeEZDMkhTRFRBa09jekZ0T0ttdGJ1a2xielJqOG1OOHZUbmViU016SUtEQkM4bkdsb3FjY3JveXZUSVJXNnNaS3d0TjBtM0R6cmRYQ1Q3SWItQk1TRjlWeGFIUVdfTnpVSmhZTVhxNkwxNGVLTlZOcmRRVVNoQkFaWTVFVkhGanB6cld0TDVjTDB2MDdwNXlGZzJn?oc=5",
    "date": "2024-10-22T07:00:00.000Z",
    "dateFormatted": "22/10/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Namita A. Goyal, M.D. - 677324 - 10/10/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "7438b07105768a5beedd61f27811a46a",
    "title": "Cutera, Inc. - 639552 - 03/09/2023 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQek9qNEhCT3BQNDE2SDBpUzJRcF9sOGQ4ZnhhRml1MjhFZlhaWVY0aHE1bUJBS0FnVld5Rml0OXdwSGNBMFBPTGJxN3RYdjI5R3ZiVFhXVzlxaWpvNlNtVWpfS0JmTkdLOFV2bUt2RFdDSU12OFJYSkxQNTdKT2hCczVfSTRpSnhsanVOaFBoU2drMVE1aFlxUVJzb1h1amxsUXJZODItUk5IR3BQcWpVOUZwVndHQzY1TXRTeWVJQ0JtZXc?oc=5",
    "date": "2024-10-18T07:00:00.000Z",
    "dateFormatted": "18/10/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Cutera, Inc. - 639552 - 03/09/2023  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "18da9d5e331f5a8cd8a2f06182e164b8",
    "title": "Biocon Gets FDA Observations At Key Biosimilars Facilities - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPdW9IWHZYMVBWaGRBdUF5OHVFV3pkZ1JDRUFZU2psYWN5NFIzY0VsVDBfaFJqNGViY0wyNllqaDRISUtTWktoSElNemhYQzZGeEdqRzEyTWwtVE5vZUVTUUxNc19SVXlGTEhCaElLTENHcEwwMGZ2a0U5QVdRS1hPNEVkLVhNNFBlR2RzTWJLSWI0ZkllWjYwWVFkRTh3UjA?oc=5",
    "date": "2024-10-17T19:27:51.000Z",
    "dateFormatted": "17/10/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Biocon Gets FDA Observations At Key Biosimilars Facilities  insights.citeline.com",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "32d13e717374c0b6c556078e81972602",
    "title": "Outin Futures Corp. - 684688 - 09/25/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNS3ZuUFFMNzdyb1hFamFvempVYjFkSnQ4ZWRqRzMtZkN3SGdrdld1WnRvbG9PVUhLX0JoejhnRENDZXZ6b2xub1JGZ25NRzVQcXVXUHRSSWlkSlpLYlc3ZFQxd1F1cnRfSDZZOW9DN2JDYW50TGxtV1owX1FOZld2dG5NYTd4NVMxVnBFYWtvQUE0dlR2bXRWQzZBcjM3ZGtSUzVPNTBBXzMwbGtvb2tNX1JEYl9LZ2pGaTZERFNTTlQ3Qk5SVEo3bGpUZ0stUQ?oc=5",
    "date": "2024-10-15T07:00:00.000Z",
    "dateFormatted": "15/10/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Outin Futures Corp. - 684688 - 09/25/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "5ceed69be8b350314d73ff48fe5f58d8",
    "title": "The Brief Summary October 2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1jcGhkSkt2X3BxT3RwNXlUM2pIaGpqR054X2J4aGtEc1p6ZDBMUjJ2QUlwdVZlNmR4bVB2b3BGWXZRa0FtRU56Q09fWFdRazZOVGhR?oc=5",
    "date": "2024-10-07T07:00:00.000Z",
    "dateFormatted": "07/10/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "The Brief Summary October 2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "682cbd546de5cfceb027cd0d1540db41",
    "title": "HFP Constituent Updates - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMickFVX3lxTE5zbmJfOS1ROVFQMGlZSDdleUVmYVNyVVgzeS1qdWF3YXdfbll1OTJISzJvRTJ3VFNsMkc3cmtwRDJaR1Z1TTZEREtEaU9EYWtNT3ZMRGJjSld3a2FXVzhwaVBpZmJLcHJ6Q184Y0Y4d3lSZw?oc=5",
    "date": "2024-10-01T14:50:26.000Z",
    "dateFormatted": "01/10/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "HFP Constituent Updates  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "20588e5ebb0d7f7b3ed6be9bdae064ce",
    "title": "Pinnacle Transplant Technologies, LLC - 646783 - 10/01/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNNEw2UmJCamF2bVdCcV83Q0Q5empYQlpNRmhubFhsUjJiVzk4T0h4d3RiV1dzRUFkZ3RfdzVOZWVsUjBJTXlVX1FONllZbDU0WWpHbUtRMVdQeEM2ZzJzbk0ybzZYUzVNVkVFNWI2RGVWLXdJWHBzOFkxcUxjMTdSZkNRRWJyNGJ5NVpHUlp1a1FCUElMX2xYSEtTMGtfQzRmaVpkTGV0UjZLd010blQ1OXJNbkFNQlZCa1V3ZU5iT3J1NzV5YkFoQ1BPd1RtZXNnVmtWOVBlVHhERHBfbXV4OWVobF83UQ?oc=5",
    "date": "2024-10-01T07:00:00.000Z",
    "dateFormatted": "01/10/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Pinnacle Transplant Technologies, LLC - 646783 - 10/01/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "59eb455741022b75eaa2d303bfd7c7f2",
    "title": "Diamond Chemical Co., Inc. - 687078 - 09/06/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOYW12eTAwOGp2UGRHdE8tNXd3cVRiR3l5bi0zd1J0cDBDb2pmRWV2MWpJZ2x3SU1PM1p4OVZCYUpEZVV4MWJLaF9MUFJ4S2ZHMHA2Rk55UnMzQjFLa2JxZDFON3M0ellseFo1eGxyZXc3ajZEMGZtbEZuMDB6WUJfV2xMQWlyS0p6UVoxLUM0ZzZxS3ZjaHdwSDA1LUFsek93a0huVU9mTzlBbDdNM2t4V09IRFdLMVZLN2pXRmk2R2R1dlFlbzBvYkJDSEZndlZqOTdzSw?oc=5",
    "date": "2024-10-01T07:00:00.000Z",
    "dateFormatted": "01/10/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Diamond Chemical Co., Inc. - 687078 - 09/06/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "9162b53a0938df642c67b8f2b140c1a9",
    "title": "Quicksilver Scientific, Inc. - 612476 - 09/30/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxORXZPNEF0a0xsYWVabzkzeWtaTks4b0dYMTZBTklVdmU3aDRyVFozN2pVazlfMmR6U3VnSDIwN3NZSnFiMGxHMVlsWFE5T2ROR0xsNVRqam9FcUYxMzAtY3J2LXRsblI3R1hCR1A5SXhCN0RhNXZ2dkg1bnRERWJDSDc0bkRXbllyY2NJZUNqUVN4eHkyekRlNFhnbDRsamhyWFdOLTBNdmNPdTNXSVJ0Mkk2RThZcTJVRW54V3gwQk5xQzAwS1EyeVY0akYtSURMTWlQaTYyMTI?oc=5",
    "date": "2024-09-30T07:00:00.000Z",
    "dateFormatted": "30/09/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Quicksilver Scientific, Inc. - 612476 - 09/30/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6688c9835ca30021fd162647a4806f25",
    "title": "Makra Kozmetika D.O.O. - 684125 - 09/26/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPZkRXbVNQckdqbzdTaGpIdHZ1a2VPLUlqWXNlMXRrZWdZdnRScDNhbklOQ3VETnZLbU9iaDJvd1hCa0p4RjAtZG9VdXhpS2daTU1MOEx4OTNIYTExNGNSbmVzSFpBZE9oRnNWblZGSTJfaTRQUWY3MGNndFlSb29vSDQwSGIyeEE4elFhTjVkaks4TzdxalVZWjM0Qmx1MkRNa0kxV3ZaT1ZWaUxrOG1QOXZoRG5nM2hCeDBnUXV2SW9uY1g5RGhNVTVlZkJONTg?oc=5",
    "date": "2024-09-26T07:00:00.000Z",
    "dateFormatted": "26/09/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Makra Kozmetika D.O.O. - 684125 - 09/26/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ec647b2ce5415b830be7f9480fda99fb",
    "title": "Wittman Pharma, Inc. - 683081 - 08/06/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOUHMyS1pYSU12Q202VWNGckJkTmZDN3NPZjVjVHpOYnZPVC0wU2o2N1FPTWkyWVFpd1VhNnVxZHJTSDVRcXUwZHV0dzZRRnljWnIycS1HNElDNXRYelloUVNDbVdFejlYeHlGbW05VjJVaVRPU2J1Yl9lWE9Xbk1RX3BJQUxneVhEZVU4dEJyZ1VIRzlReGhJa1hNblZKWFdjX2tKMmc3V0lGNmJ0S1RUX3NDalhvbFFveVQ2Y3lxU0VNdWgxczM1TVNTdGJVUQ?oc=5",
    "date": "2024-09-24T07:00:00.000Z",
    "dateFormatted": "24/09/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Wittman Pharma, Inc. - 683081 - 08/06/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ce38f78eda2477456af436aeb1d903f6",
    "title": "Accupack Midwest, Inc. - 680228 - 08/15/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOOGxvOGNQN09xeTVxbWQwa0lqTkVKQVk1RTJSY1JQcTBYLUNyNmR5U2ZmYVNzTldGTEhsel9sR3NoVXduOXV2Y2J1dXFnN05jMGl0T0U5RW5vWklNSE1qMzZRSjFHb2IxWTNIV0JRTV9NWTdQTFpKTm9sLWFNOWV6SHB0eHU5QWZ5cjRuRDF4ZWZxdHNHeTBJQlpGV2dFYUJkbE1zV3dqMGNqaXBhclB3N1JOQnpFMG5pLW5OaXlxSFU1Yl9ib0xCdVFsR29ERFAw?oc=5",
    "date": "2024-09-24T07:00:00.000Z",
    "dateFormatted": "24/09/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Accupack Midwest, Inc. - 680228 - 08/15/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "1d819e715c3a53659a8aec3c5897f5b5",
    "title": "Granules India scolded over truckloads of torn manufacturing documents after recent FDA inspection - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQa0M4b3g4LThibmRENjZLbDVNZXczX2JMc1FLYzIwOWV1dmZ5RE5JUURQdGwzS005c29Vak1qbUhRMXRsV0xkTDFSaENMZGdfaVZUNDNTQ3ZnMXNZQTEycDMzbGVHdVRnbzlQZ3NxT3dGSmNiSjFvaVAwcXpseXRjNlB6QnhGcVIxRkdPT2NYLVR4V1FQSmEtSEJkT2czVXBKZURrcktkWE1VYU5JS3lXaDBzQnJ4dHBXclRwRQ?oc=5",
    "date": "2024-09-19T07:00:00.000Z",
    "dateFormatted": "19/09/2024",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Granules India scolded over truckloads of torn manufacturing documents after recent FDA inspection  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "1997eb1c2ebbf26bec90f29242849463",
    "title": "St. Louis Calco, LLC - 669917 - 03/21/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOaVJySGFhVGVqeG1TZURPRWtqckRBM0VYMGNxYmpfeHIwU1V2a3YyWEJsNDUxNDlpTEJQdHZkTkZGalNLcFRBbzNQLUpYUzEyYkVCaTEyVG5RbXdEOXk5bUlzdV9KWm9WajZqdHhiUTU4Z1U3cXpocGRRUEZKcTFud3dwS25iVkxJMENXLTAtLUs2SHpiRmVJT3VmWExLOVM3U09UVklITGZBQWYwNWVWNXpzWWthdGh0YmxIZm0zNktxRV9ySzJ4OXJxMUdHZw?oc=5",
    "date": "2024-09-17T07:00:00.000Z",
    "dateFormatted": "17/09/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "St. Louis Calco, LLC - 669917 - 03/21/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "45dd032c1c5e43fa5b24237b6956682a",
    "title": "Beard Management Inc. d/b/a Beard Vape Co. d/b/a Lucky Bar Holdings, d/b/a Fifty Bar - 692147 - 09/12/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMimgJBVV95cUxNOVdJS2hUVG5VQWZGNEVxSDJtYXFJUFQyOWo3WnZyZE8wcXJ3dkNCal9oRzJOSXNpalRNbjFSZ1BHbXh6OG13ZkdBdG5oZzZEb3MtTGlaWjBocERyd19NSjJBSWxOVW91ZUJzbzZlSmpCTFRldWlTaERvN2RxeTdINTRSek1Pa19BdVhrc2c2WWNMLTNvYkRhb011ekEzZXBvTGlYWFhvcURiMHRTbmgxVlpsdDIyU20tdXVQVS1zbzlzcGo3NWFod245R3lESUJ1M2lTd01JUWh1OVhZV0lOQXFxMFRSUWdsWDBra05FNmxVd25qNW1vUmtUT2M5ck5RN0lkdWZpVDNkTTVRVTZ2dFRiaUFnYU9CckE?oc=5",
    "date": "2024-09-12T07:00:00.000Z",
    "dateFormatted": "12/09/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Beard Management Inc. d/b/a Beard Vape Co. d/b/a Lucky Bar Holdings, d/b/a Fifty Bar - 692147 - 09/12/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a1ea0b869cfe1773e312c14758762e16",
    "title": "The Vape Bar LLC d/b/a The Vape and More LLC - 622851 - 12/01/2023 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQR3l5UnBkUWNFTndPalg2Wk9mMUR1STRVeDFRSlhwU0d6cGV3d19yWDdOMzFkNm9iRVJuYVRNcTRuZ0NpaWpwYkZFV2hzR0VyQkdDOGZtNjBXMWRkeVdBX2ZlWG9EQ3dUcnNsRXNNdGpNMWpyNEo5RWVtVnVXWW1PWG1VaVpnUXBtZ1JTNkxGaExRQlJ5OWhYc25jUWVLTzFpOENQWU84by1jYmlxd2FVV0ozR0F0T0lSUUdEZXJlM3F1YlNkWEZhUkhZdlBmU2NIMUhndENOYXZRbFVwdjVPTzllTQ?oc=5",
    "date": "2024-09-09T07:00:00.000Z",
    "dateFormatted": "09/09/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "The Vape Bar LLC d/b/a The Vape and More LLC - 622851 - 12/01/2023  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "15c8034dfc3d7fc0816347311bd4cdbf",
    "title": "Adventure Innovations LLC - 676842 - 08/07/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOTTZaX2JMbUNlTjRMNnFkWmhsbmUwQmllZ05lWEM3X0tNdm02R3FycmUtSnJEWnZhZDNpQTB6LTVUNFlpd3hBOURjMWNYYTR1SnY3UUtpS0hvVTBvN0NhYURaNFhIRFVEUXFjcVItYy0ta3hld2dfbkl4ejVZUzNTQTFhRmJCWWVtRXBaS3hCNkd0RmFTcElleFhDdUo4UGdVajM0dzNadGRzNUU5ZkJsSzZ6MkdDNDlUd2RCRWQtSmRONUJURTRwM2RxbG55Ri1MS0lfT0RJZw?oc=5",
    "date": "2024-08-28T07:00:00.000Z",
    "dateFormatted": "28/08/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Adventure Innovations LLC - 676842 - 08/07/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ca31d86a1b980196b6123cbaed2a6196",
    "title": "CARsgen Therapeutics Corporation - 686504 - 07/26/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNdEFKYXpFT1ZoT05ENjJmcVpyWEJPWFJYTWtIdWVEbzlkMmFJeEdVUk0tNGl4TTBlSnJWYkNTV0Z2elUtc0lCQ1lJVFlUaTV4N1BKUTZObXJaZ19VdFZkZG5qZ3ZWb01PelFhRmE3aGRqc0JCX0VvT1RCdWZBTkdtelpRY2JyODhpNGFObklqTGh0UXowMUpGc2RYSmtrMFJCb0pJM1h2RnY1Z2hBN0pmajd2NEx4dkxzdDMteTlkVXFleDczZE1fMDV6LVhvSjJTQ1Q5N25zZWxtb2VpZHpnRg?oc=5",
    "date": "2024-08-27T07:00:00.000Z",
    "dateFormatted": "27/08/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "CARsgen Therapeutics Corporation - 686504 - 07/26/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "96c3506670fc90b39644dd0aa5e04a15",
    "title": "Apollo Future Technology, Inc. - 690452 - 08/16/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNZUhvNGFGaWRsUm5tTlFwZkd1c1ByOEI0bS0wdnBub19IbFZvblFTZ09wY0dDWWpGMUxyMktIY2hRSFlTc3BUZzJxVlRhOG9LUWEwYlNkWDJQX1JMZ1kya0VTZWdqc3RhaFhvaGM4a2RzWF9RTGRmRHN2S3I5aThNRWluNUJPTl9CRDRWbHZ0eTF5M3pHV3l6NnhfQ1puV3FldXc2S2tsWUpvTTc2ZmZlVFlMVDhIb1hFTlYyUjRQcklxTVp1b0g2RzZBN29qbm0yVllnRHVHWENvX3M?oc=5",
    "date": "2024-08-27T07:00:00.000Z",
    "dateFormatted": "27/08/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Apollo Future Technology, Inc. - 690452 - 08/16/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "b338503d56f8fd10f69efa11734b5248",
    "title": "Oops, They Did It Again: Indian Pharma’s Frequent Flyers on FDA's Naughty List - BioSpectrum India",
    "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQcXhIeFlXdlJhSGdRV18zdWhYRGUyVjQyZms3WFBSVGRoREIxZGZHckhLSXlzdTZ3WkhTVkJub2l0Q2puZkwyWTRKUjN5U01hS1ZUVElRUFRveGkwSVNwSEh1MENxekRFMk8wX0VXYm8xTkpHaG1kVS1MaDV5c2p5eEpiUHZMVXdWU0F1VGh4ZGdHeG1qY0hYaVhPbzhQNXdZWktYNXV6dFNwVEd0eE9wODBsZlE1amZVVFQ2cHlHdHNZZlFTelRCVnNHS1A5ZVFOcElac1FEQTJxdw?oc=5",
    "date": "2024-07-18T07:00:00.000Z",
    "dateFormatted": "18/07/2024",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Oops, They Did It Again: Indian Pharma’s Frequent Flyers on FDA's Naughty List  BioSpectrum India",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "f39cb255822e5ff91da8ac1b6c3c7994",
    "title": "Donggang Wanrui Food Co., Ltd. - 678557 - 06/25/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNeEVxMVM2VmZLbUpjek5ycFBUai0wQTJiZ3JIYkVLWnFDRWlVYWRlVFV5R3pNUkx1RmZaakdKYnZocHBDdlN2WGphdGlDZHVGY2dVSTFNM3ZOcDBsWXVNbmhGMW1jNENFbENuODRrbkdkWVloSFFybzJJMHpPaUlxaVA0alotVzk5dlhUZW1BXzF5R3hoVTBQUUg3Zlo4OEpQeVVIOEM1UnVfVGNlV01KM2h2UnN5LXpzRERQMUxYdHVsRTV1SmF2WlJ1N0RqRjZoMFY1UjVjZmhRQQ?oc=5",
    "date": "2024-07-16T07:00:00.000Z",
    "dateFormatted": "16/07/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Donggang Wanrui Food Co., Ltd. - 678557 - 06/25/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d4f02729c51a0df81bfcf730cd21703d",
    "title": "Art of Beauty Company, Inc. - 674144 - 05/22/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQQnpDdjVvUnRJaTNhWXlwdzJrT0oxUFZnbkozQ2lTWEhxTUMzcl9OYUF0b0xlNERxUmtkUi14UUpwODAxM25WYk4tckE2RXlsQVFOT1ZBWmhKbFAzQ1ZzOEVBdW8xcENfQlVsRU9GT1A5dGNUY2o1RGZQUFJOQ3NvenZMdDVMQjY3c0VBUEZQSlpXUUdIaFlNdy1iNTZlWXdZN3N3dG9rNzV4elkyWmt1ZzlnUzMtTW9Wbi11aUR4U0ktNzkydFFRdElGemRNNWFWVm5F?oc=5",
    "date": "2024-07-16T07:00:00.000Z",
    "dateFormatted": "16/07/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Art of Beauty Company, Inc. - 674144 - 05/22/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d9802c366361d9c8c12587a63db817ad",
    "title": "G&FIRE INC - 688176 - 07/15/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNckxjSXJXR3pGOHhlbFJuc0Y3bWh4aFgxa2phQVp4Z0FweFl4TS1fcTJhZzV6X2tlRjV6Ml9QUm8zZmVLS2JCNEl5bDlNV3MxcG9OY0o5ZFdYSFp2d2ZFc2tYZkZzb01iLXhnMkc5bTFqMGpjVWV1VU9Oa0RucndQY3BzZjBCRFYxRGlmM1lOUzRLNk9XcjdYTktLN2dneDRJNHQ0Y2ZueWEyY2lHOUFaV090b0M2ZGdGSmZjSHJqSHdOQQ?oc=5",
    "date": "2024-07-15T07:00:00.000Z",
    "dateFormatted": "15/07/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "G&FIRE INC - 688176 - 07/15/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "39739c0fe18068e9545414da6514d7f1",
    "title": "Jiangsu Hengrui Pharmaceuticals Co., Ltd. - 679790 - 07/11/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNTmJWcUZ4cUtMV2FsbjBKT3VncERRUVVia3hyZ3VRSHhUVkpsX3FtU1o3NnhaakpWdjMtWlZmY2VpbHdubGp5U1BJUEJLNFhsQXJ2MXFKRkRLZ1JMS3NjaDI2eHVTRVZkMVNvSFlobFRaRGtmSXIzb2tRTXZrS0x3UVJObWJZeGNyZW5McVBuZ1JUeUR6SU41WmE2Uks4N0p4Vko2OHI0ZHFweFQ5amJHYmNqdEFnaHRtTEpDQ2Zha0dWYml3YW4xcUdwLW5ZMnhFLS1FWHVaSnU4RE4yWGk3RG03QWd6Sks1?oc=5",
    "date": "2024-07-11T07:00:00.000Z",
    "dateFormatted": "11/07/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Jiangsu Hengrui Pharmaceuticals Co., Ltd. - 679790 - 07/11/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6490fcff3b633882f18c3d398ff99b03",
    "title": "AKT Trading Inc. - 676865 - 06/10/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNcGZYcGlMNkl6SlFLajQteTZnSmpJd280Y0Q3SmFqbnVpLVBPcE94U3AwWVAtUUk3dGpwamVtRkxWSmNyLTNoXzRILTdaMlZYbVI0OGd4SUUxMTBWallQVS1VV0xuMENXMUxnNzhBVG11R3RTZ05MZHNtV0xSVlhFTm9ZVzI5Rk8zWVRsbC00VjlPZGFDY1BIcFRfUE14UHk1S3ZJZVJ3T08tM0otc2lkUUl0T1E2ZHdFZUpJeHV4VW91cENKZERQV1R3?oc=5",
    "date": "2024-07-02T07:00:00.000Z",
    "dateFormatted": "02/07/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "AKT Trading Inc. - 676865 - 06/10/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "002fa1cf7f39ee71e8ebead61063a104",
    "title": "FDA again warns Sun Pharma over Dadra facility - Regulatory Affairs Professionals Society | RAPS",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZVRWX19LcnlWWGFqcWFrS3lORXNfUUR1cS1CdHAySkdBU1FzbFBSN0p1SmtUSmI2OUgxdUJZNENlaWhmeUNSNjFEOFp5d1YwTVNvVnlEWnZJUWpPaHVuak1OZUNQUlQ0QjRoRDRwdmF5aTVmSE9mRUlRZ0VGdHppX3RRVXlET1c3ZVo1TWF5Qm5CWmRwS3BydVhRb2RyVWdsUExTM2V4UFY5UQ?oc=5",
    "date": "2024-07-02T07:00:00.000Z",
    "dateFormatted": "02/07/2024",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA again warns Sun Pharma over Dadra facility  Regulatory Affairs Professionals Society | RAPS",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "afbbe43098bc8208434f9fc7d278e627",
    "title": "Angela D. Ritter, M.D. - 681999 - 06/07/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPY3RJZG55SjM1NklIcHFPaFg2MkJIMlNvNDgwcFpncHQ4ejJYcGg1UXQ4Vlp5VWpPM3dZcTQ0RngwY1hIWVpzSnAyaG01SzZSOWY3SGkzS0Z3Nk5jRWc5T1k1X2M4dEJTbTQ3U1V1a1ZyTVlKM3l1Z3EyLWR2SURKVi1YQ0k4cEp3VUd2WThvQzhpYnRZQks0OUY1NzhvbjJjWFJJZGdsOHIxUjZ1QWZDTF9pcDdOUXAxcjNpRTZSOXU2aWdYTzhYZkxXRmszQQ?oc=5",
    "date": "2024-06-18T07:00:00.000Z",
    "dateFormatted": "18/06/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Angela D. Ritter, M.D. - 681999 - 06/07/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "04e7019850c766d103ccb622c9436577",
    "title": "AstraZeneca Pharmaceuticals LP - 664789 - 05/29/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQX0RiY0NVSTBOZGxZYk5PMGpVSUZlTjQzU3hSbzgybG5LcFVBR2c5NzF1RWV6U1lFNEhoaWFRN1ZDM3FpSDBGZmRFZGJpOWk4RG1QSUxYMXMwbDhVZ1J1WXQ5X2lOTlF6am1vU0QybTc1WWNUZFNQVmNOZ01wMTVsSUR3YV9KbTZGclNFQjRvNzlzRjNUeHNuMUJIbi1Nb1lkM3N2aVczNC1qWm5sZ3MxLW12NzFIVVBqRXRxcE5aY21OeW5CMjFrcW52ZWJSb0gwQlY5YzE2Q0U1MzFJdmc?oc=5",
    "date": "2024-05-29T07:00:00.000Z",
    "dateFormatted": "29/05/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "AstraZeneca Pharmaceuticals LP - 664789 - 05/29/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d3990f6740985f20d72e3d33ee4f756a",
    "title": "Natuzen Co., Ltd. - 677942 - 05/03/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQeXhielc2SGk2cmFOOC12U19TWUVFdjJkRkZVb2dWa1pIMG9lR2daMFlxYXIyVzFVYWNaaG9yOUtWMkdvM3FfdThudk12VkhZd2FfWHNheV9rbm0xc0F3em82WEFhYUY0LThxc2k0OGFWX09JMGNvb3NFdEg0aVdXM0VvZndYd0lGbGRGeEd2Q1ZpNXB6dVNjdF9uUURFcS1XUkswQ0JKcDlLYXVrY0twQTRnMnExY0x2MlloVUVpM3VWSGFLZGw5ZQ?oc=5",
    "date": "2024-05-14T07:00:00.000Z",
    "dateFormatted": "14/05/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Natuzen Co., Ltd. - 677942 - 05/03/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "3e38fe5a07b6cbf43a81058ef8e75f1d",
    "title": "Hacienda Mexican Foods, LLC - 663221 - 04/04/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOT0FCelJSQWhBNEYxczQ2eG9rS3g5WDZlNlUzOG96NTNwdmc4RGhxX2lkSEFGSi1zQm1mcmV5VXE4eGxZYVF1SnBDd0V4TDlwZk15MkxOUERud1NZVlhhcmNOV0dEMHBQRERjT1hiMkNfZS0zNFZHVVRlVFlzd2NpNEQ2dERPQktQTnRFeW1QcnBqMlduallGalhCSnJZMU9EQ1NUV2dabkx0Rl9FWUkzV1Q0bWFFTlRfWWNnMWNWSjlNMmlfRDJmdEFUbWRyXzJjWjdqWDI3QUk?oc=5",
    "date": "2024-05-14T07:00:00.000Z",
    "dateFormatted": "14/05/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Hacienda Mexican Foods, LLC - 663221 - 04/04/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e7a2436444d4b03eb7bfb6a453343655",
    "title": "Washington Fertility Center - 678931 - 04/30/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQWk9EQVpXaENhWDQ3TXNsdWR5anhLMlF3S1haUHhBTmxTa3B0QnJXTUp3a1FOdkw1OVdUcHNzbmZidWRfSWphZ3ZFdjdaUjRCeE9ZQlNaYXVuWHlxcl9WcFFJQ1JkMTZFVlZoTEpYUmtvRy0tMXBjd1RrVE5weXpiUUlXVndkUTY2Z2wwa3ZWVTQ5ZVRxTkdYTmVPdUNOb3FNenNpdk5hNlRuUnhoNk15Nmw3UExhQjBTMHNaa2VONE9IOTNTWlpGenFsQ0p2UUVoN04yNzFvTGUydw?oc=5",
    "date": "2024-04-30T07:00:00.000Z",
    "dateFormatted": "30/04/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Washington Fertility Center - 678931 - 04/30/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "7cf97dbc269b36099577133177dd4ef4",
    "title": "Zen Enterprises LLC - 678407 - 04/18/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNM3JlU2JhOEVsd1puQmxwcHlDbzUtZlF0aUdxRlY4TVQ2WVdTSFE4ZWl4a1BGWVM1azlaaWRTb1lKVUpPNmloeHktUmJiOERtVV9nMnZubXp2azRpdlpZSDFJZG41ZHI4TmhOVE1XY3pZYjBVdU9qekw5VmxJOUhjdUFoM2dMb1pWY2dkYXcyOVNxdmpIRHBaS3NwanVRY0F3YTU1d2FWLXhBcEtBdExUc09BN0E5V3BMLXNkX1ZKaGk4MnhDUEdlclFVZWJYV28?oc=5",
    "date": "2024-04-18T07:00:00.000Z",
    "dateFormatted": "18/04/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Zen Enterprises LLC - 678407 - 04/18/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a76b02f6d1e237df6be96de7434770fd",
    "title": "Appleton City Feed Service LLC - 662279 - 11/01/2023 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOaFJMa3k0MGpZZXdMQmpyWHFRMnktbmFQcDJqMVl0dl9LM1Z2U0pGV3hENFphQWV0eWNZUVNvMEdGdHdpQ2c2Ukx6dHg3SUpxVDdTaGEtTU1iMHJscWt5UHpZeERZeUxqNkJaUzJXOVhBU2RtN3NyQThrTkZlM01NV0JzdmJWcDBuWFY0VzlfLWlxQzBHMTF0YnVZa29XNkN6WWtzV3VDQXpwd3A0S25sVHpraWhGV0phOWdaVG9LYUdPbWpqYVVXNmdheXhmc1VKdzIxcU9MeXZjcURRLXc?oc=5",
    "date": "2024-04-16T07:00:00.000Z",
    "dateFormatted": "16/04/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Appleton City Feed Service LLC - 662279 - 11/01/2023  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "db7436f43ff46ac84833bfd04e838ba3",
    "title": "Master Paints & Chemicals Corp. - 672462 - 03/13/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNQk5Ic2hmR3NxVWtDVmVFaGdQbE0xV1huSkpDamx1X0I2LU1EU1d2R1RUdHMyZGl4QnlYQkZUXzkxcWl0MjNzaGdRemRocHNxVWxZNFI0NUhQdjE4WHdNM1VnOFpUek81aUZHekhTTWstRkt6YkdTQnplV3hLc2F3UlVocGoxNjB2Z2h2emNoenA5ZVRsZFpxVEZtcUVYeDd4Y3hfcU1aVVI3NkdlVnNSUEEwZW5DQlhzcmRncVQ3UmNNU2JtVUJpLWF1OUFYU0RTN19MYnNvV1lrRTA?oc=5",
    "date": "2024-04-16T07:00:00.000Z",
    "dateFormatted": "16/04/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Master Paints & Chemicals Corp. - 672462 - 03/13/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d63a46d45f1097dda34a98ee9b35960d",
    "title": "Lipari Foods Operating Company, LLC - 669083 - 04/09/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxNR0plWG9fU3FNV3M3Q19HRXZxUnVSZEJOZVVnZ2FvZDVRU0dKdlItWmJ2MGlWQ2NnZXQzUWlEZGJpMjhZeVdvZEQ4UWtPU0E3R19jVUVWTzk3N0M1RWdvTXRZWUxTclJ5V2F5ZkhUenBUeGRtd1RoZFJ1dFU2OWYyc3djNThCODkyalhNNzlLaUJYX0daY1I1bU5EME5iYk1WUnJRVWxHNWxVblVndURRYkdZcGh2bXNjbEh6TjVPdWUwb1MwNXpjbW4zOWdscHRKeGZHY0FpaHZVdng5c0ZDQkttUQ?oc=5",
    "date": "2024-04-16T07:00:00.000Z",
    "dateFormatted": "16/04/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Lipari Foods Operating Company, LLC - 669083 - 04/09/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "09ccb145a13cbad632bab7a15fe48308",
    "title": "The Brief Summary April 2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE00bjNRcEtSMEh4Qk5yOEZoSFpvZmd5Y2tRd2VMT2JwbjJJM2RWVlpocHZ1d3pqbjRkamhwRlRnQ05qUUQ5MmxmazJRdU0xUmd2Y1dB?oc=5",
    "date": "2024-04-10T03:40:45.000Z",
    "dateFormatted": "10/04/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "The Brief Summary April 2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "05e0119a4ea7cab40b9b53738a665366",
    "title": "About Warning and Close-Out Letters - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPNGJFd0ZsMjZjTmN3SFJRekRCRmtpVy0wOEF0eWh0eXlOUUN6S0pZU0l6VHluRHdHRUFyaWtIQXk5ckZDRVUyMjE3SHN4b2xzUTgyc1dxSWR4TXdIa1hac2pKVXNLRVJkQkdNbTZtR25VbXFINTRoajVIV1RRTVhyam52TlRNV1J6MVo5NVBGLWEtX3Zqc0w2aXNUeFc2eGhmMDk2U0dkNmt0M0trLTVQV0NMbGVwZkkwLWY4eVJlei1rV1M5M0R1d3NfNHc1N1k?oc=5",
    "date": "2024-03-20T07:00:00.000Z",
    "dateFormatted": "20/03/2024",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "About Warning and Close-Out Letters  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6f36bfc11c463f3b8bf120d06d5105f5",
    "title": "The Nutrition Facts Label - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPdzV2dERWOUNiTTBGS0tSVEUwT2dBRXpRSHFocktnTG1qMi1SbjR3NUliamt2bDF5Rk1VU0NnX2tPaWo1ZF9sN0pkbXBtMHdDRDBjQ1FsNHBDZTM5WEZ3Qm9mOVJZLWw5akxwUUxjVFBUenlSRHZGRjlmQnJSVEtrQ0UtUWZsb3F0bVVWQVlDZw?oc=5",
    "date": "2024-03-05T08:00:00.000Z",
    "dateFormatted": "05/03/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "The Nutrition Facts Label  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "5e34a10647a931231290b21e0bf4f3ad",
    "title": "Fresenius Kabi AG - 671249 - 01/04/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPTHh1TFJvc2VJNG5SMDQzRGw2eEtxZkRNdFBoNTN4SWNzZll5aTRrVm9nOEZVQVRYM1ZEUnNWMmQxRHZGQkl2ZGxsa2hQdl9UWG56SUJ4SGlaUVVZa0hCUmNWOEVwSExzX1dsbFNKbGxja1lZRVhwcjNWT3dxUEhHSldaeGVQV2Y0amVpM2VtMXdMeEhJXzB5RTNrWVRWNEhkZ1pGWnpobEJBeWxoN3BWSVZpZ2U0Tm5LcFBvM29sazZWOGtpNXJRSTFPOE4?oc=5",
    "date": "2024-03-05T08:00:00.000Z",
    "dateFormatted": "05/03/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Fresenius Kabi AG - 671249 - 01/04/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "51cc874e4d5dc49f89bc9e95f38e4faf",
    "title": "Colgin, Inc. - 670332 - 01/25/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxONF9kRHAwTlhHeDQzU284U0Q0WFFuTjZlcXRpSC1TaVd0VmZmRGpGSm9yaUtSZVREQkdwRUV4NHpkWGpmdFVOMURQS25hSnp5Z0lvMEY4OFVyNURBZXh0R01Gb2R4LW93a3lNLV9SbjdldmpJZFkzalZ1b1dLVG1mZHRrT3FvZVRBQ19JNXlfQ3JHUTlkQjcyR1EzRmY2eWRUSF80T0p1TEprQnFmVEdGWU41Tkt0bWxIdERzNkFuNlhnb1k?oc=5",
    "date": "2024-03-05T08:00:00.000Z",
    "dateFormatted": "05/03/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Colgin, Inc. - 670332 - 01/25/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e3f7bd682c44ec45a513ca7c7d4a8daa",
    "title": "FDA Warns Five More Online Retailers for Selling Unauthorized E-Cigarettes Popular with Youth - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQOTc2WWt4WnlTc2N3OUxxeWpLQzh0M3liQTl1ZERTb1FMYXJfZXd6MW9ubERBeUFDQVNXVDhZcFB5c2dMTFdSUXdxWnpkUGFxWXE4ZTZkX2ZFaDVGakNsZUtPOHhLOTVLRUtYSjFKYWQ5alBLNy0wam9uVVE2eWdrQ1Q1bEpJSXlGSjdjRkJXelJSaFFxUV8tY1AwekxMbEcydUxuNmFfY3ZVV1dpc0pQYVJwcjhFR2RtQ1I4eTRjNDl6dnBGQ0locHpsa1BKa0U?oc=5",
    "date": "2024-02-28T08:00:00.000Z",
    "dateFormatted": "28/02/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Warns Five More Online Retailers for Selling Unauthorized E-Cigarettes Popular with Youth  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a4a889744f2f75d1b426f335e435491a",
    "title": "How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues - PharmaVoice",
    "link": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNTU4tTnYtcjJSWHBpaVJIYzVVUjNYNTJxQmhXNjlYSkNOTjZKQkp0Z1ZweGJIN3pFaFJyT0I5bW85N2UxY0d4LVkyNnNtR05DSEhaMXYzd2RUUkFMcmhsOURtS3JYQWIwWG5kUFdzM21tUjRheW9OTWtLU3R6UmVoQlFuSUp5NVU?oc=5",
    "date": "2024-02-26T08:00:00.000Z",
    "dateFormatted": "26/02/2024",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues  PharmaVoice",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "de60723597df17b3923157bdcf747891",
    "title": "Fabrazyme litigation back in play for Sanofi's Genzyme as appeals court overturns dismissal of 2020 lawsuit - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQUWwyYWFRcjBhTkdLOWhIOXlqQTl0WFBCR3daNjBRNzJPQmNfckFuTW0yZjdvbllpcXNEVnJhamExdkV4czRlQXlNNlI3cUdSSnV6TzBoQzNUSjNic09WTkk4eUhJR0FhVVU2QlJ5Mnk2Z1Z0aWJTNnJTeGhnMEtwOTJqZ2xYRzlqVWI0S010XzRTY19hUXlzbHgxRnN6STdfTFlEb2ZfOWhjLXduSjZENzFBdHFYNUp5djBuazd4VkNMRG1OTG5B?oc=5",
    "date": "2024-02-20T08:00:00.000Z",
    "dateFormatted": "20/02/2024",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Fabrazyme litigation back in play for Sanofi's Genzyme as appeals court overturns dismissal of 2020 lawsuit  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ade43425fbb220bf26ab96a7f40025f8",
    "title": "Nantong Furuida Packaging Products Co., Ltd. - 667984 - 11/17/2023 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQOFhwQXhEMHRlOHdweXBqeXdUSDJzY182UDk4S09seXpHNDJ6NkZ1VGlmcDdQbFNicEprNWVRV0cyMThja01HQmI2bHFadXI2OE55TUxYYl9aQWFlcUpFeXFTS3NWUHN2Qi1nUDJreE42Vm5TOVJLSXp6bC1oX3ZteXNiNy1kTlBReE0xOE5xVXVmdlIzeFRJeDlya2JlMWU0TlFGenJ0NDdhekU2RENnOGJMaGh6bzdFNnQxOGdPMHJCcEdmaVlSVUtfWTRTdGY3MXZjTVphbEt5X0h5eks0THUwV0NCLXZ3TUh6Yw?oc=5",
    "date": "2024-02-06T08:00:00.000Z",
    "dateFormatted": "06/02/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Nantong Furuida Packaging Products Co., Ltd. - 667984 - 11/17/2023  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "5dd0fb4603bb26bae395e238083d6239",
    "title": "FDA Warns Online Retailers for Selling Unauthorized Disposable E-Cigarette Brands Popular Among Youth - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNYXBCaVd6Z0FtX3lXOXBYNm43aUZTSFRqUGpZM19JUlNpekk0UlgwcGI0aWJmcUZnVlFUQmppd0c5QzNqejQxUmd5Z213VmV4dnNid3hEUEJ2MmJYV25qN2tscGFvUWhfMlZlbTRrSE1LMTFraHByODNWQ2ZuUEtIQm5yNzZLNWUtcl9Uall6Mlk3VG9udDZUUXZHMGRDUG9lelhHOFFTVWRKUHh5WmNxdXhramFYbzVfM3VVQ3BsdVBKV1FjVjN1Z1M2RnVtMVJSb1lXcUpYc3FLZjFRdzdhUw?oc=5",
    "date": "2024-02-01T08:00:00.000Z",
    "dateFormatted": "01/02/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "FDA Warns Online Retailers for Selling Unauthorized Disposable E-Cigarette Brands Popular Among Youth  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "edd70f8a80c4e6aa6cd8ec43e030ccbd",
    "title": "Philips' US sales of sleep apnea devices face years-long halt after FDA deal - Reuters",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQT0pUakJLQXNLeXNaNXd2QUwtd01nRDFMWVI0c0VBNjNXYzhRQWVUVWM5UEtZaW5KLW8zdTlnOWN0ajFjNzN3Q25MeEw5TERLa05feV9CMlRZcnZsaWtfZmd3VW5rTTZzVHFsdFpJNHRnU2JEc2dGRkJHZkdtMUtDOWFPM3FiSGFreGQtbG0xZTRJZklmalF0aVVIUzhJelZ3MUtQUU5lbkVCY1lvcFYxVkZDNERSVHZxSTdTUFNFYU9rOElOdXJsLVZPTHVTMll1WHF1T1h2VQ?oc=5",
    "date": "2024-01-29T08:00:00.000Z",
    "dateFormatted": "29/01/2024",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Philips' US sales of sleep apnea devices face years-long halt after FDA deal  Reuters",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ea6b78797a715ee60b284060192b5344",
    "title": "Sambrosa Care Inc. - 673321 - 01/24/2024 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNMnBlbkQtRkYtYk5nZi1vNkp0ZktVMU5JRF9iTC1xbUNFOUs2MXE2NjNZd05XREplYXctSUJWZzd6aFo3X29ycjFkMU9sMUxEMGxuM0g5Rk03djBWWVpPR0p3dUdadnNYNmJRb0cyVEJTcWF0RktkQm9udGM3dV8zX2piS1VHeXVPbS0yTGJPQUhxaEQ5U3pGWGI0YUg1cFpGa3ZEVWVqbnZzN3VOc3h0dHl5Z0Q1cW5ILWM4ZUhiM0k4RDN0MVhDaDFyWkM?oc=5",
    "date": "2024-01-24T08:00:00.000Z",
    "dateFormatted": "24/01/2024",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Sambrosa Care Inc. - 673321 - 01/24/2024  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e85df5ce0d825af8a6065ed7a87a3152",
    "title": "After manufacturing blunders, Pharmasol is shuttered by US court for distributing adulterated drugs - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNdThWVXh3R214Rk1MOWFLUGR5OGFuMzlHNUNlajRNN2Y1a1FFNnFBMW5mYkhnUy11cC1CdzhmOUhMR28xLVJ4V2UteU5Vc2VHMGgydDNUZmJNS0l2NVJwdW8wS0xYMTNrZklld1h4RWhmRzlWcllmeUptY3JELXh1am5PR0FBbFl4ZHpIaG5MM0JjVXp3TWUxR3oxUnRNNUIyWFNVUWctbzJXVm9VMC1vNmJjVlV2eHc?oc=5",
    "date": "2023-12-18T08:00:00.000Z",
    "dateFormatted": "18/12/2023",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "After manufacturing blunders, Pharmasol is shuttered by US court for distributing adulterated drugs  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "83e727ab18ddffd14c361c33d1c99132",
    "title": "Experts discuss red flags that can trigger legal action against drug and device makers - Regulatory Affairs Professionals Society | RAPS",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOT3FGT1dxR2w0akRBSXBIejBUOExQWXVmOTFtUVRsejNrVDM2aHZmOVlmQTdGYW5ncGFTNEtVLXB3S1VubnQxbnc4bmlwM2ZlT1hqLTdWbFljZmF5NFlwZ3pZdUlGS0hUbDBHM05UR1JNR2xpdW9VVWQ3dnVHRjdMVmpOQUZ0NEZfaUMwaXZ3YVUzVm84aXp2cUVzQWNQbHN5QnVwRWZfeE9WLS1oZ25oVw?oc=5",
    "date": "2023-12-12T08:00:00.000Z",
    "dateFormatted": "12/12/2023",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Experts discuss red flags that can trigger legal action against drug and device makers  Regulatory Affairs Professionals Society | RAPS",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "34059e495d5291dd37c099b13cadb882",
    "title": "Prestige 22, Inc. d/b/a The Vapers World - 671630 - 11/16/2023 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPR1lTS3VhQ2RpVWJxY09HMFdoTDBTNWJ1TjI0Q1p2U0JXZHhLVzBBanpNVzlBeko4NDROY2J1TzFPUjNGYTU1c2o3NVE5YUtHNEFKeE5IUm8tLWxnbWdfSVNvU1FDbjB5REhnNDRVMm5GNXRDNXJxSU91VnpaMWlQWUdkUTRMbGhRbWk4S3EzdU5PcVB3b3dRSWtVMFRfbjlrbkdWQVZac2tER28wanctMWV5RWVZNnhvdzhIYW54Tncxc3B4MTFxLUNpNHQ4WUlUYmZxNnlNZWxCTFNUNmNURg?oc=5",
    "date": "2023-11-16T08:00:00.000Z",
    "dateFormatted": "16/11/2023",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Prestige 22, Inc. d/b/a The Vapers World - 671630 - 11/16/2023  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ad89643acd46c1c31b57b5f20100df46",
    "title": "Nortec Quimica SA - 639894 - 10/23/2023 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNZ25JSjdSWkVWUnFNVVcyWl9laEtLTWk0MndwNWNjTzZtWWFzalJvMWoyRENNVFEwUkNiVFhReW1raHpHTE1SZ09IOG1fdk1ma3NGa1Mxa0RPbnlPQ2NNSGZfaUR1WHJjSjBidEVhWEwyRnFCWHlHckpQWTRuc1RjeUNhalFpQ2xmTktOQ2xrMEtnRGY5SGRydjR5M3NoZVUwdkJ4SXVka1piOXB0NXJJLVFUdVN6NldVZzlnYXl1N2hmbWtuYVRoYm00RDE?oc=5",
    "date": "2023-10-30T07:00:00.000Z",
    "dateFormatted": "30/10/2023",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Nortec Quimica SA - 639894 - 10/23/2023  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "fe106ca1e3e6c530b5920b6866315ec5",
    "title": "Rochester Smoke Shop Inc - 664800 - 10/05/2023 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOdlh2MmJPMEZSTWVwMzcxakFDWDNaYk1PUkhpNEVZU0xLUkZ4bWlBVGozVlVOaVBzVzcyM3lvXzBWZTNuaDVpa1NURkJlVXFqUERCRVhtRzdCV28yQWRubVRNeThhMm5NVEVsU1NmWVN0cnAwZmphUVAtYlBHVi1OaG5qSF9BRS1YWFZzWVJCT1RMaDMtQXlXVUlSY0dTN3NmNTREeXNNXzM4RTV0NzB6cWsxdmxoMGRZWVFmeFFrXzVZeDB0OE9XV1V0MWE1MzI5dFkwSFVB?oc=5",
    "date": "2023-10-05T07:00:00.000Z",
    "dateFormatted": "05/10/2023",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Rochester Smoke Shop Inc - 664800 - 10/05/2023  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "f8ac52c4374cf11e12cb6fe1fdc69fa7",
    "title": "The Brief Summary October 2023 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5ZVGViOVNKY2tUNS1SdVRpWGNKcnZTdThaUGd6YkZCTjhNbmNyVUdMdDlUc3psbFh3amo0MUpzUy14RVFpSHJLWEpzeHN6cHpVVTI0?oc=5",
    "date": "2023-10-04T14:03:13.000Z",
    "dateFormatted": "04/10/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "The Brief Summary October 2023  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "72fdbf85b3b3927096060c005c3fad2a",
    "title": "K.C. Pharmaceuticals Inc. - 654986 - 08/03/2023 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNbU10cEZaN291X2FkbFBiR1Y1LUVqR19RNzM4am9ncE5KZ0RzNTBlQVFnZDNSYlQtUTZPaGlxVGNZazBvcVd1c3cxemtvcXUyaS1ocUViekRldVpaYzFkSl92cWpCMVFQZ1pLc1EyVlI0eW9kRnFwS2NodGRxLTNaWVhXMTJ3UVhZNGpyZmJxdDNHSzM0a2lxOG45d29nSmxucGVTS01fRmphZ1hDUDlfNDZBN0VXa3doakNCaWhXeHVwMWtTN1pIM19GX1R6cTZPOElN?oc=5",
    "date": "2023-08-29T07:00:00.000Z",
    "dateFormatted": "29/08/2023",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "K.C. Pharmaceuticals Inc. - 654986 - 08/03/2023  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "0b90f62f06bc43ae955bbf8e7ffc5f2b",
    "title": "Educational Case Studies - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOdmN6MGxjQjhzUUNjOFV3bW15d3JxelBfMnY0NXdhMGNrOVhjVjFlV2hHb0F0c3FkUnVrTmN1X1NmdXZTQUotNzF2cDNrZlpwZ1hlQTQ5ZjhtVnlFZXRmQTFnWXY1SWtxek94dWdqZlAtU3BLNUY2Tk5xNTFoMmZGUzRkaEgyY1pZRjZrOHhB?oc=5",
    "date": "2023-08-22T07:00:00.000Z",
    "dateFormatted": "22/08/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Educational Case Studies  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "60743b0889fc77e5a088f760eae0c2cd",
    "title": "AstraZeneca Pharmaceuticals LP - 664789 - 08/04/2023 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxNR3VHTmJPcU9kVjM1RHJ2TFlfcGRRN294VkRRb01hdlIxYlg5QW4yOTNWWTcyZC1WeUNmT09HNHdVYzFZbnI0T2V2OVpZcHp2d0ctZTBKTWtaUkpPU1JZQ0VlV08xbUtHRi1MRG5ud1p6VjM0YkxGTkZndXJwMFN6anNuYndpMG9ldi1yM2lPN0tDcjVXZ2VJaExxV2U2dE5fTjNINFRvMnotT21LdUtzclhKM1oyWEx6UlhoMUx1cjRsdkVCRDdPUE1FaHRGWF9ScEk1OUZlOWZJdEpwaEE?oc=5",
    "date": "2023-08-15T07:00:00.000Z",
    "dateFormatted": "15/08/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "AstraZeneca Pharmaceuticals LP - 664789 - 08/04/2023  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "32ee5cae7a849745e350a9383bcedf02",
    "title": "University Fertility Laboratory, Inc. - 577584 - 08/03/2023 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNMFFrb19CaEhpdFNEVDZFYm9LaEdLTEFya1VkS1hrblBZZzhwMDN3NHNvYWhIZC1PQlVKM05nTVdsVEZPam9hbG1XVWwtVVpTdlF2VFcxWHJKNmtWZlVnTi1QM0dRYWxfUEk3bEtlZndMWkN4ZHZubkl6VndRbE84V3NwNFdEZ21obk53bjBxWkVhd1YyNXdSSFNHYzZ5cndVYmNhYXhab2dqWnBXYUU2Zkp4REpvNUdiYm80YXRGOF8zdUZ5OGNuOHNwbDZhZl9haEFTR2hCd2h4VzR4YXV1Z3FoOGc?oc=5",
    "date": "2023-08-03T07:00:00.000Z",
    "dateFormatted": "03/08/2023",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "University Fertility Laboratory, Inc. - 577584 - 08/03/2023  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "4c9a860d8579d183ce7564ea7c4fd0eb",
    "title": "CytoDyn, Inc. - 626957 - 04/27/2023 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQM0VlQ3gxZ3RQZDlZSDVDeDhKSFoxX19JZlhmMkVvaDNVRUVRQ28tOFYxcjRlSWh4TmROTHI0bDZCTXY2cDhpYUZSQnk5Um4yMERvU1d4OFFxV3d2Mi1iakVULTdGU216V0d3TjVrZ0NLYWlNTE1BU2QxbVN0UTdlQ3c1SWRvaFM1aGJIZ29IVk93N2F2bjkweWttd3hUSjBuLTN6aTUwekVoME55NkNlUmlJTi0zdU43U054MFVMZzF1eHM5?oc=5",
    "date": "2023-07-25T07:00:00.000Z",
    "dateFormatted": "25/07/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "CytoDyn, Inc. - 626957 - 04/27/2023  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "1f3ff159a67617163fe016bce1f8d9a2",
    "title": "FDA slams Intas, Ipca over manufacturing shortfalls at 3 Indian plants - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOVFI4bko4OHpNX3l4LUxaczdsWmUtMmdEVkpuNUQyNzNaT3gxa3FNWWdTLTFESEl4eVNKWXZOaHMzSUlXNUVMVkpFQWZad3ptT2s2YnVNTmhCcW1Oamt1Y3VGbGpwS3R1dEZQZEtGTk4xWUxqMVZMOHRhc09hai1fV2hLeVpuX3h1SGZ3b0FYN1lzcGtJNGJr?oc=5",
    "date": "2023-07-07T07:00:00.000Z",
    "dateFormatted": "07/07/2023",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA slams Intas, Ipca over manufacturing shortfalls at 3 Indian plants  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "266ba5a1c4073be351a528a0fa56187e",
    "title": "FDA orders Sun to hire manufacturing consultant for troubled plant as export pause persists - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQUWR3SHF6aDhNSTk0TFhUUTJaYzRMZm84QlZwd0ZOZGVoWkpoUlpMRFFHdU1qRlgwNnJsUFZKZXg3T19WanNaZFdpZnByTDRzdjRQZFZTS0RrOHB0QVNRUGhOQzgwSlNkdlVVTk1pS3psMEVvekhXekN5Yk1GRXpaNjQ4NHdsaWtlOFkxUVVhR1p1SU5VMGR6TzZ5dG9sQjg3RTJtUmF0OEo4Z3B4b0NTZjd6dw?oc=5",
    "date": "2023-05-16T07:00:00.000Z",
    "dateFormatted": "16/05/2023",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA orders Sun to hire manufacturing consultant for troubled plant as export pause persists  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "b5631cb033df68a2e884831973da05a7",
    "title": "Nalpropion Pharmaceuticals LLC - 610942 - 05/10/2023 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPd0Fxczc5V1NDLXdIWEdfcjJPeVREeWNieFVwV09ub25jLWRLOGJ0TGlpckRuQmh1X0lnS0tIaU1TNHNBaEV3Tk1uR0tlZUlyS3E2ZXdhQjBnUDJQejg1a0RhRjk0b2J2d3lCaHBSdG5qclVDMTdYZmNsbW82eFg3RFlFSHQ5R215ZWVwMm5QS2tnbzktcjBna3VERVV6Q01veXBqVDBoSXNFT2RnV2FPWWszdEE5VlJaOUlVaXBxSW9kcFY4bEZYdzl3REhCeGlpM1V6VHN2eWlDZTRtOVE?oc=5",
    "date": "2023-05-10T07:00:00.000Z",
    "dateFormatted": "10/05/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Nalpropion Pharmaceuticals LLC - 610942 - 05/10/2023  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "46ccc76e6f693cc79aa3d9f634d0b6e6",
    "title": "What FDA mandate? Sun Pharma halts shipments from a plant with a troubled history - statnews.com",
    "link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNS3AyYU9KLUZqTHRuaWN2ZC16VlFiQjc1QWY5MDNoZnJxRkYwSWFrTHpEOXRJLTF6WHdaNngtM0JkU3UyZ0djaWJRTzRXVlVDU1NNd1FxdjJyN0YxV2ZNRjdmTmJaV1E3N2xBV3JjTmhuX0pTbWdNOGdZeDVDSVp5YjlkT0RDZTFSbmRuSjhKWWI?oc=5",
    "date": "2023-05-09T07:00:00.000Z",
    "dateFormatted": "09/05/2023",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "What FDA mandate? Sun Pharma halts shipments from a plant with a troubled history  statnews.com",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "78e0644ac9bbbc03bc7d9a0ae9f450e1",
    "title": "Manufacturing operations for Eli Lilly, Rentschler reprimanded by FDA - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNY2JDQ1pBWXJNeXpLZnhPLUpTYnZGYnZudUdDRF9KblE2LUJuVXZKdUF5dG55THVwU1hTdW5vajY4ei1Uc1FBVk5pXy0xRWM2LUpzWmFCVmRpWFZoeTg1S1lueE4wa3VrbzVfWXJoT2xmc1dMOW4xNmRzMEFWRHRsUkdMZFpGZnRKOU0tQTZGOEFkTk52MEFkVWhvZjNHMjA2Z1FOTTY3YWQ4ME5Rc3E1ZU5vVmk5MGxTeGMzc09B?oc=5",
    "date": "2023-05-04T07:00:00.000Z",
    "dateFormatted": "04/05/2023",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "Manufacturing operations for Eli Lilly, Rentschler reprimanded by FDA  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e0c3d3a15308a64c497d61baebd8ca58",
    "title": "Advisory Action Letters - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMijAFBVV95cUxOUE9Rc1VJUE9idVgyS0lIamdFZ2NfdkVMLXphaVRHTUsxNWlwWGktZnFWYnlXOFdoWC1rc0N6SUx0N01ZZnBPN3JQd24zRU5uSkpfSXJIeENBSFBDSzdGcEo4N0NfTXFCQzBQbnRSRFlESlJIanVrWlk0OVVGb1NDb0doazB3bmdCMU90Wg?oc=5",
    "date": "2023-05-01T07:00:00.000Z",
    "dateFormatted": "01/05/2023",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Advisory Action Letters  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6e67a7022d43cc7bf27115ae28f60b24",
    "title": "Sun Pharma pauses US drug exports from India plant after FDA scolding - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxNbHltb3ljeE1IaURpTVNNSWdCSV9xeGxBMmwxTTg0Mk1Hc0Zja3k4RG1RS25Gemlzd2cyU09TbXpPLVpKa3QtV1dodnBIZDRoMlNlMVhSNVhnMDRXWlJla083MTN3eEZaZXREdU1LX3NfTy1yRUotQ2lveTRZVU1Dd3pUYVpxS18xYUQ4MWpmSGx0S1NVTWp6dDk2bERNQQ?oc=5",
    "date": "2023-04-27T07:00:00.000Z",
    "dateFormatted": "27/04/2023",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Sun Pharma pauses US drug exports from India plant after FDA scolding  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "2beae94b3fc0bdab07a18895a52d1fa5",
    "title": "Sun Pharma shares fall after USFDA halts shipments to the US from Mohali facility - CNBC TV18",
    "link": "https://news.google.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?oc=5",
    "date": "2023-04-24T07:00:00.000Z",
    "dateFormatted": "24/04/2023",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Sun Pharma shares fall after USFDA halts shipments to the US from Mohali facility  CNBC TV18",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "c8ac16bb8460f650219b7852d2fc400b",
    "title": "Sun Pharma temporarily halts shipments from Mohali facility to implement US FDA-mandated measures - Business Today",
    "link": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNTDBEeEg2SkZoY1RISHlTSmNfRFdZbW8yWmJLQm1LYU5PN2NRM2pkeC1PSExQaFFfSk9SXzc4OWFJZXAtQWdBNEVzd3VVR0o1djdLT0FsVjZFWXNTOVVGX21MLWxVai0teGhhOWZUYjBxdklPZHRRYjQwTlM2S1ZQRzR6V3B3QkdIRktFcDFXYzV1VzRWaGNVVGdRMUkxaHFvczhoNWhPTG9qallOQ0RkSDhoN1phdDh4VzI1WnA3Rm9FcGUyV0pqbktXcmlBYUJYSG8yejZKOWtzN2JXaGJqQ1dBV1hod1lXNTI2ajZsaEZnb2prVmRVZWln0gH_AUFVX3lxTFBkTFQyVk9mOHFjS0V0cnZ2NTRfSDdJZkFjeUR0Z0NzZ2JiaUJvYmsxUDUxZGk2YzVYVnhXOUxUeG04TUR4MHc2VWphdjd1aE9DcURLY2FtTkNMWDd4b0NpcU5uZ1Nzc3VKNWZHUy1DSVhpNXhOZU9ISE5oN1FEeUJGX0RVNWhfTFpKVjE1eTRKVVl3a1dMSFJOTWhkdTlxTkxJV3VWVGJTbUxVSm9sbWZpQjFRaXMxaEg5S0N4Vi02ZzI0MHYzX3VnYmlFMWh3Vmh2VGNWcVQxWGtLaHYyblZldm1zT3dtU3VqNTBlcUczeE5OM0dVOG93Szlmak5KNA?oc=5",
    "date": "2023-04-23T07:00:00.000Z",
    "dateFormatted": "23/04/2023",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Sun Pharma temporarily halts shipments from Mohali facility to implement US FDA-mandated measures  Business Today",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "4b5516990b8f923997d61d91ca457a5d",
    "title": "U.S. FDA to restrict unlawful import of veterinary tranquilizer Xylazine - Reuters",
    "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQSFlGUVFsNXkxOEF5NXJCRFpoakhpUERRVm9UREhlTlY5SUU2T2R1QzF0T1ZVbFB5QnVRVWw5dWxYM3hNdjNCckJYYTE0ajJVR2EydmdQUEJxRXBpbEhWRUVxN2F4OWJXRmNCLS1NWkdQTUtLTmpabmVlQ0NSejctT2NXY1lfblM0M3g5Y3RKQ3diWEowbHNFNnZVUHdkRlR4SXJZZE5SdnBnNktrbklCSjlXMkpoZ3NrX0EyWlpRODIzblphLUo3ZXE1U0dqREtIV0E?oc=5",
    "date": "2023-02-28T08:00:00.000Z",
    "dateFormatted": "28/02/2023",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "U.S. FDA to restrict unlawful import of veterinary tranquilizer Xylazine  Reuters",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "c57d2c90967be9fb9b762b44edfef696",
    "title": "Sun Pharma gets U.S. FDA warning for Halol facility; share falls 2% - Fortune India",
    "link": "https://news.google.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?oc=5",
    "date": "2022-12-19T08:00:00.000Z",
    "dateFormatted": "19/12/2022",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Sun Pharma gets U.S. FDA warning for Halol facility; share falls 2%  Fortune India",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "b9ba93a0639aeb2f9c9ed34f560eb911",
    "title": "What to Expect after an Inspection: 483s, Responses and Beyond - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQNmVkRWdET0F2Wm56eGFiMWY3bFpKV2VFM0YxQ05hS3luQ2lfcFdwUFlfdXc0QktYSmtpSFRwUE5rTjdJbndSOXdmMjFVS1NjcU9ndVZ3M0t5OXVZYnpGS1NCWC1RbjFQZHRrY05fMDk4X3ppRWRMQ09nUXJFd2VyU3NsSDRxUXdZdktFeThpM0F4ZVgzZUpnNmpOSEI4QTl6enNQZExKM1NCbFdZNHBWakh2WQ?oc=5",
    "date": "2022-12-14T08:00:00.000Z",
    "dateFormatted": "14/12/2022",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "What to Expect after an Inspection: 483s, Responses and Beyond  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "4995a7da4551b574f8ae39d222d54957",
    "title": "Sun Pharma gets FDA import warning for India plant, shares drop - Reuters",
    "link": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPZVl2RkZpYVNKUU40NEFxMnZzMTNXUklENzhyLVBNckx3UGc3SERlMmNybTB0bThrX2pmQWgzS3FVY2J2aGVPWjdhUjU0QVRTVWtsUU1paWFNNklSNGx6TnRrQnQ0aS1PZkNwNkpadVFkU1RSTmxYV2FuYmNqSmhHaUV1NmM1Y0RyNm0xV0g5UFdlVkM3RFo1WHVsOXNFTHFCaENEd1hCd21nRWdhS2NqeGptWkh2NmxPdjFaVk1XYmd0VmJlSFpYXzdQd2I2VDdYazBMWDhn?oc=5",
    "date": "2022-12-08T08:00:00.000Z",
    "dateFormatted": "08/12/2022",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Sun Pharma gets FDA import warning for India plant, shares drop  Reuters",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "141a26a6845a7cce474b6b426fa69441",
    "title": "Zydus Lifesciences Limited - 584856 - 11/03/2022 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNQ3c5RG5lODlLX2s0QTdvY0RpTW95N0h3eDVRQklKbU9nRDVEUG9EX0tvQjNzemI5QWFOemFJTVhvUEVMMExWNnhZVmNUN2NjMlZac0JFeklnOVpVUTVNYzJKeGpLNWJtZTl5QkFWMC1JbWM2WUhCaGJTbFlfSV81YkhyT08xc19YVlNUTnpyc3YtRWhSaG1tYjNpWHpJT1lEMTBFRUU1cVliZl9ZbzI5V3diRmI2WkJLOVF1RGN4bVdvR2VRWXFhRk5WZGZCYlg0MWh6dWJha0E?oc=5",
    "date": "2022-11-28T08:00:00.000Z",
    "dateFormatted": "28/11/2022",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Zydus Lifesciences Limited - 584856 - 11/03/2022  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "b3ca7383e92799a2a00afcd6c166fbd7",
    "title": "CooperSurgical, Inc. - 613339 - 01/19/2022 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPM1ZsaEZ5dWVTTk03QmJjZzExeEJqTGdzTnVERTFqUjJ4YUhVaW9Ya3QzWk5pcGdlaW1DTE1pV2RqTVdPTWtKSGVWamxTR01sd3hPc0JQSTdNdjFoOEhyOWFCSkJFSVpPcF9SNmgyanBIZXBTaVVTTXlfMlV5TFphd2NubnNkeW9WYnRsdmwxVnFkSDhXdk41bWJqOGM3MWhnZTE4LUtMQ2loOVprbF9sd3VHUGdpNVlUWU5jUUw1MXZYMXh1TFhPMTBNbnpNQQ?oc=5",
    "date": "2022-06-22T07:00:00.000Z",
    "dateFormatted": "22/06/2022",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "CooperSurgical, Inc. - 613339 - 01/19/2022  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "95ca7d2f09127ecd7dd9418f24de9fdc",
    "title": "AcelRx Pharmaceuticals, Inc. - 613257 - 03/28/2022 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNWDJNTDh4Vm12SF9ENUFJTDFCenhPbHMzRWs1OTZUZWQzeE9RRFh2TXBxRDZkZnpkUmlHRnUyeDIyd0lUNUZ0SXYwbzlnWk1WNWhvamQwRXE0WFRKd3hoanV4OXVkSnRiNTd0b3RWUTVWSU5SdEIza2dpckY1QzZMWURoQUZnUXpMU29ETG9HZDNqdGZXeFZNN0FxZUZSRkZrZzZOVkcwTnJDQXNTOUZKLXNJdmRBSWNjVG9oZVlRNmNfSEp0Q3ZMaWFfQWU1M0lfbEhERXFVakY?oc=5",
    "date": "2022-06-22T07:00:00.000Z",
    "dateFormatted": "22/06/2022",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "AcelRx Pharmaceuticals, Inc. - 613257 - 03/28/2022  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "8349a207a46d9fb95b4441cf64794cf3",
    "title": "The Brief Summary_June 2022 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5KbGJuaGxkSG9mRlRoMGZ4WUFndTljc0RmdE5HZ2ZKLVJpN3B4Nk1LVEdTYzJtaXRzbFBOS0FZZ3AyM2U5YjdWTTRpYUZOa0Q3SThn?oc=5",
    "date": "2022-06-02T07:00:00.000Z",
    "dateFormatted": "02/06/2022",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "The Brief Summary_June 2022  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "a902d60f2a6ae82a7875d1b81ea13822",
    "title": "Abbott, FDA reach agreement to reopen baby formula facility in Michigan - Reuters",
    "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPdHZTMFVMT1ZSLUtuMXhSNGRsYzVYZ3h4RlpXTy1FSjlic3ZKRzNpQk5qTEptT3loVk93dXlHQVg0Zmppd25oUF9XenNHcllzQzd4QkZTSDV1VVFPaWV6blp4VTJEMWpENmhmSVNUZTctQmY2ektENFVTbEItNl9qdzh6X3FZQTEzbEdJUUlvLXc4bmRhM19KdGhEc0VwSFVOWC1NU1NBaFJOTlA0TVA4c2NOM0pCZFZLYlRSRDdZRUJpdGxmZkMtclB0MUMzQkVGSmJ5RjFNZENMZlBY?oc=5",
    "date": "2022-05-16T07:00:00.000Z",
    "dateFormatted": "16/05/2022",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Abbott, FDA reach agreement to reopen baby formula facility in Michigan  Reuters",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "bc9e6bacf6339712cb2dedbe45e925ba",
    "title": "Sun Pharma forks over $485M to settle long-running legal battle inherited in Ranbaxy buyout - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQV2hlNlNXc2EydnNFcF83RUpTVEhUTlI4QTR5OTFlRXpTa05iUW1VSVFteXRDX0N6WjlzRTFlOUMyWWJkVVA2bWlhaUFmWmVCcUxDQS00VzlXM0tfQnhNTFN0YXB0TEVUcVZ1TGJMdWtJOURZa1E2ZkJ3R1F1alUwQnNMZ3V2VWR5ZndRUTRqV1FPdThxTldXSW9ZWnVxWHpmYUJRMUxQZUo?oc=5",
    "date": "2022-03-24T07:00:00.000Z",
    "dateFormatted": "24/03/2022",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Sun Pharma forks over $485M to settle long-running legal battle inherited in Ranbaxy buyout  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "db9fc7dfb1fcb550863dfec13d1ef187",
    "title": "The Brief Summary Newsletter - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAycE1qcVRYQlMzaUdsaXFoalNKTUo0X1RSbV8yVlpkSndBbDdaT1JvU2puRmRWMXhXSkRDVmRsWXVBUzNfUWtwMmtXR2luNDl5eTdB?oc=5",
    "date": "2022-03-08T08:00:00.000Z",
    "dateFormatted": "08/03/2022",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "The Brief Summary Newsletter  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "8325af68a9cc4ac8c69fad42b963e632",
    "title": "HACCP Principles & Application Guidelines - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQNUFEaFN2V0o5Q2pCS1RIeG5MSmJYWHpEd1E3STVhNzZKNllOdk5tb054aV9LS1NLQUstamVyQWM5bVp1N1YtdExOQjl3aEZ6WlVtbVpkVWh1R2dhR1VoYWR6bGRPdldxRHNRSTlqNWJ4WG00N1FKSU9WamUySHFhdUt1R2FXZTFTZlczUWNBU2tLbms2MjJ6UmlGa01ZVjhNSlFqRkp5OWw4d0ltU0E?oc=5",
    "date": "2022-02-25T08:00:00.000Z",
    "dateFormatted": "25/02/2022",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "HACCP Principles & Application Guidelines  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "0260c2f6c2b18b399bae1d8a388fcd39",
    "title": "CytoDyn, Inc. - 626957 - 02/11/2022 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPTzJVYzRzeWFkRVJnQ01VQlREUFVHN0tQdUphWFJ1MEZqY2J4QlhNUXBSWjRnRkpObTV5ajUteWJmNXZaYTZFM1h0YmJmelNUZnNZY1FpSjZTWklzYkJmX3c2NWFQc2JSdENaYzFsWEZmUDZscWtzdktzQk5OV3BkV1VnTVFHY0lwTElScnpRZWoxaGk1bUVPTEZBOHRQcDFPVEMtaVhxTHZyUWFMRmk3M2lIMXllSjZxUWNWTzZ1bk81RzJJ?oc=5",
    "date": "2022-02-11T08:00:00.000Z",
    "dateFormatted": "11/02/2022",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "CytoDyn, Inc. - 626957 - 02/11/2022  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "2aa197a0484d7b7560681155f69d58cb",
    "title": "NOV Letter | TRULICITY® (dulaglutide) injection, for subcutaneous use - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBQNDV5YWs4SGw1N0J4X0RLeTFxRU9rbkpGbzFUa0s3RmhsLUNXdVoxZkpXM3lBaXA2SG5xdzZsQkJmR1dDNmRlMXZSc3FCa015eDF3?oc=5",
    "date": "2022-01-19T08:00:00.000Z",
    "dateFormatted": "19/01/2022",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "NOV Letter | TRULICITY® (dulaglutide) injection, for subcutaneous use  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "935021e21c4bf415568d0711946ab0f8",
    "title": "Florida Compounding Pharmacy Punished by Federal Court - Medtruth",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNbEZNTTFfTjdIWFd2YzJTQ2JJQmtvSGE0MXBMdi0zQVlwU1Zleks5dVBqN3JIVzNYMUpVeGNIYzlDaDFDbmtUbF9EbjF0MHBCNzB2SWxQcndOWklaUEZOelZtT2M2OVpXY3BZbkszVGtzM0xlTklLeHloeXNmVFBsU3BOdThhTTdpVWxYR2lMN2M5Rmx4ZnFkZlN0cktuRnBIcFE?oc=5",
    "date": "2021-09-28T20:36:46.000Z",
    "dateFormatted": "28/09/2021",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Florida Compounding Pharmacy Punished by Federal Court  Medtruth",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d5668ecedc7a16a76fa06b1d6da7d711",
    "title": "Response to Notice of Violation (RNOV) - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFB0U1AxNzc0ZGFGeV9CSGZUbnRpT3FiM0FxWEdmNEdNNlo3YmlpT0ZZVXgteXhZNkQzU05McHdYQlRUaUR0TGRrX0lyRXBfVm5KWUk0?oc=5",
    "date": "2021-09-04T19:57:33.000Z",
    "dateFormatted": "04/09/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Response to Notice of Violation (RNOV)  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "66aa2de7bcfa6c1f723b0848cecd2a80",
    "title": "RE: NDA 213876 ALKINDI® SPRINKLE (hydrocortisone) oral granules MA 13 Dear Ms. Devarakonda: The Office of Prescription Drug P - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1QRjNVZnN6bmVrLTB1ZkE3OFpSOFZ3YUcyWWRYR1ZaVGxXVTZtVUMtMnE5alhBZl8tYllneDFYN3ZNcng3UXpHLWtqemw0bzJ6NHRN?oc=5",
    "date": "2021-08-09T07:00:00.000Z",
    "dateFormatted": "09/08/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "RE: NDA 213876 ALKINDI® SPRINKLE (hydrocortisone) oral granules MA 13 Dear Ms. Devarakonda: The Office of Prescription Drug P  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "428abd6b63f834d73381b0fc8dd029a5",
    "title": "FDA blasts Syntec Pharma after importer stored drug ingredients with antifreeze, weedkiller - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOVVA4bmJsSGs5Yk9NdjRBeVdnUnJ5cEliRERvUExNbjdUU2RRLWlraXUwakk4RFh2TV9MQVdhVXlqT21KVlJKZnVGdnZ1Uk5lY1pFeXc4Mjdhc0tsMGc3Ry1GUDVBTkJvVDJpWlpOUWpVUHZUYnJMTHRfcnE2SVZSRWd3U1dzVy1vdFpHaDlOVzFIZTBacDBnemo2U1NpTXo2MzdmNnI2WWllUzhMVmd1NG4wUlhLRkptWjl1bm1nakJlS3liT1dB?oc=5",
    "date": "2021-08-04T07:00:00.000Z",
    "dateFormatted": "04/08/2021",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA blasts Syntec Pharma after importer stored drug ingredients with antifreeze, weedkiller  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "15e1cb5e3880f4a020e79adb6776bcba",
    "title": "Neulasta Letter - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFA1LVNjUmxvNk12alZ2dndfQ3hxVUNhZ0EteENIZFZkLVJvdmhoM2NwX19YdDBjeEpZQ2pqN2d1NEVpVDAySjFhWW8tRVYyVlpKSWlz?oc=5",
    "date": "2021-07-07T07:00:00.000Z",
    "dateFormatted": "07/07/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Neulasta Letter  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "c727a434267f79397a69e6be58bc5db9",
    "title": "Avanthi, Inc. - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPRVZxYmR0SE90Q3MyUGoyUm5lcVVqay1ETGljZ0xpaVFMWlNDYklnNmc1QmNHb3EtcDJnVlRKQmpYY3VJUGd1al9ZSkZjTlg1NVgtUExNSXM3akI4Zll3WkdIWklfZF9HMG5Nc1A0dm1JTG5HNTZITGpKQURPU2xDSGNLWW9KQzZ6RGxCblQ0T3pHdWdYLVYyd2hzV0h0eURrZ3FzRDlIMXNpaTN6TzJ2Vk9maEFUYlBKSHVN?oc=5",
    "date": "2021-04-14T20:49:07.000Z",
    "dateFormatted": "14/04/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Avanthi, Inc.  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "bfdf43f53dccbf3b80f217cb8d85f5d1",
    "title": "Sprout Pharmaceuticals, Inc. - 610569 - 03/15/2021 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPZUdtNmx2cmk1WGpOT19QRHdza2d6azREd3d0c1EycTdTR2F3N0dVNDh1bVRod1BBbDl4N25aUjFTTWJpVWQtR2oxUElvSy1OU0Y1LXlEXzJPd0czME1fUVdIemwzbTN0TV9rTHQyVjhiV0g0eXlXdzBjUGx6UmVNeHRVcUFqeVM5MGw1RmNlYXdoWFlHQWlkY2Yza1RHWnB2TGE5dHdwcG12Q0pBWm5BRHpyMzVDT2xlM3AyRDhtLTk5Qm1hUDhiSWJiS3I3RnUwLW9qSUhMcE0?oc=5",
    "date": "2021-03-15T07:00:00.000Z",
    "dateFormatted": "15/03/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Sprout Pharmaceuticals, Inc. - 610569 - 03/15/2021  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "579030fdcbba367e05efccea3ea4421f",
    "title": "Marianne Frost, MA Senior Vice President, Regulatory Affairs Biohaven Pharmaceuticals 215 Church Street New Haven, CT 06510 RE: - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE54UlV4VFgtTzAwMHpMdjF6UU1iR1RXRXBNdXBnVjZ6VXhaaUliSUVVU1VkZzRtMjhSajBwM2tJbTQ1UTBwdG9wd09LNnlEcWVCczRJ?oc=5",
    "date": "2021-03-08T08:00:00.000Z",
    "dateFormatted": "08/03/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Marianne Frost, MA Senior Vice President, Regulatory Affairs Biohaven Pharmaceuticals 215 Church Street New Haven, CT 06510 RE:  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "54996e99526e8ddf7a226506ff7c8000",
    "title": "CooperSurgical, Inc. - 613339 - 02/12/2021 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPN21QdzhIQnZkVkZmTkdKb2JuUHk3UkVfZU1id0FWS2VsS3RwTmwtMU9kTE1kcFRpRXRjaGR0WXhZQ0J2RTFVX1Q0QlhvN0MwVGhkYnpiQ3QxNUFvaXAzeUR3RnR4cllqTTlRQ2JqZ2locTBKNGsxNkpRMXNsSzdBdlc0RTE3VTV5VGdrVmhBQkp6OHA1czFTb3BiUVljakdqZUwyVXJHOTAtdlZBUDNYMzdGUktjNXYyVG9VTkpXaHdtTk1QazNJTWlOeEFpUQ?oc=5",
    "date": "2021-02-23T08:00:00.000Z",
    "dateFormatted": "23/02/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "CooperSurgical, Inc. - 613339 - 02/12/2021  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6b952636d160b802301517c3fc8a85ea",
    "title": "AcelRx Pharmaceuticals, Inc. - 613257 - 02/11/2021 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNMmdwZG1WTS1HWVhPZ0ZEclJzWjBCa2J1bkpES0NVa25hSXhsaHM3b3ZnaExVN3Z2ekN1aFVTMWJoS2I5WGRNYnl6bEpGOUxLdHdib0JURUxTdXNjUzB2THIyTEIxZ2t5d1NlM0g0SGw2UDZacjcwU1E3V1pTMEF6MWZUeWtKcGpuRmFDSTVjVzhQRlZxZGItSDQ1amZRR3Jxa1RITTRtVF90dTZxRWttUVFLMXhYUDZVcFI3VTlrR3FXYTdRa3dfLTRCOVFzNnlBR0tiaEt1REU?oc=5",
    "date": "2021-02-11T08:00:00.000Z",
    "dateFormatted": "11/02/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "AcelRx Pharmaceuticals, Inc. - 613257 - 02/11/2021  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "9b3d942afd5867e20248cebff181b26e",
    "title": "OPDP's 2020 Achievements, 2021 Goals - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOVGpfbW9UV2lRRDU3ckNLY00zM093UkpYa0tVLTRZRzBWWWRnX3VFMzd6Q0FrRTZEQkJNYzZka1lJR1JySERnR3VvRVh0emR2b2wwT3lvdF9XblZyZFE5SW1tMXk3YlY1TUlBNEx6TG9jZm9nbFhiQVJtMGRpcmVHeHNuVWVMNElnd1c5ZGtxUW1nTmppeG1OMV9BU0RJWnNqclFQOWxvNDUwa0RNWW5EdjVLdE11UG14Tk10MUhfRXpfM2xVNFdoLWpNa2NZUUhIUWFSc21DWTBWS3df?oc=5",
    "date": "2021-01-27T08:00:00.000Z",
    "dateFormatted": "27/01/2021",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "OPDP's 2020 Achievements, 2021 Goals  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "b9dadb5a68f85a467f4674360b7b3d54",
    "title": "Korie Osborn Director, Regulatory Affairs Azurity Pharmaceuticals Inc. 841 Woburn Street Wilmington, MA 01887 RE: NDA 208400 X - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5sZ3BXODZQWHFVTkdSWTZBTEhvandSeUd2RGJmREs0TEJ5T2plM2hjQkdIczlMcFN4M3FoS1VLUlVNN0p6ZDM4U2tnRW9Fck1qVzJF?oc=5",
    "date": "2020-11-24T08:00:00.000Z",
    "dateFormatted": "24/11/2020",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Korie Osborn Director, Regulatory Affairs Azurity Pharmaceuticals Inc. 841 Woburn Street Wilmington, MA 01887 RE: NDA 208400 X  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d51f47cd0e36fe079838b88efe2973a5",
    "title": "Nephron SC Inc. - 610867 - 09/22/2020 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQbDZNN3ZrcVc4ZEp4b3I3bFJtSm9DN1ZYLVBycFBHYTdXbVViODRfdXY1eHg5NWFfX0pnR3FUbUxHbGNCWnQ4dW5xMVI3b0hlbV9mOGZrbUIzcnF0aWVwbGgwbWdGdzJxS2llRkF5TWQ4R1M5M1NQR1ljdDlneExmWnhMalVudXlibXlUZmdTX25fWFljeFpac3lRYkRzRTY1RWR2b1o5WEFmd0dEN2Rld3VkbVA2cHpOcUI3NEN1X1NfbHREdVpZLQ?oc=5",
    "date": "2020-09-22T07:00:00.000Z",
    "dateFormatted": "22/09/2020",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Nephron SC Inc. - 610867 - 09/22/2020  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "aeda0b28da21aeb345e7d4c52f2d1c3e",
    "title": "Nalpropion Pharmaceuticals LLC - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNSWowUHp0MVIxVDJXLWlveDJZbmNFc18xdHh2VU1vSXYyRTF4anhYWFZoT3VXdVRoMG5GTWM4Z2FTNlZvcDRsWE9pZUFvam9KcHpjMkgyX3ZORTJKekc2RjN0THppcXltNzFUQkI4Ty1TZjQxN3V4TmF3bkx5RUIwM3BLTDZuVHltRHp5VzN2ZlJIekM0cWVjR1dwc05iOE94UUQwTXhiVWQ4OTlSclAzcWd4cFEzaUxNUUJrbjU1WUZGaHVKOXg5YW05Um1lRnZ4ZGJFLQ?oc=5",
    "date": "2020-09-22T07:00:00.000Z",
    "dateFormatted": "22/09/2020",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Nalpropion Pharmaceuticals LLC  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "fc733cdf1f199ae41ec0ee40b0277db2",
    "title": "Sprout Pharmaceuticals, Inc - 610569 - 08/31/2020 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQYmE4dlVicWhyRE5PSzBhWEgweTZFZFZlQktJU1VFckZxWnFVLXhmZy1FVWp1VjVELVRmazVqQVVLU0lWSXVndkcxN1JqY1RCdThaVEx3RFFLX1U5Z3RfdVJhZlBDdXRaWVZ4Y0VhZC1XamQ2T2czLXVjQ2w1MUZhWk95SEJDYzJFTVo4akIxVmx2NC1BNEV5eS1odFRqVGFnREhKd3ltWndMVTdUdGtCdEo4VTJTeXZ5Z3lDa3NPaGJZc002c1pSS1V2VFRKV21CUU9qekVwc18?oc=5",
    "date": "2020-08-31T07:00:00.000Z",
    "dateFormatted": "31/08/2020",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Sprout Pharmaceuticals, Inc - 610569 - 08/31/2020  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "44bb198c2993cc6f4f3b77f09709737d",
    "title": "Michele Yelmene Vice President, Regulatory and Quality Assurance Xeris Pharmaceuticals, Inc. 180 N LaSalle Street, Suite 1600 Ch - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBWRWFNX0UwQ2RWSTBnRVlqU2VFdjdFbHVMZGFWbk1fREhnTEFtOFl3WjRIMG9QM3ZmcUR3RXByZy12QUtjb2psbnJRdnM0TDBVSXFv?oc=5",
    "date": "2020-08-14T07:00:00.000Z",
    "dateFormatted": "14/08/2020",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Michele Yelmene Vice President, Regulatory and Quality Assurance Xeris Pharmaceuticals, Inc. 180 N LaSalle Street, Suite 1600 Ch  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "567c0c1c7b175574f881c53f663b98ab",
    "title": "FDA blasts California compounding pharmacy for facility 'contaminated with filth' - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNa3lHRmhEcXpDdkdDakVaQmxUNUpuenZnNHZHOW1BNk1NWGMwdkpXZUJ1ZV9PNVNoRXdEZktOeUI5dmpUVGxadG9odzFPNTRtNjk3b2lJalBSVFFISFRyQ2sxNjRhanJwNkxmOUNyVXRMNVhJaF9mNlI5SWJHT0hoaDl1eE44ZHRsYm1BQUtUVmE1Q1k2NGZDQ25vMXY0dDZVc0c2a1JkRlBOQngySWp1dlRIMFV4bHpm?oc=5",
    "date": "2020-07-02T07:00:00.000Z",
    "dateFormatted": "02/07/2020",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA blasts California compounding pharmacy for facility 'contaminated with filth'  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "7c8f8a73e2f0201c03f4ad86502b121e",
    "title": "Outlook Pharmaceuticals, Inc. - 605071 - 02/21/2020 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPcFg5a2gtSDZrZEh4NDdQZGtzNjZBVVl0bjdXRERQUmVWbVBFOGtybm1WRlZKRjYyVFFERWRadVdOMHhRYTFPb2N6Vk40VllsaF9qUzUxTEFidFhiVEdsd2o0cklkaVVQeHZSTVY3bkhjTVZkYzFHYjNYSEo4Tm94Q3lhYnRxRXZoRmtIRzdFekxkUHJBU01HTkhOMU4yU1JYWWNVV212WFZiVll2akhwM1RCemFkRU5qVTQzNjRaa3VvcnlrMkI5dV9ZS0h6TXNFSmZOTWllNEhKZw?oc=5",
    "date": "2020-02-21T08:00:00.000Z",
    "dateFormatted": "21/02/2020",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Outlook Pharmaceuticals, Inc. - 605071 - 02/21/2020  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "34797a747d42bab11dbfd2483383167e",
    "title": "FDA Enforcement Trends: Reflecting on 2019 and Looking Onward to 2020 - Crowell & Moring LLP",
    "link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOUDdLMVR6SzIwaVhDZFdCR0pnSjlDOWI4NHhUQzBJZFItYWhDUnRMSVZabXgwZXU4RDl1OEYzNVA4blFnRGR3MjB4c3ZGZDQ0alk3V0NoSE9zU0xRWFJIdnpGaXJ3cWgtcFN6NVRrWEdvdmR6VHR4ZVljTTVKQ2V6NDAzQ0lIby1OZUJuTWtqYXFDZmZJR1N6MTNrZFlNUi1EZ1VudlkwcFBLSy1WWE9aWjk4NVZ6ZjFnOFRZWUF3ZXBlZlg3Unc5bFFGZTZTT2N4OXkwMXNPMGE?oc=5",
    "date": "2020-02-12T08:00:00.000Z",
    "dateFormatted": "12/02/2020",
    "source": "Google News - Form 483",
    "sourceCategory": "google",
    "sourceType": "form_483",
    "summary": "FDA Enforcement Trends: Reflecting on 2019 and Looking Onward to 2020  Crowell & Moring LLP",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "f9245111f041054b6531e93c690dff48",
    "title": "Alkermes, Inc. - 597260 - 12/02/2019 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQckllXzMxNXphOFRiMnh2bFZtQjJneVdiM3FZM0o3NV90MmVjUEhYTUtVaEUxTjlYM0xYSU5ZOUpEcldaMnphejFpSldteE5sRmFwckhacmo4aVJ3WXpjc0tIUzhXakZHMGpPQ2lqZHFRMWhYakFWb3JfM19Hd1lsSEVSVXdBRVJZa280UzB5Ri1pVVJ2UmZVSXktNVp5ZWlwNXBnZ1lqUzlsZ2xBb2hRMndVYndfazNmU21LeENKQWNYa3l4V2c?oc=5",
    "date": "2019-12-02T08:00:00.000Z",
    "dateFormatted": "02/12/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Alkermes, Inc. - 597260 - 12/02/2019  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "916eb97d1922d120237da4a7c9eab67c",
    "title": "FDA Forces Actavis To Shut Down Plants - Manufacturing.net",
    "link": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQQ21qRkRaR2hBSmh5R3NnbEs0eVFwUk1zS3B4QWlDcFExWkpFQmE3bDRuSk51WHBXQWpDNXhyVnc2VXl0cEltWmNhTFJRTWNGa0dyekVySnEyR0c5S09pNFd3VXZpYnpCR05lTGpsVHN6M3REZTRacWhkaHFHb2tJYkpaNWNhb0VwbnNZOEg3bnFka1BNUjRiZA?oc=5",
    "date": "2019-11-21T23:16:15.000Z",
    "dateFormatted": "21/11/2019",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA Forces Actavis To Shut Down Plants  Manufacturing.net",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "4d3f3e3bcf4a9d93ed7b533cd61df1f9",
    "title": "Luis Caveda Senior Director of Regulatory Affairs Rockwell Medical, Inc 30142 South Wixom Road Wixom, MI 48393 RE: NDA 206317; - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE91MzJCdldFY2NzYjZYLUlFYzdMV0pkUzJwNUlqX3U4ZUR5OEo4d1c5NUg4T3NFV2tBTTRzYjN5X1JWUV9LYXpBTE1DZHRLX3BNdjdz?oc=5",
    "date": "2019-11-18T08:00:00.000Z",
    "dateFormatted": "18/11/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Luis Caveda Senior Director of Regulatory Affairs Rockwell Medical, Inc 30142 South Wixom Road Wixom, MI 48393 RE: NDA 206317;  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "3a5038c941e798e9025dc85bce246c94",
    "title": "Bruce Merchant, MD, PhD Regulatory Contact for Nascent Biotech, Inc. M - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBQODBJVXI5Q1N5NW5nNkdJYWVPUTNxVkFWTGd5eTVscHgtUWkzcDFaOUVENU5zY3RObVExMUpZVjR3U2Nmdjg4V3VVbGZIZmNBNXVB?oc=5",
    "date": "2019-11-01T07:00:00.000Z",
    "dateFormatted": "01/11/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Bruce Merchant, MD, PhD Regulatory Contact for Nascent Biotech, Inc. M  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "f6822d68d9628e377919dd9c27bbade3",
    "title": "Kimberly Skopitz, RAC Director of Regulatory Affairs Kowa Pharmaceuticals America, Inc. 530 Industrial Blvd. Montgomery, AL 3611 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE50RjcwS0lYeGJfM1QtRmVFUWhQTi1QRmFFUFVTeGNJX1R1bFdQUDNBOWlwQkJLQmVWV2pXUk9DUHJlVzY1SzkyY2xDUmxORm45QU9J?oc=5",
    "date": "2019-09-24T07:00:00.000Z",
    "dateFormatted": "24/09/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Kimberly Skopitz, RAC Director of Regulatory Affairs Kowa Pharmaceuticals America, Inc. 530 Industrial Blvd. Montgomery, AL 3611  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "9f836979436e76cffba85d5067ceb3a9",
    "title": "Galt Pharmaceuticals LLC - 593156 - 09/13/2019 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQcUNxdFp6NFdnNEJaLXJGM3ZPOUVZbGU5a08zamFVNjRHSGhhbHp2SmtQM2t2VjJfYmgtaTRhRU1FeFJtOHRMSER0a0JCb1lxeFpJQ21sOGR1SzYyYk5qQjZ4X1VoSmQ4SXM2SVA0RzFxaTNHel9VV2VBeWhKQVBuajZ6UXRIX0luaEEyb095cHRzSlU1SGJVVHVOcWhGT1A1dnFaN1ZQazFwQ1RpMTFzQkl4WEFTWktjRUlQLUlCWUhRLU83bGJoeGs1RjJxNUJXeWlKNm1R?oc=5",
    "date": "2019-09-13T07:00:00.000Z",
    "dateFormatted": "13/09/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Galt Pharmaceuticals LLC - 593156 - 09/13/2019  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "8c75d5b232cc12384a4803e8225a5e30",
    "title": "OPDP eCTD - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQSEZhNTBCVzVwa2R3Q1V3RnplZ0s2X19XTjNlUGZ5cGRBbHJmNC1tSVV3eHpsb25UUFB2T19qa0dQYzcyQWZsTVVIOG41Z0RiVDZ5RnpVODJ0R3B0cEdVZ2ZIWmRYeGRhTTNjT1IzbE5kMS1SeWpzQjVPUzhJcVNQUDNZUERIUDg?oc=5",
    "date": "2019-09-09T21:40:32.000Z",
    "dateFormatted": "09/09/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "OPDP eCTD  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6d14b0505018e7a746a572b6995bb5fb",
    "title": "Metuchen Pharmaceuticals, LLC. - 590713 - 08/16/2019 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOSzVIeEhKSk1xMHNLbVBsdTJyb0NiUmJlNUMzOXhSVXpwUGdHRUFBMmNENXpEN2NzMlRoV0d0RmtLTkdBZ2cwSFdOeWJwUTFoSGg5ckgtMlg2R1NsdFY0UUcyc3Q3NDlTR2lUNnBfZ1hBa2xmR2RkQWpyUFQ1N0ZKUTN2VDZlYTNNSGVNelBDUnVMdm1uZElqWDlzcGJaMXRPS2w2dDVlSFlKS0EzTl9JcnVTVVhHQzVNanJLVWlJVTc2dHBmZHA0OUUwOVloX0dvSkZCRDlhVjltVmM?oc=5",
    "date": "2019-08-16T07:00:00.000Z",
    "dateFormatted": "16/08/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Metuchen Pharmaceuticals, LLC. - 590713 - 08/16/2019  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d397fb476b30a44c26ec42004fb43f10",
    "title": "Kyle Hooper Regulatory Affairs Associate CooperSurgical, Inc. 75 Corporate Drive Trumbull, CT 06611 RE: NDA 018680 ParaGard® - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9TSGJ0V1EzVXA5UGlpZ19Gdko2NlFSemNhNXo4Q1oyTGNJaUFNb3dVNjFsZDJRZWxkTEFvNnRSV3M2N1V4bUhURG1qUnJhbmljNjlJ?oc=5",
    "date": "2019-07-25T07:00:00.000Z",
    "dateFormatted": "25/07/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Kyle Hooper Regulatory Affairs Associate CooperSurgical, Inc. 75 Corporate Drive Trumbull, CT 06611 RE: NDA 018680 ParaGard®  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "6563d99b1d5af55d0b4e992c4466dd0b",
    "title": "Direct-to-Consumer Television Advertisements -- FDAAA DTC Television Ad Pre-Dissemination Review Program - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE55aHlNRTZfcVA4S0dMTmxNMjZVNW1CSnpzdHZsRmIxcFhMNVo2dXZsNlBmQzM3R1FJMFloYXA0LUZTQWRTalVkVElIWjhSMm1jU2c?oc=5",
    "date": "2019-06-15T18:48:25.000Z",
    "dateFormatted": "15/06/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Direct-to-Consumer Television Advertisements -- FDAAA DTC Television Ad Pre-Dissemination Review Program  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "3c3ba8896f78508f07b470c96ef0e99f",
    "title": "Colleen Matkowski Senior Director, Regulatory Affairs Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne, PA 19087 RE: ND - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9GNUI1NFRRS3dGWllTa1NRZmoza0g5V2xCWUJzMy1LSkxJNUoxemdnVlVRd3dubWFCdkM1bnhFU3pfd0h2SXF2Rm5XaktFUTlmZmRF?oc=5",
    "date": "2019-06-14T07:00:00.000Z",
    "dateFormatted": "14/06/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Colleen Matkowski Senior Director, Regulatory Affairs Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne, PA 19087 RE: ND  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "92553e0898a26bdcf490827d11476b32",
    "title": "Santosh T. Varghese, M.D. Chief Medical Officer VIVUS, Inc. 900 East Hamilton Avenue, Suite 550 Campbell, CA 95008 RE: NDA 022 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1VbjB3LW1zUEVBMjdqN1FqVzRPMDlvU1FjYzA5RTA2SDNxTEJrOTVsOEZDMEhpWU44MTBiOTR1MnE1V3pPYjgxZFhCY296TTdlemZJ?oc=5",
    "date": "2019-05-22T07:00:00.000Z",
    "dateFormatted": "22/05/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Santosh T. Varghese, M.D. Chief Medical Officer VIVUS, Inc. 900 East Hamilton Avenue, Suite 550 Campbell, CA 95008 RE: NDA 022  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "b7319f3e6fe340ac166f88e42ddf789f",
    "title": "Vanda Pharmaceuticals - 576442 - 11/21/2018 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQVktiQzBibzZJSjFxRUY2YWt6b1FMc2RONEFySUhoa3pRY21PSG5ZbWpPRlBYenhCdGFpZ295NW9LVHJRWnFjUWlWZjFLWDRmWTZ4enZ6eG1OREZDdTFlVkdwSWRmVDhONWRrM1VzX1RPMDhrRmFsNzJvUU9wbDhYNDdNZ3R3Mm9oMWgzb1VwaTVZdjhlRG9LZk9KejlBUENGSTZQU0VvUmczTU91bVNzeXdGZEYyWGt1b2l5STVSTTlaQ2NodWtDS1ZXbGNfdHNnUEE?oc=5",
    "date": "2019-05-02T07:00:00.000Z",
    "dateFormatted": "02/05/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Vanda Pharmaceuticals - 576442 - 11/21/2018  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "22e905df2d85c0027d4f94d4c04920af",
    "title": "A resource for stakeholders that contain correspondence issued by CDRH - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNRENfajFwcURvSVlOcEQ0YXp6YWVFYktaX3NXWk5TR250RjUxWGZld3hhcGVvWE9WSUZRbzMyYWI2SmxOeFZ4cGgzSzF2Q2xQblpMaGkxWE5jMDZMZ1RtdDdNQ01UODZxU1lrYWNuVVVIc3ZkYTBfYkJ6YjJ3Q3ZTVjF5WQ?oc=5",
    "date": "2019-04-28T22:02:34.000Z",
    "dateFormatted": "28/04/2019",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "A resource for stakeholders that contain correspondence issued by CDRH  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "4d0d0ac8526112cdc817005d2c7f8a26",
    "title": "Search for FDA Guidance Documents - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMifEFVX3lxTE15cGhNT2hoLXZYaElyMHpEc1hwYzlDT1pvRl9JRm1wQkNWdU9leXk4a3gwRHZyNV8yeFVKTDdyeXRsQWswdE5aY28wN19uRmt1eTdJQW0xYkppQjl0OG9TRnBtTHVuR2U3aXlyczlXNXZ6a1FKVEZxeXpiSU4?oc=5",
    "date": "2019-04-27T01:55:06.000Z",
    "dateFormatted": "27/04/2019",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "Search for FDA Guidance Documents  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "642a5ff1b7aab9f2a43fcf1d88cb2237",
    "title": "Vanda Pharmaceuticals - 576442 - 10/22/2018 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOU1pKMzhnN0NTcnBuYVRRQy01LU9GTmFJQ3cyN2REQW5aT2RBUmlNZTdIc3R6NkZmT0JNMUdLM2UxQm5mVU4tMmxDOGpOa0xsNzZMb0ROZjFoelRzUDUzWmphRjZfWVdYRGk3ZWMyLTZuVWtjWUcyMlYxREdXcmZFWTVaVWhlRU1LaW1IdGhtY1IyQUptcjVNVkRyOC11RTBNaFN0SXhlNlNZWmg5d25LT09DV2s1aGxOMmFsSDJMTnVjZEhfQW5OT0JTT1c3b09HSFE?oc=5",
    "date": "2018-10-22T07:00:00.000Z",
    "dateFormatted": "22/10/2018",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Vanda Pharmaceuticals - 576442 - 10/22/2018  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ca7bee4679f957064ccead1195158061",
    "title": "Nada Glavan Senior Director, Regulatory Eisai Inc. 100 Tice Boulevard Woodcliff Lake, NJ 07677 RE: NDA 202834; 208277 Fycompa - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBjMFkzZnRkNlBQWlFlZ1dyQ1BOTFNJR2xXMFI1RktJV0M0UEF5YjFVeU8tclcxTGRhdjktRFV3STJKNDNHNkU1OGZROVhQWEF5ZFJz?oc=5",
    "date": "2018-10-11T07:00:00.000Z",
    "dateFormatted": "11/10/2018",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Nada Glavan Senior Director, Regulatory Eisai Inc. 100 Tice Boulevard Woodcliff Lake, NJ 07677 RE: NDA 202834; 208277 Fycompa  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e68f7a8058b05f43d3e555737e68ba80",
    "title": "Actually, it's just one site: FDA corrects previous word on embattled valsartan maker's ban - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQTXZJdHBoZ3BwYW5lU0xiU0xCU1hEQWN2MmNqdHVoMmdUWTBwUl9xUU1zQXBOSjAyaXo3TDFnZ2FHbjU4Z2drRXNPRm5rakJlUEVTMVNSUndQazRhTmFNUGhtZF9jdFBoU2VDUW42OUdIdldwV1hyN0NWckZpcmZucEhlMWlUelk0bktSdkdpaHhqcHVHQXd4SzB1UkhrSlVoQ2ExQ1VzM1JPLTlDb19JNThIbVByN2doQjB4Sw?oc=5",
    "date": "2018-10-11T07:00:00.000Z",
    "dateFormatted": "11/10/2018",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Actually, it's just one site: FDA corrects previous word on embattled valsartan maker's ban  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "080d9fc5a6d4075a096e0fe8a899449a",
    "title": "MannKind Corporation - 578282 - 10/05/2018 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPSnBtVno5bzAtTnE1MXNXQ3Zic1RsbmU5aW9ZZ29ISnBVSG1BWVZrVWdWMVJ5OC1MQkZyRzlSdzA3YTU1c0ZvcGZMUFM4Z3FHaThWdXVmRWNRcXhfUHVhN2lIb1pkSVB0ZDRvRGNFMWRxa3lNT2swRDEwRDJsS1V3a2hJQ1dyOHMzTFRTSnVNNG5ndFJQM1NhTHVGX1l2Q0NLQzNqYmVoOTZ0T0lzSm5WNnJXczBmZVlZMnhaVUJYWXFzeEFuQldISzNLMDBwZk1p?oc=5",
    "date": "2018-10-05T07:00:00.000Z",
    "dateFormatted": "05/10/2018",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "MannKind Corporation - 578282 - 10/05/2018  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "8b7328349ffd66a989520d03953fb18a",
    "title": "With U.S. nod, North Little Rock-based Cantrell Drug reopens - The Arkansas Democrat-Gazette",
    "link": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQVFktbzA4ZWVFaVU4Z3BYN3N2aHM4ZFcxb2JRUUdzekk2cE9OaTE0ZnVFbXNJZWJMRWdSU1JCT1BtOWs1bnBHU1A1SXpFR01IWEdILXNTNVZQOFNqQUJSRWtyUzR5enJsSGR2MnFJS1RQVUxIUUNEREc1OV9pU1pOMEkxa3FJYTZzd1lHejVZdnJrZw?oc=5",
    "date": "2018-09-26T07:00:00.000Z",
    "dateFormatted": "26/09/2018",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "With U.S. nod, North Little Rock-based Cantrell Drug reopens  The Arkansas Democrat-Gazette",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "f44153e1fe002a68710316ce21808de0",
    "title": "Suzanne Strang, Ph.D. Executive Director, Regulatory Affairs and Quality Assurance ASCEND Therapeutics US, LLC 607 Herndon Parkw - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAtSi1PRjBCZnUwQ1RXYXdUWVV5cnMtT04zbVh3QkxkaU9xUlFOOGlreXBSWTR2ZjNKWTdjWkdxUERXTDlWak13ZFFURFlXUFlidW9r?oc=5",
    "date": "2018-08-16T07:00:00.000Z",
    "dateFormatted": "16/08/2018",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Suzanne Strang, Ph.D. Executive Director, Regulatory Affairs and Quality Assurance ASCEND Therapeutics US, LLC 607 Herndon Parkw  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "c5f2d18cef73dfe5b96bb8499aff8db2",
    "title": "Peter Honig, MD, MPH Senior Vice President, Worldwide Safety and Regulatory Pfizer Inc. 235 East 42nd Street New York, NY 10017 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBDVDJiNXpEOWJvYXJ5UGRmTmZVLU5sTjlqT2U1cFA3cnBRemlXSU0yY3JiajdiMWJERmdta3NiLV93REJHdlRmZWVfTDdtWEg5OU9J?oc=5",
    "date": "2018-06-19T07:00:00.000Z",
    "dateFormatted": "19/06/2018",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Peter Honig, MD, MPH Senior Vice President, Worldwide Safety and Regulatory Pfizer Inc. 235 East 42nd Street New York, NY 10017  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "c9cc76c0e38c50173bf4d94808394b0d",
    "title": "FDA bans Cantrell from manufacturing, distributing sterile drugs - BioPharma Dive",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPUG9ZdUNjejNIS3prVUdZbmJIWVR0SlNIbmV2RzQwSnhYai1hWEhhUU9qLUVUSkxWT3kxWHd1YWtlSjd0TDJzd2pSd0hyWUVEdEZEY01WbmdGVkdmRW9ic3BYdzlKS200SkxMZGExTkNnVzByUkJUUENpZVphM2llZnd6NDNzNDZ6SHMzVEhZcnUwTE5GUlc5dmd1d1IwLUlFakxDNGM5djZrdw?oc=5",
    "date": "2018-04-24T07:00:00.000Z",
    "dateFormatted": "24/04/2018",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA bans Cantrell from manufacturing, distributing sterile drugs  BioPharma Dive",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "8f80a35b644e7708df62770b8a4d0466",
    "title": "We will continue to engage external consultants, Biocon assures USFDA - The Indian Express",
    "link": "https://news.google.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?oc=5",
    "date": "2018-04-17T07:00:00.000Z",
    "dateFormatted": "17/04/2018",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "We will continue to engage external consultants, Biocon assures USFDA  The Indian Express",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "df80f176431eb8ca17405797e8e1f500",
    "title": "FDA inspectors find 'vermin' in production areas of Indian API maker - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNbDRtZHV0UEx5dFlRd183SmVCYzFySHFWdGJ5ZUNRY2dab1hSS0V6dzRHWEdSZzdaM0oxc1M1eXRhbXRKeHJyV0ZJMWJFZ2kyQ0tPbEtUd0FzeHdJXzhpQ1Y0NHdMNnV4dzNpd09NTUxOSWcxUzVaZnZzaEZWRmUxLTBtREVKMGU1ZW5wclhYVDE1dVdhWUlIWUR4VDVJaDlsTjFncmt3?oc=5",
    "date": "2018-03-21T07:00:00.000Z",
    "dateFormatted": "21/03/2018",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA inspectors find 'vermin' in production areas of Indian API maker  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "3a473f3d1a543d98eb0cd16543f2180a",
    "title": "John F. Weet, PhD Vice President, Regulatory Affairs and Quality Assurance Collegium Pharmaceutical, Inc. 780 Dedham Street, Sui - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9CbzhROVR3anZiYWFieGpxZkhVcHBqRFctVjNWaWxhd2IxQTZDTE1rV3RhdXFrVmFOYVhSZjJKSGl6dnNCRmo0WDI0MFlxMjdaM0s4?oc=5",
    "date": "2018-02-09T08:00:00.000Z",
    "dateFormatted": "09/02/2018",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "John F. Weet, PhD Vice President, Regulatory Affairs and Quality Assurance Collegium Pharmaceutical, Inc. 780 Dedham Street, Sui  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "4f48333a15d70322614e57294142e3f8",
    "title": "Medtronic's pain pump redesign OK'd by FDA - Star Tribune",
    "link": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQOXdZOUJjenNsNmZyNUJZang5M2J4YnpRaUYtNW50QlpnTWVRQnZ3SXFwankzRjR4aWxhZm90d1pTYzBNMHAxVTNOb2dnaFM1OVY5eG9GaTdsR21ycFpqM3h1Ync1MEtVN0psdUxGZmdLVVFJRE5qanBLd296UlA2d1NRZk1JMms?oc=5",
    "date": "2018-01-10T08:00:00.000Z",
    "dateFormatted": "10/01/2018",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Medtronic's pain pump redesign OK'd by FDA  Star Tribune",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "3e3c959335ef3885a1369922e7883427",
    "title": "Untitled - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5QMy1pdHo0NG5XVXpSZzZTTS0telR3c1RPTnMyekk1MDJxMU9iVzdqYTlMVDFyaDFBckZNcmZaYnNfWEo5d1lHVjlkTXhNNmlONmtB?oc=5",
    "date": "2017-12-28T08:00:00.000Z",
    "dateFormatted": "28/12/2017",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Untitled  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ced2e998639b35dec7733023bfcc89be",
    "title": "Avanthi, Inc. - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNU05NLU1acDRuNFZkN1J4ajJ6bWZQNFE2MTdkeUxyTGpmSUF5akVEUFVDWlZGTXAzM3Y5NXljQkYtLVE4RVo3YVI4RGV2QWFaLVVFYTl0dXQ5S2IwT0RLTkM5S25ENkJMSUpfVndtRFhZVXRHSGJiT01Ea2lVS1NiZXYxNm9VNXZ5eEtMWV9sanM1OE5yd2JoUnN6eEtaSWNpM3o0cUROOXh2TTV5anJNZlNlanBNeFhpYWc0?oc=5",
    "date": "2017-12-19T08:00:00.000Z",
    "dateFormatted": "19/12/2017",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Avanthi, Inc.  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "3244a9a6f1c30da9dd73c4b7b38a8c0b",
    "title": "Cipher Pharmaceuticals Inc. - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPdkR0MUhwYW14Rk9GX1FpMkF3Y2h2NFBTVHJubU9kSmV5S0hJSG9ncXowOGlYZDVUZVhiNFFxUDVQTFBCUWl0c0JNUFZhMEpSLUFDb25tTDdMRjZ4c0hoYmx2eVk1ZGpYeEUzYmIyNV96a3ppN1kyZ2dNVS0zbjFPYVJjUGVvV0lUVXg5TmYzOEYzN1ZuSHZfdV9Oc3JKQ01LbmNiZUtuM1FZNlR3cEVVbzlTc3B3dnd3Zko5Wjg1TExRY2IwWE9SeUR3TVRwSzQ?oc=5",
    "date": "2017-11-30T08:00:00.000Z",
    "dateFormatted": "30/11/2017",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Cipher Pharmaceuticals Inc.  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "baa9c4873c45c9169c4734920f6d5a48",
    "title": "Amherst Pharmaceuticals, LLC/Magna Pharmaceuticals, Inc. - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxQZV9LLWViZl9lNFZMalBFMlhKYkgzQ0FfYy12SC1YWVZMd1pzV2FQVlI5ZjJsN1FxWTZOWnQ1dzZ1XzJidnhBcDQ4ajUtRy1aS3hVTkZXVFJKUmhKajFCMnZ0X0lFV2Uxc2dGSTBSVEc0NjdYcVNsdDVVOExCQ3dVMkE2RUVBcFd1YzV2TGFURnBnSEd1NU03RlllanFtN2JCQm5LUVp2amhkZzI1QnhBYjBOZWNzUWIzX3ViVWFCM2RFam9UVnNHbXJCQ2R5S1JFWmVwMVNaY3pycDJIQU84dGlhR3FLdGlTS0s2cU53c1JoZw?oc=5",
    "date": "2017-11-14T08:00:00.000Z",
    "dateFormatted": "14/11/2017",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Amherst Pharmaceuticals, LLC/Magna Pharmaceuticals, Inc.  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "89b1a759522bfb19f0f843819e44a6fb",
    "title": "Cipher Pharmaceuticals US LLC - 460380 - 08/24/2017 - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPekpKUEx0TFZQODRVcnM4Q1g3cnJ1U3ZpQVVERGZJVjdYRlFsY1c2UXR1RXlUX1FhcmctaVg5NXN5aVhDZ2pyZHhucVZ2RGpuRGhCdmJvRWlrLWFPNjQ5NDJjZF9nNHpyY25abWp1TmEtSTBjZmxUU3NIeDZNRnA1SkdmRzZJb3N2T09fVjZPTTF4R3dlTWpITzFOUVozNUEtQVRSSmU0M0dyQmZhRlZyOUpqdy1SRXV0S2tkMzJMNm1VcS1WcDJHcHRxal9jSlpoMzZ2TGZ0UEdzR0pH?oc=5",
    "date": "2017-08-24T07:00:00.000Z",
    "dateFormatted": "24/08/2017",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Cipher Pharmaceuticals US LLC - 460380 - 08/24/2017  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "bf3a7b92f5c1cdb83f48ea328f0cb347",
    "title": "FDA forces Carlstadt company to shut down - Bergen Record",
    "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQUW9xcWtZLTNFRzFMZHhWc0lqOUR3aHNFUWpxdlE0LUFfT2N6UjFtbUtBR21sZzJYNWZzVEJfZDM4UU8xd3VjMjZPRVBlcXdRczJlWE1ENm9VQ19NQjVIaEV0ZVdiS1ZjWUVLMWd6RVdlU2VUUTFEUlpRMlZtcy11OTZiOTU5UC1yU2RFel9wTHNMM1BnM3FTUlVQZ1J2bEpu?oc=5",
    "date": "2017-06-18T07:00:00.000Z",
    "dateFormatted": "18/06/2017",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA forces Carlstadt company to shut down  Bergen Record",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "abde1fe1b485ae965dcb95cc6f89a8f4",
    "title": "FDA slams Indian API firm for faking certificates of analysis - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNdy11MlJ4a2M5c3BtUlpXUFBnWG9qVk1OVndrd2MyY0YxRVFpZU9RUExSYlJlVG9zTUJraE5fUXR1V0hzZlpEYjdpYVZTTlluQzBSZ0tKLV9xOHJSYnR5aktZZEJ2WmFxbHJfTUpfalRJc2hqOE1sS0xfWG5fZWFkejkwSXdaWl9HMndtdHVLMUUxcEtlTExyYWdWMzNuQzlrUm5Z?oc=5",
    "date": "2017-05-03T07:00:00.000Z",
    "dateFormatted": "03/05/2017",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA slams Indian API firm for faking certificates of analysis  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "42d922b18ed73b47cd5ecea36902ed33",
    "title": "US FDA ban on Sun Pharma unit lifted after over 3 years - Business Standard",
    "link": "https://news.google.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?oc=5",
    "date": "2017-03-15T07:00:00.000Z",
    "dateFormatted": "15/03/2017",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "US FDA ban on Sun Pharma unit lifted after over 3 years  Business Standard",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "bee5a95bcc19511f395270ff8d3ba256",
    "title": "Sun Pharma reaches small goal in unburdening its regulatory load - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOcWFhRVFva2JSYmFLZlFWa21VT3F4LXRKOVFnMVdUVF8zMTRMWjdrMFBlY1d2b2tiOHNFaTNweGllMG1RWHhnN1UwakxpbXhGQkVudDY5RFVNMVF5amR2Qzh1TFkxT3g3Vjl5MHdCWmt2aWJxVFFLRzVyZjdDZ0ItUjh1QzdWU0QwOHIydmJlMVZVT2pmS2o3SktqRWdtUC1PcXZRYmdNcw?oc=5",
    "date": "2017-03-14T07:00:00.000Z",
    "dateFormatted": "14/03/2017",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Sun Pharma reaches small goal in unburdening its regulatory load  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e522e53d82097cc35aa634355700ff92",
    "title": "Xellia expects ex-Boehringer sterile plant to be ready for production in 2018 - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQk52cV8xT2pOemp5V21pRjU0TXIxSFZRb2djTWJIUm5mcTVFdmlpdDM1N2hBSXNVU2gxNzhwaloydFZjQlQyUWFaNUc4N0hiRzNVQXY2SnZXUWdkTVZ3RW9QNmtkanVReFlhNFc5LU51MU5pREVIMEh4S2hRYUp4WWtPTHBCeXcxYXJjbEltYmdTTk5XR0ZFcjR5Y0R1Y2czakQtMEpjc0U5QWZGYTdrSW5XWEpuM2JF?oc=5",
    "date": "2016-11-15T08:00:00.000Z",
    "dateFormatted": "15/11/2016",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Xellia expects ex-Boehringer sterile plant to be ready for production in 2018  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d570a7244e3cae7a5506f534f7266566",
    "title": "More deaths tied to Medtronic’s SynchroMed II drug pump - MassDevice",
    "link": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBnYXZack9JcHozaC1LWTJJNVVCU3RQWGxQZ1RtN2xZMmxRVEM2a2V2VThqNmljamFkTzhiNzRQdEFkUEpZb2NGdm5GZWR0bXRkdWhIMm9fZTlPUUE4YTBCaE4xQjM5Q0x0SGVZYVJMazh6RFVEQ09TZkNfcVdMeGs?oc=5",
    "date": "2016-11-02T07:00:00.000Z",
    "dateFormatted": "02/11/2016",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "More deaths tied to Medtronic’s SynchroMed II drug pump  MassDevice",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "865105f59569fd8c22e4ee0e1756a674",
    "title": "FDA warns China facility over 'persistent' contamination - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxON0JKd0V4Z2JnYjYxb2JHaGhoT3gzSXdOdXk2Z3VjUWRRdllpLU9TYjF3ZFRBSHBiNUsybDcxTVBnNG9CNG9lZnBqb214MHAtMkx4Zi1pX0FEQlRnSmZMdy14MEtabzJjZ19NalJObkY2dWpzN1ZpcWNHQnYyWWlacV80aVJkUlBRN0FIdUZzNjNUQUJFUEdTakg0alZtUQ?oc=5",
    "date": "2016-09-20T07:00:00.000Z",
    "dateFormatted": "20/09/2016",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA warns China facility over 'persistent' contamination  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "2e91229390ce03a4b75624ecede98806",
    "title": "FDA bans a third Wockhardt plant - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPQm9oX2hKMk9yTGxJSVVMMG00anBJeXVoRDRKMmVtRk13MllpTzdVVnBvRG9zSTlRNEtRMVNyWUZ3MVUwV0FVRGZWNHZSZkQtejAwdGNmeDdiRTdGcGVQaEpzQUNla1VTMGZYNkQ1Yy1mTm1PNUlROE9Sck8zV1JSdg?oc=5",
    "date": "2016-08-08T07:00:00.000Z",
    "dateFormatted": "08/08/2016",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA bans a third Wockhardt plant  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "cffbf20674de3be610e8a1eff713d730",
    "title": "To avoid shortages, FDA allows imports from 8 drug plants banned for quality shortfalls - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZHVLM3NYTHFaWGJqc2FiNjRmWGFRNHl2aFhwWjQ2azlJUC0yTUtCTVR5UFR4cFMxdGFJaTc5QXdnOGFqa0hpdnU5LWJiNW8zZF9wTGlFbkE1UUg2eko1T3cxaFZ6RS10QXhad0VteXB0eWZYZGhxbDVRSlViS2Q3T0JBcjZGNm1qOUd4RVJQWHdoMkNNVEtYUHVwanRIRDJUUThnVkJ3UG9RUQ?oc=5",
    "date": "2016-07-25T07:00:00.000Z",
    "dateFormatted": "25/07/2016",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "To avoid shortages, FDA allows imports from 8 drug plants banned for quality shortfalls  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "2ce0df90238588cd5fcdca6eafd24ef0",
    "title": "FDA whacks Megafine India API plant with warning for faked test data - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQS1lqVmdYMFkwaG5XcThtRmNuS0J0V1EtQy1JZV9CZDhTVm1yMkVWYThBeWVSZGYyNXM5eVROWlNCclcxNThMS2o3dlRybTQ3eURtaHlVVXZtM3JmOUt2ZlJ0MVpkSzR3cjljQ0FsWHplRjM1YXNJa2VlbzZvMi1GbG5pemJpdnl6ZGoya2dwU2pWVFMySmp6UHFEeTZzc2tXekIxSA?oc=5",
    "date": "2016-05-31T07:00:00.000Z",
    "dateFormatted": "31/05/2016",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA whacks Megafine India API plant with warning for faked test data  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d44528daddf107154b9e0b88e1822f88",
    "title": "Xellia kicks off Budapest manufacturing expansion - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOM3h2QmxseFVscjBzVHNHNWNIYnd2c3JzTUJwNnN4bG1id0Zoa1hXVnJIbVZ0NzJKTElIUko4Y2V1cGNaTGhVZUsyZldHR1lLTXM0N1lVa3V3bFl2OGlKNkUyVllSWWVHSW9FZDVwWkxKcXI0MW1OYWktblN5VEcwc2NGSGVCcUJHTy1XYXF1bDRvbmlTVDhV?oc=5",
    "date": "2016-05-25T07:00:00.000Z",
    "dateFormatted": "25/05/2016",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Xellia kicks off Budapest manufacturing expansion  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "56b1f91f08f0efcd7c37d5e7c06ea7ae",
    "title": "FDA reaches agreement with Xellia on troubled manufacturing plant - BioPharma Dive",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPbDM3UU1uaXJrb2lwaWY2ZHpDbkQ5Z0xWRmFPTlFHem9fQkt2a1dlLXJSLWtqcnA0YmpYT04xSmdJRk5SR3V5REhaVlA0Znc5VDBLMEVtTnNVVElvNlY1NExYaW1ybVZ1SGdKX0NUSllPdHB3RlZIVTZ1NUFHd0hobHJ1aEdxdzJ6VExHOXFKN3lFVWMtZzlpQTMwWXUtbjBkSnpjRGQ3enh3a1Fu?oc=5",
    "date": "2016-05-05T07:00:00.000Z",
    "dateFormatted": "05/05/2016",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA reaches agreement with Xellia on troubled manufacturing plant  BioPharma Dive",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "5be108fb8e884045fc729d5c921388e1",
    "title": "Xellia Pharmaceuticals, FDA reach agreement on how to revive former Ben Venue complex - Crain's Cleveland Business",
    "link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPVmJKaXR4VzBuZzd0S09sQ25vS1ZvQ3p6SktCUXBDTmpOM1U3dnFfdWN1Z216UWNGR0gyRmNRUkZ0dGg4eFVHWXp1TkhWaDZZaW9vTV9jRUh3NlR4UEk0RE13dWZuTnlRNUtSSkVMQm05eGZzR0ctLWw4ZWdtdHMwSDUzeXRqQWpKdUZwcTZzYjVxOEhscXVsRnVyLWRBY3lVV2k3azNxbWlMN2tkQ04xd1FhSkZYVnlKdmRsUFJVYXZIVDFiVmNSdUl3?oc=5",
    "date": "2016-04-28T07:00:00.000Z",
    "dateFormatted": "28/04/2016",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Xellia Pharmaceuticals, FDA reach agreement on how to revive former Ben Venue complex  Crain's Cleveland Business",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "8d186b333f2c29bfe5ccb84f572c5414",
    "title": "Drug Labeling and Its Impact on Promotion - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPbmpPb05fRTRwa1NKVUpyU0JFVndMdGVJN1Z2UTE5OGZLbVQ0VUdqbV9RVmNlWHNiZ0VkeEJteWhWZjJ0dlhuQU9feXZld2c4RkFYbjNJZ0Nhb1QzWDNWRkpSTUg5bkI1a0FFVjFYdHZBRHMtbW5uN3RwcFowYmpJRnBWb0txX1VLdVFGVUxLNmc?oc=5",
    "date": "2015-11-04T08:00:00.000Z",
    "dateFormatted": "04/11/2015",
    "source": "Google News - OPDP Letters",
    "sourceCategory": "google",
    "sourceType": "opdp",
    "summary": "Drug Labeling and Its Impact on Promotion  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "e7139dbdb3160437d44cecf5ae1ea742",
    "title": "FDA Bans Imports From Major Indian API Manufacturer - Regulatory Affairs Professionals Society | RAPS",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNbVpxYmVEZVJwUS13MWJrUk9xX3ZUOHJmRk0wVTlGallGaE9KZ2RmU2paZm1XemstTkdIeUMwcWFISmJoZnR2VlB2VWNEQkJXTV8tZHlnZElRT1l4YzhlWEFzak1SVmNkellvbk0yU2oyeXJnVTZ3MDB5ZjFqbm9vVEJXemdyM0Faal9DMHppZEdxT25QbHFncm9DTmxrbFZtN2hyODJYUWRFNVYtVlBWNA?oc=5",
    "date": "2015-10-15T07:00:00.000Z",
    "dateFormatted": "15/10/2015",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA Bans Imports From Major Indian API Manufacturer  Regulatory Affairs Professionals Society | RAPS",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "469adc7b5e96419852d23c9debee092a",
    "title": "Emcure India plant banned by the FDA - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9fdUFxWFhUSExMbjJ2UC1PU1BKdTVLZmw5aGM5UHEwb1R3QmZsVmpxVklTVGVGWnhHblZlc09kRHg1TzJFMlpMa19XWFJRMi1sUW1JY2IxV0luenF6ODJlVVZodTdnMWt6cXZKYjVUYUM1X3BIbUJZbklZY0g?oc=5",
    "date": "2015-07-14T07:00:00.000Z",
    "dateFormatted": "14/07/2015",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "Emcure India plant banned by the FDA  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "ba763df25d9238e38b8f854c565de117",
    "title": "FDA alert on IPCA Labs, US export halted from MP unit - Business Standard",
    "link": "https://news.google.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?oc=5",
    "date": "2014-07-25T07:00:00.000Z",
    "dateFormatted": "25/07/2014",
    "source": "Google News - Import Alerts",
    "sourceCategory": "google",
    "sourceType": "import_alert",
    "summary": "FDA alert on IPCA Labs, US export halted from MP unit  Business Standard",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "9cc567f875d12a62dc272558f074d8d7",
    "title": "FDA approves generic Doxil to combat drug shortage - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQZ2h0eWRrdzR2YVM1QktwRTN4LXNrcWZ1ODBCT0tscmVBdFhVNnF3dTNwNTJGRXpWYjk5UTVfRnhVNjdsWXc3WVo3VnF0M2pzSUNfbF9nRndTcUYtdEVOdmRiN3hCMHdaaXdXTV81WGZWeWVpV25NVi0yMVhOLWJDY0M1cTZEV3hjUmFGbVM0dFo4ZUhDN2tVc296anNCZF9V?oc=5",
    "date": "2013-02-04T08:00:00.000Z",
    "dateFormatted": "04/02/2013",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "FDA approves generic Doxil to combat drug shortage  Fierce Pharma",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "75ef0fe9267d3fa5a64456bb33bcc5cd",
    "title": "Caraco Pharmaceutical Names New CEO - CBS News",
    "link": "https://news.google.com/rss/articles/CBMifkFVX3lxTE13cVJxdG1scU5Yb0dkc2VkaGhCQmpoX3hVcnRTS2E4YVNMQUJkRWtmT3BsdDdmbWxSalFxWXNyOUtwSnhySEpqUWE2ZFRCSlczR0Ixck11LU5lWU85b2lHazU3a1JfVEJOWVdQc0x1T1R6WkRaVFVJQV8tMTNCQQ?oc=5",
    "date": "2010-10-10T07:00:00.000Z",
    "dateFormatted": "10/10/2010",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Caraco Pharmaceutical Names New CEO  CBS News",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "99c7b8df2d4b16e171c75d7817f176cd",
    "title": "Actavis Reintroduces Oxycodone In The US - Pharmaceutical Online",
    "link": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPYXpvVnowU0M3M2tHWW8tRjhiQzFTa1doZzI3VXBDUnV4cjV3ajlIQlJ4bkFiaG9RODdSTkxiTVVSNHNVejVsVHRRVjNSa3NBV0JKbWVDNloxdzRLcHd3NkF1b0w2QWlQYkNWRE5HUF9zV2dYYlZ1ZWdteThtalFTTHVIeDF2VXpYNjlBNU43OA?oc=5",
    "date": "2009-04-21T07:00:00.000Z",
    "dateFormatted": "21/04/2009",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Actavis Reintroduces Oxycodone In The US  Pharmaceutical Online",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "22709fe4be8dddc80b689527144f57f2",
    "title": "U.S. Food and Drug Administration - fda.gov",
    "link": "https://news.google.com/rss/articles/CBMiN0FVX3lxTE91QXlENXNrYWFFQjFEUHhWUjFwMURtMXROY0FtV0FZcUdsSmhiVmJwaVdqWTh4Zm8?oc=5",
    "date": "2006-06-24T04:02:30.000Z",
    "dateFormatted": "24/06/2006",
    "source": "Google News - FDA Warning Letters",
    "sourceCategory": "google",
    "sourceType": "foia",
    "summary": "U.S. Food and Drug Administration  fda.gov",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "c45779a15ac6eeafe77bda76cdf31d4a",
    "title": "ALZHEIMER'S DRUG APPROVED BY F.D.A. (Published 1993) - The New York Times",
    "link": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPS1ZiLTJSb3ExNDZMZXJBUDVoaGhEZ1NoTUFMWU9xVmFTQkFZbFhGQk4wUFdTMVdpV19fZGFKR0xESGFpZmt2QjZCaTFkRy1ySGRXaTcybXZlekRRS1hRTXpqYXZXUmdXVWQ0SXVHdDhGOHFvSW9RcFpRUzFaTmJUTA?oc=5",
    "date": "1993-09-10T07:00:00.000Z",
    "dateFormatted": "10/09/1993",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "ALZHEIMER'S DRUG APPROVED BY F.D.A. (Published 1993)  The New York Times",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  },
  {
    "id": "d61ad1c9b66d74425f7de4a9636efe71",
    "title": "Syntex Settles With F.D.A. (Published 1991) - The New York Times",
    "link": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9qdWZlemJncDh3Y21RT2VaV3AteWNQMUhxTzNwS2o2Tnd6Z2ZQVG1IS3lUbkZpS2xWZ2VndVNSbTR4dm1fczA0YkVIMFBrcE53UEJyaGpVdkU3N3IxejNYb2pxMUNKMjdPWWFPVUtpdkVIZ3BDNTZUVzB5LVI?oc=5",
    "date": "1991-10-11T07:00:00.000Z",
    "dateFormatted": "11/10/1991",
    "source": "Google News - Consent Decrees",
    "sourceCategory": "google",
    "sourceType": "consent_decree",
    "summary": "Syntex Settles With F.D.A. (Published 1991)  The New York Times",
    "company": "TBD",
    "types": [
      "regulatory_news"
    ],
    "severity": 0,
    "priority": 3
  }
]